{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Instructions\n",
    "\n",
    "We first downloaded the files from this link <http://nlp.stanford.edu/software/stanford-corenlp-full-2017-06-09.zip> \n",
    "\n",
    "Then we dragged the pubmed folder into that same folder, with the copied abstracts (if you don't want to re-download them all again).\n",
    "\n",
    "There are a few files you will need to make sure are present:\n",
    "\n",
    "`lexparser-gui.bat                  \n",
    "lexparser-gui.command              \n",
    "lexparser-gui.sh                   \n",
    "lexparser-lang-train-test.sh       \n",
    "lexparser-lang.sh                  \n",
    "lexparser.bat                      \n",
    "lexparser.sh                       `\n",
    "\n",
    "You will also need to add the `edu` folder that can be found here:\n",
    "<https://www.dropbox.com/s/t9uk4z1xznpo0jz/jars.zip?dl=0>\n",
    "\n",
    "Add the .zip extension to the `stanford-corenlp-3.8.0-models.jar` file, and unzip it. Copy that `edu` folder and paste it in to your home directory."
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Parsing the Pubmed Abstracts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 96,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "import pubmed.utils as pb\n",
    "import json\n",
    "import re\n",
    "from collections import defaultdict\n",
    "from pprint import pprint\n",
    "import string\n",
    "# utf-8 support\n",
    "import codecs\n",
    "import nltk\n",
    "# spit abstracts to sentences\n",
    "from nltk.tokenize import sent_tokenize\n",
    "import ast"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[nltk_data] Downloading package punkt to /home/barcelise/nltk_data...\n",
      "[nltk_data]   Package punkt is already up-to-date!\n"
     ]
    },
    {
     "data": {
      "text/plain": [
       "True"
      ]
     },
     "execution_count": 9,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "nltk.download('punkt')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "#search_term = 'ACE inhibitor'\n",
    "search_term = 'statin'\n",
    "max_results = 100\n",
    "query = pb.PubMedQuery(search_term, max_results)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'query' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-7-b3ccd4b25f14>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mids\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mquery\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mid_getter\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m      2\u001b[0m \u001b[0;32mprint\u001b[0m \u001b[0;34m\"Num abstracts: \"\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mids\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mNameError\u001b[0m: name 'query' is not defined"
     ]
    }
   ],
   "source": [
    "ids = query.id_getter()\n",
    "print \"Num abstracts: \", len(ids)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## This is to just download a few of the abstracts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "collapsed": false,
    "scrolled": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "CPU times: user 316 ms, sys: 8 ms, total: 324 ms\n",
      "Wall time: 1.31 s\n"
     ]
    }
   ],
   "source": [
    "%%time\n",
    "#I just tried to download a few \n",
    "# if you don't want to download all abstracts, please do not use the download_all_abstracts() method, but rather the \n",
    "# abstract_getter() as below\n",
    "pb.PubMedQuery.COUNT = 0\n",
    "max_results = 100\n",
    "query = pb.PubMedQuery(search_term, max_results)\n",
    "ids = query.id_getter()\n",
    "abstracts = query.abstract_getter(ids)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## This is to download a TON of the abstracts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# %%time\n",
    "# pb.PubMedQuery.COUNT = 0\n",
    "# max_results = 100\n",
    "# full_query = pb.download_all_abstracts(search_term, max_results)\n",
    "# ids = full_query.id_getter()\n",
    "# abstracts = full_query.id_getter(ids)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Save all abstracts to JSON file"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "ename": "NameError",
     "evalue": "name 'ids' is not defined",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m                                 Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-5-72d7ccf7b6a9>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m()\u001b[0m\n\u001b[0;32m----> 1\u001b[0;31m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mids\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;31mNameError\u001b[0m: name 'ids' is not defined"
     ]
    }
   ],
   "source": [
    "len(ids)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Saving to statins_abstracts.json\n"
     ]
    }
   ],
   "source": [
    "json_file = 'statins_abstracts.json'\n",
    "#json_file = 'more_abstracts.json'\n",
    "print 'Saving to ' + json_file\n",
    "with codecs.open(json_file, 'w','utf-8') as outfile:\n",
    "    json.dump(abstracts, outfile, indent=4)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## We might not need all the sentences in the abstract, so I am seeing what would happen if we just parse out the ones with key words, and write them to a textfile, and then parse the resulting file.\n",
    "\n",
    "Keyword selection could happen here in the sentence tokenizer."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentences:  970\n"
     ]
    }
   ],
   "source": [
    "sentences = []\n",
    "with codecs.open('statins_pbabstract/statins_abstracts.json','r','utf-8') as data_file:    \n",
    "    data = json.load(data_file)\n",
    "    for abstract in data.itervalues():\n",
    "        sentences.append(sent_tokenize(abstract))\n",
    "    # flatten the list of abstracts into one long list of sentences\n",
    "    sentences = [sent for s in sentences for sent in s]\n",
    "    print \"Sentences: \",len(sentences)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "# keyword = 'statin'\n",
    "# key_sentences = []\n",
    "# transformed_sentences = pb.ace_substitutor(sentences, 'ACEI')\n",
    "# for sent in transformed_sentences:\n",
    "#     if keyword in sent:\n",
    "#         key_sentences.append(sent)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Overwriting KeywordSentences.py\n"
     ]
    }
   ],
   "source": [
    "%%writefile KeywordSentences.py\n",
    "import json\n",
    "import codecs\n",
    "import pubmed.utils as pb\n",
    "\n",
    "#change keyword to ACE\n",
    "keyword = 'statin'\n",
    "with codecs.open('statins_pbabstract/statins_abstracts.json','r','utf-8') as data_file:    \n",
    "    data = json.load(data_file)\n",
    "    #pick snippets related to ACE inhibitors\n",
    "    for abstract in data.itervalues():\n",
    "        transformed_abstract = pb.ace_substitutor(abstract, 'statin') \n",
    "        if keyword in transformed_abstract:\n",
    "            print transformed_abstract.encode('utf-8') + '\\n'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "!python2 KeywordSentences.py > KeywordSentences.txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "clinically stable patients who underwent des implantation 12 months previously and received aspirin monotherapy were randomly assigned to receive either high-intensity (40mg atorvastatin, n = 1000) or low-intensity (20mg pravastatin, n = 1000) statin treatment. the primary endpoint was adverse clinical events at 12-month follow-up (a composite of all death, myocardial infarction, revascularization, stent thrombosis, stroke, renal deterioration, intervention for peripheral artery disease, and admission for cardiac events).\r\n",
      "\r\n",
      "the primary endpoint at 12-month follow-up occurred in 25 patients (2.5%) receiving high-intensity statin treatment and in 40 patients (4.1%) receiving low-intensity statin treatment (hr, 0.58; 95%ci, 0.36-0.92; p = .018). this difference was mainly driven by a lower rate of cardiac death (0 vs 0.4%, p = .025) and nontarget vessel myocardial infarction (0.1 vs 0.7%, p = .033) in the high-intensity statin treatment group.\r\n",
      "\r\n",
      "patients with heterozygous familial hypercholesterolemia (hefh) have been reported to be less vulnerable to type 2 diabetes mellitus (t2dm), although the mechanism is unknown. the aims of the present study were to assess the effects of low density lipoprotein (ldl) cholesterol concentration and the presence of fh-causing mutations on t2dm prevalence in hefh. data were collected from the dyslipidemia registry of the spanish arteriosclerosis society. inclusion criteria were definite or probable hefh in patients aged ≥18 years. t2dm prevalence in hefh patients was compared with data of the general population. 1732 patients were included. the prevalence of t2dm was lower in patients with hefh compared with the general population (5.94% vs 9.44%; or: 0.606, 95% ci 0.486-0.755, p < 0.001). risk factors for developing t2dm were male sex, age, body mass index, hypertension, baseline triglyceride levels and years on statin therapy. the prevalence of t2dm in hefh patients was 40% lower than that observed in the general population. gene mutations and ldl cholesterol concentrations were not risk factors associated with the prevalence of t2dm in patients with hefh. the prevalence of t2dm in patients with hefh was 40% lower than in the general population matched for age and sex.\r\n",
      "\r\n",
      "current guidelines on the treatment of blood cholesterol recommend continuous maintenance of high-intensity statin treatment in drug-eluting stent (des)-treated patients. however, high-intensity statin treatment is frequently underused in clinical practice after stabilization of des-treated patients. currently, the impact of continuous high-intensity statin treatment on the incidence of late adverse events in these patients is unknown. we investigated whether high-intensity statin treatment reduces late adverse events in clinically stable patients on aspirin monotherapy 12 months after des implantation.\r\n",
      "\r\n",
      "use of statin therapy in patients with type 2 diabetes mellitus (t2dm) has been recommended by most clinical guidelines. cardiovascular disease (cvd) is a leading cause of morbidity and mortality among t2dm patients. it has been proved that statins are effective for primary or secondary cvd prophylaxis. reports have highlighted the underutilization of statins in clinical practice and the suboptimal adherence to guideline recommendations. this review article points to summarize the current evidence confirming the role of statins in t2dm patients and to provide an overview of factors that may affect statins' prescribing patterns and compliance in clinical practice. initiatives to enhance statin therapy prescribing should recognize the comprehensive nature of the prescribing process. attempts to assure proper statin prescribing and utilization can help in achieving better clinical outcomes of statin therapy.\r\n",
      "\r\n"
     ]
    }
   ],
   "source": [
    "#This mimics the format that the example parser file has\n",
    "!head KeywordSentences.txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "collapsed": true
   },
   "outputs": [],
   "source": [
    "!chmod a+x lexparser.sh"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "# Testing with PCFG Model*\n",
    "\n",
    "*notice I made a change to the lexparser file to allow for more memory"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "#!/usr/bin/env bash\r\n",
      "#\r\n",
      "# Runs the English PCFG parser on one or more files, printing trees only\r\n",
      "\r\n",
      "if [ ! $# -ge 1 ]; then\r\n",
      "  echo Usage: `basename $0` 'file(s)'\r\n",
      "  echo\r\n",
      "  exit\r\n",
      "fi\r\n",
      "\r\n",
      "scriptdir=`dirname $0`\r\n",
      "\r\n",
      "java -mx500m -cp \"$scriptdir/*:\" edu.stanford.nlp.parser.lexparser.LexicalizedParser \\\r\n",
      " -outputFormat \"penn,typedDependencies\" edu/stanford/nlp/models/lexparser/englishPCFG.ser.gz $*\r\n"
     ]
    }
   ],
   "source": [
    "!cat ./lexparser.sh"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "%%timeit\n",
    "! ./lexparser.sh  KeywordSentences.txt"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Testing with RNN Model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "!cat ./lexparser_rnn.sh"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "SLF4J: Failed to load class \"org.slf4j.impl.StaticLoggerBinder\".\n",
      "SLF4J: Defaulting to no-operation (NOP) logger implementation\n",
      "SLF4J: See http://www.slf4j.org/codes.html#StaticLoggerBinder for further details.\n",
      "Parsing file: KeywordSentences.txt\n",
      "Parsing [sent. 1 len. 52]: RAAS , a major pharmacological target in cardiovascular medicine , is inhibited by pharmacological classes including angiotensin converting enzyme -LRB- ACE -RRB- inhibitors -LRB- ACEIs -RRB- , angiotensin-II type 1 blockers -LRB- ARBs -RRB- and aldosterone receptors antagonists , in addition to the recently introduced direct renin inhibitors -LRB- DRIs -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNS RAAS))\n",
      "      (, ,)\n",
      "      (NP\n",
      "        (NP (DT a) (JJ major) (JJ pharmacological) (NN target))\n",
      "        (PP (IN in)\n",
      "          (NP (JJ cardiovascular) (NN medicine))))\n",
      "      (, ,))\n",
      "    (VP (VBZ is)\n",
      "      (ADJP (JJ inhibited)\n",
      "        (PP (IN by)\n",
      "          (NP\n",
      "            (NP (JJ pharmacological) (NNS classes))\n",
      "            (PP (VBG including)\n",
      "              (NP\n",
      "                (NP\n",
      "                  (NP (NN angiotensin))\n",
      "                  (S\n",
      "                    (VP (VBG converting)\n",
      "                      (NP (JJ enzyme)\n",
      "                        (PRN (-LRB- -LRB-)\n",
      "                          (NP (NNP ACE))\n",
      "                          (-RRB- -RRB-))\n",
      "                        (NNS inhibitors))))\n",
      "                  (PRN (-LRB- -LRB-)\n",
      "                    (NP (NNP ACEIs))\n",
      "                    (-RRB- -RRB-)))\n",
      "                (, ,)\n",
      "                (NP\n",
      "                  (ADJP (RB angiotensin-II) (NN type)\n",
      "                    (PRN\n",
      "                      (NP (CD 1))\n",
      "                      (PP\n",
      "                        (NP\n",
      "                          (NP (NNS blockers))\n",
      "                          (PRN (-LRB- -LRB-)\n",
      "                            (NP (NNP ARBs))\n",
      "                            (-RRB- -RRB-))\n",
      "                          (CC and)\n",
      "                          (NP (JJ aldosterone) (NNS receptors) (NNS antagonists))\n",
      "                          (, ,))\n",
      "                        (IN in)\n",
      "                        (NP (NN addition))))\n",
      "                    (PP (TO to)\n",
      "                      (NP (DT the)\n",
      "                        (ADJP (RB recently) (VBN introduced))\n",
      "                        (JJ direct) (NN renin))))\n",
      "                  (NNS inhibitors))))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP (NNP DRIs))\n",
      "              (-RRB- -RRB-))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(inhibited-12, RAAS-1)\n",
      "det(target-6, a-3)\n",
      "amod(target-6, major-4)\n",
      "amod(target-6, pharmacological-5)\n",
      "appos(RAAS-1, target-6)\n",
      "case(medicine-9, in-7)\n",
      "amod(medicine-9, cardiovascular-8)\n",
      "nmod:in(target-6, medicine-9)\n",
      "cop(inhibited-12, is-11)\n",
      "root(ROOT-0, inhibited-12)\n",
      "case(classes-15, by-13)\n",
      "amod(classes-15, pharmacological-14)\n",
      "nmod:by(inhibited-12, classes-15)\n",
      "case(angiotensin-17, including-16)\n",
      "nmod:including(classes-15, angiotensin-17)\n",
      "dep(angiotensin-17, converting-18)\n",
      "amod(inhibitors-23, enzyme-19)\n",
      "appos(inhibitors-23, ACE-21)\n",
      "dobj(converting-18, inhibitors-23)\n",
      "appos(angiotensin-17, ACEIs-25)\n",
      "advmod(type-29, angiotensin-II-28)\n",
      "amod(inhibitors-48, type-29)\n",
      "dep(type-29, 1-30)\n",
      "nmod:in(1-30, blockers-31)\n",
      "appos(blockers-31, ARBs-33)\n",
      "cc(blockers-31, and-35)\n",
      "amod(antagonists-38, aldosterone-36)\n",
      "compound(antagonists-38, receptors-37)\n",
      "nmod:in(1-30, antagonists-38)\n",
      "conj:and(blockers-31, antagonists-38)\n",
      "case(blockers-31, in-40)\n",
      "dep(blockers-31, addition-41)\n",
      "case(renin-47, to-42)\n",
      "det(renin-47, the-43)\n",
      "advmod(introduced-45, recently-44)\n",
      "amod(renin-47, introduced-45)\n",
      "amod(renin-47, direct-46)\n",
      "nmod:to(type-29, renin-47)\n",
      "appos(angiotensin-17, inhibitors-48)\n",
      "appos(classes-15, DRIs-50)\n",
      "\n",
      "Parsing [sent. 2 len. 36]: However , currently used RAAS inhibitors still can not achieve their desired effects and are associated with certain drawbacks , such as adverse side effects , incomplete blockage of the system and poor end-organ protection .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (ADVP (RB currently))\n",
      "    (VP (VBD used)\n",
      "      (SBAR\n",
      "        (S\n",
      "          (NP (NNP RAAS) (NNS inhibitors))\n",
      "          (ADVP (RB still))\n",
      "          (VP\n",
      "            (VP (MD can) (RB not)\n",
      "              (VP (VB achieve)\n",
      "                (NP (PRP$ their) (VBN desired) (NNS effects))))\n",
      "            (CC and)\n",
      "            (VP (VBP are)\n",
      "              (VP (VBN associated)\n",
      "                (PP (IN with)\n",
      "                  (NP\n",
      "                    (NP (JJ certain) (NNS drawbacks))\n",
      "                    (, ,)\n",
      "                    (PP (JJ such) (IN as)\n",
      "                      (NP (JJ adverse) (NN side) (NNS effects)))\n",
      "                    (, ,)\n",
      "                    (ADJP (JJ incomplete) (JJ blockage))\n",
      "                    (PP (IN of)\n",
      "                      (NP\n",
      "                        (NP (DT the) (NN system))\n",
      "                        (CC and)\n",
      "                        (NP (JJ poor) (JJ end-organ) (NN protection))))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(used-4, However-1)\n",
      "advmod(used-4, currently-3)\n",
      "root(ROOT-0, used-4)\n",
      "compound(inhibitors-6, RAAS-5)\n",
      "nsubj(achieve-10, inhibitors-6)\n",
      "nsubjpass(associated-16, inhibitors-6)\n",
      "advmod(achieve-10, still-7)\n",
      "aux(achieve-10, can-8)\n",
      "neg(achieve-10, not-9)\n",
      "ccomp(used-4, achieve-10)\n",
      "nmod:poss(effects-13, their-11)\n",
      "amod(effects-13, desired-12)\n",
      "dobj(achieve-10, effects-13)\n",
      "cc(achieve-10, and-14)\n",
      "auxpass(associated-16, are-15)\n",
      "ccomp(used-4, associated-16)\n",
      "conj:and(achieve-10, associated-16)\n",
      "case(drawbacks-19, with-17)\n",
      "amod(drawbacks-19, certain-18)\n",
      "nmod:with(associated-16, drawbacks-19)\n",
      "case(effects-25, such-21)\n",
      "mwe(such-21, as-22)\n",
      "amod(effects-25, adverse-23)\n",
      "compound(effects-25, side-24)\n",
      "nmod:such_as(drawbacks-19, effects-25)\n",
      "amod(blockage-28, incomplete-27)\n",
      "amod(drawbacks-19, blockage-28)\n",
      "case(system-31, of-29)\n",
      "det(system-31, the-30)\n",
      "nmod:of(drawbacks-19, system-31)\n",
      "cc(system-31, and-32)\n",
      "amod(protection-35, poor-33)\n",
      "amod(protection-35, end-organ-34)\n",
      "nmod:of(drawbacks-19, protection-35)\n",
      "conj:and(system-31, protection-35)\n",
      "\n",
      "Parsing [sent. 3 len. 42]: In this review , we discuss the efficiency and specificity of the current RAAS inhibitors and propose some recommendations for achieving better treatments with better end-organ protection.Hypertension Research advance online publication , 6 July 2017 ; doi :10.1038 / hr .2017.65 .\n",
      "(ROOT\n",
      "  (S\n",
      "    (PP (IN In)\n",
      "      (NP (DT this) (NN review)))\n",
      "    (, ,)\n",
      "    (S\n",
      "      (NP (PRP we))\n",
      "      (VP\n",
      "        (VP (VB discuss)\n",
      "          (NP\n",
      "            (NP (DT the) (NN efficiency)\n",
      "              (CC and)\n",
      "              (NN specificity))\n",
      "            (PP (IN of)\n",
      "              (NP (DT the) (JJ current) (NNS RAAS) (NNS inhibitors)))))\n",
      "        (CC and)\n",
      "        (VP (VB propose)\n",
      "          (NP (DT some) (NNS recommendations))\n",
      "          (PP (IN for)\n",
      "            (S\n",
      "              (VP (VBG achieving)\n",
      "                (NP (JJR better) (NNS treatments))\n",
      "                (PP (IN with)\n",
      "                  (NP (JJR better) (JJ end-organ) (NN protection.Hypertension) (NNP Research) (NN advance) (JJ online) (NN publication) (, ,) (CD 6) (NNP July) (NNS 2017)))))))))\n",
      "    (: ;)\n",
      "    (FRAG\n",
      "      (X\n",
      "        (X (SYM doi))\n",
      "        (NP (CD :10.1038)))\n",
      "      (: /)\n",
      "      (NP (CD hr) (CD .2017.65)))\n",
      "    (. .)))\n",
      "\n",
      "case(review-3, In-1)\n",
      "det(review-3, this-2)\n",
      "nmod:in(discuss-6, review-3)\n",
      "nsubj(discuss-6, we-5)\n",
      "nsubj(propose-17, we-5)\n",
      "root(ROOT-0, discuss-6)\n",
      "det(efficiency-8, the-7)\n",
      "dobj(discuss-6, efficiency-8)\n",
      "cc(efficiency-8, and-9)\n",
      "dobj(discuss-6, specificity-10)\n",
      "conj:and(efficiency-8, specificity-10)\n",
      "case(inhibitors-15, of-11)\n",
      "det(inhibitors-15, the-12)\n",
      "amod(inhibitors-15, current-13)\n",
      "compound(inhibitors-15, RAAS-14)\n",
      "nmod:of(efficiency-8, inhibitors-15)\n",
      "cc(discuss-6, and-16)\n",
      "conj:and(discuss-6, propose-17)\n",
      "det(recommendations-19, some-18)\n",
      "dobj(propose-17, recommendations-19)\n",
      "mark(achieving-21, for-20)\n",
      "advcl(propose-17, achieving-21)\n",
      "amod(treatments-23, better-22)\n",
      "dobj(achieving-21, treatments-23)\n",
      "case(2017-35, with-24)\n",
      "amod(2017-35, better-25)\n",
      "amod(2017-35, end-organ-26)\n",
      "compound(2017-35, protection.Hypertension-27)\n",
      "compound(2017-35, Research-28)\n",
      "compound(2017-35, advance-29)\n",
      "amod(2017-35, online-30)\n",
      "compound(2017-35, publication-31)\n",
      "nummod(2017-35, 6-33)\n",
      "compound(2017-35, July-34)\n",
      "nmod:with(achieving-21, 2017-35)\n",
      "dep(:10.1038-38, doi-37)\n",
      "dep(.2017.65-41, :10.1038-38)\n",
      "nummod(.2017.65-41, hr-40)\n",
      "dep(discuss-6, .2017.65-41)\n",
      "\n",
      "Parsing [sent. 4 len. 51]: The beneficial effects of angiotensin converting enzyme -LRB- ACE -RRB- inhibitors and angiotensin II -LRB- AII -RRB- receptor antagonists in patients with heart failure secondary to reduced ejection fraction -LRB- HFrEF -RRB- are felt to result from prevention of the adverse effects of AII on systemic afterload and renal homeostasis .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (JJ beneficial) (NNS effects))\n",
      "      (PP (IN of)\n",
      "        (NP\n",
      "          (NP (NN angiotensin))\n",
      "          (VP (VBG converting)\n",
      "            (NP\n",
      "              (NP (JJ enzyme)\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP ACE))\n",
      "                  (-RRB- -RRB-))\n",
      "                (NN inhibitors))\n",
      "              (CC and)\n",
      "              (NP\n",
      "                (NP (NNP angiotensin) (NNP II))\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP AII))\n",
      "                  (-RRB- -RRB-)))\n",
      "              (NP\n",
      "                (NP (NN receptor) (NNS antagonists))\n",
      "                (PP (IN in)\n",
      "                  (NP (NNS patients)))))\n",
      "            (PP (IN with)\n",
      "              (NP\n",
      "                (NP (NN heart) (NN failure))\n",
      "                (ADJP (JJ secondary)\n",
      "                  (PP (TO to)\n",
      "                    (NP\n",
      "                      (NP (VBN reduced) (NN ejection) (NN fraction))\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP HFrEF))\n",
      "                        (-RRB- -RRB-)))))))))))\n",
      "    (VP (VBP are)\n",
      "      (VP (VBN felt)\n",
      "        (S\n",
      "          (VP (TO to)\n",
      "            (VP (VB result)\n",
      "              (PP (IN from)\n",
      "                (NP\n",
      "                  (NP (NN prevention))\n",
      "                  (PP (IN of)\n",
      "                    (NP\n",
      "                      (NP (DT the) (JJ adverse) (NNS effects))\n",
      "                      (PP (IN of)\n",
      "                        (NP (NNP AII)))))))\n",
      "              (PP (IN on)\n",
      "                (NP (JJ systemic) (JJ afterload)\n",
      "                  (CC and)\n",
      "                  (JJ renal) (NNS homeostasis))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(effects-3, The-1)\n",
      "amod(effects-3, beneficial-2)\n",
      "nsubjpass(felt-34, effects-3)\n",
      "nsubj:xsubj(result-36, effects-3)\n",
      "case(angiotensin-5, of-4)\n",
      "nmod:of(effects-3, angiotensin-5)\n",
      "acl(angiotensin-5, converting-6)\n",
      "amod(inhibitors-11, enzyme-7)\n",
      "appos(inhibitors-11, ACE-9)\n",
      "dobj(converting-6, inhibitors-11)\n",
      "cc(inhibitors-11, and-12)\n",
      "compound(II-14, angiotensin-13)\n",
      "dobj(converting-6, II-14)\n",
      "conj:and(inhibitors-11, II-14)\n",
      "appos(II-14, AII-16)\n",
      "compound(antagonists-19, receptor-18)\n",
      "dep(inhibitors-11, antagonists-19)\n",
      "case(patients-21, in-20)\n",
      "nmod:in(antagonists-19, patients-21)\n",
      "case(failure-24, with-22)\n",
      "compound(failure-24, heart-23)\n",
      "nmod:with(converting-6, failure-24)\n",
      "amod(failure-24, secondary-25)\n",
      "case(fraction-29, to-26)\n",
      "amod(fraction-29, reduced-27)\n",
      "compound(fraction-29, ejection-28)\n",
      "nmod:to(secondary-25, fraction-29)\n",
      "appos(fraction-29, HFrEF-31)\n",
      "auxpass(felt-34, are-33)\n",
      "root(ROOT-0, felt-34)\n",
      "mark(result-36, to-35)\n",
      "xcomp(felt-34, result-36)\n",
      "case(prevention-38, from-37)\n",
      "nmod:from(result-36, prevention-38)\n",
      "case(effects-42, of-39)\n",
      "det(effects-42, the-40)\n",
      "amod(effects-42, adverse-41)\n",
      "nmod:of(prevention-38, effects-42)\n",
      "case(AII-44, of-43)\n",
      "nmod:of(effects-42, AII-44)\n",
      "case(afterload-47, on-45)\n",
      "amod(afterload-47, systemic-46)\n",
      "nmod:on(result-36, afterload-47)\n",
      "cc(afterload-47, and-48)\n",
      "amod(homeostasis-50, renal-49)\n",
      "nmod:on(result-36, homeostasis-50)\n",
      "conj:and(afterload-47, homeostasis-50)\n",
      "\n",
      "Parsing [sent. 5 len. 31]: However , AII can activate the sympathetic nervous system and part of the beneficial effects of ACE inhibitors and AII antagonists may result from their ability to inhibit such activation .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (S\n",
      "      (NP (NNP AII))\n",
      "      (VP (MD can)\n",
      "        (VP (VB activate)\n",
      "          (NP\n",
      "            (NP (DT the)\n",
      "              (ADJP (JJ sympathetic) (JJ nervous))\n",
      "              (NN system))\n",
      "            (CC and)\n",
      "            (NP\n",
      "              (NP (NN part))\n",
      "              (PP (IN of)\n",
      "                (NP\n",
      "                  (NP (DT the) (JJ beneficial) (NNS effects))\n",
      "                  (PP (IN of)\n",
      "                    (NP (NNP ACE) (NNS inhibitors))))))))))\n",
      "    (CC and)\n",
      "    (S\n",
      "      (NP (NNP AII) (NNS antagonists))\n",
      "      (VP (MD may)\n",
      "        (VP (VB result)\n",
      "          (PP (IN from)\n",
      "            (NP (PRP$ their) (NN ability)\n",
      "              (S\n",
      "                (VP (TO to)\n",
      "                  (VP (VB inhibit)\n",
      "                    (NP (JJ such) (NN activation))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(activate-5, However-1)\n",
      "nsubj(activate-5, AII-3)\n",
      "aux(activate-5, can-4)\n",
      "root(ROOT-0, activate-5)\n",
      "det(system-9, the-6)\n",
      "amod(nervous-8, sympathetic-7)\n",
      "amod(system-9, nervous-8)\n",
      "dobj(activate-5, system-9)\n",
      "cc(system-9, and-10)\n",
      "dobj(activate-5, part-11)\n",
      "conj:and(system-9, part-11)\n",
      "case(effects-15, of-12)\n",
      "det(effects-15, the-13)\n",
      "amod(effects-15, beneficial-14)\n",
      "nmod:of(part-11, effects-15)\n",
      "case(inhibitors-18, of-16)\n",
      "compound(inhibitors-18, ACE-17)\n",
      "nmod:of(effects-15, inhibitors-18)\n",
      "cc(activate-5, and-19)\n",
      "compound(antagonists-21, AII-20)\n",
      "nsubj(result-23, antagonists-21)\n",
      "aux(result-23, may-22)\n",
      "conj:and(activate-5, result-23)\n",
      "case(ability-26, from-24)\n",
      "nmod:poss(ability-26, their-25)\n",
      "nmod:from(result-23, ability-26)\n",
      "mark(inhibit-28, to-27)\n",
      "acl(ability-26, inhibit-28)\n",
      "amod(activation-30, such-29)\n",
      "dobj(inhibit-28, activation-30)\n",
      "\n",
      "Parsing [sent. 6 len. 49]: We examined the acute effects of the ACE inhibitor captopril -LRB- 25 mg , n = 9 -RRB- and the AII receptor antagonist losartan -LRB- 50 mg , n = 10 -RRB- on hemodynamics as well as total body and cardiac norepinephrine spillover in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (PRP We))\n",
      "    (VP (VBD examined)\n",
      "      (NP\n",
      "        (NP (DT the) (JJ acute) (NNS effects))\n",
      "        (PP (IN of)\n",
      "          (NP\n",
      "            (NP (DT the) (NNP ACE) (NN inhibitor) (NN captopril))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 25) (NN mg))\n",
      "                (, ,)\n",
      "                (NP\n",
      "                  (NP (NN n))\n",
      "                  (SBAR\n",
      "                    (S\n",
      "                      (VP (SYM =)\n",
      "                        (NP (CD 9)))))))\n",
      "              (-RRB- -RRB-))\n",
      "            (CC and)\n",
      "            (NP (DT the) (NNP AII) (NN receptor) (NN antagonist) (NN losartan))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 50) (NN mg))\n",
      "                (, ,)\n",
      "                (NP\n",
      "                  (NP (NN n))\n",
      "                  (SBAR\n",
      "                    (S\n",
      "                      (VP (SYM =)\n",
      "                        (NP (CD 10)))))))\n",
      "              (-RRB- -RRB-)))))\n",
      "      (PP (IN on)\n",
      "        (NP\n",
      "          (NP (NNS hemodynamics))\n",
      "          (CONJP (RB as) (RB well) (IN as))\n",
      "          (NP (JJ total) (NN body)\n",
      "            (CC and)\n",
      "            (JJ cardiac) (NN norepinephrine) (NN spillover))))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (NNS patients))\n",
      "          (PP (IN with)\n",
      "            (NP (JJ chronic) (NNP HFrEF))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(examined-2, We-1)\n",
      "root(ROOT-0, examined-2)\n",
      "det(effects-5, the-3)\n",
      "amod(effects-5, acute-4)\n",
      "dobj(examined-2, effects-5)\n",
      "case(captopril-10, of-6)\n",
      "det(captopril-10, the-7)\n",
      "compound(captopril-10, ACE-8)\n",
      "compound(captopril-10, inhibitor-9)\n",
      "nmod:of(effects-5, captopril-10)\n",
      "nummod(mg-13, 25-12)\n",
      "dep(captopril-10, mg-13)\n",
      "appos(mg-13, n-15)\n",
      "dep(9-17, =-16)\n",
      "acl:relcl(n-15, 9-17)\n",
      "cc(captopril-10, and-19)\n",
      "det(losartan-24, the-20)\n",
      "compound(losartan-24, AII-21)\n",
      "compound(losartan-24, receptor-22)\n",
      "compound(losartan-24, antagonist-23)\n",
      "nmod:of(effects-5, losartan-24)\n",
      "conj:and(captopril-10, losartan-24)\n",
      "nummod(mg-27, 50-26)\n",
      "dep(captopril-10, mg-27)\n",
      "appos(mg-27, n-29)\n",
      "dep(10-31, =-30)\n",
      "acl:relcl(n-29, 10-31)\n",
      "case(hemodynamics-34, on-33)\n",
      "nmod:on(examined-2, hemodynamics-34)\n",
      "cc(hemodynamics-34, as-35)\n",
      "mwe(as-35, well-36)\n",
      "mwe(as-35, as-37)\n",
      "amod(body-39, total-38)\n",
      "nmod:on(examined-2, body-39)\n",
      "conj:and(hemodynamics-34, body-39)\n",
      "cc(body-39, and-40)\n",
      "amod(spillover-43, cardiac-41)\n",
      "compound(spillover-43, norepinephrine-42)\n",
      "conj:and(hemodynamics-34, spillover-43)\n",
      "conj:and(body-39, spillover-43)\n",
      "case(patients-45, in-44)\n",
      "nmod:in(examined-2, patients-45)\n",
      "case(HFrEF-48, with-46)\n",
      "amod(HFrEF-48, chronic-47)\n",
      "nmod:with(patients-45, HFrEF-48)\n",
      "\n",
      "Parsing [sent. 7 len. 20]: Hemodynamic and neurochemical measurements were made at baseline and at 1 , 2 and 4 hours after oral dosing .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (JJ Hemodynamic)\n",
      "      (CC and)\n",
      "      (JJ neurochemical) (NNS measurements))\n",
      "    (VP (VBD were)\n",
      "      (VP (VBN made)\n",
      "        (PP\n",
      "          (PP (IN at)\n",
      "            (NP (NN baseline)))\n",
      "          (CC and)\n",
      "          (PP (IN at)\n",
      "            (NP (CD 1) (, ,) (CD 2)\n",
      "              (CC and)\n",
      "              (CD 4)))\n",
      "          (NP (NNS hours)))\n",
      "        (PP (IN after)\n",
      "          (NP (JJ oral) (NN dosing)))))\n",
      "    (. .)))\n",
      "\n",
      "amod(measurements-4, Hemodynamic-1)\n",
      "cc(Hemodynamic-1, and-2)\n",
      "conj:and(Hemodynamic-1, neurochemical-3)\n",
      "amod(measurements-4, neurochemical-3)\n",
      "nsubjpass(made-6, measurements-4)\n",
      "auxpass(made-6, were-5)\n",
      "root(ROOT-0, made-6)\n",
      "case(baseline-8, at-7)\n",
      "nmod:at(hours-16, baseline-8)\n",
      "cc(hours-16, and-9)\n",
      "case(1-11, at-10)\n",
      "nmod(made-6, 1-11)\n",
      "conj:and(hours-16, 1-11)\n",
      "nummod(1-11, 2-13)\n",
      "cc(1-11, and-14)\n",
      "conj:and(1-11, 4-15)\n",
      "conj:and(hours-16, 4-15)\n",
      "nmod(made-6, hours-16)\n",
      "case(dosing-19, after-17)\n",
      "amod(dosing-19, oral-18)\n",
      "nmod:after(made-6, dosing-19)\n",
      "\n",
      "Parsing [sent. 8 len. 25]: Administration of both drugs caused significant reductions in systemic arterial , cardiac filling and pulmonary artery pressures -LRB- P < 0.05 vs baseline -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNP Administration))\n",
      "      (PP (IN of)\n",
      "        (NP (DT both) (NNS drugs))))\n",
      "    (VP (VBD caused)\n",
      "      (NP (JJ significant) (NNS reductions))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (JJ systemic) (NN arterial))\n",
      "          (, ,)\n",
      "          (NP (JJ cardiac) (NN filling))\n",
      "          (CC and)\n",
      "          (NP (JJ pulmonary) (NN artery) (NNS pressures))))\n",
      "      (PRN (-LRB- -LRB-)\n",
      "        (NP\n",
      "          (NP (NNP P) (NNP <))\n",
      "          (NP (CD 0.05) (NN vs) (NN baseline)))\n",
      "        (-RRB- -RRB-)))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(caused-5, Administration-1)\n",
      "case(drugs-4, of-2)\n",
      "det(drugs-4, both-3)\n",
      "nmod:of(Administration-1, drugs-4)\n",
      "root(ROOT-0, caused-5)\n",
      "amod(reductions-7, significant-6)\n",
      "dobj(caused-5, reductions-7)\n",
      "case(arterial-10, in-8)\n",
      "amod(arterial-10, systemic-9)\n",
      "nmod:in(caused-5, arterial-10)\n",
      "amod(filling-13, cardiac-12)\n",
      "nmod:in(caused-5, filling-13)\n",
      "conj:and(arterial-10, filling-13)\n",
      "cc(arterial-10, and-14)\n",
      "amod(pressures-17, pulmonary-15)\n",
      "compound(pressures-17, artery-16)\n",
      "nmod:in(caused-5, pressures-17)\n",
      "conj:and(arterial-10, pressures-17)\n",
      "compound(<-20, P-19)\n",
      "dep(caused-5, <-20)\n",
      "nummod(baseline-23, 0.05-21)\n",
      "compound(baseline-23, vs-22)\n",
      "dep(<-20, baseline-23)\n",
      "\n",
      "Parsing [sent. 9 len. 13]: There was no significant difference in the magnitude of those hemodynamic effects .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (EX There))\n",
      "    (VP (VBD was)\n",
      "      (NP\n",
      "        (NP (DT no) (JJ significant) (NN difference))\n",
      "        (PP (IN in)\n",
      "          (NP\n",
      "            (NP (DT the) (NN magnitude))\n",
      "            (PP (IN of)\n",
      "              (NP (DT those) (JJ hemodynamic) (NNS effects)))))))\n",
      "    (. .)))\n",
      "\n",
      "expl(was-2, There-1)\n",
      "root(ROOT-0, was-2)\n",
      "neg(difference-5, no-3)\n",
      "amod(difference-5, significant-4)\n",
      "nsubj(was-2, difference-5)\n",
      "case(magnitude-8, in-6)\n",
      "det(magnitude-8, the-7)\n",
      "nmod:in(difference-5, magnitude-8)\n",
      "case(effects-12, of-9)\n",
      "det(effects-12, those-10)\n",
      "amod(effects-12, hemodynamic-11)\n",
      "nmod:of(magnitude-8, effects-12)\n",
      "\n",
      "Parsing [sent. 10 len. 23]: Plasma concentrations of AII were significantly decreased by captopril and increased by losartan -LRB- P < 0.05 vs baseline for both -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNP Plasma) (NNS concentrations))\n",
      "      (PP (IN of)\n",
      "        (NP (NNP AII))))\n",
      "    (VP (VBD were)\n",
      "      (ADVP (RB significantly))\n",
      "      (VP\n",
      "        (VP (VBN decreased)\n",
      "          (PP (IN by)\n",
      "            (NP (NN captopril))))\n",
      "        (CC and)\n",
      "        (VP (VBN increased)\n",
      "          (PP (IN by)\n",
      "            (NP\n",
      "              (NP (NN losartan))\n",
      "              (PRN (-LRB- -LRB-)\n",
      "                (NP\n",
      "                  (NP (NNP P) (NNP <))\n",
      "                  (NP\n",
      "                    (NP (CD 0.05) (NN vs) (NN baseline))\n",
      "                    (PP (IN for)\n",
      "                      (NP (DT both)))))\n",
      "                (-RRB- -RRB-)))))))\n",
      "    (. .)))\n",
      "\n",
      "compound(concentrations-2, Plasma-1)\n",
      "nsubjpass(decreased-7, concentrations-2)\n",
      "nsubjpass(increased-11, concentrations-2)\n",
      "case(AII-4, of-3)\n",
      "nmod:of(concentrations-2, AII-4)\n",
      "auxpass(decreased-7, were-5)\n",
      "advmod(decreased-7, significantly-6)\n",
      "root(ROOT-0, decreased-7)\n",
      "case(captopril-9, by-8)\n",
      "nmod:by(decreased-7, captopril-9)\n",
      "cc(decreased-7, and-10)\n",
      "conj:and(decreased-7, increased-11)\n",
      "case(losartan-13, by-12)\n",
      "nmod:by(increased-11, losartan-13)\n",
      "compound(<-16, P-15)\n",
      "dep(losartan-13, <-16)\n",
      "nummod(baseline-19, 0.05-17)\n",
      "compound(baseline-19, vs-18)\n",
      "dep(<-16, baseline-19)\n",
      "case(both-21, for-20)\n",
      "nmod:for(baseline-19, both-21)\n",
      "\n",
      "Parsing [sent. 11 len. 37]: Total body sympathetic activity increased in response to both captopril and losartan -LRB- P < 0.05 vs baseline for both -RRB- , however there was no change in cardiac sympathetic activity in response to either drug .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (JJ Total) (NN body) (JJ sympathetic) (NN activity))\n",
      "      (VP (VBN increased)\n",
      "        (PP (IN in)\n",
      "          (NP (NN response)))\n",
      "        (PP (TO to)\n",
      "          (NP\n",
      "            (NP (DT both) (NN captopril)\n",
      "              (CC and)\n",
      "              (NN losartan))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (NNP P) (NNP <))\n",
      "                (NP\n",
      "                  (NP (CD 0.05) (NN vs) (NN baseline))\n",
      "                  (PP (IN for)\n",
      "                    (NP (DT both)))))\n",
      "              (-RRB- -RRB-))))))\n",
      "    (, ,)\n",
      "    (ADVP (RB however))\n",
      "    (NP (EX there))\n",
      "    (VP (VBD was)\n",
      "      (NP\n",
      "        (NP (DT no) (NN change))\n",
      "        (PP (IN in)\n",
      "          (NP\n",
      "            (NP (JJ cardiac) (JJ sympathetic) (NN activity))\n",
      "            (PP (IN in)\n",
      "              (NP (NN response))))))\n",
      "      (PP (TO to)\n",
      "        (NP (DT either) (NN drug))))\n",
      "    (. .)))\n",
      "\n",
      "amod(activity-4, Total-1)\n",
      "compound(activity-4, body-2)\n",
      "amod(activity-4, sympathetic-3)\n",
      "nsubj(was-25, activity-4)\n",
      "acl(activity-4, increased-5)\n",
      "case(response-7, in-6)\n",
      "nmod:in(increased-5, response-7)\n",
      "case(captopril-10, to-8)\n",
      "cc:preconj(captopril-10, both-9)\n",
      "nmod:to(increased-5, captopril-10)\n",
      "cc(captopril-10, and-11)\n",
      "nmod:to(increased-5, losartan-12)\n",
      "conj:and(captopril-10, losartan-12)\n",
      "compound(<-15, P-14)\n",
      "dep(captopril-10, <-15)\n",
      "nummod(baseline-18, 0.05-16)\n",
      "compound(baseline-18, vs-17)\n",
      "dep(<-15, baseline-18)\n",
      "case(both-20, for-19)\n",
      "nmod:for(baseline-18, both-20)\n",
      "expl(was-25, however-23)\n",
      "dep(however-23, there-24)\n",
      "root(ROOT-0, was-25)\n",
      "neg(change-27, no-26)\n",
      "nsubj(was-25, change-27)\n",
      "case(activity-31, in-28)\n",
      "amod(activity-31, cardiac-29)\n",
      "amod(activity-31, sympathetic-30)\n",
      "nmod:in(change-27, activity-31)\n",
      "case(response-33, in-32)\n",
      "nmod:in(activity-31, response-33)\n",
      "case(drug-36, to-34)\n",
      "det(drug-36, either-35)\n",
      "nmod:to(was-25, drug-36)\n",
      "\n",
      "Parsing [sent. 12 len. 29]: The results of the current study do not support the hypothesis that the acute inhibition of the renin angiotensin system has sympathoinhibitory effects in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (NNS results))\n",
      "      (PP (IN of)\n",
      "        (NP (DT the) (JJ current) (NN study))))\n",
      "    (VP (VBP do) (RB not)\n",
      "      (VP (VB support)\n",
      "        (NP (DT the) (NNS hypothesis))\n",
      "        (SBAR (IN that)\n",
      "          (S\n",
      "            (NP\n",
      "              (NP (DT the) (JJ acute) (NN inhibition))\n",
      "              (PP (IN of)\n",
      "                (NP (DT the) (NN renin) (NN angiotensin) (NN system))))\n",
      "            (VP (VBZ has)\n",
      "              (NP\n",
      "                (NP (JJ sympathoinhibitory) (NNS effects))\n",
      "                (PP (IN in)\n",
      "                  (NP\n",
      "                    (NP (NNS patients))\n",
      "                    (PP (IN with)\n",
      "                      (NP (JJ chronic) (NNP HFrEF)))))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(results-2, The-1)\n",
      "nsubj(support-9, results-2)\n",
      "case(study-6, of-3)\n",
      "det(study-6, the-4)\n",
      "amod(study-6, current-5)\n",
      "nmod:of(results-2, study-6)\n",
      "aux(support-9, do-7)\n",
      "neg(support-9, not-8)\n",
      "root(ROOT-0, support-9)\n",
      "det(hypothesis-11, the-10)\n",
      "dobj(support-9, hypothesis-11)\n",
      "mark(has-21, that-12)\n",
      "det(inhibition-15, the-13)\n",
      "amod(inhibition-15, acute-14)\n",
      "nsubj(has-21, inhibition-15)\n",
      "case(system-20, of-16)\n",
      "det(system-20, the-17)\n",
      "compound(system-20, renin-18)\n",
      "compound(system-20, angiotensin-19)\n",
      "nmod:of(inhibition-15, system-20)\n",
      "ccomp(support-9, has-21)\n",
      "amod(effects-23, sympathoinhibitory-22)\n",
      "dobj(has-21, effects-23)\n",
      "case(patients-25, in-24)\n",
      "nmod:in(effects-23, patients-25)\n",
      "case(HFrEF-28, with-26)\n",
      "amod(HFrEF-28, chronic-27)\n",
      "nmod:with(patients-25, HFrEF-28)\n",
      "\n",
      "Parsed file: KeywordSentences.txt [12 sentences].\n",
      "Parsed 408 words in 12 sentences (42.79 wds/sec; 1.26 sents/sec).\n",
      "SLF4J: Failed to load class \"org.slf4j.impl.StaticLoggerBinder\".\n",
      "SLF4J: Defaulting to no-operation (NOP) logger implementation\n",
      "SLF4J: See http://www.slf4j.org/codes.html#StaticLoggerBinder for further details.\n",
      "Parsing file: KeywordSentences.txt\n",
      "Parsing [sent. 1 len. 52]: RAAS , a major pharmacological target in cardiovascular medicine , is inhibited by pharmacological classes including angiotensin converting enzyme -LRB- ACE -RRB- inhibitors -LRB- ACEIs -RRB- , angiotensin-II type 1 blockers -LRB- ARBs -RRB- and aldosterone receptors antagonists , in addition to the recently introduced direct renin inhibitors -LRB- DRIs -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNS RAAS))\n",
      "      (, ,)\n",
      "      (NP\n",
      "        (NP (DT a) (JJ major) (JJ pharmacological) (NN target))\n",
      "        (PP (IN in)\n",
      "          (NP (JJ cardiovascular) (NN medicine))))\n",
      "      (, ,))\n",
      "    (VP (VBZ is)\n",
      "      (ADJP (JJ inhibited)\n",
      "        (PP (IN by)\n",
      "          (NP\n",
      "            (NP (JJ pharmacological) (NNS classes))\n",
      "            (PP (VBG including)\n",
      "              (NP\n",
      "                (NP\n",
      "                  (NP (NN angiotensin))\n",
      "                  (S\n",
      "                    (VP (VBG converting)\n",
      "                      (NP (JJ enzyme)\n",
      "                        (PRN (-LRB- -LRB-)\n",
      "                          (NP (NNP ACE))\n",
      "                          (-RRB- -RRB-))\n",
      "                        (NNS inhibitors))))\n",
      "                  (PRN (-LRB- -LRB-)\n",
      "                    (NP (NNP ACEIs))\n",
      "                    (-RRB- -RRB-)))\n",
      "                (, ,)\n",
      "                (NP\n",
      "                  (ADJP (RB angiotensin-II) (NN type)\n",
      "                    (PRN\n",
      "                      (NP (CD 1))\n",
      "                      (PP\n",
      "                        (NP\n",
      "                          (NP (NNS blockers))\n",
      "                          (PRN (-LRB- -LRB-)\n",
      "                            (NP (NNP ARBs))\n",
      "                            (-RRB- -RRB-))\n",
      "                          (CC and)\n",
      "                          (NP (JJ aldosterone) (NNS receptors) (NNS antagonists))\n",
      "                          (, ,))\n",
      "                        (IN in)\n",
      "                        (NP (NN addition))))\n",
      "                    (PP (TO to)\n",
      "                      (NP (DT the)\n",
      "                        (ADJP (RB recently) (VBN introduced))\n",
      "                        (JJ direct) (NN renin))))\n",
      "                  (NNS inhibitors))))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP (NNP DRIs))\n",
      "              (-RRB- -RRB-))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(inhibited-12, RAAS-1)\n",
      "det(target-6, a-3)\n",
      "amod(target-6, major-4)\n",
      "amod(target-6, pharmacological-5)\n",
      "appos(RAAS-1, target-6)\n",
      "case(medicine-9, in-7)\n",
      "amod(medicine-9, cardiovascular-8)\n",
      "nmod:in(target-6, medicine-9)\n",
      "cop(inhibited-12, is-11)\n",
      "root(ROOT-0, inhibited-12)\n",
      "case(classes-15, by-13)\n",
      "amod(classes-15, pharmacological-14)\n",
      "nmod:by(inhibited-12, classes-15)\n",
      "case(angiotensin-17, including-16)\n",
      "nmod:including(classes-15, angiotensin-17)\n",
      "dep(angiotensin-17, converting-18)\n",
      "amod(inhibitors-23, enzyme-19)\n",
      "appos(inhibitors-23, ACE-21)\n",
      "dobj(converting-18, inhibitors-23)\n",
      "appos(angiotensin-17, ACEIs-25)\n",
      "advmod(type-29, angiotensin-II-28)\n",
      "amod(inhibitors-48, type-29)\n",
      "dep(type-29, 1-30)\n",
      "nmod:in(1-30, blockers-31)\n",
      "appos(blockers-31, ARBs-33)\n",
      "cc(blockers-31, and-35)\n",
      "amod(antagonists-38, aldosterone-36)\n",
      "compound(antagonists-38, receptors-37)\n",
      "nmod:in(1-30, antagonists-38)\n",
      "conj:and(blockers-31, antagonists-38)\n",
      "case(blockers-31, in-40)\n",
      "dep(blockers-31, addition-41)\n",
      "case(renin-47, to-42)\n",
      "det(renin-47, the-43)\n",
      "advmod(introduced-45, recently-44)\n",
      "amod(renin-47, introduced-45)\n",
      "amod(renin-47, direct-46)\n",
      "nmod:to(type-29, renin-47)\n",
      "appos(angiotensin-17, inhibitors-48)\n",
      "appos(classes-15, DRIs-50)\n",
      "\n",
      "Parsing [sent. 2 len. 36]: However , currently used RAAS inhibitors still can not achieve their desired effects and are associated with certain drawbacks , such as adverse side effects , incomplete blockage of the system and poor end-organ protection .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (ADVP (RB currently))\n",
      "    (VP (VBD used)\n",
      "      (SBAR\n",
      "        (S\n",
      "          (NP (NNP RAAS) (NNS inhibitors))\n",
      "          (ADVP (RB still))\n",
      "          (VP\n",
      "            (VP (MD can) (RB not)\n",
      "              (VP (VB achieve)\n",
      "                (NP (PRP$ their) (VBN desired) (NNS effects))))\n",
      "            (CC and)\n",
      "            (VP (VBP are)\n",
      "              (VP (VBN associated)\n",
      "                (PP (IN with)\n",
      "                  (NP\n",
      "                    (NP (JJ certain) (NNS drawbacks))\n",
      "                    (, ,)\n",
      "                    (PP (JJ such) (IN as)\n",
      "                      (NP (JJ adverse) (NN side) (NNS effects)))\n",
      "                    (, ,)\n",
      "                    (ADJP (JJ incomplete) (JJ blockage))\n",
      "                    (PP (IN of)\n",
      "                      (NP\n",
      "                        (NP (DT the) (NN system))\n",
      "                        (CC and)\n",
      "                        (NP (JJ poor) (JJ end-organ) (NN protection))))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(used-4, However-1)\n",
      "advmod(used-4, currently-3)\n",
      "root(ROOT-0, used-4)\n",
      "compound(inhibitors-6, RAAS-5)\n",
      "nsubj(achieve-10, inhibitors-6)\n",
      "nsubjpass(associated-16, inhibitors-6)\n",
      "advmod(achieve-10, still-7)\n",
      "aux(achieve-10, can-8)\n",
      "neg(achieve-10, not-9)\n",
      "ccomp(used-4, achieve-10)\n",
      "nmod:poss(effects-13, their-11)\n",
      "amod(effects-13, desired-12)\n",
      "dobj(achieve-10, effects-13)\n",
      "cc(achieve-10, and-14)\n",
      "auxpass(associated-16, are-15)\n",
      "ccomp(used-4, associated-16)\n",
      "conj:and(achieve-10, associated-16)\n",
      "case(drawbacks-19, with-17)\n",
      "amod(drawbacks-19, certain-18)\n",
      "nmod:with(associated-16, drawbacks-19)\n",
      "case(effects-25, such-21)\n",
      "mwe(such-21, as-22)\n",
      "amod(effects-25, adverse-23)\n",
      "compound(effects-25, side-24)\n",
      "nmod:such_as(drawbacks-19, effects-25)\n",
      "amod(blockage-28, incomplete-27)\n",
      "amod(drawbacks-19, blockage-28)\n",
      "case(system-31, of-29)\n",
      "det(system-31, the-30)\n",
      "nmod:of(drawbacks-19, system-31)\n",
      "cc(system-31, and-32)\n",
      "amod(protection-35, poor-33)\n",
      "amod(protection-35, end-organ-34)\n",
      "nmod:of(drawbacks-19, protection-35)\n",
      "conj:and(system-31, protection-35)\n",
      "\n",
      "Parsing [sent. 3 len. 42]: In this review , we discuss the efficiency and specificity of the current RAAS inhibitors and propose some recommendations for achieving better treatments with better end-organ protection.Hypertension Research advance online publication , 6 July 2017 ; doi :10.1038 / hr .2017.65 .\n",
      "(ROOT\n",
      "  (S\n",
      "    (PP (IN In)\n",
      "      (NP (DT this) (NN review)))\n",
      "    (, ,)\n",
      "    (S\n",
      "      (NP (PRP we))\n",
      "      (VP\n",
      "        (VP (VB discuss)\n",
      "          (NP\n",
      "            (NP (DT the) (NN efficiency)\n",
      "              (CC and)\n",
      "              (NN specificity))\n",
      "            (PP (IN of)\n",
      "              (NP (DT the) (JJ current) (NNS RAAS) (NNS inhibitors)))))\n",
      "        (CC and)\n",
      "        (VP (VB propose)\n",
      "          (NP (DT some) (NNS recommendations))\n",
      "          (PP (IN for)\n",
      "            (S\n",
      "              (VP (VBG achieving)\n",
      "                (NP (JJR better) (NNS treatments))\n",
      "                (PP (IN with)\n",
      "                  (NP (JJR better) (JJ end-organ) (NN protection.Hypertension) (NNP Research) (NN advance) (JJ online) (NN publication) (, ,) (CD 6) (NNP July) (NNS 2017)))))))))\n",
      "    (: ;)\n",
      "    (FRAG\n",
      "      (X\n",
      "        (X (SYM doi))\n",
      "        (NP (CD :10.1038)))\n",
      "      (: /)\n",
      "      (NP (CD hr) (CD .2017.65)))\n",
      "    (. .)))\n",
      "\n",
      "case(review-3, In-1)\n",
      "det(review-3, this-2)\n",
      "nmod:in(discuss-6, review-3)\n",
      "nsubj(discuss-6, we-5)\n",
      "nsubj(propose-17, we-5)\n",
      "root(ROOT-0, discuss-6)\n",
      "det(efficiency-8, the-7)\n",
      "dobj(discuss-6, efficiency-8)\n",
      "cc(efficiency-8, and-9)\n",
      "dobj(discuss-6, specificity-10)\n",
      "conj:and(efficiency-8, specificity-10)\n",
      "case(inhibitors-15, of-11)\n",
      "det(inhibitors-15, the-12)\n",
      "amod(inhibitors-15, current-13)\n",
      "compound(inhibitors-15, RAAS-14)\n",
      "nmod:of(efficiency-8, inhibitors-15)\n",
      "cc(discuss-6, and-16)\n",
      "conj:and(discuss-6, propose-17)\n",
      "det(recommendations-19, some-18)\n",
      "dobj(propose-17, recommendations-19)\n",
      "mark(achieving-21, for-20)\n",
      "advcl(propose-17, achieving-21)\n",
      "amod(treatments-23, better-22)\n",
      "dobj(achieving-21, treatments-23)\n",
      "case(2017-35, with-24)\n",
      "amod(2017-35, better-25)\n",
      "amod(2017-35, end-organ-26)\n",
      "compound(2017-35, protection.Hypertension-27)\n",
      "compound(2017-35, Research-28)\n",
      "compound(2017-35, advance-29)\n",
      "amod(2017-35, online-30)\n",
      "compound(2017-35, publication-31)\n",
      "nummod(2017-35, 6-33)\n",
      "compound(2017-35, July-34)\n",
      "nmod:with(achieving-21, 2017-35)\n",
      "dep(:10.1038-38, doi-37)\n",
      "dep(.2017.65-41, :10.1038-38)\n",
      "nummod(.2017.65-41, hr-40)\n",
      "dep(discuss-6, .2017.65-41)\n",
      "\n",
      "Parsing [sent. 4 len. 51]: The beneficial effects of angiotensin converting enzyme -LRB- ACE -RRB- inhibitors and angiotensin II -LRB- AII -RRB- receptor antagonists in patients with heart failure secondary to reduced ejection fraction -LRB- HFrEF -RRB- are felt to result from prevention of the adverse effects of AII on systemic afterload and renal homeostasis .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (JJ beneficial) (NNS effects))\n",
      "      (PP (IN of)\n",
      "        (NP\n",
      "          (NP (NN angiotensin))\n",
      "          (VP (VBG converting)\n",
      "            (NP\n",
      "              (NP (JJ enzyme)\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP ACE))\n",
      "                  (-RRB- -RRB-))\n",
      "                (NN inhibitors))\n",
      "              (CC and)\n",
      "              (NP\n",
      "                (NP (NNP angiotensin) (NNP II))\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP AII))\n",
      "                  (-RRB- -RRB-)))\n",
      "              (NP\n",
      "                (NP (NN receptor) (NNS antagonists))\n",
      "                (PP (IN in)\n",
      "                  (NP (NNS patients)))))\n",
      "            (PP (IN with)\n",
      "              (NP\n",
      "                (NP (NN heart) (NN failure))\n",
      "                (ADJP (JJ secondary)\n",
      "                  (PP (TO to)\n",
      "                    (NP\n",
      "                      (NP (VBN reduced) (NN ejection) (NN fraction))\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP HFrEF))\n",
      "                        (-RRB- -RRB-)))))))))))\n",
      "    (VP (VBP are)\n",
      "      (VP (VBN felt)\n",
      "        (S\n",
      "          (VP (TO to)\n",
      "            (VP (VB result)\n",
      "              (PP (IN from)\n",
      "                (NP\n",
      "                  (NP (NN prevention))\n",
      "                  (PP (IN of)\n",
      "                    (NP\n",
      "                      (NP (DT the) (JJ adverse) (NNS effects))\n",
      "                      (PP (IN of)\n",
      "                        (NP (NNP AII)))))))\n",
      "              (PP (IN on)\n",
      "                (NP (JJ systemic) (JJ afterload)\n",
      "                  (CC and)\n",
      "                  (JJ renal) (NNS homeostasis))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(effects-3, The-1)\n",
      "amod(effects-3, beneficial-2)\n",
      "nsubjpass(felt-34, effects-3)\n",
      "nsubj:xsubj(result-36, effects-3)\n",
      "case(angiotensin-5, of-4)\n",
      "nmod:of(effects-3, angiotensin-5)\n",
      "acl(angiotensin-5, converting-6)\n",
      "amod(inhibitors-11, enzyme-7)\n",
      "appos(inhibitors-11, ACE-9)\n",
      "dobj(converting-6, inhibitors-11)\n",
      "cc(inhibitors-11, and-12)\n",
      "compound(II-14, angiotensin-13)\n",
      "dobj(converting-6, II-14)\n",
      "conj:and(inhibitors-11, II-14)\n",
      "appos(II-14, AII-16)\n",
      "compound(antagonists-19, receptor-18)\n",
      "dep(inhibitors-11, antagonists-19)\n",
      "case(patients-21, in-20)\n",
      "nmod:in(antagonists-19, patients-21)\n",
      "case(failure-24, with-22)\n",
      "compound(failure-24, heart-23)\n",
      "nmod:with(converting-6, failure-24)\n",
      "amod(failure-24, secondary-25)\n",
      "case(fraction-29, to-26)\n",
      "amod(fraction-29, reduced-27)\n",
      "compound(fraction-29, ejection-28)\n",
      "nmod:to(secondary-25, fraction-29)\n",
      "appos(fraction-29, HFrEF-31)\n",
      "auxpass(felt-34, are-33)\n",
      "root(ROOT-0, felt-34)\n",
      "mark(result-36, to-35)\n",
      "xcomp(felt-34, result-36)\n",
      "case(prevention-38, from-37)\n",
      "nmod:from(result-36, prevention-38)\n",
      "case(effects-42, of-39)\n",
      "det(effects-42, the-40)\n",
      "amod(effects-42, adverse-41)\n",
      "nmod:of(prevention-38, effects-42)\n",
      "case(AII-44, of-43)\n",
      "nmod:of(effects-42, AII-44)\n",
      "case(afterload-47, on-45)\n",
      "amod(afterload-47, systemic-46)\n",
      "nmod:on(result-36, afterload-47)\n",
      "cc(afterload-47, and-48)\n",
      "amod(homeostasis-50, renal-49)\n",
      "nmod:on(result-36, homeostasis-50)\n",
      "conj:and(afterload-47, homeostasis-50)\n",
      "\n",
      "Parsing [sent. 5 len. 31]: However , AII can activate the sympathetic nervous system and part of the beneficial effects of ACE inhibitors and AII antagonists may result from their ability to inhibit such activation .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (S\n",
      "      (NP (NNP AII))\n",
      "      (VP (MD can)\n",
      "        (VP (VB activate)\n",
      "          (NP\n",
      "            (NP (DT the)\n",
      "              (ADJP (JJ sympathetic) (JJ nervous))\n",
      "              (NN system))\n",
      "            (CC and)\n",
      "            (NP\n",
      "              (NP (NN part))\n",
      "              (PP (IN of)\n",
      "                (NP\n",
      "                  (NP (DT the) (JJ beneficial) (NNS effects))\n",
      "                  (PP (IN of)\n",
      "                    (NP (NNP ACE) (NNS inhibitors))))))))))\n",
      "    (CC and)\n",
      "    (S\n",
      "      (NP (NNP AII) (NNS antagonists))\n",
      "      (VP (MD may)\n",
      "        (VP (VB result)\n",
      "          (PP (IN from)\n",
      "            (NP (PRP$ their) (NN ability)\n",
      "              (S\n",
      "                (VP (TO to)\n",
      "                  (VP (VB inhibit)\n",
      "                    (NP (JJ such) (NN activation))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(activate-5, However-1)\n",
      "nsubj(activate-5, AII-3)\n",
      "aux(activate-5, can-4)\n",
      "root(ROOT-0, activate-5)\n",
      "det(system-9, the-6)\n",
      "amod(nervous-8, sympathetic-7)\n",
      "amod(system-9, nervous-8)\n",
      "dobj(activate-5, system-9)\n",
      "cc(system-9, and-10)\n",
      "dobj(activate-5, part-11)\n",
      "conj:and(system-9, part-11)\n",
      "case(effects-15, of-12)\n",
      "det(effects-15, the-13)\n",
      "amod(effects-15, beneficial-14)\n",
      "nmod:of(part-11, effects-15)\n",
      "case(inhibitors-18, of-16)\n",
      "compound(inhibitors-18, ACE-17)\n",
      "nmod:of(effects-15, inhibitors-18)\n",
      "cc(activate-5, and-19)\n",
      "compound(antagonists-21, AII-20)\n",
      "nsubj(result-23, antagonists-21)\n",
      "aux(result-23, may-22)\n",
      "conj:and(activate-5, result-23)\n",
      "case(ability-26, from-24)\n",
      "nmod:poss(ability-26, their-25)\n",
      "nmod:from(result-23, ability-26)\n",
      "mark(inhibit-28, to-27)\n",
      "acl(ability-26, inhibit-28)\n",
      "amod(activation-30, such-29)\n",
      "dobj(inhibit-28, activation-30)\n",
      "\n",
      "Parsing [sent. 6 len. 49]: We examined the acute effects of the ACE inhibitor captopril -LRB- 25 mg , n = 9 -RRB- and the AII receptor antagonist losartan -LRB- 50 mg , n = 10 -RRB- on hemodynamics as well as total body and cardiac norepinephrine spillover in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (PRP We))\n",
      "    (VP (VBD examined)\n",
      "      (NP\n",
      "        (NP (DT the) (JJ acute) (NNS effects))\n",
      "        (PP (IN of)\n",
      "          (NP\n",
      "            (NP (DT the) (NNP ACE) (NN inhibitor) (NN captopril))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 25) (NN mg))\n",
      "                (, ,)\n",
      "                (NP\n",
      "                  (NP (NN n))\n",
      "                  (SBAR\n",
      "                    (S\n",
      "                      (VP (SYM =)\n",
      "                        (NP (CD 9)))))))\n",
      "              (-RRB- -RRB-))\n",
      "            (CC and)\n",
      "            (NP (DT the) (NNP AII) (NN receptor) (NN antagonist) (NN losartan))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 50) (NN mg))\n",
      "                (, ,)\n",
      "                (NP\n",
      "                  (NP (NN n))\n",
      "                  (SBAR\n",
      "                    (S\n",
      "                      (VP (SYM =)\n",
      "                        (NP (CD 10)))))))\n",
      "              (-RRB- -RRB-)))))\n",
      "      (PP (IN on)\n",
      "        (NP\n",
      "          (NP (NNS hemodynamics))\n",
      "          (CONJP (RB as) (RB well) (IN as))\n",
      "          (NP (JJ total) (NN body)\n",
      "            (CC and)\n",
      "            (JJ cardiac) (NN norepinephrine) (NN spillover))))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (NNS patients))\n",
      "          (PP (IN with)\n",
      "            (NP (JJ chronic) (NNP HFrEF))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(examined-2, We-1)\n",
      "root(ROOT-0, examined-2)\n",
      "det(effects-5, the-3)\n",
      "amod(effects-5, acute-4)\n",
      "dobj(examined-2, effects-5)\n",
      "case(captopril-10, of-6)\n",
      "det(captopril-10, the-7)\n",
      "compound(captopril-10, ACE-8)\n",
      "compound(captopril-10, inhibitor-9)\n",
      "nmod:of(effects-5, captopril-10)\n",
      "nummod(mg-13, 25-12)\n",
      "dep(captopril-10, mg-13)\n",
      "appos(mg-13, n-15)\n",
      "dep(9-17, =-16)\n",
      "acl:relcl(n-15, 9-17)\n",
      "cc(captopril-10, and-19)\n",
      "det(losartan-24, the-20)\n",
      "compound(losartan-24, AII-21)\n",
      "compound(losartan-24, receptor-22)\n",
      "compound(losartan-24, antagonist-23)\n",
      "nmod:of(effects-5, losartan-24)\n",
      "conj:and(captopril-10, losartan-24)\n",
      "nummod(mg-27, 50-26)\n",
      "dep(captopril-10, mg-27)\n",
      "appos(mg-27, n-29)\n",
      "dep(10-31, =-30)\n",
      "acl:relcl(n-29, 10-31)\n",
      "case(hemodynamics-34, on-33)\n",
      "nmod:on(examined-2, hemodynamics-34)\n",
      "cc(hemodynamics-34, as-35)\n",
      "mwe(as-35, well-36)\n",
      "mwe(as-35, as-37)\n",
      "amod(body-39, total-38)\n",
      "nmod:on(examined-2, body-39)\n",
      "conj:and(hemodynamics-34, body-39)\n",
      "cc(body-39, and-40)\n",
      "amod(spillover-43, cardiac-41)\n",
      "compound(spillover-43, norepinephrine-42)\n",
      "conj:and(hemodynamics-34, spillover-43)\n",
      "conj:and(body-39, spillover-43)\n",
      "case(patients-45, in-44)\n",
      "nmod:in(examined-2, patients-45)\n",
      "case(HFrEF-48, with-46)\n",
      "amod(HFrEF-48, chronic-47)\n",
      "nmod:with(patients-45, HFrEF-48)\n",
      "\n",
      "Parsing [sent. 7 len. 20]: Hemodynamic and neurochemical measurements were made at baseline and at 1 , 2 and 4 hours after oral dosing .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (JJ Hemodynamic)\n",
      "      (CC and)\n",
      "      (JJ neurochemical) (NNS measurements))\n",
      "    (VP (VBD were)\n",
      "      (VP (VBN made)\n",
      "        (PP\n",
      "          (PP (IN at)\n",
      "            (NP (NN baseline)))\n",
      "          (CC and)\n",
      "          (PP (IN at)\n",
      "            (NP (CD 1) (, ,) (CD 2)\n",
      "              (CC and)\n",
      "              (CD 4)))\n",
      "          (NP (NNS hours)))\n",
      "        (PP (IN after)\n",
      "          (NP (JJ oral) (NN dosing)))))\n",
      "    (. .)))\n",
      "\n",
      "amod(measurements-4, Hemodynamic-1)\n",
      "cc(Hemodynamic-1, and-2)\n",
      "conj:and(Hemodynamic-1, neurochemical-3)\n",
      "amod(measurements-4, neurochemical-3)\n",
      "nsubjpass(made-6, measurements-4)\n",
      "auxpass(made-6, were-5)\n",
      "root(ROOT-0, made-6)\n",
      "case(baseline-8, at-7)\n",
      "nmod:at(hours-16, baseline-8)\n",
      "cc(hours-16, and-9)\n",
      "case(1-11, at-10)\n",
      "nmod(made-6, 1-11)\n",
      "conj:and(hours-16, 1-11)\n",
      "nummod(1-11, 2-13)\n",
      "cc(1-11, and-14)\n",
      "conj:and(1-11, 4-15)\n",
      "conj:and(hours-16, 4-15)\n",
      "nmod(made-6, hours-16)\n",
      "case(dosing-19, after-17)\n",
      "amod(dosing-19, oral-18)\n",
      "nmod:after(made-6, dosing-19)\n",
      "\n",
      "Parsing [sent. 8 len. 25]: Administration of both drugs caused significant reductions in systemic arterial , cardiac filling and pulmonary artery pressures -LRB- P < 0.05 vs baseline -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNP Administration))\n",
      "      (PP (IN of)\n",
      "        (NP (DT both) (NNS drugs))))\n",
      "    (VP (VBD caused)\n",
      "      (NP (JJ significant) (NNS reductions))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (JJ systemic) (NN arterial))\n",
      "          (, ,)\n",
      "          (NP (JJ cardiac) (NN filling))\n",
      "          (CC and)\n",
      "          (NP (JJ pulmonary) (NN artery) (NNS pressures))))\n",
      "      (PRN (-LRB- -LRB-)\n",
      "        (NP\n",
      "          (NP (NNP P) (NNP <))\n",
      "          (NP (CD 0.05) (NN vs) (NN baseline)))\n",
      "        (-RRB- -RRB-)))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(caused-5, Administration-1)\n",
      "case(drugs-4, of-2)\n",
      "det(drugs-4, both-3)\n",
      "nmod:of(Administration-1, drugs-4)\n",
      "root(ROOT-0, caused-5)\n",
      "amod(reductions-7, significant-6)\n",
      "dobj(caused-5, reductions-7)\n",
      "case(arterial-10, in-8)\n",
      "amod(arterial-10, systemic-9)\n",
      "nmod:in(caused-5, arterial-10)\n",
      "amod(filling-13, cardiac-12)\n",
      "nmod:in(caused-5, filling-13)\n",
      "conj:and(arterial-10, filling-13)\n",
      "cc(arterial-10, and-14)\n",
      "amod(pressures-17, pulmonary-15)\n",
      "compound(pressures-17, artery-16)\n",
      "nmod:in(caused-5, pressures-17)\n",
      "conj:and(arterial-10, pressures-17)\n",
      "compound(<-20, P-19)\n",
      "dep(caused-5, <-20)\n",
      "nummod(baseline-23, 0.05-21)\n",
      "compound(baseline-23, vs-22)\n",
      "dep(<-20, baseline-23)\n",
      "\n",
      "Parsing [sent. 9 len. 13]: There was no significant difference in the magnitude of those hemodynamic effects .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (EX There))\n",
      "    (VP (VBD was)\n",
      "      (NP\n",
      "        (NP (DT no) (JJ significant) (NN difference))\n",
      "        (PP (IN in)\n",
      "          (NP\n",
      "            (NP (DT the) (NN magnitude))\n",
      "            (PP (IN of)\n",
      "              (NP (DT those) (JJ hemodynamic) (NNS effects)))))))\n",
      "    (. .)))\n",
      "\n",
      "expl(was-2, There-1)\n",
      "root(ROOT-0, was-2)\n",
      "neg(difference-5, no-3)\n",
      "amod(difference-5, significant-4)\n",
      "nsubj(was-2, difference-5)\n",
      "case(magnitude-8, in-6)\n",
      "det(magnitude-8, the-7)\n",
      "nmod:in(difference-5, magnitude-8)\n",
      "case(effects-12, of-9)\n",
      "det(effects-12, those-10)\n",
      "amod(effects-12, hemodynamic-11)\n",
      "nmod:of(magnitude-8, effects-12)\n",
      "\n",
      "Parsing [sent. 10 len. 23]: Plasma concentrations of AII were significantly decreased by captopril and increased by losartan -LRB- P < 0.05 vs baseline for both -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNP Plasma) (NNS concentrations))\n",
      "      (PP (IN of)\n",
      "        (NP (NNP AII))))\n",
      "    (VP (VBD were)\n",
      "      (ADVP (RB significantly))\n",
      "      (VP\n",
      "        (VP (VBN decreased)\n",
      "          (PP (IN by)\n",
      "            (NP (NN captopril))))\n",
      "        (CC and)\n",
      "        (VP (VBN increased)\n",
      "          (PP (IN by)\n",
      "            (NP\n",
      "              (NP (NN losartan))\n",
      "              (PRN (-LRB- -LRB-)\n",
      "                (NP\n",
      "                  (NP (NNP P) (NNP <))\n",
      "                  (NP\n",
      "                    (NP (CD 0.05) (NN vs) (NN baseline))\n",
      "                    (PP (IN for)\n",
      "                      (NP (DT both)))))\n",
      "                (-RRB- -RRB-)))))))\n",
      "    (. .)))\n",
      "\n",
      "compound(concentrations-2, Plasma-1)\n",
      "nsubjpass(decreased-7, concentrations-2)\n",
      "nsubjpass(increased-11, concentrations-2)\n",
      "case(AII-4, of-3)\n",
      "nmod:of(concentrations-2, AII-4)\n",
      "auxpass(decreased-7, were-5)\n",
      "advmod(decreased-7, significantly-6)\n",
      "root(ROOT-0, decreased-7)\n",
      "case(captopril-9, by-8)\n",
      "nmod:by(decreased-7, captopril-9)\n",
      "cc(decreased-7, and-10)\n",
      "conj:and(decreased-7, increased-11)\n",
      "case(losartan-13, by-12)\n",
      "nmod:by(increased-11, losartan-13)\n",
      "compound(<-16, P-15)\n",
      "dep(losartan-13, <-16)\n",
      "nummod(baseline-19, 0.05-17)\n",
      "compound(baseline-19, vs-18)\n",
      "dep(<-16, baseline-19)\n",
      "case(both-21, for-20)\n",
      "nmod:for(baseline-19, both-21)\n",
      "\n",
      "Parsing [sent. 11 len. 37]: Total body sympathetic activity increased in response to both captopril and losartan -LRB- P < 0.05 vs baseline for both -RRB- , however there was no change in cardiac sympathetic activity in response to either drug .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (JJ Total) (NN body) (JJ sympathetic) (NN activity))\n",
      "      (VP (VBN increased)\n",
      "        (PP (IN in)\n",
      "          (NP (NN response)))\n",
      "        (PP (TO to)\n",
      "          (NP\n",
      "            (NP (DT both) (NN captopril)\n",
      "              (CC and)\n",
      "              (NN losartan))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (NNP P) (NNP <))\n",
      "                (NP\n",
      "                  (NP (CD 0.05) (NN vs) (NN baseline))\n",
      "                  (PP (IN for)\n",
      "                    (NP (DT both)))))\n",
      "              (-RRB- -RRB-))))))\n",
      "    (, ,)\n",
      "    (ADVP (RB however))\n",
      "    (NP (EX there))\n",
      "    (VP (VBD was)\n",
      "      (NP\n",
      "        (NP (DT no) (NN change))\n",
      "        (PP (IN in)\n",
      "          (NP\n",
      "            (NP (JJ cardiac) (JJ sympathetic) (NN activity))\n",
      "            (PP (IN in)\n",
      "              (NP (NN response))))))\n",
      "      (PP (TO to)\n",
      "        (NP (DT either) (NN drug))))\n",
      "    (. .)))\n",
      "\n",
      "amod(activity-4, Total-1)\n",
      "compound(activity-4, body-2)\n",
      "amod(activity-4, sympathetic-3)\n",
      "nsubj(was-25, activity-4)\n",
      "acl(activity-4, increased-5)\n",
      "case(response-7, in-6)\n",
      "nmod:in(increased-5, response-7)\n",
      "case(captopril-10, to-8)\n",
      "cc:preconj(captopril-10, both-9)\n",
      "nmod:to(increased-5, captopril-10)\n",
      "cc(captopril-10, and-11)\n",
      "nmod:to(increased-5, losartan-12)\n",
      "conj:and(captopril-10, losartan-12)\n",
      "compound(<-15, P-14)\n",
      "dep(captopril-10, <-15)\n",
      "nummod(baseline-18, 0.05-16)\n",
      "compound(baseline-18, vs-17)\n",
      "dep(<-15, baseline-18)\n",
      "case(both-20, for-19)\n",
      "nmod:for(baseline-18, both-20)\n",
      "expl(was-25, however-23)\n",
      "dep(however-23, there-24)\n",
      "root(ROOT-0, was-25)\n",
      "neg(change-27, no-26)\n",
      "nsubj(was-25, change-27)\n",
      "case(activity-31, in-28)\n",
      "amod(activity-31, cardiac-29)\n",
      "amod(activity-31, sympathetic-30)\n",
      "nmod:in(change-27, activity-31)\n",
      "case(response-33, in-32)\n",
      "nmod:in(activity-31, response-33)\n",
      "case(drug-36, to-34)\n",
      "det(drug-36, either-35)\n",
      "nmod:to(was-25, drug-36)\n",
      "\n",
      "Parsing [sent. 12 len. 29]: The results of the current study do not support the hypothesis that the acute inhibition of the renin angiotensin system has sympathoinhibitory effects in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (NNS results))\n",
      "      (PP (IN of)\n",
      "        (NP (DT the) (JJ current) (NN study))))\n",
      "    (VP (VBP do) (RB not)\n",
      "      (VP (VB support)\n",
      "        (NP (DT the) (NNS hypothesis))\n",
      "        (SBAR (IN that)\n",
      "          (S\n",
      "            (NP\n",
      "              (NP (DT the) (JJ acute) (NN inhibition))\n",
      "              (PP (IN of)\n",
      "                (NP (DT the) (NN renin) (NN angiotensin) (NN system))))\n",
      "            (VP (VBZ has)\n",
      "              (NP\n",
      "                (NP (JJ sympathoinhibitory) (NNS effects))\n",
      "                (PP (IN in)\n",
      "                  (NP\n",
      "                    (NP (NNS patients))\n",
      "                    (PP (IN with)\n",
      "                      (NP (JJ chronic) (NNP HFrEF)))))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(results-2, The-1)\n",
      "nsubj(support-9, results-2)\n",
      "case(study-6, of-3)\n",
      "det(study-6, the-4)\n",
      "amod(study-6, current-5)\n",
      "nmod:of(results-2, study-6)\n",
      "aux(support-9, do-7)\n",
      "neg(support-9, not-8)\n",
      "root(ROOT-0, support-9)\n",
      "det(hypothesis-11, the-10)\n",
      "dobj(support-9, hypothesis-11)\n",
      "mark(has-21, that-12)\n",
      "det(inhibition-15, the-13)\n",
      "amod(inhibition-15, acute-14)\n",
      "nsubj(has-21, inhibition-15)\n",
      "case(system-20, of-16)\n",
      "det(system-20, the-17)\n",
      "compound(system-20, renin-18)\n",
      "compound(system-20, angiotensin-19)\n",
      "nmod:of(inhibition-15, system-20)\n",
      "ccomp(support-9, has-21)\n",
      "amod(effects-23, sympathoinhibitory-22)\n",
      "dobj(has-21, effects-23)\n",
      "case(patients-25, in-24)\n",
      "nmod:in(effects-23, patients-25)\n",
      "case(HFrEF-28, with-26)\n",
      "amod(HFrEF-28, chronic-27)\n",
      "nmod:with(patients-25, HFrEF-28)\n",
      "\n",
      "Parsed file: KeywordSentences.txt [12 sentences].\n",
      "Parsed 408 words in 12 sentences (39.35 wds/sec; 1.16 sents/sec).\n",
      "SLF4J: Failed to load class \"org.slf4j.impl.StaticLoggerBinder\".\n",
      "SLF4J: Defaulting to no-operation (NOP) logger implementation\n",
      "SLF4J: See http://www.slf4j.org/codes.html#StaticLoggerBinder for further details.\n",
      "Parsing file: KeywordSentences.txt\n",
      "Parsing [sent. 1 len. 52]: RAAS , a major pharmacological target in cardiovascular medicine , is inhibited by pharmacological classes including angiotensin converting enzyme -LRB- ACE -RRB- inhibitors -LRB- ACEIs -RRB- , angiotensin-II type 1 blockers -LRB- ARBs -RRB- and aldosterone receptors antagonists , in addition to the recently introduced direct renin inhibitors -LRB- DRIs -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNS RAAS))\n",
      "      (, ,)\n",
      "      (NP\n",
      "        (NP (DT a) (JJ major) (JJ pharmacological) (NN target))\n",
      "        (PP (IN in)\n",
      "          (NP (JJ cardiovascular) (NN medicine))))\n",
      "      (, ,))\n",
      "    (VP (VBZ is)\n",
      "      (ADJP (JJ inhibited)\n",
      "        (PP (IN by)\n",
      "          (NP\n",
      "            (NP (JJ pharmacological) (NNS classes))\n",
      "            (PP (VBG including)\n",
      "              (NP\n",
      "                (NP\n",
      "                  (NP (NN angiotensin))\n",
      "                  (S\n",
      "                    (VP (VBG converting)\n",
      "                      (NP (JJ enzyme)\n",
      "                        (PRN (-LRB- -LRB-)\n",
      "                          (NP (NNP ACE))\n",
      "                          (-RRB- -RRB-))\n",
      "                        (NNS inhibitors))))\n",
      "                  (PRN (-LRB- -LRB-)\n",
      "                    (NP (NNP ACEIs))\n",
      "                    (-RRB- -RRB-)))\n",
      "                (, ,)\n",
      "                (NP\n",
      "                  (ADJP (RB angiotensin-II) (NN type)\n",
      "                    (PRN\n",
      "                      (NP (CD 1))\n",
      "                      (PP\n",
      "                        (NP\n",
      "                          (NP (NNS blockers))\n",
      "                          (PRN (-LRB- -LRB-)\n",
      "                            (NP (NNP ARBs))\n",
      "                            (-RRB- -RRB-))\n",
      "                          (CC and)\n",
      "                          (NP (JJ aldosterone) (NNS receptors) (NNS antagonists))\n",
      "                          (, ,))\n",
      "                        (IN in)\n",
      "                        (NP (NN addition))))\n",
      "                    (PP (TO to)\n",
      "                      (NP (DT the)\n",
      "                        (ADJP (RB recently) (VBN introduced))\n",
      "                        (JJ direct) (NN renin))))\n",
      "                  (NNS inhibitors))))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP (NNP DRIs))\n",
      "              (-RRB- -RRB-))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(inhibited-12, RAAS-1)\n",
      "det(target-6, a-3)\n",
      "amod(target-6, major-4)\n",
      "amod(target-6, pharmacological-5)\n",
      "appos(RAAS-1, target-6)\n",
      "case(medicine-9, in-7)\n",
      "amod(medicine-9, cardiovascular-8)\n",
      "nmod:in(target-6, medicine-9)\n",
      "cop(inhibited-12, is-11)\n",
      "root(ROOT-0, inhibited-12)\n",
      "case(classes-15, by-13)\n",
      "amod(classes-15, pharmacological-14)\n",
      "nmod:by(inhibited-12, classes-15)\n",
      "case(angiotensin-17, including-16)\n",
      "nmod:including(classes-15, angiotensin-17)\n",
      "dep(angiotensin-17, converting-18)\n",
      "amod(inhibitors-23, enzyme-19)\n",
      "appos(inhibitors-23, ACE-21)\n",
      "dobj(converting-18, inhibitors-23)\n",
      "appos(angiotensin-17, ACEIs-25)\n",
      "advmod(type-29, angiotensin-II-28)\n",
      "amod(inhibitors-48, type-29)\n",
      "dep(type-29, 1-30)\n",
      "nmod:in(1-30, blockers-31)\n",
      "appos(blockers-31, ARBs-33)\n",
      "cc(blockers-31, and-35)\n",
      "amod(antagonists-38, aldosterone-36)\n",
      "compound(antagonists-38, receptors-37)\n",
      "nmod:in(1-30, antagonists-38)\n",
      "conj:and(blockers-31, antagonists-38)\n",
      "case(blockers-31, in-40)\n",
      "dep(blockers-31, addition-41)\n",
      "case(renin-47, to-42)\n",
      "det(renin-47, the-43)\n",
      "advmod(introduced-45, recently-44)\n",
      "amod(renin-47, introduced-45)\n",
      "amod(renin-47, direct-46)\n",
      "nmod:to(type-29, renin-47)\n",
      "appos(angiotensin-17, inhibitors-48)\n",
      "appos(classes-15, DRIs-50)\n",
      "\n",
      "Parsing [sent. 2 len. 36]: However , currently used RAAS inhibitors still can not achieve their desired effects and are associated with certain drawbacks , such as adverse side effects , incomplete blockage of the system and poor end-organ protection .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (ADVP (RB currently))\n",
      "    (VP (VBD used)\n",
      "      (SBAR\n",
      "        (S\n",
      "          (NP (NNP RAAS) (NNS inhibitors))\n",
      "          (ADVP (RB still))\n",
      "          (VP\n",
      "            (VP (MD can) (RB not)\n",
      "              (VP (VB achieve)\n",
      "                (NP (PRP$ their) (VBN desired) (NNS effects))))\n",
      "            (CC and)\n",
      "            (VP (VBP are)\n",
      "              (VP (VBN associated)\n",
      "                (PP (IN with)\n",
      "                  (NP\n",
      "                    (NP (JJ certain) (NNS drawbacks))\n",
      "                    (, ,)\n",
      "                    (PP (JJ such) (IN as)\n",
      "                      (NP (JJ adverse) (NN side) (NNS effects)))\n",
      "                    (, ,)\n",
      "                    (ADJP (JJ incomplete) (JJ blockage))\n",
      "                    (PP (IN of)\n",
      "                      (NP\n",
      "                        (NP (DT the) (NN system))\n",
      "                        (CC and)\n",
      "                        (NP (JJ poor) (JJ end-organ) (NN protection))))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(used-4, However-1)\n",
      "advmod(used-4, currently-3)\n",
      "root(ROOT-0, used-4)\n",
      "compound(inhibitors-6, RAAS-5)\n",
      "nsubj(achieve-10, inhibitors-6)\n",
      "nsubjpass(associated-16, inhibitors-6)\n",
      "advmod(achieve-10, still-7)\n",
      "aux(achieve-10, can-8)\n",
      "neg(achieve-10, not-9)\n",
      "ccomp(used-4, achieve-10)\n",
      "nmod:poss(effects-13, their-11)\n",
      "amod(effects-13, desired-12)\n",
      "dobj(achieve-10, effects-13)\n",
      "cc(achieve-10, and-14)\n",
      "auxpass(associated-16, are-15)\n",
      "ccomp(used-4, associated-16)\n",
      "conj:and(achieve-10, associated-16)\n",
      "case(drawbacks-19, with-17)\n",
      "amod(drawbacks-19, certain-18)\n",
      "nmod:with(associated-16, drawbacks-19)\n",
      "case(effects-25, such-21)\n",
      "mwe(such-21, as-22)\n",
      "amod(effects-25, adverse-23)\n",
      "compound(effects-25, side-24)\n",
      "nmod:such_as(drawbacks-19, effects-25)\n",
      "amod(blockage-28, incomplete-27)\n",
      "amod(drawbacks-19, blockage-28)\n",
      "case(system-31, of-29)\n",
      "det(system-31, the-30)\n",
      "nmod:of(drawbacks-19, system-31)\n",
      "cc(system-31, and-32)\n",
      "amod(protection-35, poor-33)\n",
      "amod(protection-35, end-organ-34)\n",
      "nmod:of(drawbacks-19, protection-35)\n",
      "conj:and(system-31, protection-35)\n",
      "\n",
      "Parsing [sent. 3 len. 42]: In this review , we discuss the efficiency and specificity of the current RAAS inhibitors and propose some recommendations for achieving better treatments with better end-organ protection.Hypertension Research advance online publication , 6 July 2017 ; doi :10.1038 / hr .2017.65 .\n",
      "(ROOT\n",
      "  (S\n",
      "    (PP (IN In)\n",
      "      (NP (DT this) (NN review)))\n",
      "    (, ,)\n",
      "    (S\n",
      "      (NP (PRP we))\n",
      "      (VP\n",
      "        (VP (VB discuss)\n",
      "          (NP\n",
      "            (NP (DT the) (NN efficiency)\n",
      "              (CC and)\n",
      "              (NN specificity))\n",
      "            (PP (IN of)\n",
      "              (NP (DT the) (JJ current) (NNS RAAS) (NNS inhibitors)))))\n",
      "        (CC and)\n",
      "        (VP (VB propose)\n",
      "          (NP (DT some) (NNS recommendations))\n",
      "          (PP (IN for)\n",
      "            (S\n",
      "              (VP (VBG achieving)\n",
      "                (NP (JJR better) (NNS treatments))\n",
      "                (PP (IN with)\n",
      "                  (NP (JJR better) (JJ end-organ) (NN protection.Hypertension) (NNP Research) (NN advance) (JJ online) (NN publication) (, ,) (CD 6) (NNP July) (NNS 2017)))))))))\n",
      "    (: ;)\n",
      "    (FRAG\n",
      "      (X\n",
      "        (X (SYM doi))\n",
      "        (NP (CD :10.1038)))\n",
      "      (: /)\n",
      "      (NP (CD hr) (CD .2017.65)))\n",
      "    (. .)))\n",
      "\n",
      "case(review-3, In-1)\n",
      "det(review-3, this-2)\n",
      "nmod:in(discuss-6, review-3)\n",
      "nsubj(discuss-6, we-5)\n",
      "nsubj(propose-17, we-5)\n",
      "root(ROOT-0, discuss-6)\n",
      "det(efficiency-8, the-7)\n",
      "dobj(discuss-6, efficiency-8)\n",
      "cc(efficiency-8, and-9)\n",
      "dobj(discuss-6, specificity-10)\n",
      "conj:and(efficiency-8, specificity-10)\n",
      "case(inhibitors-15, of-11)\n",
      "det(inhibitors-15, the-12)\n",
      "amod(inhibitors-15, current-13)\n",
      "compound(inhibitors-15, RAAS-14)\n",
      "nmod:of(efficiency-8, inhibitors-15)\n",
      "cc(discuss-6, and-16)\n",
      "conj:and(discuss-6, propose-17)\n",
      "det(recommendations-19, some-18)\n",
      "dobj(propose-17, recommendations-19)\n",
      "mark(achieving-21, for-20)\n",
      "advcl(propose-17, achieving-21)\n",
      "amod(treatments-23, better-22)\n",
      "dobj(achieving-21, treatments-23)\n",
      "case(2017-35, with-24)\n",
      "amod(2017-35, better-25)\n",
      "amod(2017-35, end-organ-26)\n",
      "compound(2017-35, protection.Hypertension-27)\n",
      "compound(2017-35, Research-28)\n",
      "compound(2017-35, advance-29)\n",
      "amod(2017-35, online-30)\n",
      "compound(2017-35, publication-31)\n",
      "nummod(2017-35, 6-33)\n",
      "compound(2017-35, July-34)\n",
      "nmod:with(achieving-21, 2017-35)\n",
      "dep(:10.1038-38, doi-37)\n",
      "dep(.2017.65-41, :10.1038-38)\n",
      "nummod(.2017.65-41, hr-40)\n",
      "dep(discuss-6, .2017.65-41)\n",
      "\n",
      "Parsing [sent. 4 len. 51]: The beneficial effects of angiotensin converting enzyme -LRB- ACE -RRB- inhibitors and angiotensin II -LRB- AII -RRB- receptor antagonists in patients with heart failure secondary to reduced ejection fraction -LRB- HFrEF -RRB- are felt to result from prevention of the adverse effects of AII on systemic afterload and renal homeostasis .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (JJ beneficial) (NNS effects))\n",
      "      (PP (IN of)\n",
      "        (NP\n",
      "          (NP (NN angiotensin))\n",
      "          (VP (VBG converting)\n",
      "            (NP\n",
      "              (NP (JJ enzyme)\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP ACE))\n",
      "                  (-RRB- -RRB-))\n",
      "                (NN inhibitors))\n",
      "              (CC and)\n",
      "              (NP\n",
      "                (NP (NNP angiotensin) (NNP II))\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP AII))\n",
      "                  (-RRB- -RRB-)))\n",
      "              (NP\n",
      "                (NP (NN receptor) (NNS antagonists))\n",
      "                (PP (IN in)\n",
      "                  (NP (NNS patients)))))\n",
      "            (PP (IN with)\n",
      "              (NP\n",
      "                (NP (NN heart) (NN failure))\n",
      "                (ADJP (JJ secondary)\n",
      "                  (PP (TO to)\n",
      "                    (NP\n",
      "                      (NP (VBN reduced) (NN ejection) (NN fraction))\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP HFrEF))\n",
      "                        (-RRB- -RRB-)))))))))))\n",
      "    (VP (VBP are)\n",
      "      (VP (VBN felt)\n",
      "        (S\n",
      "          (VP (TO to)\n",
      "            (VP (VB result)\n",
      "              (PP (IN from)\n",
      "                (NP\n",
      "                  (NP (NN prevention))\n",
      "                  (PP (IN of)\n",
      "                    (NP\n",
      "                      (NP (DT the) (JJ adverse) (NNS effects))\n",
      "                      (PP (IN of)\n",
      "                        (NP (NNP AII)))))))\n",
      "              (PP (IN on)\n",
      "                (NP (JJ systemic) (JJ afterload)\n",
      "                  (CC and)\n",
      "                  (JJ renal) (NNS homeostasis))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(effects-3, The-1)\n",
      "amod(effects-3, beneficial-2)\n",
      "nsubjpass(felt-34, effects-3)\n",
      "nsubj:xsubj(result-36, effects-3)\n",
      "case(angiotensin-5, of-4)\n",
      "nmod:of(effects-3, angiotensin-5)\n",
      "acl(angiotensin-5, converting-6)\n",
      "amod(inhibitors-11, enzyme-7)\n",
      "appos(inhibitors-11, ACE-9)\n",
      "dobj(converting-6, inhibitors-11)\n",
      "cc(inhibitors-11, and-12)\n",
      "compound(II-14, angiotensin-13)\n",
      "dobj(converting-6, II-14)\n",
      "conj:and(inhibitors-11, II-14)\n",
      "appos(II-14, AII-16)\n",
      "compound(antagonists-19, receptor-18)\n",
      "dep(inhibitors-11, antagonists-19)\n",
      "case(patients-21, in-20)\n",
      "nmod:in(antagonists-19, patients-21)\n",
      "case(failure-24, with-22)\n",
      "compound(failure-24, heart-23)\n",
      "nmod:with(converting-6, failure-24)\n",
      "amod(failure-24, secondary-25)\n",
      "case(fraction-29, to-26)\n",
      "amod(fraction-29, reduced-27)\n",
      "compound(fraction-29, ejection-28)\n",
      "nmod:to(secondary-25, fraction-29)\n",
      "appos(fraction-29, HFrEF-31)\n",
      "auxpass(felt-34, are-33)\n",
      "root(ROOT-0, felt-34)\n",
      "mark(result-36, to-35)\n",
      "xcomp(felt-34, result-36)\n",
      "case(prevention-38, from-37)\n",
      "nmod:from(result-36, prevention-38)\n",
      "case(effects-42, of-39)\n",
      "det(effects-42, the-40)\n",
      "amod(effects-42, adverse-41)\n",
      "nmod:of(prevention-38, effects-42)\n",
      "case(AII-44, of-43)\n",
      "nmod:of(effects-42, AII-44)\n",
      "case(afterload-47, on-45)\n",
      "amod(afterload-47, systemic-46)\n",
      "nmod:on(result-36, afterload-47)\n",
      "cc(afterload-47, and-48)\n",
      "amod(homeostasis-50, renal-49)\n",
      "nmod:on(result-36, homeostasis-50)\n",
      "conj:and(afterload-47, homeostasis-50)\n",
      "\n",
      "Parsing [sent. 5 len. 31]: However , AII can activate the sympathetic nervous system and part of the beneficial effects of ACE inhibitors and AII antagonists may result from their ability to inhibit such activation .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (S\n",
      "      (NP (NNP AII))\n",
      "      (VP (MD can)\n",
      "        (VP (VB activate)\n",
      "          (NP\n",
      "            (NP (DT the)\n",
      "              (ADJP (JJ sympathetic) (JJ nervous))\n",
      "              (NN system))\n",
      "            (CC and)\n",
      "            (NP\n",
      "              (NP (NN part))\n",
      "              (PP (IN of)\n",
      "                (NP\n",
      "                  (NP (DT the) (JJ beneficial) (NNS effects))\n",
      "                  (PP (IN of)\n",
      "                    (NP (NNP ACE) (NNS inhibitors))))))))))\n",
      "    (CC and)\n",
      "    (S\n",
      "      (NP (NNP AII) (NNS antagonists))\n",
      "      (VP (MD may)\n",
      "        (VP (VB result)\n",
      "          (PP (IN from)\n",
      "            (NP (PRP$ their) (NN ability)\n",
      "              (S\n",
      "                (VP (TO to)\n",
      "                  (VP (VB inhibit)\n",
      "                    (NP (JJ such) (NN activation))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(activate-5, However-1)\n",
      "nsubj(activate-5, AII-3)\n",
      "aux(activate-5, can-4)\n",
      "root(ROOT-0, activate-5)\n",
      "det(system-9, the-6)\n",
      "amod(nervous-8, sympathetic-7)\n",
      "amod(system-9, nervous-8)\n",
      "dobj(activate-5, system-9)\n",
      "cc(system-9, and-10)\n",
      "dobj(activate-5, part-11)\n",
      "conj:and(system-9, part-11)\n",
      "case(effects-15, of-12)\n",
      "det(effects-15, the-13)\n",
      "amod(effects-15, beneficial-14)\n",
      "nmod:of(part-11, effects-15)\n",
      "case(inhibitors-18, of-16)\n",
      "compound(inhibitors-18, ACE-17)\n",
      "nmod:of(effects-15, inhibitors-18)\n",
      "cc(activate-5, and-19)\n",
      "compound(antagonists-21, AII-20)\n",
      "nsubj(result-23, antagonists-21)\n",
      "aux(result-23, may-22)\n",
      "conj:and(activate-5, result-23)\n",
      "case(ability-26, from-24)\n",
      "nmod:poss(ability-26, their-25)\n",
      "nmod:from(result-23, ability-26)\n",
      "mark(inhibit-28, to-27)\n",
      "acl(ability-26, inhibit-28)\n",
      "amod(activation-30, such-29)\n",
      "dobj(inhibit-28, activation-30)\n",
      "\n",
      "Parsing [sent. 6 len. 49]: We examined the acute effects of the ACE inhibitor captopril -LRB- 25 mg , n = 9 -RRB- and the AII receptor antagonist losartan -LRB- 50 mg , n = 10 -RRB- on hemodynamics as well as total body and cardiac norepinephrine spillover in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (PRP We))\n",
      "    (VP (VBD examined)\n",
      "      (NP\n",
      "        (NP (DT the) (JJ acute) (NNS effects))\n",
      "        (PP (IN of)\n",
      "          (NP\n",
      "            (NP (DT the) (NNP ACE) (NN inhibitor) (NN captopril))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 25) (NN mg))\n",
      "                (, ,)\n",
      "                (NP\n",
      "                  (NP (NN n))\n",
      "                  (SBAR\n",
      "                    (S\n",
      "                      (VP (SYM =)\n",
      "                        (NP (CD 9)))))))\n",
      "              (-RRB- -RRB-))\n",
      "            (CC and)\n",
      "            (NP (DT the) (NNP AII) (NN receptor) (NN antagonist) (NN losartan))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 50) (NN mg))\n",
      "                (, ,)\n",
      "                (NP\n",
      "                  (NP (NN n))\n",
      "                  (SBAR\n",
      "                    (S\n",
      "                      (VP (SYM =)\n",
      "                        (NP (CD 10)))))))\n",
      "              (-RRB- -RRB-)))))\n",
      "      (PP (IN on)\n",
      "        (NP\n",
      "          (NP (NNS hemodynamics))\n",
      "          (CONJP (RB as) (RB well) (IN as))\n",
      "          (NP (JJ total) (NN body)\n",
      "            (CC and)\n",
      "            (JJ cardiac) (NN norepinephrine) (NN spillover))))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (NNS patients))\n",
      "          (PP (IN with)\n",
      "            (NP (JJ chronic) (NNP HFrEF))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(examined-2, We-1)\n",
      "root(ROOT-0, examined-2)\n",
      "det(effects-5, the-3)\n",
      "amod(effects-5, acute-4)\n",
      "dobj(examined-2, effects-5)\n",
      "case(captopril-10, of-6)\n",
      "det(captopril-10, the-7)\n",
      "compound(captopril-10, ACE-8)\n",
      "compound(captopril-10, inhibitor-9)\n",
      "nmod:of(effects-5, captopril-10)\n",
      "nummod(mg-13, 25-12)\n",
      "dep(captopril-10, mg-13)\n",
      "appos(mg-13, n-15)\n",
      "dep(9-17, =-16)\n",
      "acl:relcl(n-15, 9-17)\n",
      "cc(captopril-10, and-19)\n",
      "det(losartan-24, the-20)\n",
      "compound(losartan-24, AII-21)\n",
      "compound(losartan-24, receptor-22)\n",
      "compound(losartan-24, antagonist-23)\n",
      "nmod:of(effects-5, losartan-24)\n",
      "conj:and(captopril-10, losartan-24)\n",
      "nummod(mg-27, 50-26)\n",
      "dep(captopril-10, mg-27)\n",
      "appos(mg-27, n-29)\n",
      "dep(10-31, =-30)\n",
      "acl:relcl(n-29, 10-31)\n",
      "case(hemodynamics-34, on-33)\n",
      "nmod:on(examined-2, hemodynamics-34)\n",
      "cc(hemodynamics-34, as-35)\n",
      "mwe(as-35, well-36)\n",
      "mwe(as-35, as-37)\n",
      "amod(body-39, total-38)\n",
      "nmod:on(examined-2, body-39)\n",
      "conj:and(hemodynamics-34, body-39)\n",
      "cc(body-39, and-40)\n",
      "amod(spillover-43, cardiac-41)\n",
      "compound(spillover-43, norepinephrine-42)\n",
      "conj:and(hemodynamics-34, spillover-43)\n",
      "conj:and(body-39, spillover-43)\n",
      "case(patients-45, in-44)\n",
      "nmod:in(examined-2, patients-45)\n",
      "case(HFrEF-48, with-46)\n",
      "amod(HFrEF-48, chronic-47)\n",
      "nmod:with(patients-45, HFrEF-48)\n",
      "\n",
      "Parsing [sent. 7 len. 20]: Hemodynamic and neurochemical measurements were made at baseline and at 1 , 2 and 4 hours after oral dosing .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (JJ Hemodynamic)\n",
      "      (CC and)\n",
      "      (JJ neurochemical) (NNS measurements))\n",
      "    (VP (VBD were)\n",
      "      (VP (VBN made)\n",
      "        (PP\n",
      "          (PP (IN at)\n",
      "            (NP (NN baseline)))\n",
      "          (CC and)\n",
      "          (PP (IN at)\n",
      "            (NP (CD 1) (, ,) (CD 2)\n",
      "              (CC and)\n",
      "              (CD 4)))\n",
      "          (NP (NNS hours)))\n",
      "        (PP (IN after)\n",
      "          (NP (JJ oral) (NN dosing)))))\n",
      "    (. .)))\n",
      "\n",
      "amod(measurements-4, Hemodynamic-1)\n",
      "cc(Hemodynamic-1, and-2)\n",
      "conj:and(Hemodynamic-1, neurochemical-3)\n",
      "amod(measurements-4, neurochemical-3)\n",
      "nsubjpass(made-6, measurements-4)\n",
      "auxpass(made-6, were-5)\n",
      "root(ROOT-0, made-6)\n",
      "case(baseline-8, at-7)\n",
      "nmod:at(hours-16, baseline-8)\n",
      "cc(hours-16, and-9)\n",
      "case(1-11, at-10)\n",
      "nmod(made-6, 1-11)\n",
      "conj:and(hours-16, 1-11)\n",
      "nummod(1-11, 2-13)\n",
      "cc(1-11, and-14)\n",
      "conj:and(1-11, 4-15)\n",
      "conj:and(hours-16, 4-15)\n",
      "nmod(made-6, hours-16)\n",
      "case(dosing-19, after-17)\n",
      "amod(dosing-19, oral-18)\n",
      "nmod:after(made-6, dosing-19)\n",
      "\n",
      "Parsing [sent. 8 len. 25]: Administration of both drugs caused significant reductions in systemic arterial , cardiac filling and pulmonary artery pressures -LRB- P < 0.05 vs baseline -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNP Administration))\n",
      "      (PP (IN of)\n",
      "        (NP (DT both) (NNS drugs))))\n",
      "    (VP (VBD caused)\n",
      "      (NP (JJ significant) (NNS reductions))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (JJ systemic) (NN arterial))\n",
      "          (, ,)\n",
      "          (NP (JJ cardiac) (NN filling))\n",
      "          (CC and)\n",
      "          (NP (JJ pulmonary) (NN artery) (NNS pressures))))\n",
      "      (PRN (-LRB- -LRB-)\n",
      "        (NP\n",
      "          (NP (NNP P) (NNP <))\n",
      "          (NP (CD 0.05) (NN vs) (NN baseline)))\n",
      "        (-RRB- -RRB-)))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(caused-5, Administration-1)\n",
      "case(drugs-4, of-2)\n",
      "det(drugs-4, both-3)\n",
      "nmod:of(Administration-1, drugs-4)\n",
      "root(ROOT-0, caused-5)\n",
      "amod(reductions-7, significant-6)\n",
      "dobj(caused-5, reductions-7)\n",
      "case(arterial-10, in-8)\n",
      "amod(arterial-10, systemic-9)\n",
      "nmod:in(caused-5, arterial-10)\n",
      "amod(filling-13, cardiac-12)\n",
      "nmod:in(caused-5, filling-13)\n",
      "conj:and(arterial-10, filling-13)\n",
      "cc(arterial-10, and-14)\n",
      "amod(pressures-17, pulmonary-15)\n",
      "compound(pressures-17, artery-16)\n",
      "nmod:in(caused-5, pressures-17)\n",
      "conj:and(arterial-10, pressures-17)\n",
      "compound(<-20, P-19)\n",
      "dep(caused-5, <-20)\n",
      "nummod(baseline-23, 0.05-21)\n",
      "compound(baseline-23, vs-22)\n",
      "dep(<-20, baseline-23)\n",
      "\n",
      "Parsing [sent. 9 len. 13]: There was no significant difference in the magnitude of those hemodynamic effects .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (EX There))\n",
      "    (VP (VBD was)\n",
      "      (NP\n",
      "        (NP (DT no) (JJ significant) (NN difference))\n",
      "        (PP (IN in)\n",
      "          (NP\n",
      "            (NP (DT the) (NN magnitude))\n",
      "            (PP (IN of)\n",
      "              (NP (DT those) (JJ hemodynamic) (NNS effects)))))))\n",
      "    (. .)))\n",
      "\n",
      "expl(was-2, There-1)\n",
      "root(ROOT-0, was-2)\n",
      "neg(difference-5, no-3)\n",
      "amod(difference-5, significant-4)\n",
      "nsubj(was-2, difference-5)\n",
      "case(magnitude-8, in-6)\n",
      "det(magnitude-8, the-7)\n",
      "nmod:in(difference-5, magnitude-8)\n",
      "case(effects-12, of-9)\n",
      "det(effects-12, those-10)\n",
      "amod(effects-12, hemodynamic-11)\n",
      "nmod:of(magnitude-8, effects-12)\n",
      "\n",
      "Parsing [sent. 10 len. 23]: Plasma concentrations of AII were significantly decreased by captopril and increased by losartan -LRB- P < 0.05 vs baseline for both -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNP Plasma) (NNS concentrations))\n",
      "      (PP (IN of)\n",
      "        (NP (NNP AII))))\n",
      "    (VP (VBD were)\n",
      "      (ADVP (RB significantly))\n",
      "      (VP\n",
      "        (VP (VBN decreased)\n",
      "          (PP (IN by)\n",
      "            (NP (NN captopril))))\n",
      "        (CC and)\n",
      "        (VP (VBN increased)\n",
      "          (PP (IN by)\n",
      "            (NP\n",
      "              (NP (NN losartan))\n",
      "              (PRN (-LRB- -LRB-)\n",
      "                (NP\n",
      "                  (NP (NNP P) (NNP <))\n",
      "                  (NP\n",
      "                    (NP (CD 0.05) (NN vs) (NN baseline))\n",
      "                    (PP (IN for)\n",
      "                      (NP (DT both)))))\n",
      "                (-RRB- -RRB-)))))))\n",
      "    (. .)))\n",
      "\n",
      "compound(concentrations-2, Plasma-1)\n",
      "nsubjpass(decreased-7, concentrations-2)\n",
      "nsubjpass(increased-11, concentrations-2)\n",
      "case(AII-4, of-3)\n",
      "nmod:of(concentrations-2, AII-4)\n",
      "auxpass(decreased-7, were-5)\n",
      "advmod(decreased-7, significantly-6)\n",
      "root(ROOT-0, decreased-7)\n",
      "case(captopril-9, by-8)\n",
      "nmod:by(decreased-7, captopril-9)\n",
      "cc(decreased-7, and-10)\n",
      "conj:and(decreased-7, increased-11)\n",
      "case(losartan-13, by-12)\n",
      "nmod:by(increased-11, losartan-13)\n",
      "compound(<-16, P-15)\n",
      "dep(losartan-13, <-16)\n",
      "nummod(baseline-19, 0.05-17)\n",
      "compound(baseline-19, vs-18)\n",
      "dep(<-16, baseline-19)\n",
      "case(both-21, for-20)\n",
      "nmod:for(baseline-19, both-21)\n",
      "\n",
      "Parsing [sent. 11 len. 37]: Total body sympathetic activity increased in response to both captopril and losartan -LRB- P < 0.05 vs baseline for both -RRB- , however there was no change in cardiac sympathetic activity in response to either drug .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (JJ Total) (NN body) (JJ sympathetic) (NN activity))\n",
      "      (VP (VBN increased)\n",
      "        (PP (IN in)\n",
      "          (NP (NN response)))\n",
      "        (PP (TO to)\n",
      "          (NP\n",
      "            (NP (DT both) (NN captopril)\n",
      "              (CC and)\n",
      "              (NN losartan))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (NNP P) (NNP <))\n",
      "                (NP\n",
      "                  (NP (CD 0.05) (NN vs) (NN baseline))\n",
      "                  (PP (IN for)\n",
      "                    (NP (DT both)))))\n",
      "              (-RRB- -RRB-))))))\n",
      "    (, ,)\n",
      "    (ADVP (RB however))\n",
      "    (NP (EX there))\n",
      "    (VP (VBD was)\n",
      "      (NP\n",
      "        (NP (DT no) (NN change))\n",
      "        (PP (IN in)\n",
      "          (NP\n",
      "            (NP (JJ cardiac) (JJ sympathetic) (NN activity))\n",
      "            (PP (IN in)\n",
      "              (NP (NN response))))))\n",
      "      (PP (TO to)\n",
      "        (NP (DT either) (NN drug))))\n",
      "    (. .)))\n",
      "\n",
      "amod(activity-4, Total-1)\n",
      "compound(activity-4, body-2)\n",
      "amod(activity-4, sympathetic-3)\n",
      "nsubj(was-25, activity-4)\n",
      "acl(activity-4, increased-5)\n",
      "case(response-7, in-6)\n",
      "nmod:in(increased-5, response-7)\n",
      "case(captopril-10, to-8)\n",
      "cc:preconj(captopril-10, both-9)\n",
      "nmod:to(increased-5, captopril-10)\n",
      "cc(captopril-10, and-11)\n",
      "nmod:to(increased-5, losartan-12)\n",
      "conj:and(captopril-10, losartan-12)\n",
      "compound(<-15, P-14)\n",
      "dep(captopril-10, <-15)\n",
      "nummod(baseline-18, 0.05-16)\n",
      "compound(baseline-18, vs-17)\n",
      "dep(<-15, baseline-18)\n",
      "case(both-20, for-19)\n",
      "nmod:for(baseline-18, both-20)\n",
      "expl(was-25, however-23)\n",
      "dep(however-23, there-24)\n",
      "root(ROOT-0, was-25)\n",
      "neg(change-27, no-26)\n",
      "nsubj(was-25, change-27)\n",
      "case(activity-31, in-28)\n",
      "amod(activity-31, cardiac-29)\n",
      "amod(activity-31, sympathetic-30)\n",
      "nmod:in(change-27, activity-31)\n",
      "case(response-33, in-32)\n",
      "nmod:in(activity-31, response-33)\n",
      "case(drug-36, to-34)\n",
      "det(drug-36, either-35)\n",
      "nmod:to(was-25, drug-36)\n",
      "\n",
      "Parsing [sent. 12 len. 29]: The results of the current study do not support the hypothesis that the acute inhibition of the renin angiotensin system has sympathoinhibitory effects in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (NNS results))\n",
      "      (PP (IN of)\n",
      "        (NP (DT the) (JJ current) (NN study))))\n",
      "    (VP (VBP do) (RB not)\n",
      "      (VP (VB support)\n",
      "        (NP (DT the) (NNS hypothesis))\n",
      "        (SBAR (IN that)\n",
      "          (S\n",
      "            (NP\n",
      "              (NP (DT the) (JJ acute) (NN inhibition))\n",
      "              (PP (IN of)\n",
      "                (NP (DT the) (NN renin) (NN angiotensin) (NN system))))\n",
      "            (VP (VBZ has)\n",
      "              (NP\n",
      "                (NP (JJ sympathoinhibitory) (NNS effects))\n",
      "                (PP (IN in)\n",
      "                  (NP\n",
      "                    (NP (NNS patients))\n",
      "                    (PP (IN with)\n",
      "                      (NP (JJ chronic) (NNP HFrEF)))))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(results-2, The-1)\n",
      "nsubj(support-9, results-2)\n",
      "case(study-6, of-3)\n",
      "det(study-6, the-4)\n",
      "amod(study-6, current-5)\n",
      "nmod:of(results-2, study-6)\n",
      "aux(support-9, do-7)\n",
      "neg(support-9, not-8)\n",
      "root(ROOT-0, support-9)\n",
      "det(hypothesis-11, the-10)\n",
      "dobj(support-9, hypothesis-11)\n",
      "mark(has-21, that-12)\n",
      "det(inhibition-15, the-13)\n",
      "amod(inhibition-15, acute-14)\n",
      "nsubj(has-21, inhibition-15)\n",
      "case(system-20, of-16)\n",
      "det(system-20, the-17)\n",
      "compound(system-20, renin-18)\n",
      "compound(system-20, angiotensin-19)\n",
      "nmod:of(inhibition-15, system-20)\n",
      "ccomp(support-9, has-21)\n",
      "amod(effects-23, sympathoinhibitory-22)\n",
      "dobj(has-21, effects-23)\n",
      "case(patients-25, in-24)\n",
      "nmod:in(effects-23, patients-25)\n",
      "case(HFrEF-28, with-26)\n",
      "amod(HFrEF-28, chronic-27)\n",
      "nmod:with(patients-25, HFrEF-28)\n",
      "\n",
      "Parsed file: KeywordSentences.txt [12 sentences].\n",
      "Parsed 408 words in 12 sentences (42.50 wds/sec; 1.25 sents/sec).\n",
      "SLF4J: Failed to load class \"org.slf4j.impl.StaticLoggerBinder\".\n",
      "SLF4J: Defaulting to no-operation (NOP) logger implementation\n",
      "SLF4J: See http://www.slf4j.org/codes.html#StaticLoggerBinder for further details.\n",
      "Parsing file: KeywordSentences.txt\n",
      "Parsing [sent. 1 len. 52]: RAAS , a major pharmacological target in cardiovascular medicine , is inhibited by pharmacological classes including angiotensin converting enzyme -LRB- ACE -RRB- inhibitors -LRB- ACEIs -RRB- , angiotensin-II type 1 blockers -LRB- ARBs -RRB- and aldosterone receptors antagonists , in addition to the recently introduced direct renin inhibitors -LRB- DRIs -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNS RAAS))\n",
      "      (, ,)\n",
      "      (NP\n",
      "        (NP (DT a) (JJ major) (JJ pharmacological) (NN target))\n",
      "        (PP (IN in)\n",
      "          (NP (JJ cardiovascular) (NN medicine))))\n",
      "      (, ,))\n",
      "    (VP (VBZ is)\n",
      "      (ADJP (JJ inhibited)\n",
      "        (PP (IN by)\n",
      "          (NP\n",
      "            (NP (JJ pharmacological) (NNS classes))\n",
      "            (PP (VBG including)\n",
      "              (NP\n",
      "                (NP\n",
      "                  (NP (NN angiotensin))\n",
      "                  (S\n",
      "                    (VP (VBG converting)\n",
      "                      (NP (JJ enzyme)\n",
      "                        (PRN (-LRB- -LRB-)\n",
      "                          (NP (NNP ACE))\n",
      "                          (-RRB- -RRB-))\n",
      "                        (NNS inhibitors))))\n",
      "                  (PRN (-LRB- -LRB-)\n",
      "                    (NP (NNP ACEIs))\n",
      "                    (-RRB- -RRB-)))\n",
      "                (, ,)\n",
      "                (NP\n",
      "                  (ADJP (RB angiotensin-II) (NN type)\n",
      "                    (PRN\n",
      "                      (NP (CD 1))\n",
      "                      (PP\n",
      "                        (NP\n",
      "                          (NP (NNS blockers))\n",
      "                          (PRN (-LRB- -LRB-)\n",
      "                            (NP (NNP ARBs))\n",
      "                            (-RRB- -RRB-))\n",
      "                          (CC and)\n",
      "                          (NP (JJ aldosterone) (NNS receptors) (NNS antagonists))\n",
      "                          (, ,))\n",
      "                        (IN in)\n",
      "                        (NP (NN addition))))\n",
      "                    (PP (TO to)\n",
      "                      (NP (DT the)\n",
      "                        (ADJP (RB recently) (VBN introduced))\n",
      "                        (JJ direct) (NN renin))))\n",
      "                  (NNS inhibitors))))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP (NNP DRIs))\n",
      "              (-RRB- -RRB-))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(inhibited-12, RAAS-1)\n",
      "det(target-6, a-3)\n",
      "amod(target-6, major-4)\n",
      "amod(target-6, pharmacological-5)\n",
      "appos(RAAS-1, target-6)\n",
      "case(medicine-9, in-7)\n",
      "amod(medicine-9, cardiovascular-8)\n",
      "nmod:in(target-6, medicine-9)\n",
      "cop(inhibited-12, is-11)\n",
      "root(ROOT-0, inhibited-12)\n",
      "case(classes-15, by-13)\n",
      "amod(classes-15, pharmacological-14)\n",
      "nmod:by(inhibited-12, classes-15)\n",
      "case(angiotensin-17, including-16)\n",
      "nmod:including(classes-15, angiotensin-17)\n",
      "dep(angiotensin-17, converting-18)\n",
      "amod(inhibitors-23, enzyme-19)\n",
      "appos(inhibitors-23, ACE-21)\n",
      "dobj(converting-18, inhibitors-23)\n",
      "appos(angiotensin-17, ACEIs-25)\n",
      "advmod(type-29, angiotensin-II-28)\n",
      "amod(inhibitors-48, type-29)\n",
      "dep(type-29, 1-30)\n",
      "nmod:in(1-30, blockers-31)\n",
      "appos(blockers-31, ARBs-33)\n",
      "cc(blockers-31, and-35)\n",
      "amod(antagonists-38, aldosterone-36)\n",
      "compound(antagonists-38, receptors-37)\n",
      "nmod:in(1-30, antagonists-38)\n",
      "conj:and(blockers-31, antagonists-38)\n",
      "case(blockers-31, in-40)\n",
      "dep(blockers-31, addition-41)\n",
      "case(renin-47, to-42)\n",
      "det(renin-47, the-43)\n",
      "advmod(introduced-45, recently-44)\n",
      "amod(renin-47, introduced-45)\n",
      "amod(renin-47, direct-46)\n",
      "nmod:to(type-29, renin-47)\n",
      "appos(angiotensin-17, inhibitors-48)\n",
      "appos(classes-15, DRIs-50)\n",
      "\n",
      "Parsing [sent. 2 len. 36]: However , currently used RAAS inhibitors still can not achieve their desired effects and are associated with certain drawbacks , such as adverse side effects , incomplete blockage of the system and poor end-organ protection .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (ADVP (RB currently))\n",
      "    (VP (VBD used)\n",
      "      (SBAR\n",
      "        (S\n",
      "          (NP (NNP RAAS) (NNS inhibitors))\n",
      "          (ADVP (RB still))\n",
      "          (VP\n",
      "            (VP (MD can) (RB not)\n",
      "              (VP (VB achieve)\n",
      "                (NP (PRP$ their) (VBN desired) (NNS effects))))\n",
      "            (CC and)\n",
      "            (VP (VBP are)\n",
      "              (VP (VBN associated)\n",
      "                (PP (IN with)\n",
      "                  (NP\n",
      "                    (NP (JJ certain) (NNS drawbacks))\n",
      "                    (, ,)\n",
      "                    (PP (JJ such) (IN as)\n",
      "                      (NP (JJ adverse) (NN side) (NNS effects)))\n",
      "                    (, ,)\n",
      "                    (ADJP (JJ incomplete) (JJ blockage))\n",
      "                    (PP (IN of)\n",
      "                      (NP\n",
      "                        (NP (DT the) (NN system))\n",
      "                        (CC and)\n",
      "                        (NP (JJ poor) (JJ end-organ) (NN protection))))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(used-4, However-1)\n",
      "advmod(used-4, currently-3)\n",
      "root(ROOT-0, used-4)\n",
      "compound(inhibitors-6, RAAS-5)\n",
      "nsubj(achieve-10, inhibitors-6)\n",
      "nsubjpass(associated-16, inhibitors-6)\n",
      "advmod(achieve-10, still-7)\n",
      "aux(achieve-10, can-8)\n",
      "neg(achieve-10, not-9)\n",
      "ccomp(used-4, achieve-10)\n",
      "nmod:poss(effects-13, their-11)\n",
      "amod(effects-13, desired-12)\n",
      "dobj(achieve-10, effects-13)\n",
      "cc(achieve-10, and-14)\n",
      "auxpass(associated-16, are-15)\n",
      "ccomp(used-4, associated-16)\n",
      "conj:and(achieve-10, associated-16)\n",
      "case(drawbacks-19, with-17)\n",
      "amod(drawbacks-19, certain-18)\n",
      "nmod:with(associated-16, drawbacks-19)\n",
      "case(effects-25, such-21)\n",
      "mwe(such-21, as-22)\n",
      "amod(effects-25, adverse-23)\n",
      "compound(effects-25, side-24)\n",
      "nmod:such_as(drawbacks-19, effects-25)\n",
      "amod(blockage-28, incomplete-27)\n",
      "amod(drawbacks-19, blockage-28)\n",
      "case(system-31, of-29)\n",
      "det(system-31, the-30)\n",
      "nmod:of(drawbacks-19, system-31)\n",
      "cc(system-31, and-32)\n",
      "amod(protection-35, poor-33)\n",
      "amod(protection-35, end-organ-34)\n",
      "nmod:of(drawbacks-19, protection-35)\n",
      "conj:and(system-31, protection-35)\n",
      "\n",
      "Parsing [sent. 3 len. 42]: In this review , we discuss the efficiency and specificity of the current RAAS inhibitors and propose some recommendations for achieving better treatments with better end-organ protection.Hypertension Research advance online publication , 6 July 2017 ; doi :10.1038 / hr .2017.65 .\n",
      "(ROOT\n",
      "  (S\n",
      "    (PP (IN In)\n",
      "      (NP (DT this) (NN review)))\n",
      "    (, ,)\n",
      "    (S\n",
      "      (NP (PRP we))\n",
      "      (VP\n",
      "        (VP (VB discuss)\n",
      "          (NP\n",
      "            (NP (DT the) (NN efficiency)\n",
      "              (CC and)\n",
      "              (NN specificity))\n",
      "            (PP (IN of)\n",
      "              (NP (DT the) (JJ current) (NNS RAAS) (NNS inhibitors)))))\n",
      "        (CC and)\n",
      "        (VP (VB propose)\n",
      "          (NP (DT some) (NNS recommendations))\n",
      "          (PP (IN for)\n",
      "            (S\n",
      "              (VP (VBG achieving)\n",
      "                (NP (JJR better) (NNS treatments))\n",
      "                (PP (IN with)\n",
      "                  (NP (JJR better) (JJ end-organ) (NN protection.Hypertension) (NNP Research) (NN advance) (JJ online) (NN publication) (, ,) (CD 6) (NNP July) (NNS 2017)))))))))\n",
      "    (: ;)\n",
      "    (FRAG\n",
      "      (X\n",
      "        (X (SYM doi))\n",
      "        (NP (CD :10.1038)))\n",
      "      (: /)\n",
      "      (NP (CD hr) (CD .2017.65)))\n",
      "    (. .)))\n",
      "\n",
      "case(review-3, In-1)\n",
      "det(review-3, this-2)\n",
      "nmod:in(discuss-6, review-3)\n",
      "nsubj(discuss-6, we-5)\n",
      "nsubj(propose-17, we-5)\n",
      "root(ROOT-0, discuss-6)\n",
      "det(efficiency-8, the-7)\n",
      "dobj(discuss-6, efficiency-8)\n",
      "cc(efficiency-8, and-9)\n",
      "dobj(discuss-6, specificity-10)\n",
      "conj:and(efficiency-8, specificity-10)\n",
      "case(inhibitors-15, of-11)\n",
      "det(inhibitors-15, the-12)\n",
      "amod(inhibitors-15, current-13)\n",
      "compound(inhibitors-15, RAAS-14)\n",
      "nmod:of(efficiency-8, inhibitors-15)\n",
      "cc(discuss-6, and-16)\n",
      "conj:and(discuss-6, propose-17)\n",
      "det(recommendations-19, some-18)\n",
      "dobj(propose-17, recommendations-19)\n",
      "mark(achieving-21, for-20)\n",
      "advcl(propose-17, achieving-21)\n",
      "amod(treatments-23, better-22)\n",
      "dobj(achieving-21, treatments-23)\n",
      "case(2017-35, with-24)\n",
      "amod(2017-35, better-25)\n",
      "amod(2017-35, end-organ-26)\n",
      "compound(2017-35, protection.Hypertension-27)\n",
      "compound(2017-35, Research-28)\n",
      "compound(2017-35, advance-29)\n",
      "amod(2017-35, online-30)\n",
      "compound(2017-35, publication-31)\n",
      "nummod(2017-35, 6-33)\n",
      "compound(2017-35, July-34)\n",
      "nmod:with(achieving-21, 2017-35)\n",
      "dep(:10.1038-38, doi-37)\n",
      "dep(.2017.65-41, :10.1038-38)\n",
      "nummod(.2017.65-41, hr-40)\n",
      "dep(discuss-6, .2017.65-41)\n",
      "\n",
      "Parsing [sent. 4 len. 51]: The beneficial effects of angiotensin converting enzyme -LRB- ACE -RRB- inhibitors and angiotensin II -LRB- AII -RRB- receptor antagonists in patients with heart failure secondary to reduced ejection fraction -LRB- HFrEF -RRB- are felt to result from prevention of the adverse effects of AII on systemic afterload and renal homeostasis .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (JJ beneficial) (NNS effects))\n",
      "      (PP (IN of)\n",
      "        (NP\n",
      "          (NP (NN angiotensin))\n",
      "          (VP (VBG converting)\n",
      "            (NP\n",
      "              (NP (JJ enzyme)\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP ACE))\n",
      "                  (-RRB- -RRB-))\n",
      "                (NN inhibitors))\n",
      "              (CC and)\n",
      "              (NP\n",
      "                (NP (NNP angiotensin) (NNP II))\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP AII))\n",
      "                  (-RRB- -RRB-)))\n",
      "              (NP\n",
      "                (NP (NN receptor) (NNS antagonists))\n",
      "                (PP (IN in)\n",
      "                  (NP (NNS patients)))))\n",
      "            (PP (IN with)\n",
      "              (NP\n",
      "                (NP (NN heart) (NN failure))\n",
      "                (ADJP (JJ secondary)\n",
      "                  (PP (TO to)\n",
      "                    (NP\n",
      "                      (NP (VBN reduced) (NN ejection) (NN fraction))\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP HFrEF))\n",
      "                        (-RRB- -RRB-)))))))))))\n",
      "    (VP (VBP are)\n",
      "      (VP (VBN felt)\n",
      "        (S\n",
      "          (VP (TO to)\n",
      "            (VP (VB result)\n",
      "              (PP (IN from)\n",
      "                (NP\n",
      "                  (NP (NN prevention))\n",
      "                  (PP (IN of)\n",
      "                    (NP\n",
      "                      (NP (DT the) (JJ adverse) (NNS effects))\n",
      "                      (PP (IN of)\n",
      "                        (NP (NNP AII)))))))\n",
      "              (PP (IN on)\n",
      "                (NP (JJ systemic) (JJ afterload)\n",
      "                  (CC and)\n",
      "                  (JJ renal) (NNS homeostasis))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(effects-3, The-1)\n",
      "amod(effects-3, beneficial-2)\n",
      "nsubjpass(felt-34, effects-3)\n",
      "nsubj:xsubj(result-36, effects-3)\n",
      "case(angiotensin-5, of-4)\n",
      "nmod:of(effects-3, angiotensin-5)\n",
      "acl(angiotensin-5, converting-6)\n",
      "amod(inhibitors-11, enzyme-7)\n",
      "appos(inhibitors-11, ACE-9)\n",
      "dobj(converting-6, inhibitors-11)\n",
      "cc(inhibitors-11, and-12)\n",
      "compound(II-14, angiotensin-13)\n",
      "dobj(converting-6, II-14)\n",
      "conj:and(inhibitors-11, II-14)\n",
      "appos(II-14, AII-16)\n",
      "compound(antagonists-19, receptor-18)\n",
      "dep(inhibitors-11, antagonists-19)\n",
      "case(patients-21, in-20)\n",
      "nmod:in(antagonists-19, patients-21)\n",
      "case(failure-24, with-22)\n",
      "compound(failure-24, heart-23)\n",
      "nmod:with(converting-6, failure-24)\n",
      "amod(failure-24, secondary-25)\n",
      "case(fraction-29, to-26)\n",
      "amod(fraction-29, reduced-27)\n",
      "compound(fraction-29, ejection-28)\n",
      "nmod:to(secondary-25, fraction-29)\n",
      "appos(fraction-29, HFrEF-31)\n",
      "auxpass(felt-34, are-33)\n",
      "root(ROOT-0, felt-34)\n",
      "mark(result-36, to-35)\n",
      "xcomp(felt-34, result-36)\n",
      "case(prevention-38, from-37)\n",
      "nmod:from(result-36, prevention-38)\n",
      "case(effects-42, of-39)\n",
      "det(effects-42, the-40)\n",
      "amod(effects-42, adverse-41)\n",
      "nmod:of(prevention-38, effects-42)\n",
      "case(AII-44, of-43)\n",
      "nmod:of(effects-42, AII-44)\n",
      "case(afterload-47, on-45)\n",
      "amod(afterload-47, systemic-46)\n",
      "nmod:on(result-36, afterload-47)\n",
      "cc(afterload-47, and-48)\n",
      "amod(homeostasis-50, renal-49)\n",
      "nmod:on(result-36, homeostasis-50)\n",
      "conj:and(afterload-47, homeostasis-50)\n",
      "\n",
      "Parsing [sent. 5 len. 31]: However , AII can activate the sympathetic nervous system and part of the beneficial effects of ACE inhibitors and AII antagonists may result from their ability to inhibit such activation .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (S\n",
      "      (NP (NNP AII))\n",
      "      (VP (MD can)\n",
      "        (VP (VB activate)\n",
      "          (NP\n",
      "            (NP (DT the)\n",
      "              (ADJP (JJ sympathetic) (JJ nervous))\n",
      "              (NN system))\n",
      "            (CC and)\n",
      "            (NP\n",
      "              (NP (NN part))\n",
      "              (PP (IN of)\n",
      "                (NP\n",
      "                  (NP (DT the) (JJ beneficial) (NNS effects))\n",
      "                  (PP (IN of)\n",
      "                    (NP (NNP ACE) (NNS inhibitors))))))))))\n",
      "    (CC and)\n",
      "    (S\n",
      "      (NP (NNP AII) (NNS antagonists))\n",
      "      (VP (MD may)\n",
      "        (VP (VB result)\n",
      "          (PP (IN from)\n",
      "            (NP (PRP$ their) (NN ability)\n",
      "              (S\n",
      "                (VP (TO to)\n",
      "                  (VP (VB inhibit)\n",
      "                    (NP (JJ such) (NN activation))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(activate-5, However-1)\n",
      "nsubj(activate-5, AII-3)\n",
      "aux(activate-5, can-4)\n",
      "root(ROOT-0, activate-5)\n",
      "det(system-9, the-6)\n",
      "amod(nervous-8, sympathetic-7)\n",
      "amod(system-9, nervous-8)\n",
      "dobj(activate-5, system-9)\n",
      "cc(system-9, and-10)\n",
      "dobj(activate-5, part-11)\n",
      "conj:and(system-9, part-11)\n",
      "case(effects-15, of-12)\n",
      "det(effects-15, the-13)\n",
      "amod(effects-15, beneficial-14)\n",
      "nmod:of(part-11, effects-15)\n",
      "case(inhibitors-18, of-16)\n",
      "compound(inhibitors-18, ACE-17)\n",
      "nmod:of(effects-15, inhibitors-18)\n",
      "cc(activate-5, and-19)\n",
      "compound(antagonists-21, AII-20)\n",
      "nsubj(result-23, antagonists-21)\n",
      "aux(result-23, may-22)\n",
      "conj:and(activate-5, result-23)\n",
      "case(ability-26, from-24)\n",
      "nmod:poss(ability-26, their-25)\n",
      "nmod:from(result-23, ability-26)\n",
      "mark(inhibit-28, to-27)\n",
      "acl(ability-26, inhibit-28)\n",
      "amod(activation-30, such-29)\n",
      "dobj(inhibit-28, activation-30)\n",
      "\n",
      "Parsing [sent. 6 len. 49]: We examined the acute effects of the ACE inhibitor captopril -LRB- 25 mg , n = 9 -RRB- and the AII receptor antagonist losartan -LRB- 50 mg , n = 10 -RRB- on hemodynamics as well as total body and cardiac norepinephrine spillover in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (PRP We))\n",
      "    (VP (VBD examined)\n",
      "      (NP\n",
      "        (NP (DT the) (JJ acute) (NNS effects))\n",
      "        (PP (IN of)\n",
      "          (NP\n",
      "            (NP (DT the) (NNP ACE) (NN inhibitor) (NN captopril))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 25) (NN mg))\n",
      "                (, ,)\n",
      "                (NP\n",
      "                  (NP (NN n))\n",
      "                  (SBAR\n",
      "                    (S\n",
      "                      (VP (SYM =)\n",
      "                        (NP (CD 9)))))))\n",
      "              (-RRB- -RRB-))\n",
      "            (CC and)\n",
      "            (NP (DT the) (NNP AII) (NN receptor) (NN antagonist) (NN losartan))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 50) (NN mg))\n",
      "                (, ,)\n",
      "                (NP\n",
      "                  (NP (NN n))\n",
      "                  (SBAR\n",
      "                    (S\n",
      "                      (VP (SYM =)\n",
      "                        (NP (CD 10)))))))\n",
      "              (-RRB- -RRB-)))))\n",
      "      (PP (IN on)\n",
      "        (NP\n",
      "          (NP (NNS hemodynamics))\n",
      "          (CONJP (RB as) (RB well) (IN as))\n",
      "          (NP (JJ total) (NN body)\n",
      "            (CC and)\n",
      "            (JJ cardiac) (NN norepinephrine) (NN spillover))))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (NNS patients))\n",
      "          (PP (IN with)\n",
      "            (NP (JJ chronic) (NNP HFrEF))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(examined-2, We-1)\n",
      "root(ROOT-0, examined-2)\n",
      "det(effects-5, the-3)\n",
      "amod(effects-5, acute-4)\n",
      "dobj(examined-2, effects-5)\n",
      "case(captopril-10, of-6)\n",
      "det(captopril-10, the-7)\n",
      "compound(captopril-10, ACE-8)\n",
      "compound(captopril-10, inhibitor-9)\n",
      "nmod:of(effects-5, captopril-10)\n",
      "nummod(mg-13, 25-12)\n",
      "dep(captopril-10, mg-13)\n",
      "appos(mg-13, n-15)\n",
      "dep(9-17, =-16)\n",
      "acl:relcl(n-15, 9-17)\n",
      "cc(captopril-10, and-19)\n",
      "det(losartan-24, the-20)\n",
      "compound(losartan-24, AII-21)\n",
      "compound(losartan-24, receptor-22)\n",
      "compound(losartan-24, antagonist-23)\n",
      "nmod:of(effects-5, losartan-24)\n",
      "conj:and(captopril-10, losartan-24)\n",
      "nummod(mg-27, 50-26)\n",
      "dep(captopril-10, mg-27)\n",
      "appos(mg-27, n-29)\n",
      "dep(10-31, =-30)\n",
      "acl:relcl(n-29, 10-31)\n",
      "case(hemodynamics-34, on-33)\n",
      "nmod:on(examined-2, hemodynamics-34)\n",
      "cc(hemodynamics-34, as-35)\n",
      "mwe(as-35, well-36)\n",
      "mwe(as-35, as-37)\n",
      "amod(body-39, total-38)\n",
      "nmod:on(examined-2, body-39)\n",
      "conj:and(hemodynamics-34, body-39)\n",
      "cc(body-39, and-40)\n",
      "amod(spillover-43, cardiac-41)\n",
      "compound(spillover-43, norepinephrine-42)\n",
      "conj:and(hemodynamics-34, spillover-43)\n",
      "conj:and(body-39, spillover-43)\n",
      "case(patients-45, in-44)\n",
      "nmod:in(examined-2, patients-45)\n",
      "case(HFrEF-48, with-46)\n",
      "amod(HFrEF-48, chronic-47)\n",
      "nmod:with(patients-45, HFrEF-48)\n",
      "\n",
      "Parsing [sent. 7 len. 20]: Hemodynamic and neurochemical measurements were made at baseline and at 1 , 2 and 4 hours after oral dosing .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (JJ Hemodynamic)\n",
      "      (CC and)\n",
      "      (JJ neurochemical) (NNS measurements))\n",
      "    (VP (VBD were)\n",
      "      (VP (VBN made)\n",
      "        (PP\n",
      "          (PP (IN at)\n",
      "            (NP (NN baseline)))\n",
      "          (CC and)\n",
      "          (PP (IN at)\n",
      "            (NP (CD 1) (, ,) (CD 2)\n",
      "              (CC and)\n",
      "              (CD 4)))\n",
      "          (NP (NNS hours)))\n",
      "        (PP (IN after)\n",
      "          (NP (JJ oral) (NN dosing)))))\n",
      "    (. .)))\n",
      "\n",
      "amod(measurements-4, Hemodynamic-1)\n",
      "cc(Hemodynamic-1, and-2)\n",
      "conj:and(Hemodynamic-1, neurochemical-3)\n",
      "amod(measurements-4, neurochemical-3)\n",
      "nsubjpass(made-6, measurements-4)\n",
      "auxpass(made-6, were-5)\n",
      "root(ROOT-0, made-6)\n",
      "case(baseline-8, at-7)\n",
      "nmod:at(hours-16, baseline-8)\n",
      "cc(hours-16, and-9)\n",
      "case(1-11, at-10)\n",
      "nmod(made-6, 1-11)\n",
      "conj:and(hours-16, 1-11)\n",
      "nummod(1-11, 2-13)\n",
      "cc(1-11, and-14)\n",
      "conj:and(1-11, 4-15)\n",
      "conj:and(hours-16, 4-15)\n",
      "nmod(made-6, hours-16)\n",
      "case(dosing-19, after-17)\n",
      "amod(dosing-19, oral-18)\n",
      "nmod:after(made-6, dosing-19)\n",
      "\n",
      "Parsing [sent. 8 len. 25]: Administration of both drugs caused significant reductions in systemic arterial , cardiac filling and pulmonary artery pressures -LRB- P < 0.05 vs baseline -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNP Administration))\n",
      "      (PP (IN of)\n",
      "        (NP (DT both) (NNS drugs))))\n",
      "    (VP (VBD caused)\n",
      "      (NP (JJ significant) (NNS reductions))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (JJ systemic) (NN arterial))\n",
      "          (, ,)\n",
      "          (NP (JJ cardiac) (NN filling))\n",
      "          (CC and)\n",
      "          (NP (JJ pulmonary) (NN artery) (NNS pressures))))\n",
      "      (PRN (-LRB- -LRB-)\n",
      "        (NP\n",
      "          (NP (NNP P) (NNP <))\n",
      "          (NP (CD 0.05) (NN vs) (NN baseline)))\n",
      "        (-RRB- -RRB-)))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(caused-5, Administration-1)\n",
      "case(drugs-4, of-2)\n",
      "det(drugs-4, both-3)\n",
      "nmod:of(Administration-1, drugs-4)\n",
      "root(ROOT-0, caused-5)\n",
      "amod(reductions-7, significant-6)\n",
      "dobj(caused-5, reductions-7)\n",
      "case(arterial-10, in-8)\n",
      "amod(arterial-10, systemic-9)\n",
      "nmod:in(caused-5, arterial-10)\n",
      "amod(filling-13, cardiac-12)\n",
      "nmod:in(caused-5, filling-13)\n",
      "conj:and(arterial-10, filling-13)\n",
      "cc(arterial-10, and-14)\n",
      "amod(pressures-17, pulmonary-15)\n",
      "compound(pressures-17, artery-16)\n",
      "nmod:in(caused-5, pressures-17)\n",
      "conj:and(arterial-10, pressures-17)\n",
      "compound(<-20, P-19)\n",
      "dep(caused-5, <-20)\n",
      "nummod(baseline-23, 0.05-21)\n",
      "compound(baseline-23, vs-22)\n",
      "dep(<-20, baseline-23)\n",
      "\n",
      "Parsing [sent. 9 len. 13]: There was no significant difference in the magnitude of those hemodynamic effects .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (EX There))\n",
      "    (VP (VBD was)\n",
      "      (NP\n",
      "        (NP (DT no) (JJ significant) (NN difference))\n",
      "        (PP (IN in)\n",
      "          (NP\n",
      "            (NP (DT the) (NN magnitude))\n",
      "            (PP (IN of)\n",
      "              (NP (DT those) (JJ hemodynamic) (NNS effects)))))))\n",
      "    (. .)))\n",
      "\n",
      "expl(was-2, There-1)\n",
      "root(ROOT-0, was-2)\n",
      "neg(difference-5, no-3)\n",
      "amod(difference-5, significant-4)\n",
      "nsubj(was-2, difference-5)\n",
      "case(magnitude-8, in-6)\n",
      "det(magnitude-8, the-7)\n",
      "nmod:in(difference-5, magnitude-8)\n",
      "case(effects-12, of-9)\n",
      "det(effects-12, those-10)\n",
      "amod(effects-12, hemodynamic-11)\n",
      "nmod:of(magnitude-8, effects-12)\n",
      "\n",
      "Parsing [sent. 10 len. 23]: Plasma concentrations of AII were significantly decreased by captopril and increased by losartan -LRB- P < 0.05 vs baseline for both -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNP Plasma) (NNS concentrations))\n",
      "      (PP (IN of)\n",
      "        (NP (NNP AII))))\n",
      "    (VP (VBD were)\n",
      "      (ADVP (RB significantly))\n",
      "      (VP\n",
      "        (VP (VBN decreased)\n",
      "          (PP (IN by)\n",
      "            (NP (NN captopril))))\n",
      "        (CC and)\n",
      "        (VP (VBN increased)\n",
      "          (PP (IN by)\n",
      "            (NP\n",
      "              (NP (NN losartan))\n",
      "              (PRN (-LRB- -LRB-)\n",
      "                (NP\n",
      "                  (NP (NNP P) (NNP <))\n",
      "                  (NP\n",
      "                    (NP (CD 0.05) (NN vs) (NN baseline))\n",
      "                    (PP (IN for)\n",
      "                      (NP (DT both)))))\n",
      "                (-RRB- -RRB-)))))))\n",
      "    (. .)))\n",
      "\n",
      "compound(concentrations-2, Plasma-1)\n",
      "nsubjpass(decreased-7, concentrations-2)\n",
      "nsubjpass(increased-11, concentrations-2)\n",
      "case(AII-4, of-3)\n",
      "nmod:of(concentrations-2, AII-4)\n",
      "auxpass(decreased-7, were-5)\n",
      "advmod(decreased-7, significantly-6)\n",
      "root(ROOT-0, decreased-7)\n",
      "case(captopril-9, by-8)\n",
      "nmod:by(decreased-7, captopril-9)\n",
      "cc(decreased-7, and-10)\n",
      "conj:and(decreased-7, increased-11)\n",
      "case(losartan-13, by-12)\n",
      "nmod:by(increased-11, losartan-13)\n",
      "compound(<-16, P-15)\n",
      "dep(losartan-13, <-16)\n",
      "nummod(baseline-19, 0.05-17)\n",
      "compound(baseline-19, vs-18)\n",
      "dep(<-16, baseline-19)\n",
      "case(both-21, for-20)\n",
      "nmod:for(baseline-19, both-21)\n",
      "\n",
      "Parsing [sent. 11 len. 37]: Total body sympathetic activity increased in response to both captopril and losartan -LRB- P < 0.05 vs baseline for both -RRB- , however there was no change in cardiac sympathetic activity in response to either drug .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (JJ Total) (NN body) (JJ sympathetic) (NN activity))\n",
      "      (VP (VBN increased)\n",
      "        (PP (IN in)\n",
      "          (NP (NN response)))\n",
      "        (PP (TO to)\n",
      "          (NP\n",
      "            (NP (DT both) (NN captopril)\n",
      "              (CC and)\n",
      "              (NN losartan))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (NNP P) (NNP <))\n",
      "                (NP\n",
      "                  (NP (CD 0.05) (NN vs) (NN baseline))\n",
      "                  (PP (IN for)\n",
      "                    (NP (DT both)))))\n",
      "              (-RRB- -RRB-))))))\n",
      "    (, ,)\n",
      "    (ADVP (RB however))\n",
      "    (NP (EX there))\n",
      "    (VP (VBD was)\n",
      "      (NP\n",
      "        (NP (DT no) (NN change))\n",
      "        (PP (IN in)\n",
      "          (NP\n",
      "            (NP (JJ cardiac) (JJ sympathetic) (NN activity))\n",
      "            (PP (IN in)\n",
      "              (NP (NN response))))))\n",
      "      (PP (TO to)\n",
      "        (NP (DT either) (NN drug))))\n",
      "    (. .)))\n",
      "\n",
      "amod(activity-4, Total-1)\n",
      "compound(activity-4, body-2)\n",
      "amod(activity-4, sympathetic-3)\n",
      "nsubj(was-25, activity-4)\n",
      "acl(activity-4, increased-5)\n",
      "case(response-7, in-6)\n",
      "nmod:in(increased-5, response-7)\n",
      "case(captopril-10, to-8)\n",
      "cc:preconj(captopril-10, both-9)\n",
      "nmod:to(increased-5, captopril-10)\n",
      "cc(captopril-10, and-11)\n",
      "nmod:to(increased-5, losartan-12)\n",
      "conj:and(captopril-10, losartan-12)\n",
      "compound(<-15, P-14)\n",
      "dep(captopril-10, <-15)\n",
      "nummod(baseline-18, 0.05-16)\n",
      "compound(baseline-18, vs-17)\n",
      "dep(<-15, baseline-18)\n",
      "case(both-20, for-19)\n",
      "nmod:for(baseline-18, both-20)\n",
      "expl(was-25, however-23)\n",
      "dep(however-23, there-24)\n",
      "root(ROOT-0, was-25)\n",
      "neg(change-27, no-26)\n",
      "nsubj(was-25, change-27)\n",
      "case(activity-31, in-28)\n",
      "amod(activity-31, cardiac-29)\n",
      "amod(activity-31, sympathetic-30)\n",
      "nmod:in(change-27, activity-31)\n",
      "case(response-33, in-32)\n",
      "nmod:in(activity-31, response-33)\n",
      "case(drug-36, to-34)\n",
      "det(drug-36, either-35)\n",
      "nmod:to(was-25, drug-36)\n",
      "\n",
      "Parsing [sent. 12 len. 29]: The results of the current study do not support the hypothesis that the acute inhibition of the renin angiotensin system has sympathoinhibitory effects in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (NNS results))\n",
      "      (PP (IN of)\n",
      "        (NP (DT the) (JJ current) (NN study))))\n",
      "    (VP (VBP do) (RB not)\n",
      "      (VP (VB support)\n",
      "        (NP (DT the) (NNS hypothesis))\n",
      "        (SBAR (IN that)\n",
      "          (S\n",
      "            (NP\n",
      "              (NP (DT the) (JJ acute) (NN inhibition))\n",
      "              (PP (IN of)\n",
      "                (NP (DT the) (NN renin) (NN angiotensin) (NN system))))\n",
      "            (VP (VBZ has)\n",
      "              (NP\n",
      "                (NP (JJ sympathoinhibitory) (NNS effects))\n",
      "                (PP (IN in)\n",
      "                  (NP\n",
      "                    (NP (NNS patients))\n",
      "                    (PP (IN with)\n",
      "                      (NP (JJ chronic) (NNP HFrEF)))))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(results-2, The-1)\n",
      "nsubj(support-9, results-2)\n",
      "case(study-6, of-3)\n",
      "det(study-6, the-4)\n",
      "amod(study-6, current-5)\n",
      "nmod:of(results-2, study-6)\n",
      "aux(support-9, do-7)\n",
      "neg(support-9, not-8)\n",
      "root(ROOT-0, support-9)\n",
      "det(hypothesis-11, the-10)\n",
      "dobj(support-9, hypothesis-11)\n",
      "mark(has-21, that-12)\n",
      "det(inhibition-15, the-13)\n",
      "amod(inhibition-15, acute-14)\n",
      "nsubj(has-21, inhibition-15)\n",
      "case(system-20, of-16)\n",
      "det(system-20, the-17)\n",
      "compound(system-20, renin-18)\n",
      "compound(system-20, angiotensin-19)\n",
      "nmod:of(inhibition-15, system-20)\n",
      "ccomp(support-9, has-21)\n",
      "amod(effects-23, sympathoinhibitory-22)\n",
      "dobj(has-21, effects-23)\n",
      "case(patients-25, in-24)\n",
      "nmod:in(effects-23, patients-25)\n",
      "case(HFrEF-28, with-26)\n",
      "amod(HFrEF-28, chronic-27)\n",
      "nmod:with(patients-25, HFrEF-28)\n",
      "\n",
      "Parsed file: KeywordSentences.txt [12 sentences].\n",
      "Parsed 408 words in 12 sentences (37.87 wds/sec; 1.11 sents/sec).\n",
      "1 loop, best of 3: 10.8 s per loop\n"
     ]
    }
   ],
   "source": [
    "%%timeit\n",
    "! ./lexparser_rnn.sh  KeywordSentences.txt"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Test with Caseless PCFG  Model"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "#!/usr/bin/env bash\r\n",
      "#\r\n",
      "# Runs the English PCFG parser on one or more files, printing trees only\r\n",
      "\r\n",
      "if [ ! $# -ge 1 ]; then\r\n",
      "  echo Usage: `basename $0` 'file(s)'\r\n",
      "  echo\r\n",
      "  exit\r\n",
      "fi\r\n",
      "\r\n",
      "scriptdir=`dirname $0`\r\n",
      "\r\n",
      "java -mx500m -cp \"$scriptdir/*:\" edu.stanford.nlp.parser.lexparser.LexicalizedParser \\\r\n",
      " -outputFormat \"penn,typedDependencies\" edu/stanford/nlp/models/lexparser/englishPCFG.caseless.ser.gz $*\r\n"
     ]
    }
   ],
   "source": [
    "!cat ./lexparser_caseless.sh"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "SLF4J: Failed to load class \"org.slf4j.impl.StaticLoggerBinder\".\n",
      "SLF4J: Defaulting to no-operation (NOP) logger implementation\n",
      "SLF4J: See http://www.slf4j.org/codes.html#StaticLoggerBinder for further details.\n",
      "Parsing file: KeywordSentences.txt\n",
      "Parsing [sent. 1 len. 52]: RAAS , a major pharmacological target in cardiovascular medicine , is inhibited by pharmacological classes including angiotensin converting enzyme -LRB- ACE -RRB- inhibitors -LRB- ACEIs -RRB- , angiotensin-II type 1 blockers -LRB- ARBs -RRB- and aldosterone receptors antagonists , in addition to the recently introduced direct renin inhibitors -LRB- DRIs -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNS RAAS))\n",
      "      (, ,)\n",
      "      (NP\n",
      "        (NP (DT a) (JJ major) (JJ pharmacological) (NN target))\n",
      "        (PP (IN in)\n",
      "          (NP (JJ cardiovascular) (NN medicine))))\n",
      "      (, ,))\n",
      "    (VP (VBZ is)\n",
      "      (ADJP (JJ inhibited)\n",
      "        (PP (IN by)\n",
      "          (NP\n",
      "            (NP (JJ pharmacological) (NNS classes))\n",
      "            (PP (VBG including)\n",
      "              (NP\n",
      "                (NP (NN angiotensin))\n",
      "                (VP (VBG converting)\n",
      "                  (NP\n",
      "                    (NP (NNP enzyme)\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP ACE))\n",
      "                        (-RRB- -RRB-))\n",
      "                      (NNP inhibitors))\n",
      "                    (PRN (-LRB- -LRB-)\n",
      "                      (NP (NNP ACEIs))\n",
      "                      (-RRB- -RRB-))\n",
      "                    (, ,)\n",
      "                    (NP\n",
      "                      (NP (JJ angiotensin-II) (NN type))\n",
      "                      (NP\n",
      "                        (NP (CD 1) (NNS blockers))\n",
      "                        (PRN (-LRB- -LRB-)\n",
      "                          (NP (NNS ARBs))\n",
      "                          (-RRB- -RRB-))))\n",
      "                    (CC and)\n",
      "                    (NP\n",
      "                      (NP\n",
      "                        (NP (JJ aldosterone) (NNS receptors) (NNS antagonists))\n",
      "                        (, ,)\n",
      "                        (PP (IN in)\n",
      "                          (NP\n",
      "                            (NP (NN addition))\n",
      "                            (PP (TO to)\n",
      "                              (NP (DT the)\n",
      "                                (ADJP (RB recently) (VBN introduced))\n",
      "                                (NNP direct) (NNP renin) (NNP inhibitors))))))\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP DRIs))\n",
      "                        (-RRB- -RRB-)))))))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(inhibited-12, RAAS-1)\n",
      "det(target-6, a-3)\n",
      "amod(target-6, major-4)\n",
      "amod(target-6, pharmacological-5)\n",
      "appos(RAAS-1, target-6)\n",
      "case(medicine-9, in-7)\n",
      "amod(medicine-9, cardiovascular-8)\n",
      "nmod:in(target-6, medicine-9)\n",
      "cop(inhibited-12, is-11)\n",
      "root(ROOT-0, inhibited-12)\n",
      "case(classes-15, by-13)\n",
      "amod(classes-15, pharmacological-14)\n",
      "nmod:by(inhibited-12, classes-15)\n",
      "case(angiotensin-17, including-16)\n",
      "nmod:including(classes-15, angiotensin-17)\n",
      "acl(angiotensin-17, converting-18)\n",
      "compound(inhibitors-23, enzyme-19)\n",
      "appos(inhibitors-23, ACE-21)\n",
      "dobj(converting-18, inhibitors-23)\n",
      "appos(inhibitors-23, ACEIs-25)\n",
      "amod(type-29, angiotensin-II-28)\n",
      "dobj(converting-18, type-29)\n",
      "conj:and(inhibitors-23, type-29)\n",
      "nummod(blockers-31, 1-30)\n",
      "dep(type-29, blockers-31)\n",
      "appos(blockers-31, ARBs-33)\n",
      "cc(inhibitors-23, and-35)\n",
      "amod(antagonists-38, aldosterone-36)\n",
      "compound(antagonists-38, receptors-37)\n",
      "dobj(converting-18, antagonists-38)\n",
      "conj:and(inhibitors-23, antagonists-38)\n",
      "case(inhibitors-48, in-40)\n",
      "mwe(in-40, addition-41)\n",
      "mwe(in-40, to-42)\n",
      "det(inhibitors-48, the-43)\n",
      "advmod(introduced-45, recently-44)\n",
      "amod(inhibitors-48, introduced-45)\n",
      "compound(inhibitors-48, direct-46)\n",
      "compound(inhibitors-48, renin-47)\n",
      "nmod:in_addition_to(antagonists-38, inhibitors-48)\n",
      "appos(antagonists-38, DRIs-50)\n",
      "\n",
      "Parsing [sent. 2 len. 36]: However , currently used RAAS inhibitors still can not achieve their desired effects and are associated with certain drawbacks , such as adverse side effects , incomplete blockage of the system and poor end-organ protection .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (ADVP (RB currently))\n",
      "    (VP (VBD used)\n",
      "      (SBAR\n",
      "        (S\n",
      "          (NP (NNP RAAS) (NNP inhibitors))\n",
      "          (ADVP (RB still))\n",
      "          (VP\n",
      "            (VP (MD can) (RB not)\n",
      "              (VP (VB achieve)\n",
      "                (NP (PRP$ their) (VBN desired) (NNS effects))))\n",
      "            (CC and)\n",
      "            (VP (VBP are)\n",
      "              (VP (VBN associated)\n",
      "                (PP (IN with)\n",
      "                  (NP\n",
      "                    (NP (JJ certain) (NNS drawbacks))\n",
      "                    (, ,)\n",
      "                    (PP (JJ such) (IN as)\n",
      "                      (NP (JJ adverse) (NN side) (NNS effects)))\n",
      "                    (, ,)\n",
      "                    (ADJP (JJ incomplete) (JJ blockage))\n",
      "                    (PP (IN of)\n",
      "                      (NP\n",
      "                        (NP (DT the) (NN system))\n",
      "                        (CC and)\n",
      "                        (NP (JJ poor) (JJ end-organ) (NN protection))))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(used-4, However-1)\n",
      "advmod(used-4, currently-3)\n",
      "root(ROOT-0, used-4)\n",
      "compound(inhibitors-6, RAAS-5)\n",
      "nsubj(achieve-10, inhibitors-6)\n",
      "nsubjpass(associated-16, inhibitors-6)\n",
      "advmod(achieve-10, still-7)\n",
      "aux(achieve-10, can-8)\n",
      "neg(achieve-10, not-9)\n",
      "ccomp(used-4, achieve-10)\n",
      "nmod:poss(effects-13, their-11)\n",
      "amod(effects-13, desired-12)\n",
      "dobj(achieve-10, effects-13)\n",
      "cc(achieve-10, and-14)\n",
      "auxpass(associated-16, are-15)\n",
      "ccomp(used-4, associated-16)\n",
      "conj:and(achieve-10, associated-16)\n",
      "case(drawbacks-19, with-17)\n",
      "amod(drawbacks-19, certain-18)\n",
      "nmod:with(associated-16, drawbacks-19)\n",
      "case(effects-25, such-21)\n",
      "mwe(such-21, as-22)\n",
      "amod(effects-25, adverse-23)\n",
      "compound(effects-25, side-24)\n",
      "nmod:such_as(drawbacks-19, effects-25)\n",
      "amod(blockage-28, incomplete-27)\n",
      "amod(drawbacks-19, blockage-28)\n",
      "case(system-31, of-29)\n",
      "det(system-31, the-30)\n",
      "nmod:of(drawbacks-19, system-31)\n",
      "cc(system-31, and-32)\n",
      "amod(protection-35, poor-33)\n",
      "amod(protection-35, end-organ-34)\n",
      "nmod:of(drawbacks-19, protection-35)\n",
      "conj:and(system-31, protection-35)\n",
      "\n",
      "Parsing [sent. 3 len. 42]: In this review , we discuss the efficiency and specificity of the current RAAS inhibitors and propose some recommendations for achieving better treatments with better end-organ protection.Hypertension Research advance online publication , 6 July 2017 ; doi :10.1038 / hr .2017.65 .\n",
      "(ROOT\n",
      "  (S\n",
      "    (PP (IN In)\n",
      "      (NP (DT this) (NN review)))\n",
      "    (, ,)\n",
      "    (NP (PRP we))\n",
      "    (VP\n",
      "      (VP (VB discuss)\n",
      "        (NP\n",
      "          (NP (DT the) (NN efficiency)\n",
      "            (CC and)\n",
      "            (NN specificity))\n",
      "          (PP (IN of)\n",
      "            (NP (DT the) (JJ current) (JJ RAAS) (NNS inhibitors)))))\n",
      "      (CC and)\n",
      "      (VP (VB propose)\n",
      "        (NP\n",
      "          (NP\n",
      "            (NP (DT some) (NNS recommendations))\n",
      "            (PP (IN for)\n",
      "              (S\n",
      "                (VP (VBG achieving)\n",
      "                  (NP (JJR better) (NNS treatments))\n",
      "                  (PP (IN with)\n",
      "                    (NP (NNP better) (NNP end-organ) (NNP protection.Hypertension) (NNP Research) (NNP advance) (JJ online) (NN publication)))))))\n",
      "          (, ,)\n",
      "          (NP\n",
      "            (NP (CD 6))\n",
      "            (NP (NNP July) (CD 2017)))\n",
      "          (: ;)\n",
      "          (NP\n",
      "            (QP (CD doi) (CD :10.1038))\n",
      "            (NNS /))\n",
      "          (NP (NNP hr) (CD .2017.65)))))\n",
      "    (. .)))\n",
      "\n",
      "case(review-3, In-1)\n",
      "det(review-3, this-2)\n",
      "nmod:in(discuss-6, review-3)\n",
      "nsubj(discuss-6, we-5)\n",
      "nsubj(propose-17, we-5)\n",
      "root(ROOT-0, discuss-6)\n",
      "det(efficiency-8, the-7)\n",
      "dobj(discuss-6, efficiency-8)\n",
      "cc(efficiency-8, and-9)\n",
      "dobj(discuss-6, specificity-10)\n",
      "conj:and(efficiency-8, specificity-10)\n",
      "case(inhibitors-15, of-11)\n",
      "det(inhibitors-15, the-12)\n",
      "amod(inhibitors-15, current-13)\n",
      "amod(inhibitors-15, RAAS-14)\n",
      "nmod:of(efficiency-8, inhibitors-15)\n",
      "cc(discuss-6, and-16)\n",
      "conj:and(discuss-6, propose-17)\n",
      "det(recommendations-19, some-18)\n",
      "dobj(propose-17, recommendations-19)\n",
      "mark(achieving-21, for-20)\n",
      "acl(recommendations-19, achieving-21)\n",
      "amod(treatments-23, better-22)\n",
      "dobj(achieving-21, treatments-23)\n",
      "case(publication-31, with-24)\n",
      "compound(publication-31, better-25)\n",
      "compound(publication-31, end-organ-26)\n",
      "compound(publication-31, protection.Hypertension-27)\n",
      "compound(publication-31, Research-28)\n",
      "compound(publication-31, advance-29)\n",
      "amod(publication-31, online-30)\n",
      "nmod:with(achieving-21, publication-31)\n",
      "appos(recommendations-19, 6-33)\n",
      "dep(6-33, July-34)\n",
      "nummod(July-34, 2017-35)\n",
      "compound(:10.1038-38, doi-37)\n",
      "nummod(/-39, :10.1038-38)\n",
      "dep(recommendations-19, /-39)\n",
      "dep(recommendations-19, hr-40)\n",
      "nummod(hr-40, .2017.65-41)\n",
      "\n",
      "Parsing [sent. 4 len. 51]: The beneficial effects of angiotensin converting enzyme -LRB- ACE -RRB- inhibitors and angiotensin II -LRB- AII -RRB- receptor antagonists in patients with heart failure secondary to reduced ejection fraction -LRB- HFrEF -RRB- are felt to result from prevention of the adverse effects of AII on systemic afterload and renal homeostasis .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (JJ beneficial) (NNS effects))\n",
      "      (PP (IN of)\n",
      "        (NP\n",
      "          (NP (NN angiotensin))\n",
      "          (VP (VBG converting)\n",
      "            (NP\n",
      "              (NP (NNP enzyme)\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP ACE))\n",
      "                  (-RRB- -RRB-))\n",
      "                (NNP inhibitors))\n",
      "              (CC and)\n",
      "              (NP\n",
      "                (NP (NNP angiotensin) (NNP II))\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP AII))\n",
      "                  (-RRB- -RRB-)))\n",
      "              (NP\n",
      "                (NP (NN receptor) (NNS antagonists))\n",
      "                (PP (IN in)\n",
      "                  (NP (NNS patients)))))\n",
      "            (PP (IN with)\n",
      "              (NP\n",
      "                (NP (NN heart) (NN failure))\n",
      "                (ADJP (JJ secondary)\n",
      "                  (PP (TO to)\n",
      "                    (NP\n",
      "                      (NP (VBN reduced) (JJ ejection) (NN fraction))\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP HFrEF))\n",
      "                        (-RRB- -RRB-)))))))))))\n",
      "    (VP (VBP are)\n",
      "      (VP (VBN felt)\n",
      "        (S\n",
      "          (VP (TO to)\n",
      "            (VP (VB result)\n",
      "              (PP (IN from)\n",
      "                (NP\n",
      "                  (NP (NN prevention))\n",
      "                  (PP (IN of)\n",
      "                    (NP\n",
      "                      (NP (DT the) (JJ adverse) (NNS effects))\n",
      "                      (PP (IN of)\n",
      "                        (NP (NNP AII)))))))\n",
      "              (PP (IN on)\n",
      "                (NP (JJ systemic) (JJ afterload)\n",
      "                  (CC and)\n",
      "                  (JJ renal) (NNS homeostasis))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(effects-3, The-1)\n",
      "amod(effects-3, beneficial-2)\n",
      "nsubjpass(felt-34, effects-3)\n",
      "nsubj:xsubj(result-36, effects-3)\n",
      "case(angiotensin-5, of-4)\n",
      "nmod:of(effects-3, angiotensin-5)\n",
      "acl(angiotensin-5, converting-6)\n",
      "compound(inhibitors-11, enzyme-7)\n",
      "appos(inhibitors-11, ACE-9)\n",
      "dobj(converting-6, inhibitors-11)\n",
      "cc(inhibitors-11, and-12)\n",
      "compound(II-14, angiotensin-13)\n",
      "dobj(converting-6, II-14)\n",
      "conj:and(inhibitors-11, II-14)\n",
      "appos(II-14, AII-16)\n",
      "compound(antagonists-19, receptor-18)\n",
      "dep(inhibitors-11, antagonists-19)\n",
      "case(patients-21, in-20)\n",
      "nmod:in(antagonists-19, patients-21)\n",
      "case(failure-24, with-22)\n",
      "compound(failure-24, heart-23)\n",
      "nmod:with(converting-6, failure-24)\n",
      "amod(failure-24, secondary-25)\n",
      "case(fraction-29, to-26)\n",
      "amod(fraction-29, reduced-27)\n",
      "amod(fraction-29, ejection-28)\n",
      "nmod:to(secondary-25, fraction-29)\n",
      "appos(fraction-29, HFrEF-31)\n",
      "auxpass(felt-34, are-33)\n",
      "root(ROOT-0, felt-34)\n",
      "mark(result-36, to-35)\n",
      "xcomp(felt-34, result-36)\n",
      "case(prevention-38, from-37)\n",
      "nmod:from(result-36, prevention-38)\n",
      "case(effects-42, of-39)\n",
      "det(effects-42, the-40)\n",
      "amod(effects-42, adverse-41)\n",
      "nmod:of(prevention-38, effects-42)\n",
      "case(AII-44, of-43)\n",
      "nmod:of(effects-42, AII-44)\n",
      "case(afterload-47, on-45)\n",
      "amod(afterload-47, systemic-46)\n",
      "nmod:on(result-36, afterload-47)\n",
      "cc(afterload-47, and-48)\n",
      "amod(homeostasis-50, renal-49)\n",
      "nmod:on(result-36, homeostasis-50)\n",
      "conj:and(afterload-47, homeostasis-50)\n",
      "\n",
      "Parsing [sent. 5 len. 31]: However , AII can activate the sympathetic nervous system and part of the beneficial effects of ACE inhibitors and AII antagonists may result from their ability to inhibit such activation .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (S\n",
      "      (NP (NNP AII))\n",
      "      (VP (MD can)\n",
      "        (VP (VB activate)\n",
      "          (NP\n",
      "            (NP (DT the)\n",
      "              (ADJP (JJ sympathetic) (JJ nervous))\n",
      "              (NN system))\n",
      "            (CC and)\n",
      "            (NP\n",
      "              (NP (NN part))\n",
      "              (PP (IN of)\n",
      "                (NP\n",
      "                  (NP (DT the) (JJ beneficial) (NNS effects))\n",
      "                  (PP (IN of)\n",
      "                    (NP (NN ACE) (NNS inhibitors))))))))))\n",
      "    (CC and)\n",
      "    (S\n",
      "      (NP (NNP AII) (NNS antagonists))\n",
      "      (VP (MD may)\n",
      "        (VP (VB result)\n",
      "          (PP (IN from)\n",
      "            (NP (PRP$ their) (NN ability)\n",
      "              (S\n",
      "                (VP (TO to)\n",
      "                  (VP (VB inhibit)\n",
      "                    (NP (JJ such) (NN activation))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(activate-5, However-1)\n",
      "nsubj(activate-5, AII-3)\n",
      "aux(activate-5, can-4)\n",
      "root(ROOT-0, activate-5)\n",
      "det(system-9, the-6)\n",
      "amod(nervous-8, sympathetic-7)\n",
      "amod(system-9, nervous-8)\n",
      "dobj(activate-5, system-9)\n",
      "cc(system-9, and-10)\n",
      "dobj(activate-5, part-11)\n",
      "conj:and(system-9, part-11)\n",
      "case(effects-15, of-12)\n",
      "det(effects-15, the-13)\n",
      "amod(effects-15, beneficial-14)\n",
      "nmod:of(part-11, effects-15)\n",
      "case(inhibitors-18, of-16)\n",
      "compound(inhibitors-18, ACE-17)\n",
      "nmod:of(effects-15, inhibitors-18)\n",
      "cc(activate-5, and-19)\n",
      "compound(antagonists-21, AII-20)\n",
      "nsubj(result-23, antagonists-21)\n",
      "aux(result-23, may-22)\n",
      "conj:and(activate-5, result-23)\n",
      "case(ability-26, from-24)\n",
      "nmod:poss(ability-26, their-25)\n",
      "nmod:from(result-23, ability-26)\n",
      "mark(inhibit-28, to-27)\n",
      "acl(ability-26, inhibit-28)\n",
      "amod(activation-30, such-29)\n",
      "dobj(inhibit-28, activation-30)\n",
      "\n",
      "Parsing [sent. 6 len. 49]: We examined the acute effects of the ACE inhibitor captopril -LRB- 25 mg , n = 9 -RRB- and the AII receptor antagonist losartan -LRB- 50 mg , n = 10 -RRB- on hemodynamics as well as total body and cardiac norepinephrine spillover in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (PRP We))\n",
      "    (VP (VBD examined)\n",
      "      (NP\n",
      "        (NP (DT the) (JJ acute) (NNS effects))\n",
      "        (PP (IN of)\n",
      "          (NP\n",
      "            (NP (DT the) (NNP ACE) (NNP inhibitor) (NNP captopril))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 25) (NN mg))\n",
      "                (, ,)\n",
      "                (NP (NNP n) (NNP =) (CD 9)))\n",
      "              (-RRB- -RRB-))\n",
      "            (CC and)\n",
      "            (NP (DT the) (NNP AII) (NN receptor) (NN antagonist) (NN losartan))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 50) (NN mg))\n",
      "                (, ,)\n",
      "                (NP (NNP n) (NNP =) (CD 10)))\n",
      "              (-RRB- -RRB-)))))\n",
      "      (PP (IN on)\n",
      "        (NP\n",
      "          (NP (NNS hemodynamics))\n",
      "          (CONJP (RB as) (RB well) (IN as))\n",
      "          (NP (JJ total) (NN body)\n",
      "            (CC and)\n",
      "            (JJ cardiac) (NN norepinephrine) (NN spillover))))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (NNS patients))\n",
      "          (PP (IN with)\n",
      "            (NP (JJ chronic) (NN HFrEF))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(examined-2, We-1)\n",
      "root(ROOT-0, examined-2)\n",
      "det(effects-5, the-3)\n",
      "amod(effects-5, acute-4)\n",
      "dobj(examined-2, effects-5)\n",
      "case(captopril-10, of-6)\n",
      "det(captopril-10, the-7)\n",
      "compound(captopril-10, ACE-8)\n",
      "compound(captopril-10, inhibitor-9)\n",
      "nmod:of(effects-5, captopril-10)\n",
      "nummod(mg-13, 25-12)\n",
      "dep(captopril-10, mg-13)\n",
      "compound(=-16, n-15)\n",
      "appos(mg-13, =-16)\n",
      "nummod(=-16, 9-17)\n",
      "cc(captopril-10, and-19)\n",
      "det(losartan-24, the-20)\n",
      "compound(losartan-24, AII-21)\n",
      "compound(losartan-24, receptor-22)\n",
      "compound(losartan-24, antagonist-23)\n",
      "nmod:of(effects-5, losartan-24)\n",
      "conj:and(captopril-10, losartan-24)\n",
      "nummod(mg-27, 50-26)\n",
      "dep(captopril-10, mg-27)\n",
      "compound(=-30, n-29)\n",
      "appos(mg-27, =-30)\n",
      "nummod(=-30, 10-31)\n",
      "case(hemodynamics-34, on-33)\n",
      "nmod:on(examined-2, hemodynamics-34)\n",
      "cc(hemodynamics-34, as-35)\n",
      "mwe(as-35, well-36)\n",
      "mwe(as-35, as-37)\n",
      "amod(body-39, total-38)\n",
      "nmod:on(examined-2, body-39)\n",
      "conj:and(hemodynamics-34, body-39)\n",
      "cc(body-39, and-40)\n",
      "amod(spillover-43, cardiac-41)\n",
      "compound(spillover-43, norepinephrine-42)\n",
      "conj:and(hemodynamics-34, spillover-43)\n",
      "conj:and(body-39, spillover-43)\n",
      "case(patients-45, in-44)\n",
      "nmod:in(examined-2, patients-45)\n",
      "case(HFrEF-48, with-46)\n",
      "amod(HFrEF-48, chronic-47)\n",
      "nmod:with(patients-45, HFrEF-48)\n",
      "\n",
      "Parsing [sent. 7 len. 20]: Hemodynamic and neurochemical measurements were made at baseline and at 1 , 2 and 4 hours after oral dosing .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (ADJP (JJ Hemodynamic)\n",
      "        (CC and)\n",
      "        (JJ neurochemical))\n",
      "      (NNS measurements))\n",
      "    (VP (VBD were)\n",
      "      (VP (VBN made)\n",
      "        (PP\n",
      "          (PP (IN at)\n",
      "            (NP (NN baseline)))\n",
      "          (CC and)\n",
      "          (PP (IN at)\n",
      "            (NP (CD 1) (, ,) (CD 2)\n",
      "              (CC and)\n",
      "              (CD 4)))\n",
      "          (NP (NNS hours)))\n",
      "        (PP (IN after)\n",
      "          (NP (JJ oral) (NN dosing)))))\n",
      "    (. .)))\n",
      "\n",
      "amod(measurements-4, Hemodynamic-1)\n",
      "cc(Hemodynamic-1, and-2)\n",
      "conj:and(Hemodynamic-1, neurochemical-3)\n",
      "amod(measurements-4, neurochemical-3)\n",
      "nsubjpass(made-6, measurements-4)\n",
      "auxpass(made-6, were-5)\n",
      "root(ROOT-0, made-6)\n",
      "case(baseline-8, at-7)\n",
      "nmod:at(hours-16, baseline-8)\n",
      "cc(hours-16, and-9)\n",
      "case(1-11, at-10)\n",
      "nmod(made-6, 1-11)\n",
      "conj:and(hours-16, 1-11)\n",
      "nummod(1-11, 2-13)\n",
      "cc(1-11, and-14)\n",
      "conj:and(1-11, 4-15)\n",
      "conj:and(hours-16, 4-15)\n",
      "nmod(made-6, hours-16)\n",
      "case(dosing-19, after-17)\n",
      "amod(dosing-19, oral-18)\n",
      "nmod:after(made-6, dosing-19)\n",
      "\n",
      "Parsing [sent. 8 len. 25]: Administration of both drugs caused significant reductions in systemic arterial , cardiac filling and pulmonary artery pressures -LRB- P < 0.05 vs baseline -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NN Administration))\n",
      "      (PP (IN of)\n",
      "        (NP (DT both) (NNS drugs))))\n",
      "    (VP (VBD caused)\n",
      "      (NP (JJ significant) (NNS reductions))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (JJ systemic) (NN arterial))\n",
      "          (, ,)\n",
      "          (NP (JJ cardiac) (NN filling))\n",
      "          (CC and)\n",
      "          (NP (JJ pulmonary) (NN artery) (NNS pressures))))\n",
      "      (PRN (-LRB- -LRB-)\n",
      "        (NP\n",
      "          (NP (NNP P) (NNP <))\n",
      "          (NP (CD 0.05) (NNP vs) (NN baseline)))\n",
      "        (-RRB- -RRB-)))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(caused-5, Administration-1)\n",
      "case(drugs-4, of-2)\n",
      "det(drugs-4, both-3)\n",
      "nmod:of(Administration-1, drugs-4)\n",
      "root(ROOT-0, caused-5)\n",
      "amod(reductions-7, significant-6)\n",
      "dobj(caused-5, reductions-7)\n",
      "case(arterial-10, in-8)\n",
      "amod(arterial-10, systemic-9)\n",
      "nmod:in(caused-5, arterial-10)\n",
      "amod(filling-13, cardiac-12)\n",
      "nmod:in(caused-5, filling-13)\n",
      "conj:and(arterial-10, filling-13)\n",
      "cc(arterial-10, and-14)\n",
      "amod(pressures-17, pulmonary-15)\n",
      "compound(pressures-17, artery-16)\n",
      "nmod:in(caused-5, pressures-17)\n",
      "conj:and(arterial-10, pressures-17)\n",
      "compound(<-20, P-19)\n",
      "dep(caused-5, <-20)\n",
      "nummod(baseline-23, 0.05-21)\n",
      "compound(baseline-23, vs-22)\n",
      "dep(<-20, baseline-23)\n",
      "\n",
      "Parsing [sent. 9 len. 13]: There was no significant difference in the magnitude of those hemodynamic effects .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (EX There))\n",
      "    (VP (VBD was)\n",
      "      (NP\n",
      "        (NP (DT no) (JJ significant) (NN difference))\n",
      "        (PP (IN in)\n",
      "          (NP\n",
      "            (NP (DT the) (NN magnitude))\n",
      "            (PP (IN of)\n",
      "              (NP (DT those) (JJ hemodynamic) (NNS effects)))))))\n",
      "    (. .)))\n",
      "\n",
      "expl(was-2, There-1)\n",
      "root(ROOT-0, was-2)\n",
      "neg(difference-5, no-3)\n",
      "amod(difference-5, significant-4)\n",
      "nsubj(was-2, difference-5)\n",
      "case(magnitude-8, in-6)\n",
      "det(magnitude-8, the-7)\n",
      "nmod:in(difference-5, magnitude-8)\n",
      "case(effects-12, of-9)\n",
      "det(effects-12, those-10)\n",
      "amod(effects-12, hemodynamic-11)\n",
      "nmod:of(magnitude-8, effects-12)\n",
      "\n",
      "Parsing [sent. 10 len. 23]: Plasma concentrations of AII were significantly decreased by captopril and increased by losartan -LRB- P < 0.05 vs baseline for both -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NN Plasma) (NNS concentrations))\n",
      "      (PP (IN of)\n",
      "        (NP (NNP AII))))\n",
      "    (VP (VBD were)\n",
      "      (ADVP (RB significantly))\n",
      "      (VP\n",
      "        (VP (VBN decreased)\n",
      "          (PP (IN by)\n",
      "            (NP (NNP captopril))))\n",
      "        (CC and)\n",
      "        (VP (VBN increased)\n",
      "          (PP (IN by)\n",
      "            (NP\n",
      "              (NP (NNP losartan))\n",
      "              (PRN (-LRB- -LRB-)\n",
      "                (NP\n",
      "                  (NP (NNP P) (NNP <) (NNP 0.05) (NNP vs) (NN baseline))\n",
      "                  (PP (IN for)\n",
      "                    (NP (DT both))))\n",
      "                (-RRB- -RRB-)))))))\n",
      "    (. .)))\n",
      "\n",
      "compound(concentrations-2, Plasma-1)\n",
      "nsubjpass(decreased-7, concentrations-2)\n",
      "nsubjpass(increased-11, concentrations-2)\n",
      "case(AII-4, of-3)\n",
      "nmod:of(concentrations-2, AII-4)\n",
      "auxpass(decreased-7, were-5)\n",
      "advmod(decreased-7, significantly-6)\n",
      "root(ROOT-0, decreased-7)\n",
      "case(captopril-9, by-8)\n",
      "nmod:by(decreased-7, captopril-9)\n",
      "cc(decreased-7, and-10)\n",
      "conj:and(decreased-7, increased-11)\n",
      "case(losartan-13, by-12)\n",
      "nmod:by(increased-11, losartan-13)\n",
      "compound(baseline-19, P-15)\n",
      "compound(baseline-19, <-16)\n",
      "compound(baseline-19, 0.05-17)\n",
      "compound(baseline-19, vs-18)\n",
      "dep(losartan-13, baseline-19)\n",
      "case(both-21, for-20)\n",
      "nmod:for(baseline-19, both-21)\n",
      "\n",
      "Parsing [sent. 11 len. 37]: Total body sympathetic activity increased in response to both captopril and losartan -LRB- P < 0.05 vs baseline for both -RRB- , however there was no change in cardiac sympathetic activity in response to either drug .\n",
      "(ROOT\n",
      "  (S\n",
      "    (S\n",
      "      (NP\n",
      "        (NP (JJ Total) (NN body))\n",
      "        (NP (JJ sympathetic) (NN activity)))\n",
      "      (VP (VBD increased)\n",
      "        (PP (IN in)\n",
      "          (NP (NN response)))\n",
      "        (PP (TO to)\n",
      "          (NP (DT both) (NNP captopril)\n",
      "            (CC and)\n",
      "            (NNP losartan)))\n",
      "        (PRN (-LRB- -LRB-)\n",
      "          (NP\n",
      "            (NP (NNP P) (NNP <) (NNP 0.05) (NNP vs) (NN baseline))\n",
      "            (PP (IN for)\n",
      "              (NP (DT both))))\n",
      "          (-RRB- -RRB-))))\n",
      "    (, ,)\n",
      "    (ADVP (RB however))\n",
      "    (S\n",
      "      (NP (EX there))\n",
      "      (VP (VBD was)\n",
      "        (NP\n",
      "          (NP (DT no) (NN change))\n",
      "          (PP (IN in)\n",
      "            (NP\n",
      "              (NP (JJ cardiac) (JJ sympathetic) (NN activity))\n",
      "              (PP (IN in)\n",
      "                (NP (NN response))))))\n",
      "        (PP (TO to)\n",
      "          (NP (DT either) (NN drug)))))\n",
      "    (. .)))\n",
      "\n",
      "amod(body-2, Total-1)\n",
      "nsubj(increased-5, body-2)\n",
      "amod(activity-4, sympathetic-3)\n",
      "dep(body-2, activity-4)\n",
      "root(ROOT-0, increased-5)\n",
      "case(response-7, in-6)\n",
      "nmod:in(increased-5, response-7)\n",
      "case(captopril-10, to-8)\n",
      "cc:preconj(captopril-10, both-9)\n",
      "nmod:to(increased-5, captopril-10)\n",
      "cc(captopril-10, and-11)\n",
      "nmod:to(increased-5, losartan-12)\n",
      "conj:and(captopril-10, losartan-12)\n",
      "compound(baseline-18, P-14)\n",
      "compound(baseline-18, <-15)\n",
      "compound(baseline-18, 0.05-16)\n",
      "compound(baseline-18, vs-17)\n",
      "dep(increased-5, baseline-18)\n",
      "case(both-20, for-19)\n",
      "nmod:for(baseline-18, both-20)\n",
      "advmod(was-25, however-23)\n",
      "expl(was-25, there-24)\n",
      "parataxis(increased-5, was-25)\n",
      "neg(change-27, no-26)\n",
      "nsubj(was-25, change-27)\n",
      "case(activity-31, in-28)\n",
      "amod(activity-31, cardiac-29)\n",
      "amod(activity-31, sympathetic-30)\n",
      "nmod:in(change-27, activity-31)\n",
      "case(response-33, in-32)\n",
      "nmod:in(activity-31, response-33)\n",
      "case(drug-36, to-34)\n",
      "det(drug-36, either-35)\n",
      "nmod:to(was-25, drug-36)\n",
      "\n",
      "Parsing [sent. 12 len. 29]: The results of the current study do not support the hypothesis that the acute inhibition of the renin angiotensin system has sympathoinhibitory effects in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (NNS results))\n",
      "      (PP (IN of)\n",
      "        (NP (DT the) (JJ current) (NN study))))\n",
      "    (VP (VBP do) (RB not)\n",
      "      (VP (VB support)\n",
      "        (NP (DT the) (NNS hypothesis))\n",
      "        (SBAR (IN that)\n",
      "          (S\n",
      "            (NP\n",
      "              (NP (DT the) (JJ acute) (NN inhibition))\n",
      "              (PP (IN of)\n",
      "                (NP (DT the) (NNP renin) (NN angiotensin) (NN system))))\n",
      "            (VP (VBZ has)\n",
      "              (NP\n",
      "                (NP (JJ sympathoinhibitory) (NNS effects))\n",
      "                (PP (IN in)\n",
      "                  (NP\n",
      "                    (NP (NNS patients))\n",
      "                    (PP (IN with)\n",
      "                      (NP (JJ chronic) (NN HFrEF)))))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(results-2, The-1)\n",
      "nsubj(support-9, results-2)\n",
      "case(study-6, of-3)\n",
      "det(study-6, the-4)\n",
      "amod(study-6, current-5)\n",
      "nmod:of(results-2, study-6)\n",
      "aux(support-9, do-7)\n",
      "neg(support-9, not-8)\n",
      "root(ROOT-0, support-9)\n",
      "det(hypothesis-11, the-10)\n",
      "dobj(support-9, hypothesis-11)\n",
      "mark(has-21, that-12)\n",
      "det(inhibition-15, the-13)\n",
      "amod(inhibition-15, acute-14)\n",
      "nsubj(has-21, inhibition-15)\n",
      "case(system-20, of-16)\n",
      "det(system-20, the-17)\n",
      "compound(system-20, renin-18)\n",
      "compound(system-20, angiotensin-19)\n",
      "nmod:of(inhibition-15, system-20)\n",
      "ccomp(support-9, has-21)\n",
      "amod(effects-23, sympathoinhibitory-22)\n",
      "dobj(has-21, effects-23)\n",
      "case(patients-25, in-24)\n",
      "nmod:in(effects-23, patients-25)\n",
      "case(HFrEF-28, with-26)\n",
      "amod(HFrEF-28, chronic-27)\n",
      "nmod:with(patients-25, HFrEF-28)\n",
      "\n",
      "Parsed file: KeywordSentences.txt [12 sentences].\n",
      "Parsed 408 words in 12 sentences (35.72 wds/sec; 1.05 sents/sec).\n",
      "SLF4J: Failed to load class \"org.slf4j.impl.StaticLoggerBinder\".\n",
      "SLF4J: Defaulting to no-operation (NOP) logger implementation\n",
      "SLF4J: See http://www.slf4j.org/codes.html#StaticLoggerBinder for further details.\n",
      "Parsing file: KeywordSentences.txt\n",
      "Parsing [sent. 1 len. 52]: RAAS , a major pharmacological target in cardiovascular medicine , is inhibited by pharmacological classes including angiotensin converting enzyme -LRB- ACE -RRB- inhibitors -LRB- ACEIs -RRB- , angiotensin-II type 1 blockers -LRB- ARBs -RRB- and aldosterone receptors antagonists , in addition to the recently introduced direct renin inhibitors -LRB- DRIs -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNS RAAS))\n",
      "      (, ,)\n",
      "      (NP\n",
      "        (NP (DT a) (JJ major) (JJ pharmacological) (NN target))\n",
      "        (PP (IN in)\n",
      "          (NP (JJ cardiovascular) (NN medicine))))\n",
      "      (, ,))\n",
      "    (VP (VBZ is)\n",
      "      (ADJP (JJ inhibited)\n",
      "        (PP (IN by)\n",
      "          (NP\n",
      "            (NP (JJ pharmacological) (NNS classes))\n",
      "            (PP (VBG including)\n",
      "              (NP\n",
      "                (NP (NN angiotensin))\n",
      "                (VP (VBG converting)\n",
      "                  (NP\n",
      "                    (NP (NNP enzyme)\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP ACE))\n",
      "                        (-RRB- -RRB-))\n",
      "                      (NNP inhibitors))\n",
      "                    (PRN (-LRB- -LRB-)\n",
      "                      (NP (NNP ACEIs))\n",
      "                      (-RRB- -RRB-))\n",
      "                    (, ,)\n",
      "                    (NP\n",
      "                      (NP (JJ angiotensin-II) (NN type))\n",
      "                      (NP\n",
      "                        (NP (CD 1) (NNS blockers))\n",
      "                        (PRN (-LRB- -LRB-)\n",
      "                          (NP (NNS ARBs))\n",
      "                          (-RRB- -RRB-))))\n",
      "                    (CC and)\n",
      "                    (NP\n",
      "                      (NP\n",
      "                        (NP (JJ aldosterone) (NNS receptors) (NNS antagonists))\n",
      "                        (, ,)\n",
      "                        (PP (IN in)\n",
      "                          (NP\n",
      "                            (NP (NN addition))\n",
      "                            (PP (TO to)\n",
      "                              (NP (DT the)\n",
      "                                (ADJP (RB recently) (VBN introduced))\n",
      "                                (NNP direct) (NNP renin) (NNP inhibitors))))))\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP DRIs))\n",
      "                        (-RRB- -RRB-)))))))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(inhibited-12, RAAS-1)\n",
      "det(target-6, a-3)\n",
      "amod(target-6, major-4)\n",
      "amod(target-6, pharmacological-5)\n",
      "appos(RAAS-1, target-6)\n",
      "case(medicine-9, in-7)\n",
      "amod(medicine-9, cardiovascular-8)\n",
      "nmod:in(target-6, medicine-9)\n",
      "cop(inhibited-12, is-11)\n",
      "root(ROOT-0, inhibited-12)\n",
      "case(classes-15, by-13)\n",
      "amod(classes-15, pharmacological-14)\n",
      "nmod:by(inhibited-12, classes-15)\n",
      "case(angiotensin-17, including-16)\n",
      "nmod:including(classes-15, angiotensin-17)\n",
      "acl(angiotensin-17, converting-18)\n",
      "compound(inhibitors-23, enzyme-19)\n",
      "appos(inhibitors-23, ACE-21)\n",
      "dobj(converting-18, inhibitors-23)\n",
      "appos(inhibitors-23, ACEIs-25)\n",
      "amod(type-29, angiotensin-II-28)\n",
      "dobj(converting-18, type-29)\n",
      "conj:and(inhibitors-23, type-29)\n",
      "nummod(blockers-31, 1-30)\n",
      "dep(type-29, blockers-31)\n",
      "appos(blockers-31, ARBs-33)\n",
      "cc(inhibitors-23, and-35)\n",
      "amod(antagonists-38, aldosterone-36)\n",
      "compound(antagonists-38, receptors-37)\n",
      "dobj(converting-18, antagonists-38)\n",
      "conj:and(inhibitors-23, antagonists-38)\n",
      "case(inhibitors-48, in-40)\n",
      "mwe(in-40, addition-41)\n",
      "mwe(in-40, to-42)\n",
      "det(inhibitors-48, the-43)\n",
      "advmod(introduced-45, recently-44)\n",
      "amod(inhibitors-48, introduced-45)\n",
      "compound(inhibitors-48, direct-46)\n",
      "compound(inhibitors-48, renin-47)\n",
      "nmod:in_addition_to(antagonists-38, inhibitors-48)\n",
      "appos(antagonists-38, DRIs-50)\n",
      "\n",
      "Parsing [sent. 2 len. 36]: However , currently used RAAS inhibitors still can not achieve their desired effects and are associated with certain drawbacks , such as adverse side effects , incomplete blockage of the system and poor end-organ protection .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (ADVP (RB currently))\n",
      "    (VP (VBD used)\n",
      "      (SBAR\n",
      "        (S\n",
      "          (NP (NNP RAAS) (NNP inhibitors))\n",
      "          (ADVP (RB still))\n",
      "          (VP\n",
      "            (VP (MD can) (RB not)\n",
      "              (VP (VB achieve)\n",
      "                (NP (PRP$ their) (VBN desired) (NNS effects))))\n",
      "            (CC and)\n",
      "            (VP (VBP are)\n",
      "              (VP (VBN associated)\n",
      "                (PP (IN with)\n",
      "                  (NP\n",
      "                    (NP (JJ certain) (NNS drawbacks))\n",
      "                    (, ,)\n",
      "                    (PP (JJ such) (IN as)\n",
      "                      (NP (JJ adverse) (NN side) (NNS effects)))\n",
      "                    (, ,)\n",
      "                    (ADJP (JJ incomplete) (JJ blockage))\n",
      "                    (PP (IN of)\n",
      "                      (NP\n",
      "                        (NP (DT the) (NN system))\n",
      "                        (CC and)\n",
      "                        (NP (JJ poor) (JJ end-organ) (NN protection))))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(used-4, However-1)\n",
      "advmod(used-4, currently-3)\n",
      "root(ROOT-0, used-4)\n",
      "compound(inhibitors-6, RAAS-5)\n",
      "nsubj(achieve-10, inhibitors-6)\n",
      "nsubjpass(associated-16, inhibitors-6)\n",
      "advmod(achieve-10, still-7)\n",
      "aux(achieve-10, can-8)\n",
      "neg(achieve-10, not-9)\n",
      "ccomp(used-4, achieve-10)\n",
      "nmod:poss(effects-13, their-11)\n",
      "amod(effects-13, desired-12)\n",
      "dobj(achieve-10, effects-13)\n",
      "cc(achieve-10, and-14)\n",
      "auxpass(associated-16, are-15)\n",
      "ccomp(used-4, associated-16)\n",
      "conj:and(achieve-10, associated-16)\n",
      "case(drawbacks-19, with-17)\n",
      "amod(drawbacks-19, certain-18)\n",
      "nmod:with(associated-16, drawbacks-19)\n",
      "case(effects-25, such-21)\n",
      "mwe(such-21, as-22)\n",
      "amod(effects-25, adverse-23)\n",
      "compound(effects-25, side-24)\n",
      "nmod:such_as(drawbacks-19, effects-25)\n",
      "amod(blockage-28, incomplete-27)\n",
      "amod(drawbacks-19, blockage-28)\n",
      "case(system-31, of-29)\n",
      "det(system-31, the-30)\n",
      "nmod:of(drawbacks-19, system-31)\n",
      "cc(system-31, and-32)\n",
      "amod(protection-35, poor-33)\n",
      "amod(protection-35, end-organ-34)\n",
      "nmod:of(drawbacks-19, protection-35)\n",
      "conj:and(system-31, protection-35)\n",
      "\n",
      "Parsing [sent. 3 len. 42]: In this review , we discuss the efficiency and specificity of the current RAAS inhibitors and propose some recommendations for achieving better treatments with better end-organ protection.Hypertension Research advance online publication , 6 July 2017 ; doi :10.1038 / hr .2017.65 .\n",
      "(ROOT\n",
      "  (S\n",
      "    (PP (IN In)\n",
      "      (NP (DT this) (NN review)))\n",
      "    (, ,)\n",
      "    (NP (PRP we))\n",
      "    (VP\n",
      "      (VP (VB discuss)\n",
      "        (NP\n",
      "          (NP (DT the) (NN efficiency)\n",
      "            (CC and)\n",
      "            (NN specificity))\n",
      "          (PP (IN of)\n",
      "            (NP (DT the) (JJ current) (JJ RAAS) (NNS inhibitors)))))\n",
      "      (CC and)\n",
      "      (VP (VB propose)\n",
      "        (NP\n",
      "          (NP\n",
      "            (NP (DT some) (NNS recommendations))\n",
      "            (PP (IN for)\n",
      "              (S\n",
      "                (VP (VBG achieving)\n",
      "                  (NP (JJR better) (NNS treatments))\n",
      "                  (PP (IN with)\n",
      "                    (NP (NNP better) (NNP end-organ) (NNP protection.Hypertension) (NNP Research) (NNP advance) (JJ online) (NN publication)))))))\n",
      "          (, ,)\n",
      "          (NP\n",
      "            (NP (CD 6))\n",
      "            (NP (NNP July) (CD 2017)))\n",
      "          (: ;)\n",
      "          (NP\n",
      "            (QP (CD doi) (CD :10.1038))\n",
      "            (NNS /))\n",
      "          (NP (NNP hr) (CD .2017.65)))))\n",
      "    (. .)))\n",
      "\n",
      "case(review-3, In-1)\n",
      "det(review-3, this-2)\n",
      "nmod:in(discuss-6, review-3)\n",
      "nsubj(discuss-6, we-5)\n",
      "nsubj(propose-17, we-5)\n",
      "root(ROOT-0, discuss-6)\n",
      "det(efficiency-8, the-7)\n",
      "dobj(discuss-6, efficiency-8)\n",
      "cc(efficiency-8, and-9)\n",
      "dobj(discuss-6, specificity-10)\n",
      "conj:and(efficiency-8, specificity-10)\n",
      "case(inhibitors-15, of-11)\n",
      "det(inhibitors-15, the-12)\n",
      "amod(inhibitors-15, current-13)\n",
      "amod(inhibitors-15, RAAS-14)\n",
      "nmod:of(efficiency-8, inhibitors-15)\n",
      "cc(discuss-6, and-16)\n",
      "conj:and(discuss-6, propose-17)\n",
      "det(recommendations-19, some-18)\n",
      "dobj(propose-17, recommendations-19)\n",
      "mark(achieving-21, for-20)\n",
      "acl(recommendations-19, achieving-21)\n",
      "amod(treatments-23, better-22)\n",
      "dobj(achieving-21, treatments-23)\n",
      "case(publication-31, with-24)\n",
      "compound(publication-31, better-25)\n",
      "compound(publication-31, end-organ-26)\n",
      "compound(publication-31, protection.Hypertension-27)\n",
      "compound(publication-31, Research-28)\n",
      "compound(publication-31, advance-29)\n",
      "amod(publication-31, online-30)\n",
      "nmod:with(achieving-21, publication-31)\n",
      "appos(recommendations-19, 6-33)\n",
      "dep(6-33, July-34)\n",
      "nummod(July-34, 2017-35)\n",
      "compound(:10.1038-38, doi-37)\n",
      "nummod(/-39, :10.1038-38)\n",
      "dep(recommendations-19, /-39)\n",
      "dep(recommendations-19, hr-40)\n",
      "nummod(hr-40, .2017.65-41)\n",
      "\n",
      "Parsing [sent. 4 len. 51]: The beneficial effects of angiotensin converting enzyme -LRB- ACE -RRB- inhibitors and angiotensin II -LRB- AII -RRB- receptor antagonists in patients with heart failure secondary to reduced ejection fraction -LRB- HFrEF -RRB- are felt to result from prevention of the adverse effects of AII on systemic afterload and renal homeostasis .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (JJ beneficial) (NNS effects))\n",
      "      (PP (IN of)\n",
      "        (NP\n",
      "          (NP (NN angiotensin))\n",
      "          (VP (VBG converting)\n",
      "            (NP\n",
      "              (NP (NNP enzyme)\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP ACE))\n",
      "                  (-RRB- -RRB-))\n",
      "                (NNP inhibitors))\n",
      "              (CC and)\n",
      "              (NP\n",
      "                (NP (NNP angiotensin) (NNP II))\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP AII))\n",
      "                  (-RRB- -RRB-)))\n",
      "              (NP\n",
      "                (NP (NN receptor) (NNS antagonists))\n",
      "                (PP (IN in)\n",
      "                  (NP (NNS patients)))))\n",
      "            (PP (IN with)\n",
      "              (NP\n",
      "                (NP (NN heart) (NN failure))\n",
      "                (ADJP (JJ secondary)\n",
      "                  (PP (TO to)\n",
      "                    (NP\n",
      "                      (NP (VBN reduced) (JJ ejection) (NN fraction))\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP HFrEF))\n",
      "                        (-RRB- -RRB-)))))))))))\n",
      "    (VP (VBP are)\n",
      "      (VP (VBN felt)\n",
      "        (S\n",
      "          (VP (TO to)\n",
      "            (VP (VB result)\n",
      "              (PP (IN from)\n",
      "                (NP\n",
      "                  (NP (NN prevention))\n",
      "                  (PP (IN of)\n",
      "                    (NP\n",
      "                      (NP (DT the) (JJ adverse) (NNS effects))\n",
      "                      (PP (IN of)\n",
      "                        (NP (NNP AII)))))))\n",
      "              (PP (IN on)\n",
      "                (NP (JJ systemic) (JJ afterload)\n",
      "                  (CC and)\n",
      "                  (JJ renal) (NNS homeostasis))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(effects-3, The-1)\n",
      "amod(effects-3, beneficial-2)\n",
      "nsubjpass(felt-34, effects-3)\n",
      "nsubj:xsubj(result-36, effects-3)\n",
      "case(angiotensin-5, of-4)\n",
      "nmod:of(effects-3, angiotensin-5)\n",
      "acl(angiotensin-5, converting-6)\n",
      "compound(inhibitors-11, enzyme-7)\n",
      "appos(inhibitors-11, ACE-9)\n",
      "dobj(converting-6, inhibitors-11)\n",
      "cc(inhibitors-11, and-12)\n",
      "compound(II-14, angiotensin-13)\n",
      "dobj(converting-6, II-14)\n",
      "conj:and(inhibitors-11, II-14)\n",
      "appos(II-14, AII-16)\n",
      "compound(antagonists-19, receptor-18)\n",
      "dep(inhibitors-11, antagonists-19)\n",
      "case(patients-21, in-20)\n",
      "nmod:in(antagonists-19, patients-21)\n",
      "case(failure-24, with-22)\n",
      "compound(failure-24, heart-23)\n",
      "nmod:with(converting-6, failure-24)\n",
      "amod(failure-24, secondary-25)\n",
      "case(fraction-29, to-26)\n",
      "amod(fraction-29, reduced-27)\n",
      "amod(fraction-29, ejection-28)\n",
      "nmod:to(secondary-25, fraction-29)\n",
      "appos(fraction-29, HFrEF-31)\n",
      "auxpass(felt-34, are-33)\n",
      "root(ROOT-0, felt-34)\n",
      "mark(result-36, to-35)\n",
      "xcomp(felt-34, result-36)\n",
      "case(prevention-38, from-37)\n",
      "nmod:from(result-36, prevention-38)\n",
      "case(effects-42, of-39)\n",
      "det(effects-42, the-40)\n",
      "amod(effects-42, adverse-41)\n",
      "nmod:of(prevention-38, effects-42)\n",
      "case(AII-44, of-43)\n",
      "nmod:of(effects-42, AII-44)\n",
      "case(afterload-47, on-45)\n",
      "amod(afterload-47, systemic-46)\n",
      "nmod:on(result-36, afterload-47)\n",
      "cc(afterload-47, and-48)\n",
      "amod(homeostasis-50, renal-49)\n",
      "nmod:on(result-36, homeostasis-50)\n",
      "conj:and(afterload-47, homeostasis-50)\n",
      "\n",
      "Parsing [sent. 5 len. 31]: However , AII can activate the sympathetic nervous system and part of the beneficial effects of ACE inhibitors and AII antagonists may result from their ability to inhibit such activation .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (S\n",
      "      (NP (NNP AII))\n",
      "      (VP (MD can)\n",
      "        (VP (VB activate)\n",
      "          (NP\n",
      "            (NP (DT the)\n",
      "              (ADJP (JJ sympathetic) (JJ nervous))\n",
      "              (NN system))\n",
      "            (CC and)\n",
      "            (NP\n",
      "              (NP (NN part))\n",
      "              (PP (IN of)\n",
      "                (NP\n",
      "                  (NP (DT the) (JJ beneficial) (NNS effects))\n",
      "                  (PP (IN of)\n",
      "                    (NP (NN ACE) (NNS inhibitors))))))))))\n",
      "    (CC and)\n",
      "    (S\n",
      "      (NP (NNP AII) (NNS antagonists))\n",
      "      (VP (MD may)\n",
      "        (VP (VB result)\n",
      "          (PP (IN from)\n",
      "            (NP (PRP$ their) (NN ability)\n",
      "              (S\n",
      "                (VP (TO to)\n",
      "                  (VP (VB inhibit)\n",
      "                    (NP (JJ such) (NN activation))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(activate-5, However-1)\n",
      "nsubj(activate-5, AII-3)\n",
      "aux(activate-5, can-4)\n",
      "root(ROOT-0, activate-5)\n",
      "det(system-9, the-6)\n",
      "amod(nervous-8, sympathetic-7)\n",
      "amod(system-9, nervous-8)\n",
      "dobj(activate-5, system-9)\n",
      "cc(system-9, and-10)\n",
      "dobj(activate-5, part-11)\n",
      "conj:and(system-9, part-11)\n",
      "case(effects-15, of-12)\n",
      "det(effects-15, the-13)\n",
      "amod(effects-15, beneficial-14)\n",
      "nmod:of(part-11, effects-15)\n",
      "case(inhibitors-18, of-16)\n",
      "compound(inhibitors-18, ACE-17)\n",
      "nmod:of(effects-15, inhibitors-18)\n",
      "cc(activate-5, and-19)\n",
      "compound(antagonists-21, AII-20)\n",
      "nsubj(result-23, antagonists-21)\n",
      "aux(result-23, may-22)\n",
      "conj:and(activate-5, result-23)\n",
      "case(ability-26, from-24)\n",
      "nmod:poss(ability-26, their-25)\n",
      "nmod:from(result-23, ability-26)\n",
      "mark(inhibit-28, to-27)\n",
      "acl(ability-26, inhibit-28)\n",
      "amod(activation-30, such-29)\n",
      "dobj(inhibit-28, activation-30)\n",
      "\n",
      "Parsing [sent. 6 len. 49]: We examined the acute effects of the ACE inhibitor captopril -LRB- 25 mg , n = 9 -RRB- and the AII receptor antagonist losartan -LRB- 50 mg , n = 10 -RRB- on hemodynamics as well as total body and cardiac norepinephrine spillover in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (PRP We))\n",
      "    (VP (VBD examined)\n",
      "      (NP\n",
      "        (NP (DT the) (JJ acute) (NNS effects))\n",
      "        (PP (IN of)\n",
      "          (NP\n",
      "            (NP (DT the) (NNP ACE) (NNP inhibitor) (NNP captopril))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 25) (NN mg))\n",
      "                (, ,)\n",
      "                (NP (NNP n) (NNP =) (CD 9)))\n",
      "              (-RRB- -RRB-))\n",
      "            (CC and)\n",
      "            (NP (DT the) (NNP AII) (NN receptor) (NN antagonist) (NN losartan))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 50) (NN mg))\n",
      "                (, ,)\n",
      "                (NP (NNP n) (NNP =) (CD 10)))\n",
      "              (-RRB- -RRB-)))))\n",
      "      (PP (IN on)\n",
      "        (NP\n",
      "          (NP (NNS hemodynamics))\n",
      "          (CONJP (RB as) (RB well) (IN as))\n",
      "          (NP (JJ total) (NN body)\n",
      "            (CC and)\n",
      "            (JJ cardiac) (NN norepinephrine) (NN spillover))))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (NNS patients))\n",
      "          (PP (IN with)\n",
      "            (NP (JJ chronic) (NN HFrEF))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(examined-2, We-1)\n",
      "root(ROOT-0, examined-2)\n",
      "det(effects-5, the-3)\n",
      "amod(effects-5, acute-4)\n",
      "dobj(examined-2, effects-5)\n",
      "case(captopril-10, of-6)\n",
      "det(captopril-10, the-7)\n",
      "compound(captopril-10, ACE-8)\n",
      "compound(captopril-10, inhibitor-9)\n",
      "nmod:of(effects-5, captopril-10)\n",
      "nummod(mg-13, 25-12)\n",
      "dep(captopril-10, mg-13)\n",
      "compound(=-16, n-15)\n",
      "appos(mg-13, =-16)\n",
      "nummod(=-16, 9-17)\n",
      "cc(captopril-10, and-19)\n",
      "det(losartan-24, the-20)\n",
      "compound(losartan-24, AII-21)\n",
      "compound(losartan-24, receptor-22)\n",
      "compound(losartan-24, antagonist-23)\n",
      "nmod:of(effects-5, losartan-24)\n",
      "conj:and(captopril-10, losartan-24)\n",
      "nummod(mg-27, 50-26)\n",
      "dep(captopril-10, mg-27)\n",
      "compound(=-30, n-29)\n",
      "appos(mg-27, =-30)\n",
      "nummod(=-30, 10-31)\n",
      "case(hemodynamics-34, on-33)\n",
      "nmod:on(examined-2, hemodynamics-34)\n",
      "cc(hemodynamics-34, as-35)\n",
      "mwe(as-35, well-36)\n",
      "mwe(as-35, as-37)\n",
      "amod(body-39, total-38)\n",
      "nmod:on(examined-2, body-39)\n",
      "conj:and(hemodynamics-34, body-39)\n",
      "cc(body-39, and-40)\n",
      "amod(spillover-43, cardiac-41)\n",
      "compound(spillover-43, norepinephrine-42)\n",
      "conj:and(hemodynamics-34, spillover-43)\n",
      "conj:and(body-39, spillover-43)\n",
      "case(patients-45, in-44)\n",
      "nmod:in(examined-2, patients-45)\n",
      "case(HFrEF-48, with-46)\n",
      "amod(HFrEF-48, chronic-47)\n",
      "nmod:with(patients-45, HFrEF-48)\n",
      "\n",
      "Parsing [sent. 7 len. 20]: Hemodynamic and neurochemical measurements were made at baseline and at 1 , 2 and 4 hours after oral dosing .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (ADJP (JJ Hemodynamic)\n",
      "        (CC and)\n",
      "        (JJ neurochemical))\n",
      "      (NNS measurements))\n",
      "    (VP (VBD were)\n",
      "      (VP (VBN made)\n",
      "        (PP\n",
      "          (PP (IN at)\n",
      "            (NP (NN baseline)))\n",
      "          (CC and)\n",
      "          (PP (IN at)\n",
      "            (NP (CD 1) (, ,) (CD 2)\n",
      "              (CC and)\n",
      "              (CD 4)))\n",
      "          (NP (NNS hours)))\n",
      "        (PP (IN after)\n",
      "          (NP (JJ oral) (NN dosing)))))\n",
      "    (. .)))\n",
      "\n",
      "amod(measurements-4, Hemodynamic-1)\n",
      "cc(Hemodynamic-1, and-2)\n",
      "conj:and(Hemodynamic-1, neurochemical-3)\n",
      "amod(measurements-4, neurochemical-3)\n",
      "nsubjpass(made-6, measurements-4)\n",
      "auxpass(made-6, were-5)\n",
      "root(ROOT-0, made-6)\n",
      "case(baseline-8, at-7)\n",
      "nmod:at(hours-16, baseline-8)\n",
      "cc(hours-16, and-9)\n",
      "case(1-11, at-10)\n",
      "nmod(made-6, 1-11)\n",
      "conj:and(hours-16, 1-11)\n",
      "nummod(1-11, 2-13)\n",
      "cc(1-11, and-14)\n",
      "conj:and(1-11, 4-15)\n",
      "conj:and(hours-16, 4-15)\n",
      "nmod(made-6, hours-16)\n",
      "case(dosing-19, after-17)\n",
      "amod(dosing-19, oral-18)\n",
      "nmod:after(made-6, dosing-19)\n",
      "\n",
      "Parsing [sent. 8 len. 25]: Administration of both drugs caused significant reductions in systemic arterial , cardiac filling and pulmonary artery pressures -LRB- P < 0.05 vs baseline -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NN Administration))\n",
      "      (PP (IN of)\n",
      "        (NP (DT both) (NNS drugs))))\n",
      "    (VP (VBD caused)\n",
      "      (NP (JJ significant) (NNS reductions))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (JJ systemic) (NN arterial))\n",
      "          (, ,)\n",
      "          (NP (JJ cardiac) (NN filling))\n",
      "          (CC and)\n",
      "          (NP (JJ pulmonary) (NN artery) (NNS pressures))))\n",
      "      (PRN (-LRB- -LRB-)\n",
      "        (NP\n",
      "          (NP (NNP P) (NNP <))\n",
      "          (NP (CD 0.05) (NNP vs) (NN baseline)))\n",
      "        (-RRB- -RRB-)))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(caused-5, Administration-1)\n",
      "case(drugs-4, of-2)\n",
      "det(drugs-4, both-3)\n",
      "nmod:of(Administration-1, drugs-4)\n",
      "root(ROOT-0, caused-5)\n",
      "amod(reductions-7, significant-6)\n",
      "dobj(caused-5, reductions-7)\n",
      "case(arterial-10, in-8)\n",
      "amod(arterial-10, systemic-9)\n",
      "nmod:in(caused-5, arterial-10)\n",
      "amod(filling-13, cardiac-12)\n",
      "nmod:in(caused-5, filling-13)\n",
      "conj:and(arterial-10, filling-13)\n",
      "cc(arterial-10, and-14)\n",
      "amod(pressures-17, pulmonary-15)\n",
      "compound(pressures-17, artery-16)\n",
      "nmod:in(caused-5, pressures-17)\n",
      "conj:and(arterial-10, pressures-17)\n",
      "compound(<-20, P-19)\n",
      "dep(caused-5, <-20)\n",
      "nummod(baseline-23, 0.05-21)\n",
      "compound(baseline-23, vs-22)\n",
      "dep(<-20, baseline-23)\n",
      "\n",
      "Parsing [sent. 9 len. 13]: There was no significant difference in the magnitude of those hemodynamic effects .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (EX There))\n",
      "    (VP (VBD was)\n",
      "      (NP\n",
      "        (NP (DT no) (JJ significant) (NN difference))\n",
      "        (PP (IN in)\n",
      "          (NP\n",
      "            (NP (DT the) (NN magnitude))\n",
      "            (PP (IN of)\n",
      "              (NP (DT those) (JJ hemodynamic) (NNS effects)))))))\n",
      "    (. .)))\n",
      "\n",
      "expl(was-2, There-1)\n",
      "root(ROOT-0, was-2)\n",
      "neg(difference-5, no-3)\n",
      "amod(difference-5, significant-4)\n",
      "nsubj(was-2, difference-5)\n",
      "case(magnitude-8, in-6)\n",
      "det(magnitude-8, the-7)\n",
      "nmod:in(difference-5, magnitude-8)\n",
      "case(effects-12, of-9)\n",
      "det(effects-12, those-10)\n",
      "amod(effects-12, hemodynamic-11)\n",
      "nmod:of(magnitude-8, effects-12)\n",
      "\n",
      "Parsing [sent. 10 len. 23]: Plasma concentrations of AII were significantly decreased by captopril and increased by losartan -LRB- P < 0.05 vs baseline for both -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NN Plasma) (NNS concentrations))\n",
      "      (PP (IN of)\n",
      "        (NP (NNP AII))))\n",
      "    (VP (VBD were)\n",
      "      (ADVP (RB significantly))\n",
      "      (VP\n",
      "        (VP (VBN decreased)\n",
      "          (PP (IN by)\n",
      "            (NP (NNP captopril))))\n",
      "        (CC and)\n",
      "        (VP (VBN increased)\n",
      "          (PP (IN by)\n",
      "            (NP\n",
      "              (NP (NNP losartan))\n",
      "              (PRN (-LRB- -LRB-)\n",
      "                (NP\n",
      "                  (NP (NNP P) (NNP <) (NNP 0.05) (NNP vs) (NN baseline))\n",
      "                  (PP (IN for)\n",
      "                    (NP (DT both))))\n",
      "                (-RRB- -RRB-)))))))\n",
      "    (. .)))\n",
      "\n",
      "compound(concentrations-2, Plasma-1)\n",
      "nsubjpass(decreased-7, concentrations-2)\n",
      "nsubjpass(increased-11, concentrations-2)\n",
      "case(AII-4, of-3)\n",
      "nmod:of(concentrations-2, AII-4)\n",
      "auxpass(decreased-7, were-5)\n",
      "advmod(decreased-7, significantly-6)\n",
      "root(ROOT-0, decreased-7)\n",
      "case(captopril-9, by-8)\n",
      "nmod:by(decreased-7, captopril-9)\n",
      "cc(decreased-7, and-10)\n",
      "conj:and(decreased-7, increased-11)\n",
      "case(losartan-13, by-12)\n",
      "nmod:by(increased-11, losartan-13)\n",
      "compound(baseline-19, P-15)\n",
      "compound(baseline-19, <-16)\n",
      "compound(baseline-19, 0.05-17)\n",
      "compound(baseline-19, vs-18)\n",
      "dep(losartan-13, baseline-19)\n",
      "case(both-21, for-20)\n",
      "nmod:for(baseline-19, both-21)\n",
      "\n",
      "Parsing [sent. 11 len. 37]: Total body sympathetic activity increased in response to both captopril and losartan -LRB- P < 0.05 vs baseline for both -RRB- , however there was no change in cardiac sympathetic activity in response to either drug .\n",
      "(ROOT\n",
      "  (S\n",
      "    (S\n",
      "      (NP\n",
      "        (NP (JJ Total) (NN body))\n",
      "        (NP (JJ sympathetic) (NN activity)))\n",
      "      (VP (VBD increased)\n",
      "        (PP (IN in)\n",
      "          (NP (NN response)))\n",
      "        (PP (TO to)\n",
      "          (NP (DT both) (NNP captopril)\n",
      "            (CC and)\n",
      "            (NNP losartan)))\n",
      "        (PRN (-LRB- -LRB-)\n",
      "          (NP\n",
      "            (NP (NNP P) (NNP <) (NNP 0.05) (NNP vs) (NN baseline))\n",
      "            (PP (IN for)\n",
      "              (NP (DT both))))\n",
      "          (-RRB- -RRB-))))\n",
      "    (, ,)\n",
      "    (ADVP (RB however))\n",
      "    (S\n",
      "      (NP (EX there))\n",
      "      (VP (VBD was)\n",
      "        (NP\n",
      "          (NP (DT no) (NN change))\n",
      "          (PP (IN in)\n",
      "            (NP\n",
      "              (NP (JJ cardiac) (JJ sympathetic) (NN activity))\n",
      "              (PP (IN in)\n",
      "                (NP (NN response))))))\n",
      "        (PP (TO to)\n",
      "          (NP (DT either) (NN drug)))))\n",
      "    (. .)))\n",
      "\n",
      "amod(body-2, Total-1)\n",
      "nsubj(increased-5, body-2)\n",
      "amod(activity-4, sympathetic-3)\n",
      "dep(body-2, activity-4)\n",
      "root(ROOT-0, increased-5)\n",
      "case(response-7, in-6)\n",
      "nmod:in(increased-5, response-7)\n",
      "case(captopril-10, to-8)\n",
      "cc:preconj(captopril-10, both-9)\n",
      "nmod:to(increased-5, captopril-10)\n",
      "cc(captopril-10, and-11)\n",
      "nmod:to(increased-5, losartan-12)\n",
      "conj:and(captopril-10, losartan-12)\n",
      "compound(baseline-18, P-14)\n",
      "compound(baseline-18, <-15)\n",
      "compound(baseline-18, 0.05-16)\n",
      "compound(baseline-18, vs-17)\n",
      "dep(increased-5, baseline-18)\n",
      "case(both-20, for-19)\n",
      "nmod:for(baseline-18, both-20)\n",
      "advmod(was-25, however-23)\n",
      "expl(was-25, there-24)\n",
      "parataxis(increased-5, was-25)\n",
      "neg(change-27, no-26)\n",
      "nsubj(was-25, change-27)\n",
      "case(activity-31, in-28)\n",
      "amod(activity-31, cardiac-29)\n",
      "amod(activity-31, sympathetic-30)\n",
      "nmod:in(change-27, activity-31)\n",
      "case(response-33, in-32)\n",
      "nmod:in(activity-31, response-33)\n",
      "case(drug-36, to-34)\n",
      "det(drug-36, either-35)\n",
      "nmod:to(was-25, drug-36)\n",
      "\n",
      "Parsing [sent. 12 len. 29]: The results of the current study do not support the hypothesis that the acute inhibition of the renin angiotensin system has sympathoinhibitory effects in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (NNS results))\n",
      "      (PP (IN of)\n",
      "        (NP (DT the) (JJ current) (NN study))))\n",
      "    (VP (VBP do) (RB not)\n",
      "      (VP (VB support)\n",
      "        (NP (DT the) (NNS hypothesis))\n",
      "        (SBAR (IN that)\n",
      "          (S\n",
      "            (NP\n",
      "              (NP (DT the) (JJ acute) (NN inhibition))\n",
      "              (PP (IN of)\n",
      "                (NP (DT the) (NNP renin) (NN angiotensin) (NN system))))\n",
      "            (VP (VBZ has)\n",
      "              (NP\n",
      "                (NP (JJ sympathoinhibitory) (NNS effects))\n",
      "                (PP (IN in)\n",
      "                  (NP\n",
      "                    (NP (NNS patients))\n",
      "                    (PP (IN with)\n",
      "                      (NP (JJ chronic) (NN HFrEF)))))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(results-2, The-1)\n",
      "nsubj(support-9, results-2)\n",
      "case(study-6, of-3)\n",
      "det(study-6, the-4)\n",
      "amod(study-6, current-5)\n",
      "nmod:of(results-2, study-6)\n",
      "aux(support-9, do-7)\n",
      "neg(support-9, not-8)\n",
      "root(ROOT-0, support-9)\n",
      "det(hypothesis-11, the-10)\n",
      "dobj(support-9, hypothesis-11)\n",
      "mark(has-21, that-12)\n",
      "det(inhibition-15, the-13)\n",
      "amod(inhibition-15, acute-14)\n",
      "nsubj(has-21, inhibition-15)\n",
      "case(system-20, of-16)\n",
      "det(system-20, the-17)\n",
      "compound(system-20, renin-18)\n",
      "compound(system-20, angiotensin-19)\n",
      "nmod:of(inhibition-15, system-20)\n",
      "ccomp(support-9, has-21)\n",
      "amod(effects-23, sympathoinhibitory-22)\n",
      "dobj(has-21, effects-23)\n",
      "case(patients-25, in-24)\n",
      "nmod:in(effects-23, patients-25)\n",
      "case(HFrEF-28, with-26)\n",
      "amod(HFrEF-28, chronic-27)\n",
      "nmod:with(patients-25, HFrEF-28)\n",
      "\n",
      "Parsed file: KeywordSentences.txt [12 sentences].\n",
      "Parsed 408 words in 12 sentences (36.21 wds/sec; 1.07 sents/sec).\n",
      "SLF4J: Failed to load class \"org.slf4j.impl.StaticLoggerBinder\".\n",
      "SLF4J: Defaulting to no-operation (NOP) logger implementation\n",
      "SLF4J: See http://www.slf4j.org/codes.html#StaticLoggerBinder for further details.\n",
      "Parsing file: KeywordSentences.txt\n",
      "Parsing [sent. 1 len. 52]: RAAS , a major pharmacological target in cardiovascular medicine , is inhibited by pharmacological classes including angiotensin converting enzyme -LRB- ACE -RRB- inhibitors -LRB- ACEIs -RRB- , angiotensin-II type 1 blockers -LRB- ARBs -RRB- and aldosterone receptors antagonists , in addition to the recently introduced direct renin inhibitors -LRB- DRIs -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNS RAAS))\n",
      "      (, ,)\n",
      "      (NP\n",
      "        (NP (DT a) (JJ major) (JJ pharmacological) (NN target))\n",
      "        (PP (IN in)\n",
      "          (NP (JJ cardiovascular) (NN medicine))))\n",
      "      (, ,))\n",
      "    (VP (VBZ is)\n",
      "      (ADJP (JJ inhibited)\n",
      "        (PP (IN by)\n",
      "          (NP\n",
      "            (NP (JJ pharmacological) (NNS classes))\n",
      "            (PP (VBG including)\n",
      "              (NP\n",
      "                (NP (NN angiotensin))\n",
      "                (VP (VBG converting)\n",
      "                  (NP\n",
      "                    (NP (NNP enzyme)\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP ACE))\n",
      "                        (-RRB- -RRB-))\n",
      "                      (NNP inhibitors))\n",
      "                    (PRN (-LRB- -LRB-)\n",
      "                      (NP (NNP ACEIs))\n",
      "                      (-RRB- -RRB-))\n",
      "                    (, ,)\n",
      "                    (NP\n",
      "                      (NP (JJ angiotensin-II) (NN type))\n",
      "                      (NP\n",
      "                        (NP (CD 1) (NNS blockers))\n",
      "                        (PRN (-LRB- -LRB-)\n",
      "                          (NP (NNS ARBs))\n",
      "                          (-RRB- -RRB-))))\n",
      "                    (CC and)\n",
      "                    (NP\n",
      "                      (NP\n",
      "                        (NP (JJ aldosterone) (NNS receptors) (NNS antagonists))\n",
      "                        (, ,)\n",
      "                        (PP (IN in)\n",
      "                          (NP\n",
      "                            (NP (NN addition))\n",
      "                            (PP (TO to)\n",
      "                              (NP (DT the)\n",
      "                                (ADJP (RB recently) (VBN introduced))\n",
      "                                (NNP direct) (NNP renin) (NNP inhibitors))))))\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP DRIs))\n",
      "                        (-RRB- -RRB-)))))))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(inhibited-12, RAAS-1)\n",
      "det(target-6, a-3)\n",
      "amod(target-6, major-4)\n",
      "amod(target-6, pharmacological-5)\n",
      "appos(RAAS-1, target-6)\n",
      "case(medicine-9, in-7)\n",
      "amod(medicine-9, cardiovascular-8)\n",
      "nmod:in(target-6, medicine-9)\n",
      "cop(inhibited-12, is-11)\n",
      "root(ROOT-0, inhibited-12)\n",
      "case(classes-15, by-13)\n",
      "amod(classes-15, pharmacological-14)\n",
      "nmod:by(inhibited-12, classes-15)\n",
      "case(angiotensin-17, including-16)\n",
      "nmod:including(classes-15, angiotensin-17)\n",
      "acl(angiotensin-17, converting-18)\n",
      "compound(inhibitors-23, enzyme-19)\n",
      "appos(inhibitors-23, ACE-21)\n",
      "dobj(converting-18, inhibitors-23)\n",
      "appos(inhibitors-23, ACEIs-25)\n",
      "amod(type-29, angiotensin-II-28)\n",
      "dobj(converting-18, type-29)\n",
      "conj:and(inhibitors-23, type-29)\n",
      "nummod(blockers-31, 1-30)\n",
      "dep(type-29, blockers-31)\n",
      "appos(blockers-31, ARBs-33)\n",
      "cc(inhibitors-23, and-35)\n",
      "amod(antagonists-38, aldosterone-36)\n",
      "compound(antagonists-38, receptors-37)\n",
      "dobj(converting-18, antagonists-38)\n",
      "conj:and(inhibitors-23, antagonists-38)\n",
      "case(inhibitors-48, in-40)\n",
      "mwe(in-40, addition-41)\n",
      "mwe(in-40, to-42)\n",
      "det(inhibitors-48, the-43)\n",
      "advmod(introduced-45, recently-44)\n",
      "amod(inhibitors-48, introduced-45)\n",
      "compound(inhibitors-48, direct-46)\n",
      "compound(inhibitors-48, renin-47)\n",
      "nmod:in_addition_to(antagonists-38, inhibitors-48)\n",
      "appos(antagonists-38, DRIs-50)\n",
      "\n",
      "Parsing [sent. 2 len. 36]: However , currently used RAAS inhibitors still can not achieve their desired effects and are associated with certain drawbacks , such as adverse side effects , incomplete blockage of the system and poor end-organ protection .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (ADVP (RB currently))\n",
      "    (VP (VBD used)\n",
      "      (SBAR\n",
      "        (S\n",
      "          (NP (NNP RAAS) (NNP inhibitors))\n",
      "          (ADVP (RB still))\n",
      "          (VP\n",
      "            (VP (MD can) (RB not)\n",
      "              (VP (VB achieve)\n",
      "                (NP (PRP$ their) (VBN desired) (NNS effects))))\n",
      "            (CC and)\n",
      "            (VP (VBP are)\n",
      "              (VP (VBN associated)\n",
      "                (PP (IN with)\n",
      "                  (NP\n",
      "                    (NP (JJ certain) (NNS drawbacks))\n",
      "                    (, ,)\n",
      "                    (PP (JJ such) (IN as)\n",
      "                      (NP (JJ adverse) (NN side) (NNS effects)))\n",
      "                    (, ,)\n",
      "                    (ADJP (JJ incomplete) (JJ blockage))\n",
      "                    (PP (IN of)\n",
      "                      (NP\n",
      "                        (NP (DT the) (NN system))\n",
      "                        (CC and)\n",
      "                        (NP (JJ poor) (JJ end-organ) (NN protection))))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(used-4, However-1)\n",
      "advmod(used-4, currently-3)\n",
      "root(ROOT-0, used-4)\n",
      "compound(inhibitors-6, RAAS-5)\n",
      "nsubj(achieve-10, inhibitors-6)\n",
      "nsubjpass(associated-16, inhibitors-6)\n",
      "advmod(achieve-10, still-7)\n",
      "aux(achieve-10, can-8)\n",
      "neg(achieve-10, not-9)\n",
      "ccomp(used-4, achieve-10)\n",
      "nmod:poss(effects-13, their-11)\n",
      "amod(effects-13, desired-12)\n",
      "dobj(achieve-10, effects-13)\n",
      "cc(achieve-10, and-14)\n",
      "auxpass(associated-16, are-15)\n",
      "ccomp(used-4, associated-16)\n",
      "conj:and(achieve-10, associated-16)\n",
      "case(drawbacks-19, with-17)\n",
      "amod(drawbacks-19, certain-18)\n",
      "nmod:with(associated-16, drawbacks-19)\n",
      "case(effects-25, such-21)\n",
      "mwe(such-21, as-22)\n",
      "amod(effects-25, adverse-23)\n",
      "compound(effects-25, side-24)\n",
      "nmod:such_as(drawbacks-19, effects-25)\n",
      "amod(blockage-28, incomplete-27)\n",
      "amod(drawbacks-19, blockage-28)\n",
      "case(system-31, of-29)\n",
      "det(system-31, the-30)\n",
      "nmod:of(drawbacks-19, system-31)\n",
      "cc(system-31, and-32)\n",
      "amod(protection-35, poor-33)\n",
      "amod(protection-35, end-organ-34)\n",
      "nmod:of(drawbacks-19, protection-35)\n",
      "conj:and(system-31, protection-35)\n",
      "\n",
      "Parsing [sent. 3 len. 42]: In this review , we discuss the efficiency and specificity of the current RAAS inhibitors and propose some recommendations for achieving better treatments with better end-organ protection.Hypertension Research advance online publication , 6 July 2017 ; doi :10.1038 / hr .2017.65 .\n",
      "(ROOT\n",
      "  (S\n",
      "    (PP (IN In)\n",
      "      (NP (DT this) (NN review)))\n",
      "    (, ,)\n",
      "    (NP (PRP we))\n",
      "    (VP\n",
      "      (VP (VB discuss)\n",
      "        (NP\n",
      "          (NP (DT the) (NN efficiency)\n",
      "            (CC and)\n",
      "            (NN specificity))\n",
      "          (PP (IN of)\n",
      "            (NP (DT the) (JJ current) (JJ RAAS) (NNS inhibitors)))))\n",
      "      (CC and)\n",
      "      (VP (VB propose)\n",
      "        (NP\n",
      "          (NP\n",
      "            (NP (DT some) (NNS recommendations))\n",
      "            (PP (IN for)\n",
      "              (S\n",
      "                (VP (VBG achieving)\n",
      "                  (NP (JJR better) (NNS treatments))\n",
      "                  (PP (IN with)\n",
      "                    (NP (NNP better) (NNP end-organ) (NNP protection.Hypertension) (NNP Research) (NNP advance) (JJ online) (NN publication)))))))\n",
      "          (, ,)\n",
      "          (NP\n",
      "            (NP (CD 6))\n",
      "            (NP (NNP July) (CD 2017)))\n",
      "          (: ;)\n",
      "          (NP\n",
      "            (QP (CD doi) (CD :10.1038))\n",
      "            (NNS /))\n",
      "          (NP (NNP hr) (CD .2017.65)))))\n",
      "    (. .)))\n",
      "\n",
      "case(review-3, In-1)\n",
      "det(review-3, this-2)\n",
      "nmod:in(discuss-6, review-3)\n",
      "nsubj(discuss-6, we-5)\n",
      "nsubj(propose-17, we-5)\n",
      "root(ROOT-0, discuss-6)\n",
      "det(efficiency-8, the-7)\n",
      "dobj(discuss-6, efficiency-8)\n",
      "cc(efficiency-8, and-9)\n",
      "dobj(discuss-6, specificity-10)\n",
      "conj:and(efficiency-8, specificity-10)\n",
      "case(inhibitors-15, of-11)\n",
      "det(inhibitors-15, the-12)\n",
      "amod(inhibitors-15, current-13)\n",
      "amod(inhibitors-15, RAAS-14)\n",
      "nmod:of(efficiency-8, inhibitors-15)\n",
      "cc(discuss-6, and-16)\n",
      "conj:and(discuss-6, propose-17)\n",
      "det(recommendations-19, some-18)\n",
      "dobj(propose-17, recommendations-19)\n",
      "mark(achieving-21, for-20)\n",
      "acl(recommendations-19, achieving-21)\n",
      "amod(treatments-23, better-22)\n",
      "dobj(achieving-21, treatments-23)\n",
      "case(publication-31, with-24)\n",
      "compound(publication-31, better-25)\n",
      "compound(publication-31, end-organ-26)\n",
      "compound(publication-31, protection.Hypertension-27)\n",
      "compound(publication-31, Research-28)\n",
      "compound(publication-31, advance-29)\n",
      "amod(publication-31, online-30)\n",
      "nmod:with(achieving-21, publication-31)\n",
      "appos(recommendations-19, 6-33)\n",
      "dep(6-33, July-34)\n",
      "nummod(July-34, 2017-35)\n",
      "compound(:10.1038-38, doi-37)\n",
      "nummod(/-39, :10.1038-38)\n",
      "dep(recommendations-19, /-39)\n",
      "dep(recommendations-19, hr-40)\n",
      "nummod(hr-40, .2017.65-41)\n",
      "\n",
      "Parsing [sent. 4 len. 51]: The beneficial effects of angiotensin converting enzyme -LRB- ACE -RRB- inhibitors and angiotensin II -LRB- AII -RRB- receptor antagonists in patients with heart failure secondary to reduced ejection fraction -LRB- HFrEF -RRB- are felt to result from prevention of the adverse effects of AII on systemic afterload and renal homeostasis .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (JJ beneficial) (NNS effects))\n",
      "      (PP (IN of)\n",
      "        (NP\n",
      "          (NP (NN angiotensin))\n",
      "          (VP (VBG converting)\n",
      "            (NP\n",
      "              (NP (NNP enzyme)\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP ACE))\n",
      "                  (-RRB- -RRB-))\n",
      "                (NNP inhibitors))\n",
      "              (CC and)\n",
      "              (NP\n",
      "                (NP (NNP angiotensin) (NNP II))\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP AII))\n",
      "                  (-RRB- -RRB-)))\n",
      "              (NP\n",
      "                (NP (NN receptor) (NNS antagonists))\n",
      "                (PP (IN in)\n",
      "                  (NP (NNS patients)))))\n",
      "            (PP (IN with)\n",
      "              (NP\n",
      "                (NP (NN heart) (NN failure))\n",
      "                (ADJP (JJ secondary)\n",
      "                  (PP (TO to)\n",
      "                    (NP\n",
      "                      (NP (VBN reduced) (JJ ejection) (NN fraction))\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP HFrEF))\n",
      "                        (-RRB- -RRB-)))))))))))\n",
      "    (VP (VBP are)\n",
      "      (VP (VBN felt)\n",
      "        (S\n",
      "          (VP (TO to)\n",
      "            (VP (VB result)\n",
      "              (PP (IN from)\n",
      "                (NP\n",
      "                  (NP (NN prevention))\n",
      "                  (PP (IN of)\n",
      "                    (NP\n",
      "                      (NP (DT the) (JJ adverse) (NNS effects))\n",
      "                      (PP (IN of)\n",
      "                        (NP (NNP AII)))))))\n",
      "              (PP (IN on)\n",
      "                (NP (JJ systemic) (JJ afterload)\n",
      "                  (CC and)\n",
      "                  (JJ renal) (NNS homeostasis))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(effects-3, The-1)\n",
      "amod(effects-3, beneficial-2)\n",
      "nsubjpass(felt-34, effects-3)\n",
      "nsubj:xsubj(result-36, effects-3)\n",
      "case(angiotensin-5, of-4)\n",
      "nmod:of(effects-3, angiotensin-5)\n",
      "acl(angiotensin-5, converting-6)\n",
      "compound(inhibitors-11, enzyme-7)\n",
      "appos(inhibitors-11, ACE-9)\n",
      "dobj(converting-6, inhibitors-11)\n",
      "cc(inhibitors-11, and-12)\n",
      "compound(II-14, angiotensin-13)\n",
      "dobj(converting-6, II-14)\n",
      "conj:and(inhibitors-11, II-14)\n",
      "appos(II-14, AII-16)\n",
      "compound(antagonists-19, receptor-18)\n",
      "dep(inhibitors-11, antagonists-19)\n",
      "case(patients-21, in-20)\n",
      "nmod:in(antagonists-19, patients-21)\n",
      "case(failure-24, with-22)\n",
      "compound(failure-24, heart-23)\n",
      "nmod:with(converting-6, failure-24)\n",
      "amod(failure-24, secondary-25)\n",
      "case(fraction-29, to-26)\n",
      "amod(fraction-29, reduced-27)\n",
      "amod(fraction-29, ejection-28)\n",
      "nmod:to(secondary-25, fraction-29)\n",
      "appos(fraction-29, HFrEF-31)\n",
      "auxpass(felt-34, are-33)\n",
      "root(ROOT-0, felt-34)\n",
      "mark(result-36, to-35)\n",
      "xcomp(felt-34, result-36)\n",
      "case(prevention-38, from-37)\n",
      "nmod:from(result-36, prevention-38)\n",
      "case(effects-42, of-39)\n",
      "det(effects-42, the-40)\n",
      "amod(effects-42, adverse-41)\n",
      "nmod:of(prevention-38, effects-42)\n",
      "case(AII-44, of-43)\n",
      "nmod:of(effects-42, AII-44)\n",
      "case(afterload-47, on-45)\n",
      "amod(afterload-47, systemic-46)\n",
      "nmod:on(result-36, afterload-47)\n",
      "cc(afterload-47, and-48)\n",
      "amod(homeostasis-50, renal-49)\n",
      "nmod:on(result-36, homeostasis-50)\n",
      "conj:and(afterload-47, homeostasis-50)\n",
      "\n",
      "Parsing [sent. 5 len. 31]: However , AII can activate the sympathetic nervous system and part of the beneficial effects of ACE inhibitors and AII antagonists may result from their ability to inhibit such activation .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (S\n",
      "      (NP (NNP AII))\n",
      "      (VP (MD can)\n",
      "        (VP (VB activate)\n",
      "          (NP\n",
      "            (NP (DT the)\n",
      "              (ADJP (JJ sympathetic) (JJ nervous))\n",
      "              (NN system))\n",
      "            (CC and)\n",
      "            (NP\n",
      "              (NP (NN part))\n",
      "              (PP (IN of)\n",
      "                (NP\n",
      "                  (NP (DT the) (JJ beneficial) (NNS effects))\n",
      "                  (PP (IN of)\n",
      "                    (NP (NN ACE) (NNS inhibitors))))))))))\n",
      "    (CC and)\n",
      "    (S\n",
      "      (NP (NNP AII) (NNS antagonists))\n",
      "      (VP (MD may)\n",
      "        (VP (VB result)\n",
      "          (PP (IN from)\n",
      "            (NP (PRP$ their) (NN ability)\n",
      "              (S\n",
      "                (VP (TO to)\n",
      "                  (VP (VB inhibit)\n",
      "                    (NP (JJ such) (NN activation))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(activate-5, However-1)\n",
      "nsubj(activate-5, AII-3)\n",
      "aux(activate-5, can-4)\n",
      "root(ROOT-0, activate-5)\n",
      "det(system-9, the-6)\n",
      "amod(nervous-8, sympathetic-7)\n",
      "amod(system-9, nervous-8)\n",
      "dobj(activate-5, system-9)\n",
      "cc(system-9, and-10)\n",
      "dobj(activate-5, part-11)\n",
      "conj:and(system-9, part-11)\n",
      "case(effects-15, of-12)\n",
      "det(effects-15, the-13)\n",
      "amod(effects-15, beneficial-14)\n",
      "nmod:of(part-11, effects-15)\n",
      "case(inhibitors-18, of-16)\n",
      "compound(inhibitors-18, ACE-17)\n",
      "nmod:of(effects-15, inhibitors-18)\n",
      "cc(activate-5, and-19)\n",
      "compound(antagonists-21, AII-20)\n",
      "nsubj(result-23, antagonists-21)\n",
      "aux(result-23, may-22)\n",
      "conj:and(activate-5, result-23)\n",
      "case(ability-26, from-24)\n",
      "nmod:poss(ability-26, their-25)\n",
      "nmod:from(result-23, ability-26)\n",
      "mark(inhibit-28, to-27)\n",
      "acl(ability-26, inhibit-28)\n",
      "amod(activation-30, such-29)\n",
      "dobj(inhibit-28, activation-30)\n",
      "\n",
      "Parsing [sent. 6 len. 49]: We examined the acute effects of the ACE inhibitor captopril -LRB- 25 mg , n = 9 -RRB- and the AII receptor antagonist losartan -LRB- 50 mg , n = 10 -RRB- on hemodynamics as well as total body and cardiac norepinephrine spillover in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (PRP We))\n",
      "    (VP (VBD examined)\n",
      "      (NP\n",
      "        (NP (DT the) (JJ acute) (NNS effects))\n",
      "        (PP (IN of)\n",
      "          (NP\n",
      "            (NP (DT the) (NNP ACE) (NNP inhibitor) (NNP captopril))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 25) (NN mg))\n",
      "                (, ,)\n",
      "                (NP (NNP n) (NNP =) (CD 9)))\n",
      "              (-RRB- -RRB-))\n",
      "            (CC and)\n",
      "            (NP (DT the) (NNP AII) (NN receptor) (NN antagonist) (NN losartan))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 50) (NN mg))\n",
      "                (, ,)\n",
      "                (NP (NNP n) (NNP =) (CD 10)))\n",
      "              (-RRB- -RRB-)))))\n",
      "      (PP (IN on)\n",
      "        (NP\n",
      "          (NP (NNS hemodynamics))\n",
      "          (CONJP (RB as) (RB well) (IN as))\n",
      "          (NP (JJ total) (NN body)\n",
      "            (CC and)\n",
      "            (JJ cardiac) (NN norepinephrine) (NN spillover))))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (NNS patients))\n",
      "          (PP (IN with)\n",
      "            (NP (JJ chronic) (NN HFrEF))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(examined-2, We-1)\n",
      "root(ROOT-0, examined-2)\n",
      "det(effects-5, the-3)\n",
      "amod(effects-5, acute-4)\n",
      "dobj(examined-2, effects-5)\n",
      "case(captopril-10, of-6)\n",
      "det(captopril-10, the-7)\n",
      "compound(captopril-10, ACE-8)\n",
      "compound(captopril-10, inhibitor-9)\n",
      "nmod:of(effects-5, captopril-10)\n",
      "nummod(mg-13, 25-12)\n",
      "dep(captopril-10, mg-13)\n",
      "compound(=-16, n-15)\n",
      "appos(mg-13, =-16)\n",
      "nummod(=-16, 9-17)\n",
      "cc(captopril-10, and-19)\n",
      "det(losartan-24, the-20)\n",
      "compound(losartan-24, AII-21)\n",
      "compound(losartan-24, receptor-22)\n",
      "compound(losartan-24, antagonist-23)\n",
      "nmod:of(effects-5, losartan-24)\n",
      "conj:and(captopril-10, losartan-24)\n",
      "nummod(mg-27, 50-26)\n",
      "dep(captopril-10, mg-27)\n",
      "compound(=-30, n-29)\n",
      "appos(mg-27, =-30)\n",
      "nummod(=-30, 10-31)\n",
      "case(hemodynamics-34, on-33)\n",
      "nmod:on(examined-2, hemodynamics-34)\n",
      "cc(hemodynamics-34, as-35)\n",
      "mwe(as-35, well-36)\n",
      "mwe(as-35, as-37)\n",
      "amod(body-39, total-38)\n",
      "nmod:on(examined-2, body-39)\n",
      "conj:and(hemodynamics-34, body-39)\n",
      "cc(body-39, and-40)\n",
      "amod(spillover-43, cardiac-41)\n",
      "compound(spillover-43, norepinephrine-42)\n",
      "conj:and(hemodynamics-34, spillover-43)\n",
      "conj:and(body-39, spillover-43)\n",
      "case(patients-45, in-44)\n",
      "nmod:in(examined-2, patients-45)\n",
      "case(HFrEF-48, with-46)\n",
      "amod(HFrEF-48, chronic-47)\n",
      "nmod:with(patients-45, HFrEF-48)\n",
      "\n",
      "Parsing [sent. 7 len. 20]: Hemodynamic and neurochemical measurements were made at baseline and at 1 , 2 and 4 hours after oral dosing .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (ADJP (JJ Hemodynamic)\n",
      "        (CC and)\n",
      "        (JJ neurochemical))\n",
      "      (NNS measurements))\n",
      "    (VP (VBD were)\n",
      "      (VP (VBN made)\n",
      "        (PP\n",
      "          (PP (IN at)\n",
      "            (NP (NN baseline)))\n",
      "          (CC and)\n",
      "          (PP (IN at)\n",
      "            (NP (CD 1) (, ,) (CD 2)\n",
      "              (CC and)\n",
      "              (CD 4)))\n",
      "          (NP (NNS hours)))\n",
      "        (PP (IN after)\n",
      "          (NP (JJ oral) (NN dosing)))))\n",
      "    (. .)))\n",
      "\n",
      "amod(measurements-4, Hemodynamic-1)\n",
      "cc(Hemodynamic-1, and-2)\n",
      "conj:and(Hemodynamic-1, neurochemical-3)\n",
      "amod(measurements-4, neurochemical-3)\n",
      "nsubjpass(made-6, measurements-4)\n",
      "auxpass(made-6, were-5)\n",
      "root(ROOT-0, made-6)\n",
      "case(baseline-8, at-7)\n",
      "nmod:at(hours-16, baseline-8)\n",
      "cc(hours-16, and-9)\n",
      "case(1-11, at-10)\n",
      "nmod(made-6, 1-11)\n",
      "conj:and(hours-16, 1-11)\n",
      "nummod(1-11, 2-13)\n",
      "cc(1-11, and-14)\n",
      "conj:and(1-11, 4-15)\n",
      "conj:and(hours-16, 4-15)\n",
      "nmod(made-6, hours-16)\n",
      "case(dosing-19, after-17)\n",
      "amod(dosing-19, oral-18)\n",
      "nmod:after(made-6, dosing-19)\n",
      "\n",
      "Parsing [sent. 8 len. 25]: Administration of both drugs caused significant reductions in systemic arterial , cardiac filling and pulmonary artery pressures -LRB- P < 0.05 vs baseline -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NN Administration))\n",
      "      (PP (IN of)\n",
      "        (NP (DT both) (NNS drugs))))\n",
      "    (VP (VBD caused)\n",
      "      (NP (JJ significant) (NNS reductions))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (JJ systemic) (NN arterial))\n",
      "          (, ,)\n",
      "          (NP (JJ cardiac) (NN filling))\n",
      "          (CC and)\n",
      "          (NP (JJ pulmonary) (NN artery) (NNS pressures))))\n",
      "      (PRN (-LRB- -LRB-)\n",
      "        (NP\n",
      "          (NP (NNP P) (NNP <))\n",
      "          (NP (CD 0.05) (NNP vs) (NN baseline)))\n",
      "        (-RRB- -RRB-)))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(caused-5, Administration-1)\n",
      "case(drugs-4, of-2)\n",
      "det(drugs-4, both-3)\n",
      "nmod:of(Administration-1, drugs-4)\n",
      "root(ROOT-0, caused-5)\n",
      "amod(reductions-7, significant-6)\n",
      "dobj(caused-5, reductions-7)\n",
      "case(arterial-10, in-8)\n",
      "amod(arterial-10, systemic-9)\n",
      "nmod:in(caused-5, arterial-10)\n",
      "amod(filling-13, cardiac-12)\n",
      "nmod:in(caused-5, filling-13)\n",
      "conj:and(arterial-10, filling-13)\n",
      "cc(arterial-10, and-14)\n",
      "amod(pressures-17, pulmonary-15)\n",
      "compound(pressures-17, artery-16)\n",
      "nmod:in(caused-5, pressures-17)\n",
      "conj:and(arterial-10, pressures-17)\n",
      "compound(<-20, P-19)\n",
      "dep(caused-5, <-20)\n",
      "nummod(baseline-23, 0.05-21)\n",
      "compound(baseline-23, vs-22)\n",
      "dep(<-20, baseline-23)\n",
      "\n",
      "Parsing [sent. 9 len. 13]: There was no significant difference in the magnitude of those hemodynamic effects .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (EX There))\n",
      "    (VP (VBD was)\n",
      "      (NP\n",
      "        (NP (DT no) (JJ significant) (NN difference))\n",
      "        (PP (IN in)\n",
      "          (NP\n",
      "            (NP (DT the) (NN magnitude))\n",
      "            (PP (IN of)\n",
      "              (NP (DT those) (JJ hemodynamic) (NNS effects)))))))\n",
      "    (. .)))\n",
      "\n",
      "expl(was-2, There-1)\n",
      "root(ROOT-0, was-2)\n",
      "neg(difference-5, no-3)\n",
      "amod(difference-5, significant-4)\n",
      "nsubj(was-2, difference-5)\n",
      "case(magnitude-8, in-6)\n",
      "det(magnitude-8, the-7)\n",
      "nmod:in(difference-5, magnitude-8)\n",
      "case(effects-12, of-9)\n",
      "det(effects-12, those-10)\n",
      "amod(effects-12, hemodynamic-11)\n",
      "nmod:of(magnitude-8, effects-12)\n",
      "\n",
      "Parsing [sent. 10 len. 23]: Plasma concentrations of AII were significantly decreased by captopril and increased by losartan -LRB- P < 0.05 vs baseline for both -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NN Plasma) (NNS concentrations))\n",
      "      (PP (IN of)\n",
      "        (NP (NNP AII))))\n",
      "    (VP (VBD were)\n",
      "      (ADVP (RB significantly))\n",
      "      (VP\n",
      "        (VP (VBN decreased)\n",
      "          (PP (IN by)\n",
      "            (NP (NNP captopril))))\n",
      "        (CC and)\n",
      "        (VP (VBN increased)\n",
      "          (PP (IN by)\n",
      "            (NP\n",
      "              (NP (NNP losartan))\n",
      "              (PRN (-LRB- -LRB-)\n",
      "                (NP\n",
      "                  (NP (NNP P) (NNP <) (NNP 0.05) (NNP vs) (NN baseline))\n",
      "                  (PP (IN for)\n",
      "                    (NP (DT both))))\n",
      "                (-RRB- -RRB-)))))))\n",
      "    (. .)))\n",
      "\n",
      "compound(concentrations-2, Plasma-1)\n",
      "nsubjpass(decreased-7, concentrations-2)\n",
      "nsubjpass(increased-11, concentrations-2)\n",
      "case(AII-4, of-3)\n",
      "nmod:of(concentrations-2, AII-4)\n",
      "auxpass(decreased-7, were-5)\n",
      "advmod(decreased-7, significantly-6)\n",
      "root(ROOT-0, decreased-7)\n",
      "case(captopril-9, by-8)\n",
      "nmod:by(decreased-7, captopril-9)\n",
      "cc(decreased-7, and-10)\n",
      "conj:and(decreased-7, increased-11)\n",
      "case(losartan-13, by-12)\n",
      "nmod:by(increased-11, losartan-13)\n",
      "compound(baseline-19, P-15)\n",
      "compound(baseline-19, <-16)\n",
      "compound(baseline-19, 0.05-17)\n",
      "compound(baseline-19, vs-18)\n",
      "dep(losartan-13, baseline-19)\n",
      "case(both-21, for-20)\n",
      "nmod:for(baseline-19, both-21)\n",
      "\n",
      "Parsing [sent. 11 len. 37]: Total body sympathetic activity increased in response to both captopril and losartan -LRB- P < 0.05 vs baseline for both -RRB- , however there was no change in cardiac sympathetic activity in response to either drug .\n",
      "(ROOT\n",
      "  (S\n",
      "    (S\n",
      "      (NP\n",
      "        (NP (JJ Total) (NN body))\n",
      "        (NP (JJ sympathetic) (NN activity)))\n",
      "      (VP (VBD increased)\n",
      "        (PP (IN in)\n",
      "          (NP (NN response)))\n",
      "        (PP (TO to)\n",
      "          (NP (DT both) (NNP captopril)\n",
      "            (CC and)\n",
      "            (NNP losartan)))\n",
      "        (PRN (-LRB- -LRB-)\n",
      "          (NP\n",
      "            (NP (NNP P) (NNP <) (NNP 0.05) (NNP vs) (NN baseline))\n",
      "            (PP (IN for)\n",
      "              (NP (DT both))))\n",
      "          (-RRB- -RRB-))))\n",
      "    (, ,)\n",
      "    (ADVP (RB however))\n",
      "    (S\n",
      "      (NP (EX there))\n",
      "      (VP (VBD was)\n",
      "        (NP\n",
      "          (NP (DT no) (NN change))\n",
      "          (PP (IN in)\n",
      "            (NP\n",
      "              (NP (JJ cardiac) (JJ sympathetic) (NN activity))\n",
      "              (PP (IN in)\n",
      "                (NP (NN response))))))\n",
      "        (PP (TO to)\n",
      "          (NP (DT either) (NN drug)))))\n",
      "    (. .)))\n",
      "\n",
      "amod(body-2, Total-1)\n",
      "nsubj(increased-5, body-2)\n",
      "amod(activity-4, sympathetic-3)\n",
      "dep(body-2, activity-4)\n",
      "root(ROOT-0, increased-5)\n",
      "case(response-7, in-6)\n",
      "nmod:in(increased-5, response-7)\n",
      "case(captopril-10, to-8)\n",
      "cc:preconj(captopril-10, both-9)\n",
      "nmod:to(increased-5, captopril-10)\n",
      "cc(captopril-10, and-11)\n",
      "nmod:to(increased-5, losartan-12)\n",
      "conj:and(captopril-10, losartan-12)\n",
      "compound(baseline-18, P-14)\n",
      "compound(baseline-18, <-15)\n",
      "compound(baseline-18, 0.05-16)\n",
      "compound(baseline-18, vs-17)\n",
      "dep(increased-5, baseline-18)\n",
      "case(both-20, for-19)\n",
      "nmod:for(baseline-18, both-20)\n",
      "advmod(was-25, however-23)\n",
      "expl(was-25, there-24)\n",
      "parataxis(increased-5, was-25)\n",
      "neg(change-27, no-26)\n",
      "nsubj(was-25, change-27)\n",
      "case(activity-31, in-28)\n",
      "amod(activity-31, cardiac-29)\n",
      "amod(activity-31, sympathetic-30)\n",
      "nmod:in(change-27, activity-31)\n",
      "case(response-33, in-32)\n",
      "nmod:in(activity-31, response-33)\n",
      "case(drug-36, to-34)\n",
      "det(drug-36, either-35)\n",
      "nmod:to(was-25, drug-36)\n",
      "\n",
      "Parsing [sent. 12 len. 29]: The results of the current study do not support the hypothesis that the acute inhibition of the renin angiotensin system has sympathoinhibitory effects in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (NNS results))\n",
      "      (PP (IN of)\n",
      "        (NP (DT the) (JJ current) (NN study))))\n",
      "    (VP (VBP do) (RB not)\n",
      "      (VP (VB support)\n",
      "        (NP (DT the) (NNS hypothesis))\n",
      "        (SBAR (IN that)\n",
      "          (S\n",
      "            (NP\n",
      "              (NP (DT the) (JJ acute) (NN inhibition))\n",
      "              (PP (IN of)\n",
      "                (NP (DT the) (NNP renin) (NN angiotensin) (NN system))))\n",
      "            (VP (VBZ has)\n",
      "              (NP\n",
      "                (NP (JJ sympathoinhibitory) (NNS effects))\n",
      "                (PP (IN in)\n",
      "                  (NP\n",
      "                    (NP (NNS patients))\n",
      "                    (PP (IN with)\n",
      "                      (NP (JJ chronic) (NN HFrEF)))))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(results-2, The-1)\n",
      "nsubj(support-9, results-2)\n",
      "case(study-6, of-3)\n",
      "det(study-6, the-4)\n",
      "amod(study-6, current-5)\n",
      "nmod:of(results-2, study-6)\n",
      "aux(support-9, do-7)\n",
      "neg(support-9, not-8)\n",
      "root(ROOT-0, support-9)\n",
      "det(hypothesis-11, the-10)\n",
      "dobj(support-9, hypothesis-11)\n",
      "mark(has-21, that-12)\n",
      "det(inhibition-15, the-13)\n",
      "amod(inhibition-15, acute-14)\n",
      "nsubj(has-21, inhibition-15)\n",
      "case(system-20, of-16)\n",
      "det(system-20, the-17)\n",
      "compound(system-20, renin-18)\n",
      "compound(system-20, angiotensin-19)\n",
      "nmod:of(inhibition-15, system-20)\n",
      "ccomp(support-9, has-21)\n",
      "amod(effects-23, sympathoinhibitory-22)\n",
      "dobj(has-21, effects-23)\n",
      "case(patients-25, in-24)\n",
      "nmod:in(effects-23, patients-25)\n",
      "case(HFrEF-28, with-26)\n",
      "amod(HFrEF-28, chronic-27)\n",
      "nmod:with(patients-25, HFrEF-28)\n",
      "\n",
      "Parsed file: KeywordSentences.txt [12 sentences].\n",
      "Parsed 408 words in 12 sentences (36.45 wds/sec; 1.07 sents/sec).\n",
      "SLF4J: Failed to load class \"org.slf4j.impl.StaticLoggerBinder\".\n",
      "SLF4J: Defaulting to no-operation (NOP) logger implementation\n",
      "SLF4J: See http://www.slf4j.org/codes.html#StaticLoggerBinder for further details.\n",
      "Parsing file: KeywordSentences.txt\n",
      "Parsing [sent. 1 len. 52]: RAAS , a major pharmacological target in cardiovascular medicine , is inhibited by pharmacological classes including angiotensin converting enzyme -LRB- ACE -RRB- inhibitors -LRB- ACEIs -RRB- , angiotensin-II type 1 blockers -LRB- ARBs -RRB- and aldosterone receptors antagonists , in addition to the recently introduced direct renin inhibitors -LRB- DRIs -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NNS RAAS))\n",
      "      (, ,)\n",
      "      (NP\n",
      "        (NP (DT a) (JJ major) (JJ pharmacological) (NN target))\n",
      "        (PP (IN in)\n",
      "          (NP (JJ cardiovascular) (NN medicine))))\n",
      "      (, ,))\n",
      "    (VP (VBZ is)\n",
      "      (ADJP (JJ inhibited)\n",
      "        (PP (IN by)\n",
      "          (NP\n",
      "            (NP (JJ pharmacological) (NNS classes))\n",
      "            (PP (VBG including)\n",
      "              (NP\n",
      "                (NP (NN angiotensin))\n",
      "                (VP (VBG converting)\n",
      "                  (NP\n",
      "                    (NP (NNP enzyme)\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP ACE))\n",
      "                        (-RRB- -RRB-))\n",
      "                      (NNP inhibitors))\n",
      "                    (PRN (-LRB- -LRB-)\n",
      "                      (NP (NNP ACEIs))\n",
      "                      (-RRB- -RRB-))\n",
      "                    (, ,)\n",
      "                    (NP\n",
      "                      (NP (JJ angiotensin-II) (NN type))\n",
      "                      (NP\n",
      "                        (NP (CD 1) (NNS blockers))\n",
      "                        (PRN (-LRB- -LRB-)\n",
      "                          (NP (NNS ARBs))\n",
      "                          (-RRB- -RRB-))))\n",
      "                    (CC and)\n",
      "                    (NP\n",
      "                      (NP\n",
      "                        (NP (JJ aldosterone) (NNS receptors) (NNS antagonists))\n",
      "                        (, ,)\n",
      "                        (PP (IN in)\n",
      "                          (NP\n",
      "                            (NP (NN addition))\n",
      "                            (PP (TO to)\n",
      "                              (NP (DT the)\n",
      "                                (ADJP (RB recently) (VBN introduced))\n",
      "                                (NNP direct) (NNP renin) (NNP inhibitors))))))\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP DRIs))\n",
      "                        (-RRB- -RRB-)))))))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(inhibited-12, RAAS-1)\n",
      "det(target-6, a-3)\n",
      "amod(target-6, major-4)\n",
      "amod(target-6, pharmacological-5)\n",
      "appos(RAAS-1, target-6)\n",
      "case(medicine-9, in-7)\n",
      "amod(medicine-9, cardiovascular-8)\n",
      "nmod:in(target-6, medicine-9)\n",
      "cop(inhibited-12, is-11)\n",
      "root(ROOT-0, inhibited-12)\n",
      "case(classes-15, by-13)\n",
      "amod(classes-15, pharmacological-14)\n",
      "nmod:by(inhibited-12, classes-15)\n",
      "case(angiotensin-17, including-16)\n",
      "nmod:including(classes-15, angiotensin-17)\n",
      "acl(angiotensin-17, converting-18)\n",
      "compound(inhibitors-23, enzyme-19)\n",
      "appos(inhibitors-23, ACE-21)\n",
      "dobj(converting-18, inhibitors-23)\n",
      "appos(inhibitors-23, ACEIs-25)\n",
      "amod(type-29, angiotensin-II-28)\n",
      "dobj(converting-18, type-29)\n",
      "conj:and(inhibitors-23, type-29)\n",
      "nummod(blockers-31, 1-30)\n",
      "dep(type-29, blockers-31)\n",
      "appos(blockers-31, ARBs-33)\n",
      "cc(inhibitors-23, and-35)\n",
      "amod(antagonists-38, aldosterone-36)\n",
      "compound(antagonists-38, receptors-37)\n",
      "dobj(converting-18, antagonists-38)\n",
      "conj:and(inhibitors-23, antagonists-38)\n",
      "case(inhibitors-48, in-40)\n",
      "mwe(in-40, addition-41)\n",
      "mwe(in-40, to-42)\n",
      "det(inhibitors-48, the-43)\n",
      "advmod(introduced-45, recently-44)\n",
      "amod(inhibitors-48, introduced-45)\n",
      "compound(inhibitors-48, direct-46)\n",
      "compound(inhibitors-48, renin-47)\n",
      "nmod:in_addition_to(antagonists-38, inhibitors-48)\n",
      "appos(antagonists-38, DRIs-50)\n",
      "\n",
      "Parsing [sent. 2 len. 36]: However , currently used RAAS inhibitors still can not achieve their desired effects and are associated with certain drawbacks , such as adverse side effects , incomplete blockage of the system and poor end-organ protection .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (ADVP (RB currently))\n",
      "    (VP (VBD used)\n",
      "      (SBAR\n",
      "        (S\n",
      "          (NP (NNP RAAS) (NNP inhibitors))\n",
      "          (ADVP (RB still))\n",
      "          (VP\n",
      "            (VP (MD can) (RB not)\n",
      "              (VP (VB achieve)\n",
      "                (NP (PRP$ their) (VBN desired) (NNS effects))))\n",
      "            (CC and)\n",
      "            (VP (VBP are)\n",
      "              (VP (VBN associated)\n",
      "                (PP (IN with)\n",
      "                  (NP\n",
      "                    (NP (JJ certain) (NNS drawbacks))\n",
      "                    (, ,)\n",
      "                    (PP (JJ such) (IN as)\n",
      "                      (NP (JJ adverse) (NN side) (NNS effects)))\n",
      "                    (, ,)\n",
      "                    (ADJP (JJ incomplete) (JJ blockage))\n",
      "                    (PP (IN of)\n",
      "                      (NP\n",
      "                        (NP (DT the) (NN system))\n",
      "                        (CC and)\n",
      "                        (NP (JJ poor) (JJ end-organ) (NN protection))))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(used-4, However-1)\n",
      "advmod(used-4, currently-3)\n",
      "root(ROOT-0, used-4)\n",
      "compound(inhibitors-6, RAAS-5)\n",
      "nsubj(achieve-10, inhibitors-6)\n",
      "nsubjpass(associated-16, inhibitors-6)\n",
      "advmod(achieve-10, still-7)\n",
      "aux(achieve-10, can-8)\n",
      "neg(achieve-10, not-9)\n",
      "ccomp(used-4, achieve-10)\n",
      "nmod:poss(effects-13, their-11)\n",
      "amod(effects-13, desired-12)\n",
      "dobj(achieve-10, effects-13)\n",
      "cc(achieve-10, and-14)\n",
      "auxpass(associated-16, are-15)\n",
      "ccomp(used-4, associated-16)\n",
      "conj:and(achieve-10, associated-16)\n",
      "case(drawbacks-19, with-17)\n",
      "amod(drawbacks-19, certain-18)\n",
      "nmod:with(associated-16, drawbacks-19)\n",
      "case(effects-25, such-21)\n",
      "mwe(such-21, as-22)\n",
      "amod(effects-25, adverse-23)\n",
      "compound(effects-25, side-24)\n",
      "nmod:such_as(drawbacks-19, effects-25)\n",
      "amod(blockage-28, incomplete-27)\n",
      "amod(drawbacks-19, blockage-28)\n",
      "case(system-31, of-29)\n",
      "det(system-31, the-30)\n",
      "nmod:of(drawbacks-19, system-31)\n",
      "cc(system-31, and-32)\n",
      "amod(protection-35, poor-33)\n",
      "amod(protection-35, end-organ-34)\n",
      "nmod:of(drawbacks-19, protection-35)\n",
      "conj:and(system-31, protection-35)\n",
      "\n",
      "Parsing [sent. 3 len. 42]: In this review , we discuss the efficiency and specificity of the current RAAS inhibitors and propose some recommendations for achieving better treatments with better end-organ protection.Hypertension Research advance online publication , 6 July 2017 ; doi :10.1038 / hr .2017.65 .\n",
      "(ROOT\n",
      "  (S\n",
      "    (PP (IN In)\n",
      "      (NP (DT this) (NN review)))\n",
      "    (, ,)\n",
      "    (NP (PRP we))\n",
      "    (VP\n",
      "      (VP (VB discuss)\n",
      "        (NP\n",
      "          (NP (DT the) (NN efficiency)\n",
      "            (CC and)\n",
      "            (NN specificity))\n",
      "          (PP (IN of)\n",
      "            (NP (DT the) (JJ current) (JJ RAAS) (NNS inhibitors)))))\n",
      "      (CC and)\n",
      "      (VP (VB propose)\n",
      "        (NP\n",
      "          (NP\n",
      "            (NP (DT some) (NNS recommendations))\n",
      "            (PP (IN for)\n",
      "              (S\n",
      "                (VP (VBG achieving)\n",
      "                  (NP (JJR better) (NNS treatments))\n",
      "                  (PP (IN with)\n",
      "                    (NP (NNP better) (NNP end-organ) (NNP protection.Hypertension) (NNP Research) (NNP advance) (JJ online) (NN publication)))))))\n",
      "          (, ,)\n",
      "          (NP\n",
      "            (NP (CD 6))\n",
      "            (NP (NNP July) (CD 2017)))\n",
      "          (: ;)\n",
      "          (NP\n",
      "            (QP (CD doi) (CD :10.1038))\n",
      "            (NNS /))\n",
      "          (NP (NNP hr) (CD .2017.65)))))\n",
      "    (. .)))\n",
      "\n",
      "case(review-3, In-1)\n",
      "det(review-3, this-2)\n",
      "nmod:in(discuss-6, review-3)\n",
      "nsubj(discuss-6, we-5)\n",
      "nsubj(propose-17, we-5)\n",
      "root(ROOT-0, discuss-6)\n",
      "det(efficiency-8, the-7)\n",
      "dobj(discuss-6, efficiency-8)\n",
      "cc(efficiency-8, and-9)\n",
      "dobj(discuss-6, specificity-10)\n",
      "conj:and(efficiency-8, specificity-10)\n",
      "case(inhibitors-15, of-11)\n",
      "det(inhibitors-15, the-12)\n",
      "amod(inhibitors-15, current-13)\n",
      "amod(inhibitors-15, RAAS-14)\n",
      "nmod:of(efficiency-8, inhibitors-15)\n",
      "cc(discuss-6, and-16)\n",
      "conj:and(discuss-6, propose-17)\n",
      "det(recommendations-19, some-18)\n",
      "dobj(propose-17, recommendations-19)\n",
      "mark(achieving-21, for-20)\n",
      "acl(recommendations-19, achieving-21)\n",
      "amod(treatments-23, better-22)\n",
      "dobj(achieving-21, treatments-23)\n",
      "case(publication-31, with-24)\n",
      "compound(publication-31, better-25)\n",
      "compound(publication-31, end-organ-26)\n",
      "compound(publication-31, protection.Hypertension-27)\n",
      "compound(publication-31, Research-28)\n",
      "compound(publication-31, advance-29)\n",
      "amod(publication-31, online-30)\n",
      "nmod:with(achieving-21, publication-31)\n",
      "appos(recommendations-19, 6-33)\n",
      "dep(6-33, July-34)\n",
      "nummod(July-34, 2017-35)\n",
      "compound(:10.1038-38, doi-37)\n",
      "nummod(/-39, :10.1038-38)\n",
      "dep(recommendations-19, /-39)\n",
      "dep(recommendations-19, hr-40)\n",
      "nummod(hr-40, .2017.65-41)\n",
      "\n",
      "Parsing [sent. 4 len. 51]: The beneficial effects of angiotensin converting enzyme -LRB- ACE -RRB- inhibitors and angiotensin II -LRB- AII -RRB- receptor antagonists in patients with heart failure secondary to reduced ejection fraction -LRB- HFrEF -RRB- are felt to result from prevention of the adverse effects of AII on systemic afterload and renal homeostasis .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (JJ beneficial) (NNS effects))\n",
      "      (PP (IN of)\n",
      "        (NP\n",
      "          (NP (NN angiotensin))\n",
      "          (VP (VBG converting)\n",
      "            (NP\n",
      "              (NP (NNP enzyme)\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP ACE))\n",
      "                  (-RRB- -RRB-))\n",
      "                (NNP inhibitors))\n",
      "              (CC and)\n",
      "              (NP\n",
      "                (NP (NNP angiotensin) (NNP II))\n",
      "                (PRN (-LRB- -LRB-)\n",
      "                  (NP (NNP AII))\n",
      "                  (-RRB- -RRB-)))\n",
      "              (NP\n",
      "                (NP (NN receptor) (NNS antagonists))\n",
      "                (PP (IN in)\n",
      "                  (NP (NNS patients)))))\n",
      "            (PP (IN with)\n",
      "              (NP\n",
      "                (NP (NN heart) (NN failure))\n",
      "                (ADJP (JJ secondary)\n",
      "                  (PP (TO to)\n",
      "                    (NP\n",
      "                      (NP (VBN reduced) (JJ ejection) (NN fraction))\n",
      "                      (PRN (-LRB- -LRB-)\n",
      "                        (NP (NNP HFrEF))\n",
      "                        (-RRB- -RRB-)))))))))))\n",
      "    (VP (VBP are)\n",
      "      (VP (VBN felt)\n",
      "        (S\n",
      "          (VP (TO to)\n",
      "            (VP (VB result)\n",
      "              (PP (IN from)\n",
      "                (NP\n",
      "                  (NP (NN prevention))\n",
      "                  (PP (IN of)\n",
      "                    (NP\n",
      "                      (NP (DT the) (JJ adverse) (NNS effects))\n",
      "                      (PP (IN of)\n",
      "                        (NP (NNP AII)))))))\n",
      "              (PP (IN on)\n",
      "                (NP (JJ systemic) (JJ afterload)\n",
      "                  (CC and)\n",
      "                  (JJ renal) (NNS homeostasis))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(effects-3, The-1)\n",
      "amod(effects-3, beneficial-2)\n",
      "nsubjpass(felt-34, effects-3)\n",
      "nsubj:xsubj(result-36, effects-3)\n",
      "case(angiotensin-5, of-4)\n",
      "nmod:of(effects-3, angiotensin-5)\n",
      "acl(angiotensin-5, converting-6)\n",
      "compound(inhibitors-11, enzyme-7)\n",
      "appos(inhibitors-11, ACE-9)\n",
      "dobj(converting-6, inhibitors-11)\n",
      "cc(inhibitors-11, and-12)\n",
      "compound(II-14, angiotensin-13)\n",
      "dobj(converting-6, II-14)\n",
      "conj:and(inhibitors-11, II-14)\n",
      "appos(II-14, AII-16)\n",
      "compound(antagonists-19, receptor-18)\n",
      "dep(inhibitors-11, antagonists-19)\n",
      "case(patients-21, in-20)\n",
      "nmod:in(antagonists-19, patients-21)\n",
      "case(failure-24, with-22)\n",
      "compound(failure-24, heart-23)\n",
      "nmod:with(converting-6, failure-24)\n",
      "amod(failure-24, secondary-25)\n",
      "case(fraction-29, to-26)\n",
      "amod(fraction-29, reduced-27)\n",
      "amod(fraction-29, ejection-28)\n",
      "nmod:to(secondary-25, fraction-29)\n",
      "appos(fraction-29, HFrEF-31)\n",
      "auxpass(felt-34, are-33)\n",
      "root(ROOT-0, felt-34)\n",
      "mark(result-36, to-35)\n",
      "xcomp(felt-34, result-36)\n",
      "case(prevention-38, from-37)\n",
      "nmod:from(result-36, prevention-38)\n",
      "case(effects-42, of-39)\n",
      "det(effects-42, the-40)\n",
      "amod(effects-42, adverse-41)\n",
      "nmod:of(prevention-38, effects-42)\n",
      "case(AII-44, of-43)\n",
      "nmod:of(effects-42, AII-44)\n",
      "case(afterload-47, on-45)\n",
      "amod(afterload-47, systemic-46)\n",
      "nmod:on(result-36, afterload-47)\n",
      "cc(afterload-47, and-48)\n",
      "amod(homeostasis-50, renal-49)\n",
      "nmod:on(result-36, homeostasis-50)\n",
      "conj:and(afterload-47, homeostasis-50)\n",
      "\n",
      "Parsing [sent. 5 len. 31]: However , AII can activate the sympathetic nervous system and part of the beneficial effects of ACE inhibitors and AII antagonists may result from their ability to inhibit such activation .\n",
      "(ROOT\n",
      "  (S\n",
      "    (ADVP (RB However))\n",
      "    (, ,)\n",
      "    (S\n",
      "      (NP (NNP AII))\n",
      "      (VP (MD can)\n",
      "        (VP (VB activate)\n",
      "          (NP\n",
      "            (NP (DT the)\n",
      "              (ADJP (JJ sympathetic) (JJ nervous))\n",
      "              (NN system))\n",
      "            (CC and)\n",
      "            (NP\n",
      "              (NP (NN part))\n",
      "              (PP (IN of)\n",
      "                (NP\n",
      "                  (NP (DT the) (JJ beneficial) (NNS effects))\n",
      "                  (PP (IN of)\n",
      "                    (NP (NN ACE) (NNS inhibitors))))))))))\n",
      "    (CC and)\n",
      "    (S\n",
      "      (NP (NNP AII) (NNS antagonists))\n",
      "      (VP (MD may)\n",
      "        (VP (VB result)\n",
      "          (PP (IN from)\n",
      "            (NP (PRP$ their) (NN ability)\n",
      "              (S\n",
      "                (VP (TO to)\n",
      "                  (VP (VB inhibit)\n",
      "                    (NP (JJ such) (NN activation))))))))))\n",
      "    (. .)))\n",
      "\n",
      "advmod(activate-5, However-1)\n",
      "nsubj(activate-5, AII-3)\n",
      "aux(activate-5, can-4)\n",
      "root(ROOT-0, activate-5)\n",
      "det(system-9, the-6)\n",
      "amod(nervous-8, sympathetic-7)\n",
      "amod(system-9, nervous-8)\n",
      "dobj(activate-5, system-9)\n",
      "cc(system-9, and-10)\n",
      "dobj(activate-5, part-11)\n",
      "conj:and(system-9, part-11)\n",
      "case(effects-15, of-12)\n",
      "det(effects-15, the-13)\n",
      "amod(effects-15, beneficial-14)\n",
      "nmod:of(part-11, effects-15)\n",
      "case(inhibitors-18, of-16)\n",
      "compound(inhibitors-18, ACE-17)\n",
      "nmod:of(effects-15, inhibitors-18)\n",
      "cc(activate-5, and-19)\n",
      "compound(antagonists-21, AII-20)\n",
      "nsubj(result-23, antagonists-21)\n",
      "aux(result-23, may-22)\n",
      "conj:and(activate-5, result-23)\n",
      "case(ability-26, from-24)\n",
      "nmod:poss(ability-26, their-25)\n",
      "nmod:from(result-23, ability-26)\n",
      "mark(inhibit-28, to-27)\n",
      "acl(ability-26, inhibit-28)\n",
      "amod(activation-30, such-29)\n",
      "dobj(inhibit-28, activation-30)\n",
      "\n",
      "Parsing [sent. 6 len. 49]: We examined the acute effects of the ACE inhibitor captopril -LRB- 25 mg , n = 9 -RRB- and the AII receptor antagonist losartan -LRB- 50 mg , n = 10 -RRB- on hemodynamics as well as total body and cardiac norepinephrine spillover in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (PRP We))\n",
      "    (VP (VBD examined)\n",
      "      (NP\n",
      "        (NP (DT the) (JJ acute) (NNS effects))\n",
      "        (PP (IN of)\n",
      "          (NP\n",
      "            (NP (DT the) (NNP ACE) (NNP inhibitor) (NNP captopril))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 25) (NN mg))\n",
      "                (, ,)\n",
      "                (NP (NNP n) (NNP =) (CD 9)))\n",
      "              (-RRB- -RRB-))\n",
      "            (CC and)\n",
      "            (NP (DT the) (NNP AII) (NN receptor) (NN antagonist) (NN losartan))\n",
      "            (PRN (-LRB- -LRB-)\n",
      "              (NP\n",
      "                (NP (CD 50) (NN mg))\n",
      "                (, ,)\n",
      "                (NP (NNP n) (NNP =) (CD 10)))\n",
      "              (-RRB- -RRB-)))))\n",
      "      (PP (IN on)\n",
      "        (NP\n",
      "          (NP (NNS hemodynamics))\n",
      "          (CONJP (RB as) (RB well) (IN as))\n",
      "          (NP (JJ total) (NN body)\n",
      "            (CC and)\n",
      "            (JJ cardiac) (NN norepinephrine) (NN spillover))))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (NNS patients))\n",
      "          (PP (IN with)\n",
      "            (NP (JJ chronic) (NN HFrEF))))))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(examined-2, We-1)\n",
      "root(ROOT-0, examined-2)\n",
      "det(effects-5, the-3)\n",
      "amod(effects-5, acute-4)\n",
      "dobj(examined-2, effects-5)\n",
      "case(captopril-10, of-6)\n",
      "det(captopril-10, the-7)\n",
      "compound(captopril-10, ACE-8)\n",
      "compound(captopril-10, inhibitor-9)\n",
      "nmod:of(effects-5, captopril-10)\n",
      "nummod(mg-13, 25-12)\n",
      "dep(captopril-10, mg-13)\n",
      "compound(=-16, n-15)\n",
      "appos(mg-13, =-16)\n",
      "nummod(=-16, 9-17)\n",
      "cc(captopril-10, and-19)\n",
      "det(losartan-24, the-20)\n",
      "compound(losartan-24, AII-21)\n",
      "compound(losartan-24, receptor-22)\n",
      "compound(losartan-24, antagonist-23)\n",
      "nmod:of(effects-5, losartan-24)\n",
      "conj:and(captopril-10, losartan-24)\n",
      "nummod(mg-27, 50-26)\n",
      "dep(captopril-10, mg-27)\n",
      "compound(=-30, n-29)\n",
      "appos(mg-27, =-30)\n",
      "nummod(=-30, 10-31)\n",
      "case(hemodynamics-34, on-33)\n",
      "nmod:on(examined-2, hemodynamics-34)\n",
      "cc(hemodynamics-34, as-35)\n",
      "mwe(as-35, well-36)\n",
      "mwe(as-35, as-37)\n",
      "amod(body-39, total-38)\n",
      "nmod:on(examined-2, body-39)\n",
      "conj:and(hemodynamics-34, body-39)\n",
      "cc(body-39, and-40)\n",
      "amod(spillover-43, cardiac-41)\n",
      "compound(spillover-43, norepinephrine-42)\n",
      "conj:and(hemodynamics-34, spillover-43)\n",
      "conj:and(body-39, spillover-43)\n",
      "case(patients-45, in-44)\n",
      "nmod:in(examined-2, patients-45)\n",
      "case(HFrEF-48, with-46)\n",
      "amod(HFrEF-48, chronic-47)\n",
      "nmod:with(patients-45, HFrEF-48)\n",
      "\n",
      "Parsing [sent. 7 len. 20]: Hemodynamic and neurochemical measurements were made at baseline and at 1 , 2 and 4 hours after oral dosing .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (ADJP (JJ Hemodynamic)\n",
      "        (CC and)\n",
      "        (JJ neurochemical))\n",
      "      (NNS measurements))\n",
      "    (VP (VBD were)\n",
      "      (VP (VBN made)\n",
      "        (PP\n",
      "          (PP (IN at)\n",
      "            (NP (NN baseline)))\n",
      "          (CC and)\n",
      "          (PP (IN at)\n",
      "            (NP (CD 1) (, ,) (CD 2)\n",
      "              (CC and)\n",
      "              (CD 4)))\n",
      "          (NP (NNS hours)))\n",
      "        (PP (IN after)\n",
      "          (NP (JJ oral) (NN dosing)))))\n",
      "    (. .)))\n",
      "\n",
      "amod(measurements-4, Hemodynamic-1)\n",
      "cc(Hemodynamic-1, and-2)\n",
      "conj:and(Hemodynamic-1, neurochemical-3)\n",
      "amod(measurements-4, neurochemical-3)\n",
      "nsubjpass(made-6, measurements-4)\n",
      "auxpass(made-6, were-5)\n",
      "root(ROOT-0, made-6)\n",
      "case(baseline-8, at-7)\n",
      "nmod:at(hours-16, baseline-8)\n",
      "cc(hours-16, and-9)\n",
      "case(1-11, at-10)\n",
      "nmod(made-6, 1-11)\n",
      "conj:and(hours-16, 1-11)\n",
      "nummod(1-11, 2-13)\n",
      "cc(1-11, and-14)\n",
      "conj:and(1-11, 4-15)\n",
      "conj:and(hours-16, 4-15)\n",
      "nmod(made-6, hours-16)\n",
      "case(dosing-19, after-17)\n",
      "amod(dosing-19, oral-18)\n",
      "nmod:after(made-6, dosing-19)\n",
      "\n",
      "Parsing [sent. 8 len. 25]: Administration of both drugs caused significant reductions in systemic arterial , cardiac filling and pulmonary artery pressures -LRB- P < 0.05 vs baseline -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NN Administration))\n",
      "      (PP (IN of)\n",
      "        (NP (DT both) (NNS drugs))))\n",
      "    (VP (VBD caused)\n",
      "      (NP (JJ significant) (NNS reductions))\n",
      "      (PP (IN in)\n",
      "        (NP\n",
      "          (NP (JJ systemic) (NN arterial))\n",
      "          (, ,)\n",
      "          (NP (JJ cardiac) (NN filling))\n",
      "          (CC and)\n",
      "          (NP (JJ pulmonary) (NN artery) (NNS pressures))))\n",
      "      (PRN (-LRB- -LRB-)\n",
      "        (NP\n",
      "          (NP (NNP P) (NNP <))\n",
      "          (NP (CD 0.05) (NNP vs) (NN baseline)))\n",
      "        (-RRB- -RRB-)))\n",
      "    (. .)))\n",
      "\n",
      "nsubj(caused-5, Administration-1)\n",
      "case(drugs-4, of-2)\n",
      "det(drugs-4, both-3)\n",
      "nmod:of(Administration-1, drugs-4)\n",
      "root(ROOT-0, caused-5)\n",
      "amod(reductions-7, significant-6)\n",
      "dobj(caused-5, reductions-7)\n",
      "case(arterial-10, in-8)\n",
      "amod(arterial-10, systemic-9)\n",
      "nmod:in(caused-5, arterial-10)\n",
      "amod(filling-13, cardiac-12)\n",
      "nmod:in(caused-5, filling-13)\n",
      "conj:and(arterial-10, filling-13)\n",
      "cc(arterial-10, and-14)\n",
      "amod(pressures-17, pulmonary-15)\n",
      "compound(pressures-17, artery-16)\n",
      "nmod:in(caused-5, pressures-17)\n",
      "conj:and(arterial-10, pressures-17)\n",
      "compound(<-20, P-19)\n",
      "dep(caused-5, <-20)\n",
      "nummod(baseline-23, 0.05-21)\n",
      "compound(baseline-23, vs-22)\n",
      "dep(<-20, baseline-23)\n",
      "\n",
      "Parsing [sent. 9 len. 13]: There was no significant difference in the magnitude of those hemodynamic effects .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP (EX There))\n",
      "    (VP (VBD was)\n",
      "      (NP\n",
      "        (NP (DT no) (JJ significant) (NN difference))\n",
      "        (PP (IN in)\n",
      "          (NP\n",
      "            (NP (DT the) (NN magnitude))\n",
      "            (PP (IN of)\n",
      "              (NP (DT those) (JJ hemodynamic) (NNS effects)))))))\n",
      "    (. .)))\n",
      "\n",
      "expl(was-2, There-1)\n",
      "root(ROOT-0, was-2)\n",
      "neg(difference-5, no-3)\n",
      "amod(difference-5, significant-4)\n",
      "nsubj(was-2, difference-5)\n",
      "case(magnitude-8, in-6)\n",
      "det(magnitude-8, the-7)\n",
      "nmod:in(difference-5, magnitude-8)\n",
      "case(effects-12, of-9)\n",
      "det(effects-12, those-10)\n",
      "amod(effects-12, hemodynamic-11)\n",
      "nmod:of(magnitude-8, effects-12)\n",
      "\n",
      "Parsing [sent. 10 len. 23]: Plasma concentrations of AII were significantly decreased by captopril and increased by losartan -LRB- P < 0.05 vs baseline for both -RRB- .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (NN Plasma) (NNS concentrations))\n",
      "      (PP (IN of)\n",
      "        (NP (NNP AII))))\n",
      "    (VP (VBD were)\n",
      "      (ADVP (RB significantly))\n",
      "      (VP\n",
      "        (VP (VBN decreased)\n",
      "          (PP (IN by)\n",
      "            (NP (NNP captopril))))\n",
      "        (CC and)\n",
      "        (VP (VBN increased)\n",
      "          (PP (IN by)\n",
      "            (NP\n",
      "              (NP (NNP losartan))\n",
      "              (PRN (-LRB- -LRB-)\n",
      "                (NP\n",
      "                  (NP (NNP P) (NNP <) (NNP 0.05) (NNP vs) (NN baseline))\n",
      "                  (PP (IN for)\n",
      "                    (NP (DT both))))\n",
      "                (-RRB- -RRB-)))))))\n",
      "    (. .)))\n",
      "\n",
      "compound(concentrations-2, Plasma-1)\n",
      "nsubjpass(decreased-7, concentrations-2)\n",
      "nsubjpass(increased-11, concentrations-2)\n",
      "case(AII-4, of-3)\n",
      "nmod:of(concentrations-2, AII-4)\n",
      "auxpass(decreased-7, were-5)\n",
      "advmod(decreased-7, significantly-6)\n",
      "root(ROOT-0, decreased-7)\n",
      "case(captopril-9, by-8)\n",
      "nmod:by(decreased-7, captopril-9)\n",
      "cc(decreased-7, and-10)\n",
      "conj:and(decreased-7, increased-11)\n",
      "case(losartan-13, by-12)\n",
      "nmod:by(increased-11, losartan-13)\n",
      "compound(baseline-19, P-15)\n",
      "compound(baseline-19, <-16)\n",
      "compound(baseline-19, 0.05-17)\n",
      "compound(baseline-19, vs-18)\n",
      "dep(losartan-13, baseline-19)\n",
      "case(both-21, for-20)\n",
      "nmod:for(baseline-19, both-21)\n",
      "\n",
      "Parsing [sent. 11 len. 37]: Total body sympathetic activity increased in response to both captopril and losartan -LRB- P < 0.05 vs baseline for both -RRB- , however there was no change in cardiac sympathetic activity in response to either drug .\n",
      "(ROOT\n",
      "  (S\n",
      "    (S\n",
      "      (NP\n",
      "        (NP (JJ Total) (NN body))\n",
      "        (NP (JJ sympathetic) (NN activity)))\n",
      "      (VP (VBD increased)\n",
      "        (PP (IN in)\n",
      "          (NP (NN response)))\n",
      "        (PP (TO to)\n",
      "          (NP (DT both) (NNP captopril)\n",
      "            (CC and)\n",
      "            (NNP losartan)))\n",
      "        (PRN (-LRB- -LRB-)\n",
      "          (NP\n",
      "            (NP (NNP P) (NNP <) (NNP 0.05) (NNP vs) (NN baseline))\n",
      "            (PP (IN for)\n",
      "              (NP (DT both))))\n",
      "          (-RRB- -RRB-))))\n",
      "    (, ,)\n",
      "    (ADVP (RB however))\n",
      "    (S\n",
      "      (NP (EX there))\n",
      "      (VP (VBD was)\n",
      "        (NP\n",
      "          (NP (DT no) (NN change))\n",
      "          (PP (IN in)\n",
      "            (NP\n",
      "              (NP (JJ cardiac) (JJ sympathetic) (NN activity))\n",
      "              (PP (IN in)\n",
      "                (NP (NN response))))))\n",
      "        (PP (TO to)\n",
      "          (NP (DT either) (NN drug)))))\n",
      "    (. .)))\n",
      "\n",
      "amod(body-2, Total-1)\n",
      "nsubj(increased-5, body-2)\n",
      "amod(activity-4, sympathetic-3)\n",
      "dep(body-2, activity-4)\n",
      "root(ROOT-0, increased-5)\n",
      "case(response-7, in-6)\n",
      "nmod:in(increased-5, response-7)\n",
      "case(captopril-10, to-8)\n",
      "cc:preconj(captopril-10, both-9)\n",
      "nmod:to(increased-5, captopril-10)\n",
      "cc(captopril-10, and-11)\n",
      "nmod:to(increased-5, losartan-12)\n",
      "conj:and(captopril-10, losartan-12)\n",
      "compound(baseline-18, P-14)\n",
      "compound(baseline-18, <-15)\n",
      "compound(baseline-18, 0.05-16)\n",
      "compound(baseline-18, vs-17)\n",
      "dep(increased-5, baseline-18)\n",
      "case(both-20, for-19)\n",
      "nmod:for(baseline-18, both-20)\n",
      "advmod(was-25, however-23)\n",
      "expl(was-25, there-24)\n",
      "parataxis(increased-5, was-25)\n",
      "neg(change-27, no-26)\n",
      "nsubj(was-25, change-27)\n",
      "case(activity-31, in-28)\n",
      "amod(activity-31, cardiac-29)\n",
      "amod(activity-31, sympathetic-30)\n",
      "nmod:in(change-27, activity-31)\n",
      "case(response-33, in-32)\n",
      "nmod:in(activity-31, response-33)\n",
      "case(drug-36, to-34)\n",
      "det(drug-36, either-35)\n",
      "nmod:to(was-25, drug-36)\n",
      "\n",
      "Parsing [sent. 12 len. 29]: The results of the current study do not support the hypothesis that the acute inhibition of the renin angiotensin system has sympathoinhibitory effects in patients with chronic HFrEF .\n",
      "(ROOT\n",
      "  (S\n",
      "    (NP\n",
      "      (NP (DT The) (NNS results))\n",
      "      (PP (IN of)\n",
      "        (NP (DT the) (JJ current) (NN study))))\n",
      "    (VP (VBP do) (RB not)\n",
      "      (VP (VB support)\n",
      "        (NP (DT the) (NNS hypothesis))\n",
      "        (SBAR (IN that)\n",
      "          (S\n",
      "            (NP\n",
      "              (NP (DT the) (JJ acute) (NN inhibition))\n",
      "              (PP (IN of)\n",
      "                (NP (DT the) (NNP renin) (NN angiotensin) (NN system))))\n",
      "            (VP (VBZ has)\n",
      "              (NP\n",
      "                (NP (JJ sympathoinhibitory) (NNS effects))\n",
      "                (PP (IN in)\n",
      "                  (NP\n",
      "                    (NP (NNS patients))\n",
      "                    (PP (IN with)\n",
      "                      (NP (JJ chronic) (NN HFrEF)))))))))))\n",
      "    (. .)))\n",
      "\n",
      "det(results-2, The-1)\n",
      "nsubj(support-9, results-2)\n",
      "case(study-6, of-3)\n",
      "det(study-6, the-4)\n",
      "amod(study-6, current-5)\n",
      "nmod:of(results-2, study-6)\n",
      "aux(support-9, do-7)\n",
      "neg(support-9, not-8)\n",
      "root(ROOT-0, support-9)\n",
      "det(hypothesis-11, the-10)\n",
      "dobj(support-9, hypothesis-11)\n",
      "mark(has-21, that-12)\n",
      "det(inhibition-15, the-13)\n",
      "amod(inhibition-15, acute-14)\n",
      "nsubj(has-21, inhibition-15)\n",
      "case(system-20, of-16)\n",
      "det(system-20, the-17)\n",
      "compound(system-20, renin-18)\n",
      "compound(system-20, angiotensin-19)\n",
      "nmod:of(inhibition-15, system-20)\n",
      "ccomp(support-9, has-21)\n",
      "amod(effects-23, sympathoinhibitory-22)\n",
      "dobj(has-21, effects-23)\n",
      "case(patients-25, in-24)\n",
      "nmod:in(effects-23, patients-25)\n",
      "case(HFrEF-28, with-26)\n",
      "amod(HFrEF-28, chronic-27)\n",
      "nmod:with(patients-25, HFrEF-28)\n",
      "\n",
      "Parsed file: KeywordSentences.txt [12 sentences].\n",
      "Parsed 408 words in 12 sentences (35.62 wds/sec; 1.05 sents/sec).\n",
      "1 loop, best of 3: 12.4 s per loop\n"
     ]
    }
   ],
   "source": [
    "%%timeit\n",
    "! ./lexparser_caseless.sh  KeywordSentences.txt"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Command Line Sentiment Analysis\n",
    "\n",
    "This creates an output file with tuples and sentiments! We can modify which annotators we use. I think maybe just the sentiment and the ner is all we need."
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "clinically stable patients who underwent des implantation 12 months previously and received aspirin monotherapy were randomly assigned to receive either high-intensity (40mg atorvastatin, n = 1000) or low-intensity (20mg pravastatin, n = 1000) statin treatment. the primary endpoint was adverse clinical events at 12-month follow-up (a composite of all death, myocardial infarction, revascularization, stent thrombosis, stroke, renal deterioration, intervention for peripheral artery disease, and admission for cardiac events).\r\n",
      "\r\n",
      "the primary endpoint at 12-month follow-up occurred in 25 patients (2.5%) receiving high-intensity statin treatment and in 40 patients (4.1%) receiving low-intensity statin treatment (hr, 0.58; 95%ci, 0.36-0.92; p = .018). this difference was mainly driven by a lower rate of cardiac death (0 vs 0.4%, p = .025) and nontarget vessel myocardial infarction (0.1 vs 0.7%, p = .033) in the high-intensity statin treatment group.\r\n",
      "\r\n",
      "patients with heterozygous familial hypercholesterolemia (hefh) have been reported to be less vulnerable to type 2 diabetes mellitus (t2dm), although the mechanism is unknown. the aims of the present study were to assess the effects of low density lipoprotein (ldl) cholesterol concentration and the presence of fh-causing mutations on t2dm prevalence in hefh. data were collected from the dyslipidemia registry of the spanish arteriosclerosis society. inclusion criteria were definite or probable hefh in patients aged ≥18 years. t2dm prevalence in hefh patients was compared with data of the general population. 1732 patients were included. the prevalence of t2dm was lower in patients with hefh compared with the general population (5.94% vs 9.44%; or: 0.606, 95% ci 0.486-0.755, p < 0.001). risk factors for developing t2dm were male sex, age, body mass index, hypertension, baseline triglyceride levels and years on statin therapy. the prevalence of t2dm in hefh patients was 40% lower than that observed in the general population. gene mutations and ldl cholesterol concentrations were not risk factors associated with the prevalence of t2dm in patients with hefh. the prevalence of t2dm in patients with hefh was 40% lower than in the general population matched for age and sex.\r\n",
      "\r\n",
      "current guidelines on the treatment of blood cholesterol recommend continuous maintenance of high-intensity statin treatment in drug-eluting stent (des)-treated patients. however, high-intensity statin treatment is frequently underused in clinical practice after stabilization of des-treated patients. currently, the impact of continuous high-intensity statin treatment on the incidence of late adverse events in these patients is unknown. we investigated whether high-intensity statin treatment reduces late adverse events in clinically stable patients on aspirin monotherapy 12 months after des implantation.\r\n",
      "\r\n",
      "use of statin therapy in patients with type 2 diabetes mellitus (t2dm) has been recommended by most clinical guidelines. cardiovascular disease (cvd) is a leading cause of morbidity and mortality among t2dm patients. it has been proved that statins are effective for primary or secondary cvd prophylaxis. reports have highlighted the underutilization of statins in clinical practice and the suboptimal adherence to guideline recommendations. this review article points to summarize the current evidence confirming the role of statins in t2dm patients and to provide an overview of factors that may affect statins' prescribing patterns and compliance in clinical practice. initiatives to enhance statin therapy prescribing should recognize the comprehensive nature of the prescribing process. attempts to assure proper statin prescribing and utilization can help in achieving better clinical outcomes of statin therapy.\r\n",
      "\r\n"
     ]
    }
   ],
   "source": [
    "!head KeywordSentences.txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[main] INFO edu.stanford.nlp.pipeline.StanfordCoreNLP - Adding annotator tokenize\n",
      "[main] INFO edu.stanford.nlp.pipeline.TokenizerAnnotator - No tokenizer type provided. Defaulting to PTBTokenizer.\n",
      "[main] INFO edu.stanford.nlp.pipeline.StanfordCoreNLP - Adding annotator ssplit\n",
      "[main] INFO edu.stanford.nlp.pipeline.StanfordCoreNLP - Adding annotator pos\n",
      "[main] INFO edu.stanford.nlp.tagger.maxent.MaxentTagger - Loading POS tagger from edu/stanford/nlp/models/pos-tagger/english-left3words/english-left3words-distsim.tagger ... done [1.3 sec].\n",
      "[main] INFO edu.stanford.nlp.pipeline.StanfordCoreNLP - Adding annotator lemma\n",
      "[main] INFO edu.stanford.nlp.pipeline.StanfordCoreNLP - Adding annotator ner\n",
      "[main] INFO edu.stanford.nlp.ie.AbstractSequenceClassifier - Loading classifier from edu/stanford/nlp/models/ner/english.all.3class.distsim.crf.ser.gz ... done [1.9 sec].\n",
      "[main] INFO edu.stanford.nlp.ie.AbstractSequenceClassifier - Loading classifier from edu/stanford/nlp/models/ner/english.muc.7class.distsim.crf.ser.gz ... done [1.9 sec].\n",
      "[main] INFO edu.stanford.nlp.ie.AbstractSequenceClassifier - Loading classifier from edu/stanford/nlp/models/ner/english.conll.4class.distsim.crf.ser.gz ... done [0.9 sec].\n",
      "[main] INFO edu.stanford.nlp.time.JollyDayHolidays - Initializing JollyDayHoliday for SUTime from classpath edu/stanford/nlp/models/sutime/jollyday/Holidays_sutime.xml as sutime.binder.1.\n",
      "[main] INFO edu.stanford.nlp.pipeline.StanfordCoreNLP - Adding annotator parse\n",
      "[main] INFO edu.stanford.nlp.parser.common.ParserGrammar - Loading parser from serialized file edu/stanford/nlp/models/lexparser/englishPCFG.ser.gz ... done [2.1 sec].\n",
      "[main] INFO edu.stanford.nlp.pipeline.StanfordCoreNLP - Adding annotator dcoref\n",
      "[main] INFO edu.stanford.nlp.pipeline.StanfordCoreNLP - Adding annotator sentiment\n",
      "\n",
      "Processing file /Users/lisabarcelo/Desktop/W266/food_drug_interaction/parsing/KeywordSentences.txt ... writing to /Users/lisabarcelo/Desktop/W266/food_drug_interaction/parsing/KeywordSentences.txt.out\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 0.001\", originally part of \" 0.001\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 0.156\", originally part of \" 0.156\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 0.002\", originally part of \" 0.002\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 0.148\", originally part of \" 0.148\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 0.002\", originally part of \" 0.002\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 0.320\", originally part of \" 0.320\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 0.353\", originally part of \" 0.353\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 0.003\", originally part of \" 0.003\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 54\", originally part of \" 54\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 54\", originally part of \" 54\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 0.042\", originally part of \" 0.042\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 0.14\", originally part of \" 0.14\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 0.38\", originally part of \" 0.38\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 13\", originally part of \" 13\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 2.7\", originally part of \" 2.7\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 3.0\", originally part of \" 3.0\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 0.15\", originally part of \" 0.15\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "java.lang.NumberFormatException: Bad number put into wordToNumber.  Word is: \" 720\", originally part of \" 720\", piece # 0\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.wordToNumber(NumberNormalizer.java:308)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findNumbers(NumberNormalizer.java:636)\n",
      "  edu.stanford.nlp.ie.NumberNormalizer.findAndMergeNumbers(NumberNormalizer.java:725)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:189)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressions(TimeExpressionExtractorImpl.java:183)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:114)\n",
      "  edu.stanford.nlp.time.TimeExpressionExtractorImpl.extractTimeExpressionCoreMaps(TimeExpressionExtractorImpl.java:104)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.runSUTime(NumberSequenceClassifier.java:345)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithSUTime(NumberSequenceClassifier.java:143)\n",
      "  edu.stanford.nlp.ie.regexp.NumberSequenceClassifier.classifyWithGlobalInformation(NumberSequenceClassifier.java:106)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.recognizeNumberSequences(NERClassifierCombiner.java:369)\n",
      "  edu.stanford.nlp.ie.NERClassifierCombiner.classifyWithGlobalInformation(NERClassifierCombiner.java:312)\n",
      "  edu.stanford.nlp.ie.AbstractSequenceClassifier.classifySentenceWithGlobalInformation(AbstractSequenceClassifier.java:329)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.doOneSentence(NERCombinerAnnotator.java:169)\n",
      "  edu.stanford.nlp.pipeline.SentenceAnnotator.annotate(SentenceAnnotator.java:102)\n",
      "  edu.stanford.nlp.pipeline.NERCombinerAnnotator.annotate(NERCombinerAnnotator.java:155)\n",
      "  edu.stanford.nlp.pipeline.AnnotationPipeline.annotate(AnnotationPipeline.java:76)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:599)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.annotate(StanfordCoreNLP.java:609)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:1172)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.processFiles(StanfordCoreNLP.java:945)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.run(StanfordCoreNLP.java:1274)\n",
      "  edu.stanford.nlp.pipeline.StanfordCoreNLP.main(StanfordCoreNLP.java:1345)\n",
      "Annotating file /Users/lisabarcelo/Desktop/W266/food_drug_interaction/parsing/KeywordSentences.txt ... done [650.8 sec].\n",
      "\n",
      "Annotation pipeline timing information:\n",
      "TokenizerAnnotator: 0.2 sec.\n",
      "WordsToSentencesAnnotator: 0.1 sec.\n",
      "POSTaggerAnnotator: 1.8 sec.\n",
      "MorphaAnnotator: 0.1 sec.\n",
      "NERCombinerAnnotator: 17.3 sec.\n",
      "ParserAnnotator: 370.7 sec.\n",
      "DeterministicCorefAnnotator: 259.0 sec.\n",
      "SentimentAnnotator: 1.7 sec.\n",
      "TOTAL: 650.8 sec. for 22042 tokens at 33.9 tokens/sec.\n",
      "Pipeline setup: 10.9 sec.\n",
      "Total time for StanfordCoreNLP pipeline: 662.7 sec.\n"
     ]
    }
   ],
   "source": [
    "!java -cp \"*\" -Xmx2g edu.stanford.nlp.pipeline.StanfordCoreNLP \\\n",
    "-annotators tokenize,ssplit,pos,lemma,ner,parse,dcoref,sentiment \\\n",
    "-file KeywordSentences.txt \\\n",
    "-outputFormat text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "!cat KeywordSentences.txt.out > output_file.json"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Sentence #1 (42 tokens, sentiment: Negative):\r\n",
      "clinically stable patients who underwent des implantation 12 months previously and received aspirin monotherapy were randomly assigned to receive either high-intensity (40mg atorvastatin, n = 1000) or low-intensity (20mg pravastatin, n = 1000) statin treatment.\r\n",
      "[Text=clinically CharacterOffsetBegin=0 CharacterOffsetEnd=10 PartOfSpeech=RB Lemma=clinically NamedEntityTag=O SentimentClass=Neutral]\r\n",
      "[Text=stable CharacterOffsetBegin=11 CharacterOffsetEnd=17 PartOfSpeech=JJ Lemma=stable NamedEntityTag=O SentimentClass=Neutral]\r\n",
      "[Text=patients CharacterOffsetBegin=18 CharacterOffsetEnd=26 PartOfSpeech=NNS Lemma=patient NamedEntityTag=O SentimentClass=Neutral]\r\n",
      "[Text=who CharacterOffsetBegin=27 CharacterOffsetEnd=30 PartOfSpeech=WP Lemma=who NamedEntityTag=O SentimentClass=Neutral]\r\n",
      "[Text=underwent CharacterOffsetBegin=31 CharacterOffsetEnd=40 PartOfSpeech=VBD Lemma=undergo NamedEntityTag=O SentimentClass=Neutral]\r\n",
      "[Text=des CharacterOffsetBegin=41 CharacterOffsetEnd=44 PartOfSpeech=FW Lemma=des NamedEntityTag=O SentimentClass=Neutral]\r\n",
      "[Text=implantation CharacterOffsetBegin=45 CharacterOffsetEnd=57 PartOfSpeech=NN Lemma=implantation NamedEntityTag=O SentimentClass=Neutral]\r\n",
      "[Text=12 CharacterOffsetBegin=58 CharacterOffsetEnd=60 PartOfSpeech=CD Lemma=12 NamedEntityTag=DURATION NormalizedNamedEntityTag=P12M Timex=<TIMEX3 tid=\"t1\" type=\"DURATION\" value=\"P12M\">12 months</TIMEX3> SentimentClass=Neutral]\r\n"
     ]
    }
   ],
   "source": [
    "!head output_file.json"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Sentences of note:\n",
    "\n",
    "`Plasma concentrations of AII were significantly decreased by captopril and increased by losartan`.\n",
    "`nmod:of(concentrations-2, AII-4)`\n",
    "`nmod:agent(decreased-7, captopril-9)`\n",
    "`nmod:by(increased-11, losartan-13)`\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "collapsed": true
   },
   "source": [
    "## Experimenting with Selected Abstracts"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "# From <https://www.ncbi.nlm.nih.gov/pubmed/28656517>\n",
    "\n",
    "# !echo \"Renin-angiotensin-aldosterone system (RAAS) antagonists, including angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers (ARB), and mineralocorticoid receptor antagonists (MRA) decrease mortality and morbidity in heart failure but increase the risk of hyperkalemia, especially when used in combination. Prevention of hyperkalemia and its associated complications requires careful patient selection, counseling regarding dietary potassium intake, awareness of drug interactions, and regular laboratory surveillance. Recent data suggests that the risk of hyperkalemia may be further moderated through the use of combined angiotensin-neprilysin inhibitors, novel MRAs, and novel potassium binding agents. Clinicians should be mindful of the risk of hyperkalemia when prescribing RAAS inhibitors to patients with heart failure. In patients at highest risk, such as those with diabetes, the elderly, and advanced chronic kidney disease, more intensive laboratory surveillance of potassium and creatinine may be required. Novel therapies hold promise for reducing the risk of hyperkalemia and enhancing the tolerability of RAAS antagonists.\" > sample_abstract.txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "# !head sample_abstract.txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# !java -cp \"*\" -Xmx2g edu.stanford.nlp.pipeline.StanfordCoreNLP -annotators tokenize,ssplit,pos,lemma,ner,parse,dcoref,sentiment -file sample_abstract.txt -outputFormat text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# !cat sample_abstract.txt.out"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "Our takeaway sentence is that \"ACE Inhibitors (ACEI) [...] decrease mortality and morbidity in heart failure but increase the risk of hyperkalemia...\".\n",
    "\n",
    "`amod(inhibitors-11, angiotensin-converting-9)`\n",
    "\n",
    "`dobj(increase-38, risk-40)`\n",
    "\n",
    "`nmod:of(risk-40, hyperkalemia-42)`\n"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Experimenting with specific drug names instead of a drug class\n",
    "\n",
    "It didn't look like we had a lot of interactions between drugs and molecules, so I wonder if we change our serach terms a little bit to include the drug names. The search terms are not case sensitive.\n",
    "\n",
    "`Drugs in class: Captopril, Lisinopril, Ramipril, Benazepril`"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "# search_term = ['Captopril', 'Lisinopril','Ramipril','Benazepril']\n",
    "# max_results = 100\n",
    "# for i in search_term:\n",
    "#     query2 = pb.PubMedQuery(i, max_results)\n",
    "    \n",
    "# ids2 = query2.id_getter()\n",
    "# print \"Num abstracts: \", len(ids2)\n",
    "\n",
    "# abstracts2 = query.abstract_getter(ids2)\n",
    "\n",
    "# json_file2 = 'more_abstracts2.json'\n",
    "# print 'Saving to ' + json_file2\n",
    "# with open(json_file2, 'w') as outfile:\n",
    "#     json.dump(abstracts2, outfile, indent=4)\n",
    "    \n",
    "    \n",
    "# sentences2 = []\n",
    "# with open('more_abstracts2.json') as data_file:    \n",
    "#     data = json.load(data_file)\n",
    "#     for abstract in data.itervalues():\n",
    "#         sentences2.append(sent_tokenize(abstract))\n",
    "#     # flatten the list of abstracts into one long list of sentences\n",
    "#     sentences2 = [sent for s in sentences2 for sent in s]\n",
    "#     print \"Sentences: \",len(sentences2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "# Just looking at some sentences\n",
    "# sentences2[:5]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "# %%writefile KeywordSentences2.py\n",
    "# import json\n",
    "\n",
    "# #change keyword to ACE\n",
    "# keywords = ['Captopril', 'Lisinopril','Ramipril','Benazepril']\n",
    "# with open('more_abstracts2.json') as data_file:    \n",
    "#     data = json.load(data_file)\n",
    "#     #pick snippets related to ACE inhibitors\n",
    "#     for i in range(len(data.keys())):\n",
    "#         try:\n",
    "#             if any(k in data[str(i)] for k in keywords):\n",
    "#                 print data[str(i)] + '\\n'\n",
    "#             else:\n",
    "#                 next\n",
    "#         except:\n",
    "#             next\n",
    "            "
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 20,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "# !python KeywordSentences2.py > KeywordSentences2.txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# !cat KeywordSentences2.txt"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "collapsed": true
   },
   "source": [
    "## Experimenting with Sentiment Analysis"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 22,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# !java -cp \"*\" -Xmx2g edu.stanford.nlp.pipeline.StanfordCoreNLP -annotators tokenize,ssplit,pos,lemma,ner,parse,dcoref,sentiment -file KeywordSentences2.txt -outputFormat text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# !cat KeywordSentences2.txt.out"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Sentiment Experiment with 50 Sentences"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "# !head -50 data/FilteredSentences.txt > data/Filtered50.txt"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [],
   "source": [
    "# %%timeit\n",
    "# !java -cp \"*\" -Xmx2g edu.stanford.nlp.pipeline.StanfordCoreNLP -annotators tokenize,ssplit,pos,lemma,ner,parse,dcoref,sentiment -file data/Filtered50.txt -outputFormat text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "# !head Filtered50.txt.out"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "## Creating Dictionaries"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 31,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "co_occurrence_dict = defaultdict(list)\n",
    "\n",
    "for line in open('KeywordSentences.txt.out').readlines():\n",
    "    if 'Sentence #' in line:\n",
    "        sentence = str(line.strip('\\n')).split(\" \")[1]\n",
    "        sentiment = str(line.strip('\\n')).split(\":\")[1]\n",
    "        sentiment = re.sub(\"\\d+\",\"\",re.sub(r'[^\\w\\s]','',sentiment))\n",
    "    elif line[0:5] == '[Text':\n",
    "        word = str(line.split(\"=\")[1]).split(\" \")[0].lower()\n",
    "        pos = str(line.split(\"=\")[4]).split(\" \")[0]\n",
    "        co_occurrence_dict[(sentiment, sentence)].append(word)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 32,
   "metadata": {
    "collapsed": false,
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[((' Neutral', '#248'),\n",
      "  ['specifically',\n",
      "   ',',\n",
      "   'one',\n",
      "   'needs',\n",
      "   'to',\n",
      "   '-lrb-',\n",
      "   'i',\n",
      "   '-rrb-',\n",
      "   'recognize',\n",
      "   'the',\n",
      "   'types',\n",
      "   'of',\n",
      "   'biochemical',\n",
      "   'events',\n",
      "   'that',\n",
      "   'change',\n",
      "   'isotopic',\n",
      "   'enrichments',\n",
      "   ',',\n",
      "   '-lrb-',\n",
      "   'ii',\n",
      "   '-rrb-',\n",
      "   'appreciate',\n",
      "   'the',\n",
      "   'distinction',\n",
      "   'between',\n",
      "   'fractional',\n",
      "   'turnover',\n",
      "   'and',\n",
      "   'flux',\n",
      "   'rate',\n",
      "   'and',\n",
      "   '-lrb-',\n",
      "   'iii',\n",
      "   '-rrb-',\n",
      "   'be',\n",
      "   'aware',\n",
      "   'of',\n",
      "   'the',\n",
      "   'subtle',\n",
      "   'differences',\n",
      "   'between',\n",
      "   'tracer',\n",
      "   'kinetics',\n",
      "   'and',\n",
      "   'pharmacokinetics',\n",
      "   '.'])]\n"
     ]
    }
   ],
   "source": [
    "#Example of one of the entries in the dictionary\n",
    "\n",
    "from itertools import islice\n",
    "import  pprint\n",
    "def take(n, iterable):\n",
    "    \"Return first n items of the iterable as a list\"\n",
    "    return list(islice(iterable, n))\n",
    "\n",
    "n_items = take(1, co_occurrence_dict.iteritems())\n",
    "pp = pprint.PrettyPrinter(depth=6)\n",
    "pp.pprint(n_items)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "['specifically', ',', 'one', 'needs', 'to', '-lrb-', 'i', '-rrb-', 'recognize', 'the', 'types', 'of', 'biochemical', 'events', 'that', 'change', 'isotopic', 'enrichments', ',', '-lrb-', 'ii', '-rrb-', 'appreciate', 'the', 'distinction', 'between', 'fractional', 'turnover', 'and', 'flux', 'rate', 'and', '-lrb-', 'iii', '-rrb-', 'be', 'aware', 'of', 'the', 'subtle', 'differences', 'between', 'tracer', 'kinetics', 'and', 'pharmacokinetics', '.']\n",
      "['the', 'final', 'sample', 'consisted', 'of', '13,947', 'individuals', '-lrb-', '48', '\\xc2\\xb1', '6', 'years', ',', '71', '%', 'men', '-rrb-', '.']\n",
      "['nevertheless', ',', 'the', 'potential', 'risk', 'of', 'an', 'adverse', 'event', 'occurring', 'must', 'be', 'considered', 'when', 'prescribing', 'and', 'monitoring', 'statin', 'therapy', 'to', 'individual', 'patients', '.']\n",
      "['abiraterone', 'acetate', '-lrb-', 'aa', '-rrb-', 'may', 'also', 'undergo', 'slco-mediated', 'transport', '.']\n",
      "['the', 'primary', 'endpoint', 'at', '12-month', 'follow-up', 'occurred', 'in', '25', 'patients', '-lrb-', '2.5', '%', '-rrb-', 'receiving', 'high-intensity', 'statin', 'treatment', 'and', 'in', '40', 'patients', '-lrb-', '4.1', '%', '-rrb-', 'receiving', 'low-intensity', 'statin', 'treatment', '-lrb-', 'hr', ',', '0.58', ';', '95', '%', 'ci', ',', '0.36-0', '.92', ';', 'p', '', '.018', '-rrb-', '.']\n",
      "['gene', 'mutations', 'and', 'ldl', 'cholesterol', 'concentrations', 'were', 'not', 'risk', 'factors', 'associated', 'with', 'the', 'prevalence', 'of', 't2dm', 'in', 'patients', 'with', 'hefh', '.']\n",
      "['baseline', 'patient', 'demographics', 'were', 'well', 'matched', 'between', 'treatment', 'groups', '.']\n",
      "['all', 'rights', 'reserved', '.']\n",
      "['the', 'histopathologic', 'diagnosis', 'of', '103', 'subjects', '-lrb-', '71', 'locoregional', '-lsb-', 'group', '1', '-rsb-', 'and', '32', 'palliative', '-lsb-', 'group', '2', '-rsb-', '-rrb-', 'were', 'analyzed', 'and', 'compared', 'using', 'their', 'blood', 'samples', ',', 'total', 'cholesterol', '-lrb-', 'chl', '-rrb-', ',', 'triglycerides', '-lrb-', 'tg', '-rrb-', ',', 'high-density', 'lipoprotein', '-lrb-', 'hdl', '-rrb-', 'cholesterol', ',', 'and', 'low-density', 'lipoprotein', '-lrb-', 'ldl', '-rrb-', 'cholesterol', '.']\n",
      "['it', 'is', 'unclear', 'how', 'often', 'primary', 'care', 'physicians', '-lrb-', 'pcps', '-rrb-', 're-initiate', 'statins', 'and', 'what', 'barriers', 'they', 'encounter', '.']\n",
      "['statins', 'are', 'competitive', 'inhibitors', 'of', '3-hydroxy-3-methylglutaryl-coa', '-lrb-', 'hmg-a', '-rrb-', 'reductase', ',', 'and', 'studies', 'have', 'shown', 'that', 'statins', 'also', 'have', 'anti-inflammatory', 'and', 'immunomodulatory', 'properties', '.']\n",
      "['patients', 'with', 'type', '2', 'mi', 'were', 'older', '-lrb-', 'p', '', '0.02', '-rrb-', ',', 'had', 'lower', 'peak', 'cardiac', 'troponin', '-lrb-', 'p', '<', '0.001', '-rrb-', ',', 'and', 'were', 'less', 'likely', 'to', 'receive', 'aspirin', 'and', 'statin', 'at', 'discharge', '-lrb-', 'p', '<', '0.001', '-rrb-', 'than', 'type', '1', 'mi', 'survivors', '.']\n",
      "['prasugrel', 'reduced', 'the', 'adp-stimulated', 'increase', 'in', 'plas', 'by', '40', '%', '-lrb-', 'ir', ':', '82', 'to', '13', '-rrb-', ',', 'whereas', 'clopidogrel', 'revealed', 'no', 'such', 'effect', '-lrb-', '1', '%', 'increase', '-lrb-', 'ir', ':', '13', 'to', '50', '-rrb-', '-lrb-', 'p', '', '0.01', '-rrb-', '.']\n",
      "['a', 'cross-sectional', 'survey', 'was', 'conducted', 'in', 'rural', 'and', 'urban', 'vellore', ',', 'among', '6196', 'participants', '-lrb-', '30-64', 'years', '-rrb-', ',', 'in', '2010-2012', '.']\n",
      "['here', 'we', 'report', 'the', 'final', 'end-of-study', 'data', '-lrb-', 'on-treatment', '-rrb-', 'and', 'evaluate', 'post', 'hoc', 'the', 'safety', 'profile', 'with', 'longer', 'versus', 'shorter', 'duration', 'of', 'alirocumab', 'exposure', '.']\n",
      "['no', 'one', 'statin', 'medication', 'was', 'found', 'to', 'be', 'more', 'clinically', 'effective', 'in', 'reducing', 'ldl-c', 'or', 'chd', 'risk', ',', 'regardless', 'of', 'dose', 'intensity', '.']\n",
      "['there', 'were', 'no', 'differences', 'in', 'mitochondrial', 'superoxide', 'and', 'cytoplasmic', 'hydrogen', 'peroxide', 'between', 'statin', 'and', 'non-statin', 'users', 'within', 'aaa', 'patients', '.']\n",
      "['to', 'determine', 'how', 'disease', 'and', 'treatment', 'characteristics', 'affect', 'the', 'association', '.']\n",
      "['inclusion', 'criteria', 'were', 'met', 'by', '105', '269', 'individuals', 'in', 'the', 'database', 'cohort', '-lrb-', '57.2', '%', 'male', 'and', '42.8', '%', 'female', ';', 'mean', '-lsb-', 'sd', '-rsb-', 'age', ',', '65.1', '-lsb-', '12.1', '-rsb-', 'years', '-rrb-', '.']\n",
      "['decreased', 'risk', 'of', 'prostate', 'cancer', 'death', 'by', 'statin', 'use', 'after', 'diagnosis', 'suggests', 'that', 'statins', 'may', 'delay', 'or', 'prevent', 'prostate', 'cancer', 'progression', '.']\n",
      "['here', 'we', 'investigated', 'whether', 'specific', 'inhibition', 'of', 'rac1', 'by', 'nsc23766', 'is', 'as', 'effective', 'as', 'lovastatin', 'in', 'preventing', 'subacute', 'cardiotoxicity', 'following', 'doxorubicin', 'treatment', '.']\n",
      "['prasugrel', 'led', 'to', 'a', 'significant', 'improvement', 'of', 'fmd', 'after', '3months', '-lrb-', '9.01', '\\xc2\\xb1', '3.64', '%', 'vs.', '6.65', '\\xc2\\xb1', '3.24', '%', ',', 'p', '', '0.001', '-rrb-', '.']\n",
      "['treatments', 'with', 'either', 'simvastatin', 'or', 'pravastatin', 'were', 'tested', 'for', 'comparison', '.']\n",
      "['it', 'contains', 'monacolin', 'k', 'which', 'is', 'a', 'hypocholesterolemic', 'statin', 'used', 'to', 'prevent', 'cardiovascular', 'diseases', '.']\n",
      "['both', 'treatments', 'reduced', 'total', 'cholesterol', '-lrb-', 'tc', '-rrb-', ',', 'low-density', 'lipoprotein', 'cholesterol', '-lrb-', 'ldl-c', '-rrb-', 'and', 'triglyceride', '-lrb-', 'tg', '-rrb-', '.']\n",
      "['cardiovascular', 'disease', '-lrb-', 'cvd', '-rrb-', 'has', 'a', 'higher', 'incidence', 'in', 'patients', 'with', 'hiv', 'infection', '.']\n",
      "['we', 'investigated', 'whether', 'high-intensity', 'statin', 'treatment', 'reduces', 'late', 'adverse', 'events', 'in', 'clinically', 'stable', 'patients', 'on', 'aspirin', 'monotherapy', '12', 'months', 'after', 'des', 'implantation', '.']\n",
      "['treatment', 'with', 'pravastatin', 'intradermal', 'administration', 'significantly', 'reduced', 'scarring', 'in', 'terms', 'of', 'scar', 'elevation', 'index', '.']\n",
      "['there', 'was', 'no', 'difference', 'in', 'retear', 'rate', 'by', 'dosage', 'or', 'type', 'of', 'statin', 'mediation', '.']\n",
      "['statin', 'discontinuation', 'increased', 'in', '2008', 'following', 'a', 'media', 'event', ',', 'but', 'especially', 'among', 'individuals', 'prescribed', 'statins', 'for', 'primary', 'prevention', 'and', 'among', 'new', 'statin', 'users', '.']\n",
      "['together', ',', 'these', 'results', 'do', 'not', 'support', 'the', 'hypothesis', 'that', 'statins', 'interfere', 'with', 'aa', 'efficacy', '.']\n",
      "['patients', 'with', 'pre-diagnostic', 'statin', 'exposure', 'had', 'a', 'significant', 'reduction', 'in', 'breast', 'cancer-specific', 'mortality', ',', 'which', 'was', 'even', 'more', 'pronounced', 'in', 'women', 'with', 'er', '+', 'tumours.british', 'journal', 'of', 'cancer', 'advance', 'online', 'publication', ',', '18', 'july', '2017', ';', 'doi', ':10.1038', '/', 'bjc', '.2017.227', 'www.bjcancer.com', '.']\n",
      "['in', 'this', 'study', ',', 'we', 'demonstrate', 'the', 'efficacy', 'of', 'topical', 'statin', 'treatment', 'in', 'reducing', 'scar', 'in', 'our', 'validated', 'rabbit', 'ear', 'scar', 'model', '.']\n",
      "['no', 'patient', 'met', 'criteria', 'for', 'calcium', 'progression', '.']\n",
      "['to', 'evaluate', 'common', 'and', 'rare', 'genetic', 'variants', 'that', 'impact', 'lipid', 'responses', 'to', 'fenofibrate', 'in', 'statin-treated', 't2d', 'patients', ',', 'we', 'examined', 'lipid', 'changes', 'in', 'response', 'to', 'fenofibrate', 'therapy', 'using', 'genome-wide', 'association', '-lrb-', 'gwa', '-rrb-', '.']\n",
      "['despite', 'strong', 'evidence', 'of', 'the', 'importance', 'of', 'cholesterol', 'levels', 'in', 'primary', 'or', 'secondary', 'prevention', 'of', 'cvd', ',', 'and', 'the', 'effectiveness', 'of', 'statin', 'therapy', 'for', 'cholesterol', 'lowering', 'and', 'reduction', 'of', 'cvd', 'risk', ',', 'gaps', 'exist', 'in', 'the', 'detection', ',', 'treatment', ',', 'and', 'management', 'of', 'high', 'cholesterol', 'globally', '.']\n",
      "['patients', 'were', 'assessed', 'for', 'overall', 'survival', '-lrb-', 'os', '-rrb-', ',', 'statin', 'use', 'at', 'the', 'time', 'of', 'treatment', 'initiation', ',', 'prostate-specific', 'antigen', '-lrb-', 'psa', '-rrb-', 'variations', ',', 'and', 'other', 'variables', 'of', 'interest', '.']\n",
      "['40', '%', '-lrb-', '95', '%', 'ci', ':', '20.8', '%', '-59.2', '%', '-rrb-', 'of', 'patients', 'with', 'definite', 'or', 'probable', 'fh', 'had', 'cad', '.']\n",
      "['methods', ':', 'a', 'total', 'of', '98', 'patients', 'with', 'stable', 'angina', 'pectoris', 'who', 'received', 'chronic', 'statin', 'treatment', 'underwentpercutaneous', 'coronary', 'intervention', 'in', 'the', 'people', \"'s\", 'hospital', 'of', 'henan', 'province', 'from', 'june', '2010', 'to', 'june', '2016', 'were', 'included.we', 'prospectively', 'performed', 'intravascular', 'ultrasound', 'virtualhistology', '-lrb-', 'ivus-vh', '-rrb-', 'to', 'their', 'lmca', 'and', 'evaluated', 'the', 'tissue', 'characteristics', ',', 'and', 'the', 'blood', 'level', 'of', 'total', 'cholesterol', '-lrb-', 'tc', '-rrb-', 'and', 'low-density', 'lipoprotein', 'cholesterol', '-lrb-', 'ldl-c', '-rrb-', ',', 'high-density', 'lipoprotein', 'cholesterol', '-lrb-', 'hdl-c', '-rrb-', ',', 'triglyceride', '-lrb-', 'tg', '-rrb-', ',', 'ldl-c/hdl-c', 'ratio', ',', 'apob', ',', 'apoa1', ',', 'apob/a1', 'ratio', 'were', 'measured', ',', 'then', 'the', 'association', 'of', 'the', 'tissue', 'characteristics', 'with', 'the', 'aboved', 'lipids', 'values', 'were', 'analyzed', '.']\n",
      "['we', 'conducted', 'six', 'nominal', 'group', 'discussions', 'with', '23', 'pcps', 'from', 'the', 'deep', 'south', 'continuing', 'medical', 'education', 'network', '.']\n",
      "['in', 'individuals', 'aged', '40-75', 'years', 'consecutively', 'submitted', 'to', 'routine', 'health', 'assessment', 'at', 'one', 'single', 'center', ',', 'four', 'criteria', 'of', 'eligibility', 'for', 'statin', 'were', 'defined', ':', 'br-1', ',', 'br-2', '-lrb-', 'ldl-c', 'above', 'or', 'at', 'least', '30', 'mg/dl', 'above', 'the', 'goal', 'recommended', 'by', 'the', 'brazilian', 'guideline', ',', 'respectively', '-rrb-', ',', 'usa-1', 'and', 'usa-2', '-lrb-', '10-year', 'risk', 'estimated', 'by', 'the', 'pce', '\\xe2\\x89\\xa5', '5.0', '%', 'or', '\\xe2\\x89\\xa5', '7.5', '%', ',', 'respectively', '-rrb-', '.']\n",
      "['hypercholesterolemia', 'is', 'one', 'of', 'the', 'main', 'risk', 'factors', 'for', 'coronary', 'heart', 'disease', 'and', 'significantly', 'contributes', 'to', 'the', 'high', 'mortality', 'associated', 'with', 'cardiovascular', 'diseases', '.']\n",
      "['of', '1094', 'patients', ',', '753', '-lrb-', '68.8', '%', '-rrb-', 'met', 'the', 'inclusion', 'criteria', 'of', 'the', 'study', '.']\n",
      "['statin', 'use', 'before', 'and', 'after', 'prostate', 'cancer', 'diagnosis', 'compared', 'with', 'nonuse', '.']\n",
      "['clinical', 'trials', 'performed', 'over', 'the', 'last', '25', 'years', 'have', 'shown', 'that', 'these', 'agents', 'are', 'effective', 'in', 'improving', 'cardiovascular', 'outcomes', 'in', 'several', 'different', 'clinical', 'settings', '.']\n",
      "['in', 'the', 'current', 'study', ',', 'to', 'increase', 'the', 'effectiveness', 'of', 'statin', 'therapy', ',', 'we', 'treated', 'infected', 'mice', 'with', 'atorvastatin', ',', 'a', 'type', '2', 'statin', 'that', 'has', 'improved', 'pharmacokinetics', 'over', 'many', 'type', '1', 'statins', '.']\n",
      "['the', 'patients', 'were', 'stratified', 'by', 'baseline', 'statin', 'use', 'and', 'estimated', 'peak', 'mets', 'achieved', 'during', 'exercise', 'testing', '.']\n",
      "['this', 'combined', 'therapy', 'simultaneously', 'reduces', 'cv', 'events', 'when', 'compared', 'to', 'either', 'drug', 'type', 'used', 'as', 'monotherapy', '.']\n",
      "['pmn', 'of', 'any', 'type', 'was', 'detected', 'in', '178', 'patients', '-lrb-', '33.0', '%', '-rrb-', ',', 'while', 'major', 'pmn', 'was', 'observed', 'in', '32', 'patients', '-lrb-', '5.9', '%', '-rrb-', '.']\n",
      "['all', 'patients', 'not', 'initially', 'receiving', 'a', 'statin', 'were', 'given', 'atorvastatin', ',', '20', 'mg', ',', 'and', 'the', 'following', 'llt', 'intensification', 'steps', 'were', 'applied', ':', 'uptitration', 'to', 'atorvastatin', ',', '80', 'mg', ';', 'add-on', 'ezetimibe', 'therapy', ';', 'add-on', 'alirocumab', 'therapy', ',', '75', 'mg', '-lrb-', 'a', 'pcsk9', 'inhibitor', '-rrb-', ';', 'and', 'uptitration', 'to', 'alirocumab', ',', '150', 'mg', '.']\n",
      "['the', 'tqrf', 'and', 'tq', 'conventional', 'emulsions', '-lrb-', 'ce', '-rrb-', ',', 'named', 'as', 'tqrfce', 'and', 'tqce', ',', 'respectively', 'were', 'studied', 'for', 'comparison', '.']\n",
      "['however', ',', 'the', 'beneficial', 'role', 'of', 'ipc', 'in', 'hyperlipidemic', 'patients', ',', 'post-acute', 'administration', 'of', 'statins', 'remains', 'unknown', '.']\n",
      "['inconsistent', 'findings', 'from', 'four', 'observational', 'studies', 'suggest', 'that', 'the', 'risk', 'of', 'acute', 'kidney', 'injury', '-lrb-', 'aki', '-rrb-', 'may', 'increase', 'with', 'increasing', 'statin', 'dose', 'or', 'potency', ',', 'but', 'none', 'of', 'the', 'studies', 'took', 'statin-related', 'severe', 'muscle', 'injury', ',', 'including', 'rhabdomyolysis', ',', 'into', 'account', '.']\n",
      "['em', 'indiv\\xc3\\xadduos', 'saud\\xc3\\xa1veis', 'em', 'preven\\xc3\\xa7\\xc3\\xa3o', 'prim\\xc3\\xa1ria', ':', 'avaliar', 'a', 'rela\\xc3\\xa7\\xc3\\xa3o', 'entre', 'o', 'risco', 'cardiovascular', 'segundo', 'a', 'v', 'diretriz', 'brasileira', 'de', 'dislipidemias', 'e', 'o', 'risco', 'calculado', 'pelas', 'pooled', 'cohort', 'equations', '-lrb-', 'pce', '-rrb-', ';', 'comparar', 'a', 'propor\\xc3\\xa7\\xc3\\xa3o', 'de', 'indiv\\xc3\\xadduos', 'eleg\\xc3\\xadveis', 'para', 'estatinas', ',', 'de', 'acordo', 'com', 'diferentes', 'crit\\xc3\\xa9rios', '.']\n",
      "['risk', '-lrb-', 'adjusted', 'hazard', 'ratio', '-lsb-', '95', '%', 'ci', '-rsb-', 'per', 'sd', 'increment', '-rrb-', 'among', 'placebo-allocated', 'participants', 'was', 'associated', 'with', 'total', 'ldl', 'particles', '-lrb-', '1.19', '-lsb-', '1.02', ',', '1.38', '-rsb-', '-rrb-', 'and', 'total', 'vldl', 'particles', '-lrb-', '1.21', '-lsb-', '1.04', ',', '1.41', '-rsb-', '-rrb-', ',', 'as', 'well', 'as', 'apolipoprotein', 'b', ',', 'non-high-density', 'lipoprotein', 'cholesterol', ',', 'and', 'triglycerides', ',', 'but', 'not', 'ldl-c', '.']\n",
      "['statins', 'have', 'pleiotropic', 'effects', 'that', 'are', 'considered', 'beneficial', 'in', 'preventing', 'cerebral', 'vasospasm', 'and', 'delayed', 'cerebral', 'ischemia', 'after', 'aneurysmal', 'subarachnoid', 'hemorrhage', '-lrb-', 'asah', '-rrb-', '.']\n",
      "['we', 'have', 'previously', 'shown', 'that', 'this', 'is', 'in', 'part', 'because', 'a', 'hydrophobic', 'statin', 'with', 'a', 'long', 'half-life', 'is', 'necessary', '.']\n",
      "['nk', 'group-patients', 'were', 'given', 'nk', 'at', 'a', 'daily', 'dose', 'of', '6', '000', 'fu', 'and', 'st', 'group-patients', 'were', 'treated', 'with', 'statin', '-lrb-', 'simvastatin', '20', 'mg', '-rrb-', 'daily', '.']\n",
      "['expert', 'commentary', ':', 'the', 'body', 'of', 'evidence', 'indicates', 'statins', 'may', 'also', 'play', 'a', 'potential', 'role', 'in', 'the', 'primary', 'and', 'secondary', 'prevention', 'of', 'vte', '.']\n",
      "['additionally', ',', 'little', 'is', 'known', 'regarding', 'the', 'therapeutic', 'impact', 'of', 'renin-angiotensin-aldosterone', 'system', '-lrb-', 'raas', '-rrb-', 'blockade', 'and', 'statin', 'on', 'reducing', 'the', 'occurrence', 'of', 'cva', 'in', 'adpkd', '.']\n",
      "['patients', 'more', 'commonly', 'presented', 'with', 'intermittent', 'claudication', '-lrb-', '66.3', '%', '-rrb-', 'than', 'with', 'critical', 'limb', 'ischemia', '-lrb-', 'cli', ';', '33.7', '%', '-rrb-', '.']\n",
      "['the', 'cost-effectiveness', 'and', 'long-term', 'safety', 'of', 'therapies', 'targeted', 'at', 'inhibiting', 'pcsk9', 'remains', 'to', 'be', 'demonstrated', 'if', 'they', 'are', 'to', 'be', 'used', 'widely', 'in', 'coronary', 'prevention', '.']\n",
      "['our', 'study', 'suggests', 'a', 'prognostic', 'impact', 'of', 'statin', 'use', 'in', 'patients', 'receiving', 'abiraterone', 'for', 'mcrpc', '.']\n",
      "['treatment', 'with', 'pitavastatin-nps', 'after', 'establishment', 'of', 'mi', 'attenuated', 'post-infarct', 'lv', 'remodeling', 'accompanied', 'by', 'a', 'reduction', 'of', 'monocytes/macrophages', 'in', 'the', 'heart', ',', 'whereas', 'pitavastatin', 'solution', 'treatment', 'did', 'not', '.']\n",
      "['the', 'media', 'plays', 'a', 'role', 'in', 'shaping', 'opinions', 'about', 'medical', 'decisions', ',', 'for', 'example', ',', 'whether', 'to', 'initiate', 'or', 'stop', 'treatment', '.']\n",
      "['in', 'the', 'third', 'study', 'haerer', 'et', 'al.', ',', 'found', 'an', 'increased', 'risk', 'of', 'falls', '-lrb-', 'p', '', '.63', '-rrb-', '.']\n",
      "['only', '25.2', '%', 'achieved', 'an', 'ldl-c', 'level', 'of', 'less', 'than', '70', 'mg/dl', '.']\n",
      "['these', 'results', 'suggest', 'that', 'pitavastatin', 'has', 'potential', 'as', 'a', 'therapy', 'for', 'allergic', 'airway', 'disease', 'and', 'that', 'its', 'effects', 'are', 'associated', 'with', 'its', 'ability', 'to', 'regulate', 'cd4', '+', 'cd25', '+', 'foxp3', '+', 't', 'cell', 'counts', '.']\n",
      "['the', 'respective', 'figures', 'for', 'men', 'were', '75', '%', ',', '58', '%', ',', '31', '%', 'and', '17', '%', '-lrb-', 'p', '<', '0.01', '-rrb-', '.']\n",
      "['the', 'article', 'contains', 'descriptions', 'of', 'indications', ',', 'contraindications', 'to', 'the', 'use', 'of', 'these', 'agents', 'as', 'of', 'their', 'possible', 'side', 'effects', '.']\n",
      "['associations', 'were', 'followed-up', 'using', 'gene', 'expression', 'studies', 'in', 'mice', '.']\n",
      "['the', 'association', 'between', 'use', 'of', 'statins', 'and', 'risk', 'of', 'falls', 'could', 'not', 'be', 'determined', 'with', 'the', 'available', 'evidence', ',', 'although', 'an', 'association', 'with', 'the', 'involvement', 'of', 'some', 'determinants', 'of', 'muscular', 'function', 'was', 'found', '.']\n",
      "['amyotrophic', 'lateral', 'sclerosis', '-lrb-', 'als', '-rrb-', 'is', 'a', 'devastating', 'neurodegenerative', 'disease', 'that', 'results', 'in', 'the', 'progressive', 'death', 'of', 'motor', 'neurons', ',', 'leading', 'to', 'paralysis', 'and', 'eventual', 'death', '.']\n",
      "['aha', '10-year', 'calculated', 'cvd', 'risk', 'fell', 'from', '11.5', 'to', '7.3', '%', '-lrb-', 'median', '-', '20', '%', ',', 'p', '', '.004', '-rrb-', ',', 'and', 'nih', '10-year', 'risk', 'from', '12.9', 'to', '5.1', '%', '-lrb-', 'median', '67', '%', ',', 'p', '<', '.0001', '-rrb-', '.']\n",
      "['we', 'performed', 'a', 'cross-sectional', 'and', 'longitudinal', 'analysis', 'of', '147', 'virally-suppressed', 'plhiv', ',', 'who', 'had', 'ldl', '<', '130', 'mg/dl', 'and', 'evidence', 'of', 'heightened', 'inflammation', ',', 'in', 'a', 'randomized', 'trial', 'of', 'statin', 'therapy', '.']\n",
      "['each', '1-met', 'increment', 'was', 'associated', 'with', 'an', '8', '%', ',', '8', '%', ',', 'and', '6', '%', 'relative', 'risk', 'reduction', 'in', 'the', 'total', 'cohort', ',', 'the', 'no-statin', ',', 'and', 'the', 'statin', 'groups', ',', 'respectively', '-lrb-', '95', '%', 'confidence', 'interval', ',', '0.91', 'to', '0.93', ',', '0.91', 'to', '0.93', ',', 'and', '0.91', 'to', '0.96', ',', 'respectively', ';', 'p', '<', '0.001', 'for', 'all', '-rrb-', '.']\n",
      "['one', 'hundred', 'ten', 'adult', 'patients', 'admitted', 'with', 'a', 'diagnosis', 'of', 'dfi', 'were', 'enrolled', 'in', 'the', 'experimental', 'group', '.']\n",
      "['a', 'prespecified', 'first', 'analysis', 'was', 'reported', 'at', '52', 'weeks', '.']\n",
      "['the', 'objective', 'of', 'our', 'study', 'was', 'to', 'investigate', 'the', 'role', 'of', 'statin', 'treatment', 'on', '\\xce\\xb2-adrenergic', 'dysfunction', 'in', 'diabetic', 'rat', 'cardiomyocytes', '.']\n",
      "['ascvd', 'was', 'associated', 'with', 'male', 'gender', ',', 'higher', 'peak', 'ldl-c', ',', 'lower', 'high-density', 'lipoprotein', 'cholesterol', '-lrb-', 'hdl-c', '-rrb-', ',', 'and', 'traditional', 'risk', 'factor', 'burden', '.']\n",
      "['location-specific', 'prediction', 'of', 'future', 'high-risk', 'coronary', 'artery', 'plaques', 'is', 'feasible', 'through', 'machine', 'learning', 'using', 'focal', 'vascular', 'features', 'and', 'demographic', 'variables', '.']\n",
      "['in', 'addition', 'to', 'their', 'lipid-lowering', 'abilities', ',', 'statins', 'have', 'anti-inflammatory', 'and', 'immunomodulatory', 'properties', '.']\n",
      "['some', 'potential', 'roadblocks', 'include', 'poor', 'access', 'to', 'laboratory', 'facilities', 'or', 'trained', 'professionals', 'for', 'cholesterol', 'management', ',', 'low', 'awareness', 'of', 'fh', 'among', 'the', 'general', 'population', 'and', 'health', 'professionals', ',', 'unaffordability', 'of', 'statins', 'for', 'patient', 'households', ',', 'and', 'low', 'awareness', 'of', 'the', 'importance', 'of', 'persistent', 'adherence', 'to', 'lipid-lowering', 'medication', '.']\n",
      "['statin', 'use', 'was', 'a', 'significant', 'prognostic', 'factor', 'for', 'longer', 'os', 'in', 'univariable', '-lrb-', 'hazard', 'ratio', '-lsb-', 'hr', '-rsb-', '0.51', ',', '95', '%', 'confidence', 'interval', '-lsb-', 'ci', '-rsb-', '0.37-0', '.72', ';', 'p', '<', '0.001', '-rrb-', 'and', 'multivariable', 'analysis', '-lrb-', 'hr', '0.40', ',', '95', '%', 'ci', '0.27-0', '.59', ';', 'p', '<', '0.001', '-rrb-', 'and', 'was', 'significantly', 'associated', 'with', 'psa', 'declines', '-lrb-', '>', '50', '%', 'decline', 'at', '12', 'wk', ':', '72.1', '%', 'in', 'statin', 'users', 'vs', '38.5', '%', 'in', 'non-users', ';', 'p', '<', '0.001', '-rrb-', '.']\n",
      "['two', 'rcts', 'and', 'eleven', 'non-randomized', 'studies', '-lrb-', 'four', 'cohort', 'and', 'seven', 'case-control', 'studies', '-rrb-', 'involving', '9,517', 'cases', 'of', 'endometrial', 'cancer', 'were', 'included', 'in', 'the', 'analysis', '.']\n",
      "['this', 'australian', 'audit', 'provides', 'insight', 'into', 'adherence', 'to', 'guidelines', 'for', 'individuals', 'with', 'cvd', 'and', 'hiv', ',', 'suggesting', 'that', 'current', 'screening', 'and', 'management', 'practices', 'for', 'these', 'patients', 'falls', 'short', 'of', 'guidelines', ',', 'particularly', 'in', 'relation', 'to', 'cholesterol', 'management', '.']\n",
      "['combination', 'therapy', '-lsb-', 'adjusted', '-lrb-', 'a', '-rrb-', 'hr', '', '0.19', ',', '95', '%', 'ci', ':', '0.11-0', '.31', '-rsb-', 'was', 'superior', 'to', 'either', 'raas', 'blockade', '-lrb-', 'ahr', '', '0.37', ',', '95', '%', 'ci', ',', '0.28-0', '.5', '-rrb-', 'or', 'statin', '-lrb-', 'ahr', '', '0.44', ',', '95', '%', 'ci', ',', '0.24-0', '.79', '-rrb-', 'alone', 'for', 'reducing', 'the', 'cva', 'occurrence', 'in', 'the', 'adpkd', 'population', '.']\n",
      "['grs', ',', 'determined', 'as', 'early', 'as', 'birth', 'from', 'saliva', ',', 'is', 'inexpensive', 'and', 'could', 'transform', 'the', 'prevention', 'of', 'cad', 'in', 'low', '-', 'and', 'middle-income', 'countries', '.']\n",
      "['of', 'the', '69', 'patients', ',', '25', 'had', 'hefh', ',', '25', 'cvd', ',', 'and', '19', 'had', 'both', '.']\n",
      "['pravastatin', 'is', 'often', 'too', 'weak', 'to', 'achieve', 'target', 'low-density', 'lipoprotein', 'cholesterol', 'levels', 'despite', 'having', 'beneficial', 'metabolic', 'actions', '.']\n",
      "['therefore', ',', 'we', 'examined', 'the', 'association', 'between', 'pre-diagnostic', 'statin', 'use', 'and', ';', 'lymph', 'node', 'status', ',', 'breast', 'cancer-specific', 'and', 'all-cause', 'mortality', '.']\n",
      "['objective', ':', 'to', 'evaluate', 'the', 'efficacy', 'of', 'oral', 'nattokinase', '-lrb-', 'nk', '-rrb-', 'in', 'the', 'reduction', 'of', 'common', 'carotid', 'artery', 'intimal', 'medial', 'thickness', '-lrb-', 'cca-imt', '-rrb-', 'and', 'carotid', 'artery', 'plaque', 'size', 'and', 'in', 'lowering', 'blood', 'lipids', ',', 'and', 'to', 'explore', 'the', 'underlying', 'mechanism', 'of', 'actions', 'of', 'nk', 'and', 'its', 'potential', 'clinical', 'use', '.']\n",
      "['statin', 'use', 'after', 'diagnosis', 'was', 'associated', 'with', 'a', 'decreased', 'risk', 'of', 'prostate', 'cancer', 'death', '-lrb-', 'hr', '0.80', ';', '95', '%', 'confidence', 'interval', '0.65-0', '.98', '-rrb-', '.']\n",
      "['specimens', 'were', 'collected', 'at', '28', 'days', 'to', 'evaluate', 'the', 'effects', 'of', 'statins', 'on', 'hypertrophic', 'scarring', '.']\n",
      "['this', 'paper', 'details', 'some', 'of', 'the', 'different', 'aetiological', 'hypotheses', 'put', 'forward', ',', 'focussing', 'particularly', 'on', 'those', 'related', 'to', 'mitochondrial', 'dysfunction', '.']\n",
      "['thanks', 'to', 'the', 'different', 'photosynthetic', 'cycles', 'of', 'the', 'matrices', 'used', 'for', 'their', 'synthesis', ',', 'monacolin', 'k', 'and', 'lovastatin', 'have', 'different', '\\xce\\xb4', '-lrb-', '13', '-rrb-', 'c', 'values', '-lrb-', '-29.6', '\\xe2\\x80\\xb0', '\\xc2\\xb1', '0.6', 'and', '-16.7', '\\xe2\\x80\\xb0', '\\xc2\\xb1', '2.6', 'respectively', '-rrb-', '.']\n",
      "['in', 'the', 'diabetic', 'heart', 'the', '\\xce\\xb2-adrenergic', 'response', 'is', 'altered', 'partly', 'by', 'down-regulation', 'of', 'the', '\\xce\\xb21-adrenoceptor', ',', 'reducing', 'its', 'positive', 'inotropic', 'effect', 'and', 'up-regulation', 'of', 'the', '\\xce\\xb23-adrenoceptor', ',', 'increasing', 'its', 'negative', 'inotropic', 'effect', '.']\n",
      "['for', 'each', 'pcp', ',', 'the', 'most', 'important', 'reason', 'was', 'given', 'a', 'weight', 'of', '3', 'votes', ',', 'and', 'the', 'second', 'and', 'third', 'most', 'important', 'reasons', 'were', 'given', 'weights', 'of', '2', 'and', '1', ',', 'respectively', '.']\n",
      "['median', 'levels', 'in', 'aaa', 'patients', 'not', 'using', 'statins', 'were', 'for', 'neutrophils', '928', '-lrb-', 'range', '552-2095', ',', 'p', '', '.03', '-rrb-', ',', 'lymphocytes', '156', '-lrb-', '101-273', ',', 'ns', '-rrb-', ',', 'and', 'for', 'monocytes', '536', '-lrb-', 'range', '535-1635', ',', 'ns', '-rrb-', '.']\n",
      "['sepsis', 'is', 'a', 'major', 'public', 'health', 'problem', ',', 'frequent', ',', 'costly', ',', 'and', 'often', 'fatal', '.']\n",
      "['in', 'turn', ',', 'mevalonate', 'created', 'a', 'positive', 'feed-forward', 'loop', 'to', 'activate', 'myc', 'signaling', 'via', 'induction', 'of', 'mir-33b', '.']\n",
      "['statin', 'therapy', 'represents', 'the', 'gold', 'standard', 'in', 'the', 'reduction', 'of', 'low-density', 'lipoprotein', 'cholesterol', 'concentration', '.']\n",
      "['literature', 'points', 'towards', 'statin-induced', 'mitochondrial', 'dysfunction', 'as', 'the', 'most', 'likely', 'cause', 'of', 'sams', '.']\n",
      "['we', 'queried', 'two', 'institutional', 'clinical', 'databases', '-lrb-', 'dana-farber', 'cancer', 'institute', '-lsb-', 'dfci', '-rsb-', ',', 'johns', 'hopkins', 'university', '-lsb-', 'jhu', '-rsb-', '-rrb-', 'for', 'crpc', 'patients', 'treated', 'with', 'aa', '.']\n",
      "['in', 'the', 'simulation', 'cohort', '-lrb-', '1', 'million', 'patients', ';', '54.8', '%', 'male', 'and', '45.2', '%', 'female', ';', 'mean', '-lsb-', 'sd', '-rsb-', 'age', ',', '66.4', '-lsb-', '12.2', '-rsb-', 'years', '-rrb-', ',', 'before', 'treatment', 'intensification', ',', '51.5', '%', 'used', 'statin', 'monotherapy', 'and', '1.7', '%', 'used', 'statins', 'plus', 'ezetimibe', '.']\n",
      "['however', 'we', 'focus', 'on', 'establishing', 'whether', 'this', 'plays', 'a', 'role', 'in', 'influencing', 'coronary', 'atherosclerosis', '.']\n",
      "['in', 'multivariate', 'analyses', ',', 'pre-diagnostic', 'statin', 'use', 'was', 'associated', 'with', 'reduced', 'all-cause', '-lrb-', 'hr', '0.78', '95', '%', 'confidence', 'interval', '-lrb-', 'ci', '-rrb-', '0.69', ',', '0.89', '-rrb-', 'and', 'breast', 'cancer-specific', 'mortality', '-lrb-', 'hr', '0.81', '95', '%', 'ci', '0.68', ',', '0.96', '-rrb-', '.']\n",
      "['results', 'were', 'comparable', 'in', 'those', 'with', 'low', ',', 'medium', 'and', 'high', 'dose', 'of', 'current', 'statin', 'use', ',', 'without', 'indications', 'of', 'heterogeneity', 'of', 'study', 'results', '.']\n",
      "['results', 'were', 'compared', 'between', 'patients', 'receiving', 'high-dose', ',', 'highly', 'efficient', 'statins', 'and', 'patients', 'receiving', 'low-dose', 'statins', 'or', 'no', 'statins', '.']\n",
      "['moreover', ',', 'heart', 'function', 'was', 'monitored', 'by', 'echocardiography', '.']\n",
      "['elevated', 'circulating', 'sortilin', 'levels', 'are', 'associated', 'with', 'cad', 'and', 'diabetes', 'mellitus', 'and', 'can', 'be', 'used', 'as', 'a', 'biomarker', 'of', 'both', 'diseases', 'in', 'statin-na\\xc3\\xafve', 'subjects', '.']\n",
      "['this', 'is', 'a', 'retrospective', 'post-hoc', 'analysis', 'of', 'the', 'yellow', 'ii', 'trial', ',', 'comparing', 'patients', 'with', 'and', 'without', 'dm', '-lrb-', 'non-dm', '-rrb-', 'who', 'received', 'rosuvastatin', '40', 'mg', 'for', '8-12', 'weeks', 'and', 'underwent', 'intracoronary', 'multimodality', 'imaging', 'of', 'an', 'obstructive', 'nonculprit', 'lesion', ',', 'before', 'and', 'after', 'therapy', '.']\n",
      "['local', 'injection-site', 'reactions', 'were', 'reported', 'by', '2.5', '%', '-lrb-', 'alirocumab', '-rrb-', 'versus', '0.8', '%', '-lrb-', 'ezetimibe', '-rrb-', 'during', 'the', 'first', 'year', ',', 'and', '0.2', '%', 'versus', '0.5', '%', 'during', 'the', 'second', 'year', ',', 'indicating', 'early', 'occurrence', 'during', 'prolonged', 'alirocumab', 'exposure', '.']\n",
      "['thirteen', 'of', 'the', 'patients', 'were', 'female', ',', 'with', 'mean', 'baseline', 'age', ',', 'diabetes', 'duration', ',', 'and', 'bmi', 'of', '47.6', 'and', '28.7', 'years', 'and', '23.1', ',', 'respectively', '.']\n",
      "['hope-3', 'study', 'showed', 'that', 'people', 'with', 'medium', 'cardiovascular', 'risk', 'who', 'have', 'not', 'experienced', 'a', 'cardiovascular', 'event', ',', 'and', 'have', 'normal', 'blood', 'pressure', ',', 'benefit', 'from', 'deploying', 'a', 'statin', ',', 'and', 'in', 'the', 'presence', 'of', 'hypertension', 'benefit', 'from', 'deploying', 'a', 'combination', 'of', 'a', 'statin', 'and', 'antihypertensive', 'drugs', '.']\n",
      "['the', 'sensitivity', 'analysis', 'confirmed', 'the', 'stability', 'of', 'our', 'results', '.']\n",
      "['these', 'plaque', 'features', 'are', ':', 'thin-cap', 'fibroatheroma', '-lrb-', 'tcfa', '-rrb-', ',', 'plaque', 'burden', 'pb', '\\xe2\\x89\\xa5', '70', '%', ',', 'or', 'minimal', 'luminal', 'area', 'mla', '\\xe2\\x89\\xa4', '4mm', '\\xc2\\xb2', '.']\n",
      "['the', '3-hydroxy-3-methylglutaryl-coenzyme', 'a', 'reductase', 'inhibitors', '-lrb-', 'known', 'as', 'statins', '-rrb-', ',', 'are', 'well', 'established', 'for', 'the', 'primary', 'and', 'secondary', 'prevention', 'of', 'cardiovascular', 'disease', 'via', 'their', 'lipid-lowering', 'properties', '.']\n",
      "['pcsk9', 'mabs', ',', 'administered', 'once', 'or', 'twice', 'monthly', ',', 'reduce', 'ldl-cholesterol', 'levels', 'by', '50', '-', '70', '%', ',', 'and', 'appear', 'to', 'be', 'safe', 'and', 'acceptable', 'to', 'patients', 'over', 'at', 'least', 'two', 'years', 'of', 'treatment', '.']\n",
      "['the', 'increasing', 'research', 'into', 'this', 'combinatorial', 'gene-environment', 'process', 'is', 'just', 'starting', ',', 'but', 'shows', 'early', 'promise', 'to', 'uncover', 'the', 'underlying', 'biochemical', 'pathways', 'that', 'instigate', 'the', 'initial', 'motor', 'neuron', 'defects', 'and', 'lead', 'to', 'their', 'rapidly', 'progressive', 'dysfunction', '.']\n",
      "['during', 'the', 'median', 'follow-up', 'of', '7.5', 'yr', 'postdiagnosis', '617', 'men', 'died', 'of', 'prostate', 'cancer', '.']\n",
      "['the', 'in-hospital', 'mortality', 'rate', 'was', '31.2', '%', '-lrb-', 'n', '', '72', '-rrb-', '.']\n",
      "['overall', 'mean', 'adherence', 'for', 'both', 'treatment', 'groups', 'during', 'the', 'first', 'and', 'second', 'year', 'was', '>', '97', '%', '.']\n",
      "['many', 'patients', 'discontinue', 'statin', 'treatment', ',', 'often', 'after', 'having', 'a', 'possible', 'adverse', 'reaction', '.']\n",
      "['the', 'lipid', 'lowering', 'effect', 'observed', 'in', 'the', 'nk', 'group', 'was', 'not', 'correlated', 'to', 'the', 'reduction', 'of', 'cca-imt', 'and', 'carotid', 'artery', 'plaque', 'size', '-lrb-', 'r', '', '0.35', ',', 'p', '', '0.09', '-rrb-', '.']\n",
      "['we', 'aimed', 'to', 'identify', 'pcp', 'perspectives', 'on', 'factors', 'influencing', 'statin', 're-initiation', '.']\n",
      "['furthermore', ',', 'evolocumab', 'did', 'not', 'affect', 'neurocognitive', 'function', 'and', 'was', 'not', 'associated', 'with', 'antidrug-antibody', 'production', 'in', 'over', '60,000', 'patient-years', 'of', 'drug', 'exposure', '.']\n",
      "['drug-drug', 'interactions', 'and', 'intolerance', 'to', 'statin', 'therapy', 'were', 'not', 'considered', 'when', 'we', 'evaluated', 'adherence', 'among', 'high-risk', 'patients', '.']\n",
      "['logistic', 'regression', 'analysis', 'also', 'showed', 'that', 'previous', 'atorvastatin', 'use', 'significantly', 'reduces', 'the', 'risk', 'of', 'dfi', '-lrb-', 'odds', 'ratio', '', '0.36', ';', '95', '%', 'confidence', 'interval', ',', '0.19-0', '.71', ';', 'p', '', '.003', '-rrb-', '.']\n",
      "['we', 'categorized', 'the', 'individual', 'responses', 'into', 'themes', 'and', 'determined', 'the', 'relative', 'importance', 'of', 'each', 'theme', 'using', 'a', '``', 'percent', 'of', 'available', 'votes', \"''\", 'metric', '.']\n",
      "['patients', 'with', 'familial', 'hypercholesterolaemia', 'are', 'the', 'most', 'obvious', 'candidates', 'for', 'these', 'drugs', ',', 'but', 'other', 'patients', 'with', 'elevated', 'cardiovascular', 'risk', ',', 'statin', 'intolerance', 'or', 'hyperlipoproteinaemia', '-lrb-', 'a', '-rrb-', 'may', 'also', 'benefit', '.']\n",
      "['this', 'is', 'a', 'population-based', 'cohort', 'study', 'consisting', 'of', 'a', 'general', 'male', 'population', 'of', 'finland', 'participating', 'in', 'the', 'finnish', 'randomized', 'study', 'for', 'prostate', 'cancer', 'screening', '.']\n",
      "['clinically', 'stable', 'patients', 'who', 'underwent', 'des', 'implantation', '12', 'months', 'previously', 'and', 'received', 'aspirin', 'monotherapy', 'were', 'randomly', 'assigned', 'to', 'receive', 'either', 'high-intensity', '-lrb-', '40mg', 'atorvastatin', ',', 'n', '', '1000', '-rrb-', 'or', 'low-intensity', '-lrb-', '20mg', 'pravastatin', ',', 'n', '', '1000', '-rrb-', 'statin', 'treatment', '.']\n",
      "['risk', 'factors', 'for', 'developing', 't2dm', 'were', 'male', 'sex', ',', 'age', ',', 'body', 'mass', 'index', ',', 'hypertension', ',', 'baseline', 'triglyceride', 'levels', 'and', 'years', 'on', 'statin', 'therapy', '.']\n",
      "['whether', 'the', 'star', 'adherence', 'target', 'is', 'associated', 'with', 'reduced', 'blood', 'pressure', 'or', 'low-density', 'lipoprotein', 'cholesterol', '-lrb-', 'ldl-c', '-rrb-', 'in', 'complex', 'older', 'patients', 'is', 'not', 'well', 'understood', '.']\n",
      "['up', 'to', '10', 'controls', 'per', 'case', ',', 'matched', 'by', 'date', 'of', 'birth', ',', 'sex', ',', 'and', 'cohort', 'entry', 'date', 'were', 'randomly', 'selected', 'from', 'the', 'relevant', 'cohort', 'using', 'risk', 'set', 'sampling', '.']\n",
      "['in', 'addition', ',', 'the', 'results', 'showed', 'that', 'pitavastatin', 'inhibited', 'ova-induced', 'increases', 'in', 'eosinophil', 'counts', 'and', 'total', 'inflammatory', 'cell', 'counts', 'in', 'bronchoalveolar', 'lavage', 'fluid', '-lrb-', 'balf', '-rrb-', 'and', 'increased', 'the', 'percentage', 'of', 'cd4', '+', 'cd25', '+', 'foxp3', '+', 'treg', 'in', 'the', 'balf', 'of', 'asthmatic', 'mice', '.']\n",
      "['hazard', 'ratios', 'for', 'incident', 'diabetes', 'were', 'calculated', 'using', 'cox', 'proportional', 'hazards', 'models', 'adjusted', 'for', 'demographic', 'characteristics', ',', 'co-morbidities', ',', 'pertinent', 'medications', ',', 'and', 'stress', 'test', 'indication', '.']\n",
      "['incident', 'cancer', 'occurred', 'in', '125', '-lrb-', '15', '%', '-rrb-', 'of', 'the', '812', 'statin-eligible', 'participants', 'versus', '122', '-lrb-', '8.8', '%', '-rrb-', 'of', 'the', '1,384', 'of', 'noneligible', 'participants', '-lrb-', 'subdistribution', 'hazard', 'ratio', '-lsb-', 'sdhr', '-rsb-', ',', '1.8', '-lsb-', '1.4', 'to', '2.3', '-rsb-', ';', 'p', '<', '.001', '-rrb-', '.']\n",
      "['combined', 'analysis', 'of', 'all', 'included', 'studies', 'also', 'showed', 'that', 'statin', 'use', 'did', 'not', 'significantly', 'affect', 'endometrial', 'cancer', 'risk', '-lrb-', 'rr', ',', '0.94', ';', '95', '%', 'ci', ',', '0.82', 'to', '1.07', '-rrb-', '.']\n",
      "['a', 'significant', 'reduction', 'of', 'plasma', 'hscrp', ',', 'myeloperoxidase', 'and', 'neutrophil', 'elastase', 'and', 'an', 'increase', 'of', 'nitrate', 'levels', 'were', 'noted', 'in', 'both', 'treatment', 'arms', '.']\n",
      "['in', 'the', 'exercise', 'group', ',', 'at', 'least', '30', 'min', 'of', 'moderate', 'aerobic', 'exercise', 'per', 'day', '5', 'times', 'weekly', 'was', 'recommended', '.']\n",
      "['hmg-coa', 'reductase', 'inhibitors', '-lrb-', 'statins', '-rrb-', ',', 'which', 'inhibit', 'the', 'synthesis', 'of', 'mevalonate', ',', 'can', 'interfere', 'with', 'the', 'cardioprotective', 'effect', 'of', 'ipc', '.']\n",
      "['at', 'hospital', 'discharge', ',', 'only', '73.1', '%', 'of', 'patients', 'received', 'dual', 'antiplatelet', 'therapy', 'and', '69.2', '%', 'received', 'a', 'statin', '.']\n",
      "['sixty-one', 'patients', 'with', 'stable', 'angina', 'on', 'statin', 'therapy', 'underwent', 'baseline', 'and', 'one-year', 'follow-up', 'vh-ivus', 'non-culprit', 'vessel', 'examinations', 'followed', 'by', 'quantitative', 'image', 'analysis', '.']\n",
      "['residual', 'atherosclerotic', 'cardiovascular', 'disease', '-lrb-', 'ascvd', '-rrb-', 'risk', 'in', 'statin-treated', 'us', 'adults', 'without', 'known', 'ascvd', 'is', 'not', 'well', 'described', '.']\n",
      "['statin', 'therapy', 'in', 'low-risk', 'air', 'force', 'aviators', 'with', 'isolated', 'hypercholesterolemia', '.']\n",
      "['some', 'associations', 'were', 'modified', 'by', '25', '-lrb-', 'oh', '-rrb-', 'd', 'e.g.', 'the', 'association', 'with', 'intrusive', 'body', 'pain', 'was', 'evident', 'in', 'the', 'insufficient', '-lrb-', '13-20', 'ng/l', '-rrb-', 'and', 'deficient', '-lrb-', '<', '13', 'ng/l', '-rrb-', '25', '-lrb-', 'oh', '-rrb-', 'd', 'status', 'groups', '-lrb-', 'or', '', '2.6,95', '%', 'ci', '1.7-1', '.1', ';', 'or', '', '1.8,95', '%', 'ci', '1.2-2', '.8', ',', 'respectively', '-rrb-', 'but', 'not', 'in', 'those', 'with', 'status', '>', '20', 'ng/l', '-lrb-', 'or', '', '0.8,95', '%', 'ci', '0.5-1', '.4', '-rrb-', '-lrb-', 'p', '', '0.003', 'for', 'interaction', '-rrb-', '.']\n",
      "['demonstrating', 'whether', 'efficacy', 'and', 'safety', 'are', 'maintained', 'over', 'a', 'long', 'duration', 'of', 'exposure', 'is', 'vital', 'for', 'clinical', 'decision-making', '.']\n",
      "['femoropopliteal', 'artery', '-lrb-', '41.2', '%', '-rrb-', 'was', 'the', 'most', 'common', 'target', 'vessel', 'for', 'endovascular', 'treatment', ',', 'followed', 'by', 'the', 'aortoiliac', '-lrb-', '35.6', '%', '-rrb-', 'and', 'infrapopliteal', 'arteries', '-lrb-', '23.2', '%', '-rrb-', '.']\n",
      "['seven', 'genes', 'were', 'reduced', 'by', 'pravastatin', ',', 'and', 'one', 'gene', 'was', 'reduced', 'by', 'atorvastatin', '.']\n",
      "['ninety', 'four-weeks', 'old', 'male', 'sd', 'rats', 'fed', 'with', 'cholesterol', 'enriched', 'diet', 'for', 'six', 'weeks', 'were', 'randomized', 'into', 'nine', 'groups', '-lrb-', 'n', '', '10/group', '-rrb-', '-', 'sham', 'group', ',', 'control', 'group', ',', 'ipc', 'group', ',', 'atorvastatin', 'group', ',', 'wortmannin', 'group', ',', 'pd98059', 'group', ',', 'atorvastatin', '+', 'ipc', 'group', ',', 'atorvastatin', '+', 'ipc', '+', 'wortmannin', 'group', 'and', 'atorvastatin', '+', 'ipc', '+', 'pd98059', 'group', '.']\n",
      "['however', ',', 'guideline', 'bodies', 'should', 'review', 'the', 'overall', 'evidence', 'and', 'consider', 'including', 'statin', 'therapy', 'as', 'an', 'adjunct', 'to', 'anticoagulant', 'therapy', 'in', 'vte', 'prevention', 'in', 'specific', 'patient', 'populations', '.']\n",
      "['compared', 'to', '2007', ',', 'more', 'people', '-lrb-', '5.52', 'pp', '-rrb-', 'discontinued', 'statin', 'treatment', 'in', '2008', '.']\n",
      "['the', 'anticancer', 'efficacy', 'of', 'anthracyclines', 'is', 'limited', 'by', 'congestive', 'heart', 'failure', '.']\n",
      "['in', 'previous', 'studies', ',', 'treatment', 'of', 'scrapie-infected', 'mice', 'with', 'the', 'type', '1', 'statins', ',', 'simvastatin', 'or', 'pravastatin', ',', 'showed', 'a', 'small', 'beneficial', 'effect', 'on', 'survival', 'time', '.']\n",
      "['the', 'purpose', 'of', 'this', 'study', 'was', 'to', 'evaluate', 'the', 'effect', 'of', 'hl', 'and', 'statin', 'use', 'on', 'rotator', 'cuff', 'healing', 'after', 'arthroscopic', 'repair', '.']\n",
      "['over', 'half', '-lrb-', '57', '%', '-rrb-', 'had', 'detectable', 'coronary', 'artery', 'calcium', 'pre-transplant', '.']\n",
      "['recent', 'research', 'has', 'suggested', 'that', 'statins', 'have', 'an', 'effect', 'on', 'prostate', 'cancer', 'prognosis', '.']\n",
      "['inhibition', 'of', 'monocyte', 'mobilization', 'from', 'the', 'bone', 'marrow', 'is', 'one', 'of', 'the', 'major', 'mechanisms', 'by', 'which', 'pitavastatin-nps', 'attenuated', 'post-infarct', 'lv', 'remodeling', '.']\n",
      "['on-statin', 'levels', 'of', 'the', 'smallest', 'vldl', 'particle', 'subclass', 'were', 'associated', 'with', 'a', '68', '%', 'per-sd', '-lrb-', 'adjusted', 'hazard', 'ratio', '1.68', '-lsb-', '1.28', ',', '2.22', '-rsb-', '-rrb-', 'increase', 'in', 'residual', 'risk-this', 'risk', 'was', 'related', 'to', 'vldl', 'cholesterol', 'and', 'not', 'triglyceride', 'or', 'larger', 'vldl', 'particles', '.']\n",
      "['we', 'studied', 'the', 'association', 'between', 'statin', 'use', 'and', 'time', 'to', 'consultation', 'or', 'surgery', 'for', 'osteoarthritis', 'of', 'the', 'hip', 'or', 'knee', 'by', 'time-dependent', 'exposure', 'analysis', 'and', 'cox', 'regression', '.']\n",
      "['compared', 'to', 'control', 'group', ',', 'infarct', 'size', 'decreased', 'more', 'significantly', 'in', 'atorvastatin', '+', 'ipc', 'and', 'atorvastatin', '+', 'ipc', '+', 'wortmannin', 'groups', 'than', 'ipc', 'or', 'atorvastatin', '+', 'ipc', '+', 'pd98059', 'groups', '.']\n",
      "['the', 'mechanism', 'of', 'this', 'interaction', 'warrants', 'elucidation', ',', 'but', 'may', 'include', 'enhancement', 'of', 'the', 'antitumor', 'activity', 'of', 'abiraterone', 'as', 'well', 'as', 'cardioprotective', 'effects', '.']\n",
      "['to', 'quantitate', 'residual', 'ascvd', 'risk', 'and', 'its', 'predictors', 'in', 'statin-treated', 'adults', '.']\n",
      "['each', 'group', 'generated', 'a', 'list', 'of', 'responses', 'in', 'round-robin', 'fashion', '.']\n",
      "['their', 'production', 'may', 'be', 'decreased', 'by', 'statins', ',', 'thereby', 'reducing', 'the', 'aaa', 'growth', 'rate', '.']\n",
      "['negative', 'effects', 'were', 'noticed', 'at', 'the', 'time', 'of', 'observation', 'of', 'the', 'ldl/hdl', 'ratio', 'with', 'an', 'approximate', 'increase', 'of', '0.0025', 'each', 'day', 'in', 'palliative', 'subjects', '.']\n",
      "['cox', 'proportional', 'hazards', 'regression', 'with', 'postdiagnostic', 'statin', 'use', 'as', 'a', 'time-dependent', 'variable', '.']\n",
      "['post-translational', 'activation', 'of', 'p42', 'mapk/erk', ',', 'rather', 'than', 'pi3k/akt', ',', 'participates', 'in', 'the', 'net', 'protective', 'effect', 'of', 'ipc', 'and', 'atorvastatin', 'in', 'hyperlipidemia', '.']\n",
      "['in', 'the', 'final', 'section', 'the', 'article', 'discusses', 'options', 'for', 'improving', 'patient', 'adherence', 'to', 'antihypertensive', 'and', 'lipid', 'treatment', 'and', 'the', 'new', 'available', 'fixed', 'combinations', 'for', 'these', 'diseases.key', 'words', ':', 'arterial', 'hypertension', '-', 'cardiovascular', 'prevention', '-', 'dyslipidemia', '-', 'fixed', 'combinations', '-', 'treatment', '.']\n",
      "['compared', 'with', 'never', 'use', ',', 'current', 'use', 'of', 'statins', 'conferred', 'no', 'overall', 'reduction', 'in', 'the', 'risk', 'of', 'osteoarthritis', 'with', 'an', 'adjusted', 'pooled', 'hr', 'of', '1.04', '-lrb-', '95', '%', 'ci', '0.99', 'to', '1.10', '-rrb-', '.']\n",
      "['as', 'the', 'survival', 'of', 'cancer', 'subjects', 'increases', ',', 'frequent', 'control', 'of', 'the', 'lipid', 'profile', 'gains', 'importance', '.']\n",
      "['two', 'hundred', 'and', 'eight', '-lrb-', '27.6', '%', '-rrb-', 'patients', 'received', 'statin', 'therapy', 'at', 'an', 'inappropriate', 'intensity', 'according', 'to', 'their', 'risk', 'group', 'based', 'on', 'the', 'guideline', ';', '126', '-lrb-', '16.7', '%', '-rrb-', 'received', 'less', 'than', 'the', 'ideal', 'intensity', '.']\n",
      "['the', 'introduction', 'of', 'potent', 'therapeutic', 'agents', 'underlies', 'the', 'importance', 'of', 'improving', 'clinical', 'diagnosis', 'and', 'treatment', 'gaps', 'in', 'fh.methods', 'and', 'results', ':', 'a', 'regional', 'database', 'of', '1,690', 'adult', 'patients', 'with', 'high-probability', 'fh', 'based', 'on', 'age-dependent', 'peak-low-density', 'lipoprotein', 'cholesterol', '-lrb-', 'ldl-c', '-rrb-', 'cut-offs', 'and', 'exclusion', 'of', 'secondary', 'causes', 'of', 'severe', 'hypercholesterolemia', ',', 'was', 'examined', 'to', 'explore', 'the', 'clinical', 'manifestations', 'and', 'current', 'needs', 'in', 'the', 'management', 'of', 'ascvd', ',', 'which', 'was', 'present', 'in', '248', 'patients', '-lrb-', '15', '%', '-rrb-', ',', 'of', 'whom', '83', '%', 'had', 'coronary', 'artery', 'disease', '-lrb-', 'cad', '-rrb-', ';', '19', '%', ',', 'stroke', ';', 'and', '13', '%', ',', 'peripheral', 'artery', 'disease', '.']\n",
      "['the', 'sprague', 'dawley', 'rats', 'were', 'fed', 'with', 'hfcd', 'for', '6', 'months', ',', 'and', 'treated', 'with', 'the', 'intervention', 'groups', 'via', 'oral', 'gavage', 'daily', 'for', 'the', 'last', '3', 'months', '.']\n",
      "['multivessel', 'cad', '-lrb-', 'adjusted', 'hazard', 'ratios', '-lrb-', 'hr', '-rrb-', ',', '3.05', ';', '95', '%', 'ci', ':', '1.65-5', '.64', '-rrb-', ',', 'myocardial', 'infarction', ',', 'and', 'the', 'presence', 'of', '\\xe2\\x89\\xa5', '1', 'traditional', 'risk', 'factor', '-lrb-', 'hr', ',', '2.59', ';', '95', '%', 'ci', ':', '1.42-4', '.71', '-rrb-', ',', 'were', 'associated', 'with', 'repeat', 'coronary', 'revascularizations', ',', 'in', 'contrast', 'with', 'peak', 'ldl-c', '>', '300', 'mg/dl', '-lrb-', 'hr', ',', '1.13', ';', '95', '%', 'ci', ':', '0.66-1', '.91', '-rrb-', '.']\n",
      "['since', 'stable', 'isotope', 'tracer', 'kinetic', 'methods', 'provide', 'a', 'measure', 'of', 'traffic', 'flow', '-lrb-', 'i.e.', 'metabolic', 'flux', '-rrb-', ',', 'their', 'inclusion', 'in', 'study', 'designs', 'can', 'yield', 'novel', 'information', 'regarding', 'pathway', 'biology', ';', 'the', 'application', 'of', 'such', 'methods', 'requires', 'the', 'integration', 'of', 'knowledge', 'in', 'physiology', ',', 'analytical', 'chemistry', 'and', 'mathematical', 'modeling', '.']\n",
      "['the', 'target', 'of', 'pitavastatin', ',', 'hydroxymethylglutarate', 'coenzyme-a', 'reductase', '-lrb-', 'hmgcr', '-rrb-', ',', 'was', 'found', 'to', 'be', 'over-expressed', 'in', 'all', 'ovarian', 'cancer', 'cell', 'lines', 'examined', 'and', 'upregulated', 'by', 'mutated', 'tp53', ',', 'a', 'gene', 'commonly', 'altered', 'in', 'ovarian', 'cancer', '.']\n",
      "['cca-imt', ',', 'carotid', 'plaque', 'size', 'and', 'blood', 'lipid', 'profile', 'of', 'the', 'patients', 'were', 'measured', 'before', 'and', 'after', 'treatment', '.']\n",
      "['our', 'findings', 'do', 'not', 'support', 'a', 'protective', 'effect', 'of', 'statins', 'against', 'endometrial', 'cancer', 'at', 'the', 'population', 'level', '.']\n",
      "['among', '28', '266', 'study', 'patients', ',', '19', '989', '-lrb-', '70.7', '%', '-rrb-', 'continued', 'receiving', 'statin', 'prescriptions', 'after', 'the', 'adverse', 'reaction', '.']\n",
      "['the', 'pathophysiology', 'of', ',', 'and', 'mechanisms', 'leading', 'to', 'sams', ',', 'are', 'yet', 'to', 'be', 'fully', 'understood', '.']\n",
      "['however', ',', 'in', 'some', 'cases', 'statin', 'treatment', 'may', 'be', 'associated', 'with', 'significant', 'side', 'effects', 'and', 'adverse', 'reactions', '.']\n",
      "['monacolin', 'k', 'was', 'isolated', 'from', 'ryr', 'using', 'preparative', 'hplc', 'and', 'together', 'with', 'lovastatin', ',', 'was', 'subjected', 'to', 'analysis', 'of', '\\xce\\xb4', '-lrb-', '13', '-rrb-', 'c', 'and', '\\xce\\xb4', '-lrb-', '2', '-rrb-', 'h', 'using', 'isotope', 'ratio', 'mass', 'spectrometry', '.']\n",
      "['a', 'significant', 'proportion', 'of', 'deaths', 'were', 'attributed', 'to', 'cardiovascular', 'causes', 'in', 'all', 'subgroups', '-lrb-', 'type', '1', 'mi', ':', '34.1', '%', ',', 'type', '2', 'mi', ':', '17.8', '%', ',', 'myocardial', 'injury', ':', '30.8', '%', '-rrb-', '.']\n",
      "['the', '2014', 'guidelines', 'on', 'cardiovascular', 'risk', 'assessment', 'and', 'lipid', 'modification', 'from', 'the', 'national', 'institute', 'for', 'health', 'and', 'care', 'excellence', '-lrb-', 'nice', '-rrb-', 'recommend', 'statin', 'therapy', 'for', 'adults', 'with', 'prevalent', 'cardiovascular', 'disease', '-lrb-', 'cvd', '-rrb-', ',', 'and', 'for', 'adults', 'with', 'a', '10-year', 'cvd', 'risk', 'of', '\\xe2\\x89\\xa5', '10', '%', ',', 'estimated', 'using', 'the', 'qrisk2', 'algorithm', '.']\n",
      "['interestingly', ',', 'metformin', 'can', 'enhance', 'mitochondrial', 'function', 'and', 'may', 'affect', 'atrogin-1', 'expression', '.']\n",
      "['the', 'aim', 'of', 'this', 'study', 'is', 'to', 'explore', 'whether', 'a', 'danish', 'newspaper', 'article', 'featuring', 'the', 'side', 'effects', 'of', 'statins', 'affects', 'statin', 'discontinuation', 'in', 'incident', 'versus', 'prevalent', 'users', ',', 'with', 'the', 'reason', 'for', 'prescription', 'also', 'taken', 'into', 'account', '.']\n",
      "['prior', 'therapy', 'with', 'atorvastatin', 'considerably', 'reduces', 'the', 'onset', 'of', 'dfis', '.']\n",
      "['in', 'the', 'last', 'years', 'the', 'hypothesis', 'that', 'functional', 'properties', 'of', 'hdl', 'may', 'be', 'more', 'relevant', 'than', 'hdl-c', 'levels', 'has', 'risen', 'from', 'several', 'observations', '.']\n",
      "['collectively', ',', 'our', 'results', 'argue', 'that', 'myc', 'mediates', 'its', 'oncogenic', 'effects', 'in', 'part', 'by', 'altering', 'mevalonate', 'metabolism', 'in', 'gloma', 'cells', ',', 'suggesting', 'a', 'therapeutic', 'strategy', 'in', 'this', 'setting', '.']\n",
      "['these', 'findings', 'may', 'be', 'helpful', 'for', 'identifying', 'those', 'at', 'highest', 'risk', 'needing', 'more', 'aggressive', 'treatment', '.']\n",
      "['despite', 'of', 'improvements', 'in', 'supportive', 'treatments', 'the', 'incidence', 'of', 'sepsis', 'and', 'the', 'number', 'of', 'deaths', 'related', 'to', 'sepsis', 'is', 'increasing', '.']\n",
      "['after', 'controlling', 'for', 'potential', 'confounders', ',', 'the', 'adjusted', 'ors', 'of', 'chronic', 'osteomyelitis', 'were', '0.57', 'for', 'subjects', 'with', 'current', 'statin', 'use', '-lrb-', '95', '%', 'ci', '0.45', ',', '0.72', '-rrb-', ',', '0.80', 'for', 'subjects', 'with', 'recent', 'statin', 'use', '-lrb-', '95', '%', 'ci', '0.48', ',', '1.33', '-rrb-', ',', 'and', '1.00', 'for', 'subjects', 'with', 'past', 'statin', 'use', '-lrb-', '95', '%', 'ci', '0.83', ',', '1.20', '-rrb-', ',', 'compared', 'patients', 'with', 'no', 'prior', 'statin', 'use', '.']\n",
      "['this', 'article', 'is', 'protected', 'by', 'copyright', '.']\n",
      "['compared', 'to', 'no', 'comorbidity', ',', 'high', 'comorbidity', '-lrb-', '\\xe2\\x89\\xa5', '4', '-rrb-', 'was', 'associated', 'with', 'lower', 'acei/arb', '-lrb-', 'rr', '0.88', '-lsb-', '95', '%', 'ci', '0.87', ',', '0.89', '-rsb-', '-rrb-', 'or', 'statin', '-lrb-', 'rr', '0.91', '-lsb-', '0.90', ',', '0.92', '-rsb-', '-rrb-', 'adherence', '.']\n",
      "['we', 'sought', 'to', 'determine', 'the', 'accuracy', 'of', 'the', '2013', 'american', 'college', 'of', 'cardiology/american', 'heart', 'association', 'statin', 'eligibility', 'criteria', 'to', 'identify', 'individuals', 'at', 'a', 'higher', 'risk', 'of', 'developing', 'cancer', 'or', 'of', 'dying', 'as', 'a', 'result', 'of', 'cancer', 'or', 'other', 'noncardiovascular', 'causes', '.']\n",
      "['we', 'conclude', 'that', 'a', 'higher', 'ec', 'is', 'associated', 'with', 'a', 'lower', 'risk', 'of', 'incident', 'diabetes', 'regardless', 'of', 'statin', 'use', '.']\n",
      "['patients', 'were', 'sampled', 'with', 'replacement', '-lrb-', 'bootstrapping', '-rrb-', 'to', 'match', 'the', 'us', 'epidemiologic', 'distribution', 'and', 'entered', 'into', 'a', 'monte', 'carlo', 'simulation', '-lrb-', 'simulation', 'cohort', '-rrb-', 'that', 'applied', 'stepwise', 'treatment', 'intensification', 'algorithms', 'in', 'those', 'with', 'ldl-c', 'levels', 'of', 'at', 'least', '70', 'mg/dl', '.']\n",
      "['in', 'patients', 'with', 'atherosclerotic', 'cardiovascular', 'disease', '-lrb-', 'ascvd', '-rrb-', ',', 'guidelines', 'recommend', 'optimizing', 'statin', 'treatment', ',', 'and', 'consensus', 'pathways', 'suggest', 'use', 'of', 'ezetimibe', 'and', 'proprotein', 'convertase', 'subtilisin/kexin', 'type', '9', '-lrb-', 'pcsk9', '-rrb-', 'inhibitors', 'in', 'patients', 'with', 'persistently', 'elevated', 'low-density', 'lipoprotein', 'cholesterol', '-lrb-', 'ldl-c', '-rrb-', 'levels', 'despite', 'use', 'of', 'statins', '.']\n",
      "['the', 'treatment', 'course', 'was', '26', 'weeks', '.']\n",
      "['for', 'each', 'segmented', 'and', 'registered', 'vh-ivus', 'frame', 'pair', '-lrb-', 'n', '', '6341', '-rrb-', ',', 'location-specific', '-lrb-', '\\xe2\\x89\\x88', '0.5', 'mm', '-rrb-', 'vascular', 'features', 'and', 'demographic', 'information', 'at', 'baseline', 'were', 'identified', '.']\n",
      "['oral', 'antihyperglycemic', 'medications', 'remain', 'the', 'cornerstone', 'of', 'treatment', 'for', 'optimizing', 'glucose', 'control', 'in', 'patients', 'with', 'diabetes', '.']\n",
      "['these', 'transcriptomic', 'findings', 'might', 'provide', 'potential', 'mechanisms', 'responsible', 'for', 'the', 'higher', 'cardiovascular', 'risk', 'in', 'dm', 'patients', '.']\n",
      "['studies', 'that', 'evaluated', 'exposure', 'to', 'statins', 'and', 'endometrial', 'cancer', 'risk', 'were', 'considered', '.']\n",
      "['neutralizing', 'antibodies', '-lrb-', 'that', 'inhibit', 'binding', 'in', 'vitro', '-rrb-', 'were', 'observed', 'in', '1.5', '%', '-lrb-', '7', 'of', '454', '-rrb-', 'of', 'alirocumab-treated', 'patients', '-lrb-', '0', 'with', 'ezetimibe', '-rrb-', ',', 'mostly', 'at', 'isolated', 'time', 'points', '.']\n",
      "['only', 'il-6', ',', 'cd4', '+38', '+', 'dr', '+', 't', 'cells', ',', 'and', 'cd4', '+', 'pd1', '+', 't_cells', 'remained', 'associated', 'after', 'adjustment', 'for', 'clinical', 'factors', 'known', 'to', 'affect', 'rdw', 'in', 'the', 'general', 'population', '.']\n",
      "['hypercholesterolemia', 'and', 'hypertension', 'have', 'synergistic', 'deleterious', 'effects', 'on', 'interrelated', 'insulin', 'resistance', 'and', 'endothelial', 'dysfunction', '.']\n",
      "['mean', '\\xc2\\xb1', 'sd', 'and', 'median', 'follow-up', 'were', '49', '\\xc2\\xb1', '13', 'and', '49', 'weeks', 'on', 'ali', '75', 'mg', ',', 'and', '37', '\\xc2\\xb1', '12', 'and', '33', 'weeks', 'on', 'ali-evo', '.']\n",
      "['the', 'presence', 'of', 'diabetes', 'mellitus', 'was', 'evaluated', 'and', 'plasma', 'sortilin', 'levels', 'were', 'measured', 'with', 'a', 'commercial', 'elisa', 'kit', '.']\n",
      "['statins', ',', 'that', 'are', 'the', 'most', 'used', 'lipid-lowering', 'drugs', ',', 'can', 'also', 'increase', 'hdl-c', 'levels', ',', 'although', 'this', 'effect', 'is', 'highly', 'variable', 'among', 'studies', 'and', 'statins', ';', 'the', 'most', 'recent', 'developed', 'statin', ',', 'pitavastatin', ',', 'beside', 'its', 'role', 'as', 'ldl-c-lowering', 'agent', ',', 'increases', 'hdl-c', 'levels', 'at', 'a', 'significantly', 'higher', 'extent', 'and', 'progressively', 'upon', 'treatment', ';', 'such', 'increase', 'was', 'observed', 'also', 'when', 'patients', 'where', 'shifted', 'from', 'another', 'statin', 'to', 'pitavastatin', '.']\n",
      "['the', 'risk', 'decrease', 'was', 'clearest', 'in', 'men', 'managed', 'with', 'androgen', 'deprivation', 'therapy', '.']\n",
      "['we', 'sought', 'to', 'investigate', 'whether', 'the', 'association', 'between', 'ec', 'and', 'diabetes', 'risk', 'is', 'modified', 'by', 'statin', 'therapy', '.']\n",
      "['the', 'tqrf', 'was', 'extracted', 'from', 'nigella', 'sativa', 'seeds', 'using', 'a', 'supercritical', 'fluid', 'extraction', 'system', 'and', 'prepared', 'into', 'nanoemulsion', ',', 'which', 'later', 'named', 'as', 'tqrf', 'nanoemulsion', '-lrb-', 'tqrfne', '-rrb-', '.']\n",
      "['the', 'purpose', 'of', 'this', 'study', 'was', 'to', 'describe', 'the', 'clinical', 'outcome', 'of', 'patients', 'diagnosed', 'with', 'sepsis', 'in', 'a', 'university-affiliated', 'hospital', 'in', 'central', 'argentina', 'and', 'to', 'evaluate', 'it', 'in', 'relation', 'to', 'a', 'group', 'of', 'septic', 'patients', 'with', 'previous', 'use', 'of', 'statins', 'before', 'the', 'onset', 'of', 'sepsis', '.']\n",
      "['patients', 'with', 'asah', 'were', 'randomly', 'assigned', 'to', 'a', 'pitavastatin', 'group', '-lrb-', '4', 'mg', 'daily', ';', 'n', '', '54', '-rrb-', 'and', 'a', 'placebo', 'group', '-lrb-', 'n', '', '54', '-rrb-', 'after', 'repair', 'of', 'a', 'ruptured', 'aneurysm', '.']\n",
      "['hopefully', 'investigators', 'can', 'use', 'the', 'framework', 'that', 'is', 'presented', 'here', 'to', 'develop', 'applications', 'which', 'address', 'their', 'specific', 'questions', 'surrounding', 'biochemical', 'flux', 'and', 'therein', 'gain', 'insight', 'into', 'the', 'pathophysiology', 'of', 'disease', 'states', 'and', 'examine', 'pharmacodynamic', 'mechanisms', '.']\n",
      "['vitamin', 'd', 'has', 'been', 'traditionally', 'recognized', 'as', 'a', 'vitamin', 'quintessential', 'for', 'bone-mineral', 'health', '.']\n",
      "['alirocumab', 'sustained', 'substantial', 'ldl-c', 'reductions', 'and', 'was', 'well', 'tolerated', 'up', 'to', '2', 'years', 'in', 'the', 'combo', 'ii', 'trial', '.']\n",
      "['pre-diagnostic', 'statin', 'users', 'were', 'identified', 'from', 'linked', 'prescription', 'claims', 'data', '-lrb-', 'n', '', '2082', '-rrb-', '.']\n",
      "['aerospace', 'medicine', 'practitioners', 'are', 'following', 'cpg', 'recommendations', 'for', 'statin', 'therapy', '.']\n",
      "['here', ',', 'we', 'link', 'metabolic', 'dysregulation', 'in', 'patient-derived', 'brain', 'tumor', 'initiating', 'cells', '-lrb-', 'btics', '-rrb-', 'to', 'a', 'nexus', 'between', 'myc', 'and', 'mevalonate', 'signaling', ',', 'which', 'can', 'be', 'inhibited', 'by', 'statin', 'or', '6-fluoromevalonate', 'treatment', '.']\n",
      "['based', 'on', 'preclinical', 'findings', 'showing', 'antagonism', ',', 'we', 'hypothesized', 'that', 'statins', 'may', 'compete', 'with', 'aa', 'for', 'influx', 'via', 'slco2b1', 'and', 'could', 'negatively', 'impact', 'drug', 'efficacy', '.']\n",
      "['the', 'aims', 'of', 'the', 'present', 'study', 'were', 'to', 'assess', 'the', 'effects', 'of', 'low', 'density', 'lipoprotein', '-lrb-', 'ldl', '-rrb-', 'cholesterol', 'concentration', 'and', 'the', 'presence', 'of', 'fh-causing', 'mutations', 'on', 't2dm', 'prevalence', 'in', 'hefh', '.']\n",
      "['however', ',', 'high-intensity', 'statin', 'treatment', 'is', 'frequently', 'underused', 'in', 'clinical', 'practice', 'after', 'stabilization', 'of', 'des-treated', 'patients', '.']\n",
      "['patients', 'were', 'divided', 'into', 'those', 'with', 'elevated', 'levels', 'of', 'gdf-15', 'and', 'those', 'with', 'lower', 'levels', 'in', 'relation', 'to', 'the', 'median', 'plasma', 'concentration', '.']\n",
      "['baseline', 'demographics', ',', 'procedural', 'data', ',', 'and', 'outcomes', 'were', 'retrospectively', 'analyzed', '.']\n",
      "['statin', 'use', 'was', 'respectively', 'defined', 'as', '`', 'current', \"'\", ',', '`', 'recent', \"'\", 'or', '`', 'past', \"'\", 'if', 'the', 'most', 'recent', 'statin', 'prescription', 'was', 'filled', '<', '3', 'months', ',', '3-6', 'months', 'or', '\\xe2\\x89\\xa5', '6', 'months', 'prior', 'to', 'the', 'chronic', 'osteomyelitis', 'diagnosis', '.']\n",
      "['there', 'was', 'a', 'higher', 'prevalence', 'of', 'coronary', 'artery', 'disease', '-lrb-', '56', '%', 'versus', '75', '%', ',', 'p', '', '0.0001', '-rrb-', 'among', 'patients', 'on', 'hi', 'statin', '-lrb-', 'versus', 'lmi', '-rrb-', '.']\n",
      "['however', ',', 'prospective', 'clinical', 'trials', 'have', 'yet', 'to', 'demonstrate', 'significant', 'efficacy', '.']\n",
      "['the', 'aim', 'of', 'this', 'study', 'was', 'to', 'determine', 'whether', 'previous', 'atorvastatin', 'use', 'is', 'associated', 'with', 'reduced', 'risk', 'of', 'dfi', 'and', 'better', 'outcomes', 'of', 'these', 'infections', '.']\n",
      "['results', 'the', 'incident', 'cancer', 'rate', 'was', '11.2', '%', '-lrb-', '247', 'of', '2,196', '-rrb-', ',', 'with', '58', 'noncardiovascular', 'deaths', ',', 'including', '39', 'cancer', 'deaths', '-lrb-', '1.8', '%', '-rrb-', '.']\n",
      "['at', '2', 'years', ',', 'ldl-c', 'was', 'reduced', 'by', '49', '%', '-lrb-', 'alirocumab', '-rrb-', 'versus', '17', '%', '-lrb-', 'ezetimibe', ';', 'p', '<', '0.0001', '-rrb-', ',', 'and', 'ldl-c', '<', '70', 'mg/dl', 'was', 'achieved', 'by', '73', '%', 'of', 'alirocumab-treated', 'versus', '40', '%', 'of', 'ezetimibe-treated', 'patients', '.']\n",
      "['studies', 'show', 'risk', 'stratification', 'for', 'cad', ',', 'based', 'on', 'the', 'grs', ',', 'is', 'more', 'discriminatory', 'than', 'conventional', 'risk', 'factors', 'and', 'predicts', 'the', 'response', 'to', 'statin', 'therapy', '.']\n",
      "['coronary', 'artery', 'calcium', 'was', 'measured', 'in', '14', 'patients', 'with', 'type', '1', 'diabetes', '-lrb-', '11', 'had', 'measures', 'both', 'pre', '-', 'and', 'post-transplant', '-lsb-', 'mean', '2.3', 'years', '-rsb-', '-rrb-', 'in', 'the', 'university', 'of', 'illinois', 'at', 'chicago', \"'s\", 'clinical', 'trial', '.']\n",
      "['a', 'mild', 'long-term', 'reduction', 'in', 'blood', 'pressure', 'and', 'ldl', 'cholesterol', 'has', 'the', 'potential', 'to', 'significantly', 'reduce', 'the', 'lifetime', 'risk', 'of', 'cardiovascular', 'events', '.']\n",
      "['a', 'randomly', 'selected', 'sample', 'of', 'rural', 'diabetics', 'was', 'resurveyed', 'in', '2016', 'to', 'reassess', 'statin', 'use', '.']\n",
      "['in', 'this', 'review', ',', 'we', 'present', 'a', 'history', 'of', 'the', 'development', 'and', 'mechanisms', 'of', 'action', ',', 'as', 'well', 'as', 'the', 'results', 'of', 'the', 'most', 'important', 'studies', 'concerning', 'pcsk9', 'inhibitors', '.']\n",
      "['acei/arb', 'adherence', 'was', 'not', 'associated', 'with', 'blood', 'pressure', '<', '140/90', 'mm', 'hg', 'in', 'patients', '\\xe2\\x89\\xa5', '85', 'years', '-lrb-', 'rr', '1.01', '-lsb-', '0.96', ',', '1.07', '-rsb-', '-rrb-', 'or', 'with', 'multiple', 'comorbidities', '-lrb-', 'e.g.', ',', '3', ':', 'rr', '1.04', '-lsb-', '0.99', ',', '1.08', '-rsb-', '-rrb-', '.']\n",
      "['use', 'of', 'statin', 'therapy', 'in', 'patients', 'with', 'type', '2', 'diabetes', 'mellitus', '-lrb-', 't2dm', '-rrb-', 'has', 'been', 'recommended', 'by', 'most', 'clinical', 'guidelines', '.']\n",
      "['the', 'severity', 'of', 'sepsis', 'on', 'admission', 'was', 'as', 'follows', ':', 'sepsis', ',', 'n', '', '147', '-lrb-', '63.6', '%', '-rrb-', ',', 'severe', 'sepsis', ',', 'n', '', '26', '-lrb-', '11.3', '%', '-rrb-', 'and', 'septic', 'shock', ',', 'n', '', '58', '-lrb-', '25.1', '%', '-rrb-', '.']\n",
      "['pharmaceutical', 'nanotechnologies', 'may', 'offer', 'a', 'solution', 'to', 'this', 'problem', ',', 'as', 'local', 'or', 'targeted', 'delivery', 'of', 'nanoencapsulated', 'statins', 'may', 'increase', 'brain', 'availability', '.']\n",
      "['overall', 'agreement', 'between', 'cpg', 'recommendations', 'and', 'patient-clinician', 'decision', 'makers', 'was', '0.920', '-lrb-', '95', '%', 'confidence', 'interval', ':', '0.955', ',', '0.959', '-rrb-', 'and', '0.891', '-lrb-', '95', '%', 'confidence', 'interval', ':', '0.843', ',', '0.851', '-rrb-', 'per', '2002', 'and', '2013', 'cpgs', ',', 'respectively', '.']\n",
      "['the', 'mechanism', 'underlying', 'the', 'reduction', 'of', 'carotid', 'atherosclerosis', 'by', 'nk', 'may', 'be', 'independent', 'from', 'its', 'lipid-lowering', 'effect', ',', 'which', 'is', 'different', 'from', 'that', 'of', 'statins', '.']\n",
      "['patients', '-lrb-', 'mean', 'age', '57.9', '\\xc2\\xb1', '9.2', 'years', ';', 'male', '73', '%', ';', 'prior', 'and', 'concomitant', '3-hydroxy-3-methylglutaryl', 'coenzyme', 'a', 'reductase', 'inhibitors', '-lrb-', 'statin', '-rrb-', 'use', ',', '73', '%', 'and', '97', '%', ',', 'respectively', '-rrb-', 'demonstrated', 'overall', 'increases', 'in', 'pav', 'of', '0.41', '\\xc2\\xb1', '0.07', '%', '-lrb-', 'p', '', '0.001', 'compared', 'with', 'baseline', '-rrb-', 'and', 'in', 'cai', '-lrb-', 'median', '-rrb-', 'of', '0.04', '-lrb-', 'interquartile', 'range', '-lsb-', 'iqr', '-rsb-', ':', '0.00', 'to', '0.11', ';', 'p', '<', '0.001', 'compared', 'with', 'baseline', '-rrb-', '.']\n",
      "['clinical', 'trials', 'have', 'demonstrated', '50', '%', '-70', '%', 'reductions', 'in', 'ldl-c', 'with', 'evolocumab', 'when', 'used', 'in', 'combination', 'with', 'statin', 'therapy', '.']\n",
      "['wide', 'application', 'of', 'the', '2013', 'acc/aha', 'cholesterol', 'guidelines', 'in', 'our', 'practice', 'would', 'optimize', 'the', 'utilization', 'of', 'statin', 'therapy', 'at', 'the', 'ideal', 'intensity', 'in', 'high-risk', 'patients', '.']\n",
      "['in', 'addition', 'to', 'other', 'effects', ',', 'statins', 'may', 'be', 'useful', 'in', 'preventing', 'dfis', '.']\n",
      "['however', ',', 'treatment-emergent', 'adverse', 'effects', 'are', 'not', 'always', 'identified', 'in', 'clinical', 'trials', ',', 'as', 'well-evidenced', 'by', 'statin', 'myopathy', '.']\n",
      "['amidst', 'the', 'current', 'pool', 'of', 'ambiguous', 'evidence', ',', 'we', 'intend', 'to', 'discuss', 'the', 'role', 'of', 'vitamin', 'd', 'in', '``', 'high-value', 'cardiovascular', 'health', 'care', \"''\", '.']\n",
      "['the', 'objective', 'was', 'to', 'examine', 'whether', ':', '-lrb-', '1', '-rrb-', 'statin', 'use', 'was', 'associated', 'with', 'muscle', 'related', 'outcomes', 'at', 'age', '60-64', ',', '-lrb-', '2', '-rrb-', 'these', 'associations', 'were', 'modified', 'by', '25-hydroxyvitamin', 'd', '-lrb-', '25', '-lrb-', 'oh', '-rrb-', 'd', '-rrb-', 'status', 'and', 'explained', 'by', 'inflammation', ',', 'body-size', 'or', 'lifestyle', 'in', 'a', 'british', 'birth', 'cohort', '.']\n",
      "['this', 'study', 'provides', 'a', 'preliminary', 'description', 'of', 'changes', 'in', 'coronary', 'artery', 'calcium', 'following', 'islet', 'transplantation', ',', 'and', 'associated', 'factors', '.']\n",
      "['hi', 'statin', 'use', 'was', 'defined', 'as', 'atorvastatin', '40-80', 'mg', 'or', 'rosuvastatin', '20-40', 'mg', '.']\n",
      "['although', 'statin', 'use', 'has', 'been', 'associated', 'with', 'favorable', 'effects', 'in', 'various', 'solid', 'malignancies', ',', 'no', 'conclusive', 'evidence', 'is', 'available', 'at', 'present', '.']\n",
      "['residual', 'risk', 'of', 'ascvd', 'remains', 'high', 'despite', 'statin', 'treatment', 'and', 'is', 'predicted', 'by', 'specific', 'risk', 'factors', 'and', 'subclinical', 'atherosclerosis', '.']\n",
      "['in', 'a', 'secondary', 'analysis', 'of', '7604', 'patients', 'for', 'whom', 'a', 'different', 'statin', 'was', 'prescribed', 'after', 'the', 'adverse', 'reaction', ',', '2014', '-lrb-', '26.5', '%', '-rrb-', 'had', 'a', 'documented', 'adverse', 'reaction', 'to', 'the', 'second', 'statin', ',', 'but', '1696', '-lrb-', '84.2', '%', '-rrb-', 'of', 'those', 'patients', 'continued', 'receiving', 'statin', 'prescriptions', '.']\n",
      "['this', 'was', 'a', 'mixed', 'design', ',', '8-yr', 'retrospective', 'study', 'that', 'included', '8185', 'participants', 'with', 'isolated', 'hypercholesterolemia', ',', 'of', 'which', '1458', '-lrb-', '17.81', '%', '-rrb-', 'were', 'prescribed', 'statin', 'monotherapy', '.']\n",
      "['targeting', 'mevalonate', 'activity', 'attenuated', 'ras-erk-dependent', 'btic', 'growth', 'and', 'self-renewal', '.']\n",
      "['for', 'group', '2', ',', 'this', 'index', 'decreased', 'with', 'each', 'day', 'after', 'radiotherapy', '-lrb-', 'p', '', '.07', '-rrb-', ',', 'which', 'means', 'the', 'chl', 'was', 'increased', '.']\n",
      "['the', 'adjusted', 'odds', 'ratio', 'for', '40mg', 'in', 'cohort', '2', 'was', '1.1', '-lrb-', '95', '%', 'ci', '0.7-1', '.9', '-rrb-', ';', 'the', 'numbers', 'taking', '80mg', 'were', 'very', 'small', 'and', 'the', 'confidence', 'interval', 'was', 'correspondingly', 'wide', '.']\n",
      "['we', 'performed', 'proton', 'nuclear', 'magnetic', 'resonance', 'spectroscopy', 'to', 'quantify', 'concentrations', 'of', 'ldl', 'and', 'vldl', '-lrb-', 'very', 'low-density', 'lipoprotein', '-rrb-', 'particle', 'subclasses', 'in', '11', '984', 'jupiter', 'trial', 'participants', '-lrb-', 'nct00239681', '-rrb-', '.']\n",
      "['compared', 'with', 'the', 'statin', 'group', ',', 'the', 'no-statin', 'group', 'achieved', 'higher', 'mean', 'mets', '-lrb-', '8.9', '\\xc2\\xb1', '2.7', 'vs', '9.6', '\\xc2\\xb1', '3.0', ',', 'respectively', ';', 'p', '<', '0.001', '-rrb-', '.']\n",
      "['noncardiovascular', 'mortality', 'occurred', 'in', '49', '-lrb-', '6.0', '%', '-rrb-', 'of', 'the', '812', 'statin-eligible', 'participants', 'versus', 'nine', '-lrb-', '0.7', '%', '-rrb-', 'of', 'the', '1,384', 'noneligible', 'participants', '-lrb-', 'sdhr', ',', '10.1', '-lsb-', '5.0', 'to', '21', '-rsb-', ';', 'p', '<', '.001', '-rrb-', '.']\n",
      "['in', 'contrast', ',', 'no', 'significant', 'change', 'was', 'observed', 'in', 'the', 'clopidogrel', 'group', '-lrb-', '7.21', '\\xc2\\xb1', '2.84', '%', 'vs.', '6.30', '\\xc2\\xb1', '2.97', '%', ',', 'p', '', '0.187', '-rrb-', '.']\n",
      "['\\xce\\xb4', '-lrb-', '13', '-rrb-', 'c', 'analysis', 'can', 'be', 'therefore', 'proposed', 'as', 'a', 'suitable', 'tool', 'for', 'detecting', 'the', 'authenticity', 'of', 'ryr', 'on', 'the', 'market', '.']\n",
      "['nevertheless', ',', 'many', 'patients', 'still', 'can', 'not', 'achieve', 'the', 'recommended', 'target', 'levels', ',', 'due', 'to', 'either', 'inadequate', 'effectiveness', 'or', 'intolerance', 'of', 'these', 'drugs', '.']\n",
      "['in', 'a', 'nationally', 'representative', 'british', 'population', 'in', 'early', 'old', 'age', ',', 'statin', 'use', 'was', 'associated', 'with', 'lower', 'limb', 'muscle-related', 'outcomes', ',', 'and', 'some', 'were', 'only', 'apparent', 'in', 'those', 'with', '25', '-lrb-', 'oh', '-rrb-', 'd', 'status', 'below', '20', 'ng/l', '.']\n",
      "['the', 'mean', 'length', 'of', 'stay', 'in', 'intensive', 'care', 'unit', '-lrb-', 'icu', '-rrb-', 'was10', '.8', '\\xc2\\xb1', '9.6', 'days', 'and', '21.2', '\\xc2\\xb1', '17', 'days', 'in', 'general', 'hospital', 'ward', 'settings', ',', 'without', 'differences', 'between', 'groups', 'of', 'statin', 'users', 'and', 'controls', ',', 'p', '', '0.873', 'and', 'p', '', '0.766', ',', 'respectively', '.']\n",
      "['when', 'nude', 'mice', 'were', 'maintained', 'on', 'a', 'diet', 'lacking', 'geranylgeraniol', ',', 'oral', 'pitavastatin', 'caused', 'regression', 'of', 'ovcar-4', 'tumour', 'xenografts', '.']\n",
      "['time', 'to', 'euthanasia', 'due', 'to', 'advanced', 'clinical', 'signs', 'was', 'not', 'changed', 'in', 'statin-treated', 'mice', 'relative', 'to', 'untreated', 'mice', ',', 'a', 'finding', 'at', 'odds', 'with', 'previous', 'reports', '.']\n",
      "['the', 'total', 'retear', 'rate', '-lrb-', 'pt', 'and', 'ft', '-rrb-', 'for', 'hl', 'patients', 'was', 'significantly', 'higher', 'at', '45.5', '%', '-lrb-', '15/33', '-rrb-', 'compared', 'with', 'the', 'patients', 'without', 'hl', 'at', '11.3', '%', '-lrb-', '6/53', '-rrb-', ',', 'with', 'an', 'odds', 'ratio', 'of', '6.5', '-lrb-', 'p', '<', '.001', '-rrb-', '.']\n",
      "['further', 'evidence', 'is', 'however', 'warranted', '.']\n",
      "['additionally', ',', 'non-adpkd', 'subjects', 'were', 'assigned', 'as', 'comparison', 'group', 'by', 'matching', 'study', 'cohort', 'with', 'age', ',', 'gender', ',', 'income', 'and', 'urbanization', 'in', '1:10', 'ratio', '-lrb-', 'n', '', '26,470', '-rrb-', '.']\n",
      "['in', 'a', 'sensitivity', 'analysis', 'evaluating', 'a', '1:1', 'matched', 'cohort', '-lrb-', 'n', '', '164', 'per', 'group', '-rrb-', ',', 'significantly', 'greater', 'annualized', 'changes', 'in', 'cai', 'were', 'also', 'observed', 'in', 'warfarin-treated', 'compared', 'with', 'non-warfarin-treated', 'patients', '.']\n",
      "['there', 'was', 'no', 'association', 'between', 'statin', 'use', 'and', 'aa', 'duration', 'in', 'the', 'jhu', 'cohort', ':', '8.3', 'versus', '8.0', 'months', '-lrb-', 'hr', '0.89', ',', '95', '%', 'ci', ':', '0.69-1', '.16', ',', 'p', '', '0.38', '-rrb-', 'in', 'the', 'statin', 'users', 'versus', 'non-users', ',', 'except', 'for', 'a', 'trend', 'in', 'patients', 'that', 'had', 'not', 'previously', 'received', 'docetaxel', 'or', 'enzalutamide', '-lrb-', 'hr', '0.79', ';', '95', '%', 'ci', ':', '0.57-1', '.10', '-rrb-', '.']\n",
      "['in', 'an', 'independent', ',', 'prospective', 'cohort', 'of', '4721', 'individuals', 'referred', 'for', 'cardiac', 'catheterization', '-lrb-', 'cathgen', '-rrb-', ',', 'similar', 'patterns', 'of', 'lipoprotein-related', 'risk', 'were', 'observed', '.']\n",
      "['we', 'compared', 'statin', 'discontinuation', 'in', 'all', 'statin', 'users', 'in', 'denmark', 'in', '2007', 'before', 'the', 'media', 'event', '-lrb-', 'n', '', '343,438', '-rrb-', 'and', 'after', 'it', 'in', '2008', '-lrb-', 'n', '', '404,052', '-rrb-', '.']\n",
      "['inclusion', 'criteria', 'were', 'definite', 'or', 'probable', 'hefh', 'in', 'patients', 'aged', '\\xe2\\x89\\xa5', '18', 'years', '.']\n",
      "['however', ',', 'administration', 'of', 'any', 'type', 'of', 'statin', 'at', 'the', 'acute', 'phase', 'of', 'asah', 'is', 'not', 'recommended', '.']\n",
      "['hazard', 'ratios', '-lrb-', 'hr', '-rrb-', 'were', 'estimated', 'for', 'associations', 'between', 'pre-diagnostic', 'statin', 'use', 'and', 'breast', 'cancer-specific', 'and', 'all-cause', 'mortality', '.']\n",
      "['this', 'combined', 'therapy', 'can', 'help', 'prevent', 'or', 'treat', 'cv', 'disease', 'while', 'minimizing', 'adverse', 'metabolic', 'consequences', '.']\n",
      "['to', 'evaluate', 'the', 'adherence', 'to', 'the', '2013', 'american', 'college', 'of', 'cardiology/american', 'heart', 'association', '-lrb-', 'acc/aha', '-rrb-', 'guideline', 'recommendations', 'for', 'statin', 'therapy', 'in', 'the', 'treatment', 'of', 'elevated', 'blood', 'cholesterol', 'in', 'high-risk', 'patients', '.']\n",
      "['statins', 'are', 'a', 'class', 'of', 'drugs', 'used', 'to', 'lower', 'total', 'and', 'low-density', 'lipoprotein', '-lrb-', 'ldl', '-rrb-', '-', 'cholesterol', '.']\n",
      "['reactive', 'species', 'production', 'was', 'quantified', 'in', 'circulating', 'wbcs', 'using', 'immunofluorescence', 'microscopy', ':', 'nitrotyrosine', '-lrb-', 'footprint', 'of', 'peroxynitrite', ',', 'a', 'potent', 'reactive', 'nitrogen', 'species', '-rrb-', 'in', 'snap', 'frozen', 'blood', 'smears', ';', 'mitochondrial', 'superoxide', 'and', 'cytoplasmic', 'hydrogen', 'peroxide', '-lrb-', 'both', 'reactive', 'oxygen', 'species', '-rrb-', 'by', 'live', 'cell', 'imaging', '.']\n",
      "['it', 'is', 'currently', 'unclear', 'how', 'prostate', 'cancer', 'screening', ',', 'tumor', 'and', 'patient', 'characteristics', ',', 'or', 'treatment', 'selection', 'may', 'affect', 'this', 'association', '.']\n",
      "['the', 'treatment', 'with', 'pitavastatin', 'not', 'only', 'increased', 'hdl-c', 'levels', ',', 'but', 'also', 'increased', 'the', 'phospholipid', 'content', 'of', 'hdl', ',', 'increased', 'the', 'hdl', 'efflux', 'capacity', 'and', 'their', 'anti-oxidant', 'properties', '.']\n",
      "['pcsk9', 'inhibitors', 'can', 'significantly', 'reduce', 'ldl-cholesterol', 'levels', ',', 'being', 'administered', 'together', 'with', 'statins', '.']\n",
      "['we', 'undertook', 'a', 'nationwide', 'nested', 'case-control', 'study', 'in', 'new', 'zealand', 'to', 'examine', 'the', 'risk', 'of', 'aki', 'without', 'concurrent', 'serious', 'muscle', 'injury', 'according', 'to', 'simvastatin', 'dose', 'in', 'two', 'cohorts', ':', 'people', 'without', 'a', 'history', 'of', 'renal', 'disease', 'and', 'people', 'with', 'non-dialysis', 'dependent', 'chronic', 'kidney', 'disease', '.']\n",
      "['accuracy', 'of', 'predicted', 'mla', '\\xe2\\x89\\xa4', '4mm', '\\xc2\\xb2', 'was', '81.6', '%', 'for', 'baseline', 'mla', '\\xe2\\x89\\xa4', '4mm', '\\xc2\\xb2', 'and', '80.2', '%', 'for', '4mm', '\\xc2\\xb2', '<', 'mla', '\\xe2\\x89\\xa4', '6mm', '\\xc2\\xb2', '.']\n",
      "['tqrfne', 'demonstrated', 'comparable', 'effects', 'to', 'the', 'other', 'intervention', 'groups', 'and', 'control', 'drugs', 'in', 'serum', 'biomarkers', 'as', 'well', 'as', 'in', 'the', 'learning', 'and', 'memory', 'test', '.']\n",
      "['results', ':', 'according', 'to', 'the', 'median', 'value', 'of', 'their', 'apob/a1ratios', '-lrb-', '0.80', '-rrb-', ',', 'they', 'were', 'divided', 'into', '2', 'groups', '-lsb-', 'high', 'apob/a1', 'ratio', '-lrb-', '>', '0.80', '-rrb-', '-lrb-', 'n', '', '49', '-rrb-', 'and', 'low', 'apob/a1', 'ratio', '-lrb-', '\\xe2\\x89\\xa4', '0.80', '-rrb-', '-lrb-', 'n', '', '49', '-rrb-', '-rsb-', '.']\n",
      "['drug', 'discovery', 'and', 'development', 'efforts', 'are', 'largely', 'based', 'around', 'a', 'common', 'expectation', ',', 'namely', ',', 'direct', 'or', 'indirect', 'action', 'on', 'a', 'cellular', 'process', '-lrb-', 'e.g.', 'statin-mediated', 'enzyme', 'inhibition', 'or', 'insulin-stimulated', 'receptor', 'activation', '-rrb-', 'will', 'have', 'a', 'beneficial', 'impact', 'on', 'physiological', 'homeostasis', '.']\n",
      "['more', 'than', '60', 'genetic', 'risk', 'variants', 'predisposing', 'to', 'coronary', 'artery', 'disease', '-lrb-', 'cad', '-rrb-', 'have', 'been', 'confirmed', '.']\n",
      "['nitric', 'oxide', 'synthase', '-lrb-', 'nos', '-rrb-', 'inhibition', 'abolished', 'the', 'beneficial', 'effects', 'of', 'atorvastatin', 'on', 'the', '\\xce\\xb2-adrenoceptor', 'response', '.']\n",
      "['therefore', ',', 'statin-based', 'therapy', 'combined', 'with', 'ras', 'inhibitors', 'is', 'important', 'for', 'developing', 'optimal', 'management', 'strategies', 'in', 'patients', 'with', 'hypertension', ',', 'hypercholesterolemia', ',', 'diabetes', ',', 'metabolic', 'syndrome', ',', 'or', 'obesity', '.']\n",
      "['conclusion', ':', 'for', 'the', 'patients', 'with', 'stable', 'angina', 'pectoris', 'and', 'chronic', 'treatment', 'of', 'statins', ',', 'a', 'high', 'apob/a1', 'ratio', 'is', 'associated', 'with', 'a', 'high', 'percentage', 'of', 'fibrolipid', 'volume', 'and', 'a', 'low', 'percentage', 'of', 'fibrous', 'volume', 'in', 'lmca', 'lesions', ',', 'suggesting', 'that', 'the', 'apob/a1', 'ratios', 'could', 'predict', 'the', 'vulnerability', 'of', 'the', 'lmca', 'plaque', '.']\n",
      "['this', 'review', 'extends', 'the', 'time', 'frame', 'of', 'a', 'meta-analysis', 'performed', 'by', 'li', 'and', 'colleagues', 'in', '2014', ';', 'specifically', ',', 'we', 'looked', 'at', 'the', 'literature', 'published', 'between', 'september', '2013', 'and', 'april', '2016', '.']\n",
      "['mean', 'low-density', 'lipoprotein', 'level', 'was', 'similar', 'in', 'patients', 'on', 'lmi', 'versus', 'hi', '-lrb-', '80', '\\xc2\\xb1', '30', 'versus', '87', '\\xc2\\xb1', '44', 'mg/dl', ',', 'p', '', '0.14', '-rrb-', '.']\n",
      "['high-dose', 'simvastatin', 'topical', 'treatment', 'showed', 'a', 'major', 'effect', 'in', 'scar', 'reduction', 'but', 'induced', 'side', 'effects', 'of', 'scaling', ',', 'erythema', ',', 'and', 'epidermal', 'hyperplasia', ',', 'which', 'were', 'improved', 'with', 'coapplication', 'of', 'cholesterol', '.']\n",
      "['these', 'effects', 'are', 'especially', 'attractive', 'for', 'the', 'treatment', 'of', 'various', 'brain', 'diseases', 'ranging', 'from', 'stroke', 'to', 'neurodegenerative', 'diseases', '.']\n",
      "['the', 'reported', 'incidence', 'varies', 'greatly', ',', 'ranging', 'between', '5', '%', 'and', '29', '%', '.']\n",
      "['rare', 'variant', 'and', 'gene', 'expression', 'changes', 'were', 'assessed', 'using', 'a', 'false', 'discovery', 'rate', 'approach', '.']\n",
      "['statin', 'use', 'was', 'associated', 'with', 'intrusive', 'body', 'pain', ',', 'difficulty', 'climbing', 'stairs', 'and', 'slower', 'chair', 'rise', 'speed', '.']\n",
      "['although', 'medical', 'therapies', 'including', 'acei', 'show', 'inhibitory', 'effects', 'on', 'post-infarct', 'lv', 'remodeling', ',', 'the', 'prognosis', 'of', 'patients', 'with', 'post-infarct', 'heart', 'failure', 'is', 'still', 'poor', '.']\n",
      "['it', 'was', 'found', 'that', 'the', 'peroxynitrite', 'footprint', 'in', 'circulating', 'neutrophils', 'and', 'monocytes', 'of', 'aaa', 'patients', 'is', 'higher', 'than', 'in', 'controls', '.']\n",
      "['a', 'complete', 'blood', 'count', 'and', 'biomarkers', 'of', 'inflammation', 'and', 'immune', 'activation/exhaustion', 'were', 'measured', 'in', 'peripheral', 'blood', 'at', 'entry', 'and', 'after', '24', 'and', '48', 'weeks', '.']\n",
      "['the', 'mechanisms', 'underlying', 'statin-associated', 'muscle', 'symptoms', '-lrb-', 'sams', '-rrb-', 'are', 'not', 'understood', '.']\n",
      "['oitenta', 'e', 'cinco', 'por', 'cento', 'das', 'mulheres', 'e', '60', '%', 'dos', 'homens', 'eleg\\xc3\\xadveis', 'para', 'estatina', 'pelo', 'crit\\xc3\\xa9rio', 'br-1', 'n\\xc3\\xa3o', 'seriam', 'candidatos', 'pelo', 'crit\\xc3\\xa9rio', 'eua-1', '.']\n",
      "['we', 'compared', 'the', 'effectiveness', 'of', 'low', '-', 'or', 'moderate-intensity', '-lrb-', 'lmi', '-rrb-', 'versus', 'high-intensity', '-lrb-', 'hi', '-rrb-', 'statin', 'dose', 'on', 'clinical', 'outcomes', 'in', 'patients', 'with', 'peripheral', 'artery', 'disease', '.']\n",
      "['atorvastatin', 'restored', 'the', 'positive', 'inotropic', 'effect', 'of', 'the', '\\xce\\xb2-adrenoceptor', 'stimulation', 'in', 'diabetic', 'cardiomyopathy', '.']\n",
      "['average', 'age', 'was', '62.1', 'years', '-lrb-', '45.3-74', '.3', 'years', '-rrb-', '.']\n",
      "['the', 'therapy', 'was', 'safe', '.']\n",
      "['the', 'aim', 'of', 'this', 'study', 'was', 'to', 'evaluate', 'whether', 'growth', 'differentiation', 'factor-15', '-lrb-', 'gdf-15', '-rrb-', 'plasma', 'concentration', 'at', 'the', 'time', 'of', 'percutaneous', 'coronary', 'intervention', '-lrb-', 'pci', '-rrb-', 'might', 'help', 'identify', 'those', 'patients', 'with', 'acute', 'coronary', 'syndrome', '-lrb-', 'acs', '-rrb-', ',', 'who', 'benefit', 'most', 'from', 'high-dose', 'statin', 'treatment', '.']\n",
      "['these', 'mice', 'were', 'then', 'treated', 'with', 'inhaled', 'pitavastatin', '-lrb-', '5', 'mg/kg', '-rrb-', 'or', 'dexamethasone', '-lrb-', '2', 'mg/kg', '-rrb-', ',', 'the', 'latter', 'of', 'which', 'served', 'as', 'a', 'positive', 'control', '.']\n",
      "['data', 'are', 'presented', 'as', 'mean', 'percentage', 'of', 'baseline', '\\xc2\\xb1', 'sd', '.']\n",
      "['in', 'contrast', ',', 'in', 'patients', 'with', 'lower', 'levels', 'of', 'gdf-15', ',', 'there', 'was', 'no', 'significant', 'reduction', 'in', 'combined', 'end', 'point', 'rates', 'associated', 'with', 'high-dose', 'statin', 'treatment', '-lrb-', '1.6', '%', 'vs', '5.0', '%', ',', 'hr', '', '0.320', ';', '95', '%', 'ci', '0.029', 'to', '3.534', ';', 'p', '', '0.353', '-rrb-', '.']\n",
      "['overall', ',', '5.3', '%', 'of', 'participants', 'were', 'at', 'low', ',', '12.2', '%', 'at', 'moderate', ',', '60.3', '%', 'at', 'high', ',', 'and', '22.2', '%', 'at', 'very', 'high', 'baseline', 'risk', '.']\n",
      "['a', 'leave-one-patient-out', 'cross-validation', 'was', 'used', 'to', 'evaluate', 'the', 'prediction', 'power', 'of', 'different', 'feature', 'subsets', '.']\n",
      "['current', 'guidelines', 'for', 'the', 'treatment', 'of', 'patients', 'with', 'diabetes', 'are', 'focused', 'on', 'improving', 'glycemic', 'control', 'and', 'treating', 'appropriate', 'cardiovascular', '-lrb-', 'cv', '-rrb-', 'risk', 'factors', '.']\n",
      "['while', 'differential', 'gene', 'expression', 'analysis', 'did', 'not', 'demonstrate', 'differences', 'in', 'pbmc', 'transcriptome', 'between', 'the', 'two', 'groups', 'on', 'the', 'single-gene', 'level', ',', 'weighted', 'gene', 'coexpression', 'network', 'analysis', 'revealed', 'two', 'modules', 'of', 'coexpressed', 'genes', 'associated', 'with', 'dm', ',', 'collagen', 'module', 'and', 'platelet', 'module', ',', 'related', 'to', 'collagen', 'catabolism', 'and', 'platelet', 'function', 'respectively', '.']\n",
      "['we', 'carried', 'out', 'a', 'meta-analysis', 'of', 'randomized', 'controlled', 'trials', '-lrb-', 'rcts', '-rrb-', 'and', 'non-randomized', 'studies', 'to', 'evaluate', 'the', 'effect', 'of', 'statins', 'on', 'endometrial', 'cancer', 'risk', '.']\n",
      "['two', 'consecutive', 'calculated', 'ldl-c', 'values', '<', '25', 'mg/dl', 'were', 'observed', 'in', '28', '%', 'of', 'alirocumab-treated', 'patients', '-lrb-', 'vs', '0.4', '%', 'with', 'ezetimibe', '-rrb-', '.']\n",
      "['most', '-lrb-', '81', '%', '-rrb-', 'of', 'the', 'adverse', 'reactions', 'to', 'statins', 'were', 'identified', 'from', 'the', 'text', 'of', 'electronic', 'provider', 'notes', '.']\n",
      "['compared', 'with', 'the', 'lowest', 'rdw', 'tertile', ',', 'patients', 'in', 'the', 'highest', 'tertile', 'were', 'less', 'likely', 'to', 'be', 'male', ',', 'and', 'more', 'likely', 'to', 'be', 'african', 'american', ',', 'have', 'lower', 'hemoglobin', ',', 'lower', 'mean', 'corpuscular', 'volume', ',', 'and', 'higher', 'platelet', 'counts', '-lrb-', 'all', 'p', '<', '0.05', '-rrb-', '.']\n",
      "['efficacy', 'was', 'estimated', 'from', 'published', 'studies', 'and', 'incorporated', 'patient-level', 'variation', '.']\n",
      "['clinically', 'established', 'markers', 'of', 'early', 'onset', 'of', 'cardiotoxicity', 'following', 'anthracycline', 'treatment', 'and', 'preventive', 'measures', 'are', 'missing', '.']\n",
      "['statin', 'use', 'among', 'those', 'with', 'known', 'chd', 'and', 'diabetes', '-lrb-', 'on', 'diabetic', 'medication', '-rrb-', 'was', 'recorded', '.']\n",
      "['though', 'anticoagulants', 'are', 'effective', 'in', 'preventing', 'vte', ',', 'they', 'are', 'associated', 'with', 'major', 'bleeding', 'risk', '.']\n",
      "['furthermore', ',', 'the', 'frequencies', 'of', 'both', 'hemorrhagic', 'and', 'ischemic', 'strokes', 'were', 'also', 'significantly', 'higher', 'in', 'the', 'adpkd', 'than', 'non-adpkd', 'group', '-lrb-', 'all', 'p-values', '<', '0.0001', '-rrb-', '.']\n",
      "['this', 'study', 'sought', 'to', 'determine', 'whether', 'hiv-infected', 'patients', 'with', 'established', 'cvd', 'were', 'being', 'managed', 'according', 'to', 'national', 'guidelines', '.']\n",
      "['the', 'sample', 'of', 'our', 'study', 'consisted', 'of', 'participants', 'from', 'the', 'population-based', 'cohort', 'of', 'the', 'epidemiology', 'of', 'cardiovascular', 'risk', 'factors', 'and', 'diseases', 'in', 'regions', 'of', 'the', 'russian', 'federation', 'study', '-lrb-', 'esse-rf', '-rrb-', ',', 'conducted', 'in', 'the', 'tyumen', 'and', 'kemerovo', 'regions', '-lrb-', '1,630', 'and', '1,622', 'people', ',', 'respectively', ',', 'aged', '25-64', '-rrb-', '.']\n",
      "['prior', 'use', 'of', 'statins', 'did', 'not', 'reduce', 'in-hospital', 'or', '30-day', 'mortality', 'in', 'septic', 'patients', 'and', 'it', 'may', 'be', 'associated', 'with', 'impaired', 'renal', 'function', 'in', 'this', 'group', 'of', 'argentinian', 'participants', '.']\n",
      "['over', '48', 'weeks', ',', 'rdw', 'did', 'not', 'change', 'and', 'there', 'was', 'no', 'significant', 'effect', 'of', 'statin', '-lrb-', 'p', '', '0.45', '-rrb-', '.']\n",
      "['our', 'studies', 'indicate', 'that', 'none', 'of', 'the', 'three', 'statins', 'tested', 'were', 'effective', 'in', 'reducing', 'scrapie-induced', 'neuroinflammation', 'or', 'neuropathogenesis', '.']\n",
      "['monoclonal', 'antibodies', 'that', 'inhibit', 'proprotein', 'convertase', 'subtilisin/kexin', 'type', '9', '-lrb-', 'pcsk9', '-rrb-', 'have', 'emerged', 'as', 'a', 'promising', 'option', 'in', 'lipid-lowering', 'treatment', '.']\n",
      "['we', 'report', 'our', 'recent', 'discoveries', 'in', 'a', 'zebrafish', 'model', 'of', 'als', 'in', 'relation', 'to', 'exposure', 'to', 'the', 'cyanobacterial', 'toxin', 'bmaa', ',', 'and', 'discuss', 'several', 'results', 'from', 'mouse', 'models', 'that', 'show', 'interactions', 'with', 'exposure', 'to', 'mercury', 'and', 'statin', 'drugs', ',', 'both', 'leading', 'to', 'acceleration', 'of', 'the', 'disease', 'process', '.']\n",
      "['aerosp', 'med', 'hum', 'perform', '.']\n",
      "['grs', 'remains', 'the', 'same', 'throughout', 'one', \"'s\", 'lifetime', 'because', 'your', 'deoxyribonucleic', 'acid', 'does', 'not', 'change', '.']\n",
      "['even', 'with', 'optimal', 'risk', 'factor', 'levels', ',', 'males', 'of', 'different', 'ethnicities', 'would', 'exceed', 'the', '10', '%', 'risk', 'threshold', 'between', 'the', 'ages', 'of', '60', 'and', '70', 'years', ',', 'and', 'females', 'would', 'exceed', 'the', 'threshold', 'between', '65', 'and', '75', 'years', '.']\n",
      "['severe', 'cerebral', 'vasospasms', 'on', 'dsa', 'were', 'statistically', 'fewer', 'in', 'the', 'pitavastatin', 'group', 'than', 'in', 'the', 'placebo', 'group', '-lrb-', '14.8', '%', 'vs.', '33.3', '%', ';', 'odds', 'ratio', ',', '0.32', ';', '95', '%', 'confidence', 'interval', ',', '0.11-0', '.87', ',', 'p', '', '0.042', '-rrb-', ';', 'however', ',', 'the', 'occurrence', 'of', 'dind', 'and', 'new', 'infarctions', 'and', 'outcome', 'showed', 'no', 'statistically', 'significant', 'differences', 'between', 'the', 'groups', '.']\n",
      "['at', 'this', 'time', ',', 'the', 'use', 'of', 'evolocumab', 'monotherapy', 'seems', 'appropriate', 'only', 'for', 'individuals', 'deemed', 'statin-intolerant', 'despite', 'attempting', 'several', 'statins', '.']\n",
      "['most', 'individuals', 'at', 'intermediate', 'or', 'high', 'risk', 'based', 'on', 'the', 'v', 'brazilian', 'guideline', 'had', 'a', 'low', 'risk', 'calculated', 'by', 'the', 'pce', ',', 'and', 'more', 'than', '70', '%', 'of', 'those', 'who', 'were', 'considered', 'at', 'high', 'risk', 'had', 'this', 'categorization', 'because', 'of', 'the', 'presence', 'of', 'aggravating', 'factors', '.']\n",
      "['statins', 'compete', 'with', 'dheas', 'for', 'influx', 'through', 'the', 'slco2b1', 'transporter', ',', 'which', 'may', 'prolong', 'time', 'to', 'progression', '-lrb-', 'ttp', '-rrb-', 'on', 'androgen', 'deprivation', 'therapy', '.']\n",
      "['this', 'difference', 'was', 'mainly', 'driven', 'by', 'a', 'lower', 'rate', 'of', 'cardiac', 'death', '-lrb-', '0', 'vs', '0.4', '%', ',', 'p', '', '.025', '-rrb-', 'and', 'nontarget', 'vessel', 'myocardial', 'infarction', '-lrb-', '0.1', 'vs', '0.7', '%', ',', 'p', '', '.033', '-rrb-', 'in', 'the', 'high-intensity', 'statin', 'treatment', 'group', '.']\n",
      "['the', 'prevalence', 'of', 't2dm', 'in', 'patients', 'with', 'hefh', 'was', '40', '%', 'lower', 'than', 'in', 'the', 'general', 'population', 'matched', 'for', 'age', 'and', 'sex', '.']\n",
      "['four', 'years', 'after', 'the', 'presumed', 'adverse', 'event', ',', 'the', 'cumulative', 'incidence', 'of', 'the', 'composite', 'primary', 'outcome', 'was', '12.2', '%', 'for', 'patients', 'with', 'continued', 'statin', 'prescriptions', ',', 'compared', 'with', '13.9', '%', 'for', 'those', 'without', 'them', '-lrb-', 'difference', ',', '1.7', '%', '-lsb-', '95', '%', 'ci', ',', '0.8', '%', 'to', '2.7', '%', '-rsb-', ';', 'p', '<', '0.001', '-rrb-', '.']\n",
      "['locoregional', 'subjects', 'irradiated', 'with', 'external', 'beam', 'therapy', 'were', 'compared', 'to', 'prostate', 'cancer', 'subjects', 'with', 'bone', 'metastases', '.']\n",
      "['use', 'of', 'statins', 'after', 'prostate', 'cancer', 'diagnosis', 'was', 'associated', 'with', 'a', 'decreased', 'risk', 'of', 'prostate', 'cancer', 'death', '.']\n",
      "['the', 'primary', 'outcome', 'was', 'incident', 'cancer', 'at', 'a', 'median', 'of', '10.0', 'years', '-lrb-', 'interquartile', 'range', ',', '9.1-10', '.6', 'years', '-rrb-', 'of', 'follow-up', ',', 'and', 'secondary', 'outcomes', 'were', 'cancer', 'mortality', 'and', 'noncardiovascular', 'mortality', '.']\n",
      "['this', 'state-of-the-science', 'review', 'seeks', 'to', 'explore', 'the', 'most', 'recent', 'evidence', 'on', 'the', 'effectiveness', 'and', 'safety', 'of', 'ryr', 'supplementation', 'in', 'treating', 'dyslipidemic', 'adults', '.']\n",
      "['islet', 'cell', 'transplantation', 'can', 'functionally', 'cure', 'type', '1', 'diabetes', ',', 'and', 'also', 'improve', 'carotid-intima', 'media', 'thickness', '.']\n",
      "['atorvastatin', 'restored', 'the', 'impaired', 'positive', 'inotropic', 'effect', 'of', '\\xce\\xb2-adrenergic', 'stimulation', 'in', 'diabetic', 'hearts', 'compared', 'with', 'healthy', 'hearts', 'both', 'in', 'vivo', 'and', 'ex', 'vivo', 'but', 'did', 'not', 'suppress', 'the', 'diastolic', 'dysfunction', 'of', 'diabetes', '.']\n",
      "['bayesian', 'network', 'analysis', 'revealed', 'key', 'driver', 'genes', 'within', 'these', 'modules', '.']\n",
      "['statins', 'are', 'the', 'reference', 'standard', 'treatment', 'to', 'prevent', 'cv', 'disease', 'in', 'patients', 'with', 'hypercholesterolemia', '.']\n",
      "['the', 'median', 'levels', 'in', 'controls', 'were', 'lower', 'for', 'neutrophils', '466', '-lrb-', 'range', '340-820', ',', 'p', '<', '.01', '-rrb-', 'and', 'for', 'monocytes', '191', '-lrb-', 'range', '102-386', ',', 'p', '', '.03', '-rrb-', ',', 'but', 'similar', 'for', 'lymphocytes', '99', '-lrb-', 'range', '82-246', '-rrb-', 'when', 'compared', 'to', 'the', 'aaa', 'patients', '.']\n",
      "['cox', 'proportional-hazards', 'models', 'revealed', 'that', 'major', 'pmn', ',', 'pre-tni', ',', 'and', 'the', 'absence', 'of', 'statin', 'use', 'were', 'independently', 'associated', 'with', 'mace', '.']\n",
      "['adherence', 'differed', 'little', 'across', 'elderly', 'age', 'groups', '.']\n",
      "['consideration', 'must', 'be', 'given', 'toward', 'patient', 'willingness', 'to', 'self-inject', 'evolocumab', 'and', 'issues', 'concerning', 'third-party', 'coverage', ',', 'given', 'the', 'current', 'costs', 'of', 'evolocumab', '.']\n",
      "['out', 'of', '2906', 'patients', ',', '231', 'matched', 'study', 'and', 'diagnostic', 'criteria', 'for', 'sepsis', 'and', 'among', 'them', '33', '-lrb-', '14.3', '%', '-rrb-', 'belonged', 'to', 'the', 'group', 'of', 'statins', '.']\n",
      "['the', 'risk', 'for', 'recurrent', 'adverse', 'reactions', 'to', 'statins', 'could', 'not', 'be', 'established', 'for', 'the', 'entire', 'sample', '.']\n",
      "['we', 'evaluated', 'scrapie-infected', 'mice', 'for', 'protease-resistant', 'prp', '-lrb-', 'prpres', '-rrb-', 'accumulation', ',', 'gliosis', ',', 'neuroinflammation', 'and', 'time', 'until', 'advanced', 'clinical', 'disease', 'requiring', 'euthanasia', '.']\n",
      "['the', 'homologous', 'prescription', 'biosynthetic', 'statin', ',', 'lovastatin', ',', 'is', 'not', 'chemically', 'distinguishable', 'from', 'monacolin', 'k.', 'in', 'this', 'work', 'we', 'investigated', 'whether', '\\xce\\xb4', '-lrb-', '13', '-rrb-', 'c', 'and', '\\xce\\xb4', '-lrb-', '2', '-rrb-', 'h', 'can', 'distinguish', 'monacolin', 'k', 'from', 'lovastatin', 'and', 'can', 'detect', 'the', 'presence', 'of', 'lovastatin', 'in', 'ryr', '.']\n",
      "['the', 'reduction', 'in', 'the', 'nk', 'group', 'was', 'significantly', 'profound', '-lrb-', 'p', '<', '0.01', ',', '36.6', '%', 'reduction', 'in', 'plaque', 'size', 'in', 'nk', 'group', 'versus', '11.5', '%', 'change', 'in', 'st', 'group', '-rrb-', '.']\n",
      "['among', '61', 'with', 'chd', ',', '23', '-lrb-', '37.7', '%', '-rrb-', 'were', 'on', 'statins', '.']\n",
      "['currently', ',', 'the', 'impact', 'of', 'continuous', 'high-intensity', 'statin', 'treatment', 'on', 'the', 'incidence', 'of', 'late', 'adverse', 'events', 'in', 'these', 'patients', 'is', 'unknown', '.']\n",
      "['inhibition', 'of', 'pcsk9', 'is', 'a', 'novel', 'therapeutic', 'strategy', 'aimed', 'at', 'reducing', 'low-density-lipoprotein', 'cholesterol', '-lrb-', 'ldl-c', '-rrb-', 'and', 'cardiovascular', 'risk', '.']\n",
      "['of', 'the', '224', 'dfci', 'and', '270', 'jhu', 'patients', 'included', ',', 'the', 'majority', '-lrb-', '96', '%', '-rrb-', 'had', 'metastatic', 'disease', '.']\n",
      "['diabetic', 'foot', 'infection', '-lrb-', 'dfi', '-rrb-', 'is', 'a', 'common', 'complication', 'of', 'diabetes', 'mellitus', '.']\n",
      "['hyperlipidemia', '-lrb-', 'hl', '-rrb-', 'has', 'been', 'identified', 'as', 'a', 'risk', 'factor', 'for', 'rotator', 'cuff', 'tear', ',', 'but', 'no', 'studies', 'have', 'evaluated', 'its', 'effects', 'on', 'healing', '.']\n",
      "['proprotein', 'convertase', 'subtilisin/kexin', 'type', '9', 'inhibitors', ',', 'praluent', '-lrb-', 'alirocumab', '-lsb-', 'ali', '-rsb-', '-rrb-', 'and', 'repatha', '-lrb-', 'evolocumab', '-lsb-', 'evo', '-rsb-', '-rrb-', 'have', 'been', 'approved', 'as', 'adjuncts', 'to', 'the', 'standard-of-care', 'maximal-tolerated', 'dose', '-lrb-', 'mtd', '-rrb-', 'of', 'low-density', 'lipoprotein', 'cholesterol', '-lrb-', 'ldlc', '-rrb-', '-', 'lowering', 'therapy', '-lrb-', 'llt', '-rrb-', ',', 'statin', 'therapy', ',', 'in', 'heterozygous', '-lrb-', 'hefh', '-rrb-', '-lrb-', 'ali', 'or', 'evo', '-rrb-', 'or', 'homozygous', '-lrb-', 'evo', '-rrb-', 'familial', 'hypercholesterolemia', ',', 'or', 'clinical', 'atherosclerotic', 'cardiovascular', 'disease', '-lrb-', 'cvd', '-rrb-', 'where', 'ldlc', 'lowering', 'is', 'insufficient', '-lrb-', 'both', '-rrb-', '.']\n",
      "['these', 'molecular', 'markers', 'of', 'cardiotoxicity', 'were', 'mitigated', 'to', 'a', 'similar', 'extent', 'by', 'co-treatment', 'with', 'either', 'lovastatin', '-lrb-', '10', 'mg/kg', 'bw', ',', 'p.o.', '-rrb-', 'or', 'nsc23766', '-lrb-', '5', 'mg/kg', 'bw', ',', 'i.p.', '-rrb-', 'three', 'times', 'a', 'week', '.']\n",
      "['-lsb-', 'nct00679041', '-rsb-', 'this', 'article', 'is', 'protected', 'by', 'copyright', '.']\n",
      "['univariable', 'and', 'multivariable', 'analysis', 'was', 'used', 'to', 'explore', 'the', 'association', 'of', 'variables', 'of', 'interest', 'with', 'os', 'and', 'psa', 'declines', '.']\n",
      "['however', ',', 'only', '23', '%', '-lrb-', '95', '%', 'ci', ':', '6.3', '%', '-39.7', '%', '-rrb-', 'of', 'patients', 'with', 'definite', 'or', 'probable', 'fh', 'were', 'on', 'statins', '.']\n",
      "['those', 'with', 'myocardial', 'infarction', 'had', 'the', 'smallest', 'increase', '-lrb-', '1.98', 'pp', '-rrb-', 'and', 'those', 'with', 'hypercholesterolemia', 'or', 'primary', 'hypertension', 'had', 'the', 'largest', 'increase', '-lrb-', '3.54', 'pp', '-rrb-', '.']\n",
      "['discontinuation', 'of', 'statin', 'therapy', 'represents', 'a', 'major', 'challenge', 'for', 'effective', 'cardiovascular', 'disease', 'prevention', '.']\n",
      "['pcps', 'reported', 'that', 'side', 'effects', ',', 'especially', 'muscle/joint-related', 'symptoms', ',', 'were', 'the', 'most', 'common', 'reason', 'patients', 'reported', 'for', 'statin', 'discontinuation', '-lrb-', '47', '%', 'of', 'available', 'votes', '-rrb-', '.']\n",
      "['at', 'baseline', 'and', '3', 'months', 'later', ',', 'between-group', 'differences', 'were', 'compared', '.']\n",
      "['subjects', 'were', 'grouped', 'according', 'to', 'their', 'cancer', 'stages', 'and', 'assessed', 'using', 'statins', 'in', 'both', 'groups', '.']\n",
      "['hazard', 'ratios', '-lrb-', 'hrs', '-rrb-', 'for', 'the', 'risk', 'of', 'prostate', 'cancer', 'death', 'by', 'amount', ',', 'duration', ',', 'and', 'intensity', 'of', 'statin', 'use', '.']\n",
      "['as', 'shown', 'by', 'the', 'results', ',', 'evolocumab', 'can', 'through', 'additional', 'reduction', 'of', 'blood', 'levels', 'of', 'ldl-c', 'favorably', 'influence', '-lrb-', 'reduce', '-rrb-', 'coronary', 'atherosclerosis.key', 'words', ':', 'evolocumab', '-', 'regression', 'of', 'coronary', 'atherosclerosis', '-', 'ldl-c', 'blood', 'levels', '.']\n",
      "['high', 'exercise', 'capacity', '-lrb-', 'ec', '-rrb-', 'has', 'been', 'associated', 'with', 'a', 'lower', 'risk', 'of', 'incident', 'diabetes', ',', 'whereas', 'statin', 'therapy', 'has', 'been', 'associated', 'with', 'a', 'higher', 'risk', '.']\n",
      "['continued', 'statin', 'prescriptions', 'after', 'an', 'adverse', 'reaction', 'were', 'associated', 'with', 'a', 'lower', 'incidence', 'of', 'death', 'and', 'cardiovascular', 'events', '.']\n",
      "['the', 'purpose', 'of', 'this', 'study', 'was', 'to', 'investigate', 'the', 'anti-asthmatic', 'effects', 'of', 'pitavastatin', ',', 'a', 'type', 'of', 'statin', ',', 'in', 'an', 'asthma', 'mouse', 'model', '.']\n",
      "['type', '1', 'mi', ',', 'type', '2', 'mi', ',', 'and', 'myocardial', 'injury', 'occurred', 'in', '137', ',', '146', ',', 'and', '175', 'patients', ',', 'respectively', '.']\n",
      "['sensitivity', 'analyses', 'included', 'evolocumab', 'as', 'a', 'pcsk9', 'inhibitor', '.']\n",
      "['specific', 'independent', 'predictors', 'of', 'residual', 'risk', 'included', 'current', 'smoking', ',', 'family', 'history', ',', 'diabetes', ',', 'high-sensitivity', 'c-reactive', 'protein', ',', 'low-density', 'lipoprotein', 'particle', 'number', ',', 'carotid', 'intimal', 'medial', 'thickness', ',', 'and', 'especially', 'coronary', 'artery', 'calcium', 'score', '.']\n",
      "['coronary', 'artery', 'calcium', 'may', 'be', 'an', 'alternative', 'marker', 'besides', 'age', 'to', 'better', 'discriminate', 'between', 'lower', 'and', 'higher', 'chd', 'risk', 'in', 'older', 'adults', '.']\n",
      "['a', 'novel', 'commercial', 'software-as-a-service', 'data-mining', 'product', 'supplied', 'by', 'sysomos', 'from', 'datasift/facebook', 'was', 'used', 'to', 'mine', 'all', 'mentions', 'on', 'facebook', 'of', 'statins', 'and', 'stain-related', 'side', 'effects', 'in', 'the', 'us', 'in', 'the', '1-month', 'period', '9', 'january', '2017', 'through', '8', 'february', '2017', '.']\n",
      "['we', 'previously', 'showed', 'that', 'intradermal', 'injection', 'of', 'statins', 'is', 'a', 'successful', 'treatment', 'for', 'hypertrophic', 'scarring', '.']\n",
      "['there', 'were', 'flu-like', 'symptoms', 'in', '14', '%', 'of', 'patients', '.']\n",
      "['in', 'vitro', 'data', 'point', 'to', 'rac1', 'as', 'major', 'target', 'of', 'the', 'cytoprotective', 'statin', 'effects', '.']\n",
      "['this', 'suggests', 'that', 'a', 'diet', 'containing', 'geranylgeraniol', 'can', 'limit', 'the', 'anti-tumour', 'activity', 'of', 'pitavastatin', 'and', 'diet', 'should', 'be', 'controlled', 'in', 'clinical', 'trials', 'of', 'statins', '.']\n",
      "['the', 'wide', 'variation', 'in', 'onset', 'and', 'progression', 'of', 'the', 'disease', ',', 'both', 'in', 'sporadic', 'and', 'even', 'in', 'strongly', 'penetrant', 'monogenic', 'familial', 'forms', 'of', 'als', ',', 'indicate', 'that', 'in', 'addition', 'to', 'background', 'genetic', 'variation', 'impacting', 'the', 'disease', 'process', ',', 'environmental', 'exposures', 'are', 'likely', 'contributors', '.']\n",
      "['we', 'utilized', 'the', 'data', 'from', 'taiwan', 'national', 'health', 'insurance', 'research', 'database', '-lrb-', 'nhird', '-rrb-', 'to', 'perform', 'a', 'population-based', 'cohort', 'study', '-lrb-', '1997-2013', '-rrb-', '.']\n",
      "['there', 'is', 'insufficient', 'evidence', 'to', 'recommend', 'the', 'use', 'of', 'statins', 'to', 'replace', 'anticoagulants', 'in', 'vte', 'prevention', '.']\n",
      "['after', 'confirmation', 'of', 'their', 'efficacy', 'and', 'safety', 'in', 'clinical', 'trials', ',', 'evolocumab', 'and', 'alirocumab', 'received', 'approval', 'from', 'the', 'us', 'food', 'and', 'drug', 'administration', '-lrb-', 'fda', '-rrb-', 'and', 'european', 'medicines', 'agency', '-lrb-', 'ema', '-rrb-', 'for', 'introduction', 'into', 'clinical', 'practice', '.']\n",
      "['pitavastatin-nps', 'were', 'delivered', 'to', 'cd11b', '-lrb-', '+', '-rrb-', 'monocytes/macrophages', ',', 'but', 'not', 'to', 'cardiomyocytes', '.']\n",
      "['an', 'association', 'between', 'negative', 'media', 'attention', 'and', 'statin', 'discontinuation', 'has', 'been', 'demonstrated', ',', 'but', 'it', 'may', 'differ', 'depending', 'on', 'the', 'reason', 'for', 'prescription', 'and', 'whether', 'the', 'user', 'is', 'new', '-lrb-', 'incident', '-rrb-', 'or', 'long', 'term', '-lrb-', 'prevalent', '-rrb-', '.']\n",
      "['while', 'a', 'link', 'between', 'adherence', 'and', 'cardiovascular', 'risk', 'factor', 'control', 'is', 'established', ',', 'most', 'studies', 'included', 'young', 'patients', 'with', 'few', 'comorbidities', '.']\n",
      "['experimental', 'findings', 'and', 'previous', 'observational', 'data', 'have', 'suggested', 'lower', 'risk', 'of', 'osteoarthritis', 'with', 'statin', 'use', 'but', 'results', 'are', 'inconsistent', '.']\n",
      "['among', 'clinically', 'stable', 'des-treated', 'patients', 'on', 'aspirin', 'monotherapy', ',', 'high-intensity', 'statin', 'treatment', 'significantly', 'reduced', 'late', 'adverse', 'events', 'compared', 'with', 'low-intensity', 'statin', 'treatment', '.']\n",
      "['among', 'women', ',', '24', '%', ',', '17', '%', ',', '4', '%', 'and', '2', '%', 'were', 'eligible', 'for', 'statin', 'use', 'according', 'to', 'the', 'br-1', ',', 'br-2', ',', 'usa-1', 'and', 'usa-2', 'criteria', ',', 'respectively', '-lrb-', 'p', '<', '0.01', '-rrb-', '.']\n",
      "['mice', 'fed', 'fenofibrate', 'displayed', 'reductions', 'in', 'hsd17b13', 'gene', 'expression', '-lrb-', 'q', '<', '0.1', '-rrb-', '.']\n",
      "['purpose', 'cancer', 'and', 'cardiovascular', 'disease', 'share', 'risk', 'factors', ',', 'and', 'there', 'is', 'some', 'evidence', 'that', 'statins', 'reduce', 'cancer', 'mortality', '.']\n",
      "['selected', 'studies', 'included', 'cohort', 'populations', 'from', 'the', 'community', '-lrb-', '>', '50', 'years', 'old', '-rrb-', ',', 'and', 'analysed', 'using', 'the', 'scottish', 'intercollegiate', '-lrb-', 'sign', '-rrb-', 'methodology', 'guidelines', ',', 'as', 'no', 'randomised', 'controlled', 'study', 'was', 'found', '.']\n",
      "['there', 'is', 'presently', 'no', 'cure', 'for', 'als', ',', 'and', 'only', 'two', 'drugs', 'are', 'available', ',', 'neither', 'of', 'which', 'provide', 'significant', 'extension', 'of', 'life', '.']\n",
      "['this', 'study', 'evaluated', 'the', 'use', 'of', 'statin', 'therapy', 'in', 'u.s.', 'air', 'force', '-lrb-', 'usaf', '-rrb-', 'aviators', 'with', 'isolated', 'hypercholesterolemia', 'in', 'terms', 'of', 'compliance', 'with', 'clinical', 'practice', 'guidelines', '-lrb-', 'cpgs', '-rrb-', 'and', 'effectiveness', 'in', 'reducing', 'low-density', 'lipoprotein', 'cholesterol', '-lrb-', 'ldl-c', '-rrb-', 'and', 'coronary', 'heart', 'disease', '-lrb-', 'chd', '-rrb-', 'risk', '.']\n",
      "['akr7a3', 'and', 'hsd17b13', 'were', 'associated', 'with', 'lipid', 'changes', 'in', 'white', 'subjects', '-lrb-', 'q', '<', '0.2', '-rrb-', '.']\n",
      "['for', 'the', 'control', 'group', ',', '123', 'adult', 'patients', 'with', 'diabetes', 'mellitus', 'in', 'an', 'outpatient', 'setting', 'and', 'without', 'a', 'history', 'of', 'dfis', 'were', 'accepted', '.']\n",
      "['\\xce\\xb2-adrenergic', 'responses', 'were', 'investigated', 'in', 'vivo', '-lrb-', 'echocardiography', '-rrb-', 'and', 'ex', 'vivo', '-lrb-', 'left', 'ventricular', 'papillary', 'muscles', '-rrb-', 'in', 'healthy', 'and', 'streptozotocin-induced', 'diabetic', 'rats', ',', 'who', 'were', 'pre-treated', 'or', 'not', 'by', 'oral', 'atorvastatin', 'over', '15', 'days', '-lrb-', '50', 'mg.kg-1', '.']\n",
      "['one', 'hundred', 'subjects', 'with', 'dyslipidemia', 'and', 'without', 'statin', 'treatment', 'were', 'enrolled', 'and', 'assigned', 'to', 'exercise', 'and', 'control', 'groups', '.']\n",
      "['our', 'approach', 'outperforms', 'previously-reported', 'results', 'and', 'shows', 'the', 'importance', 'of', 'local', 'factors', 'on', 'high-risk', 'coronary', 'artery', 'plaque', 'development', '.']\n",
      "['supplementation', 'of', 'tqrfne', 'into', 'an', 'hfcd', 'thus', 'could', 'ameliorate', 'memory', 'deficit', ',', 'lipid', 'peroxidation', 'and', 'soluble', 'a\\xce\\xb2', 'levels', 'as', 'well', 'as', 'improving', 'the', 'total', 'antioxidant', 'status', 'and', 'antioxidants', 'genes', 'expression', 'levels', '.']\n",
      "['potential', 'solutions', 'include', 'point-of-care', 'testing', ',', 'provision', 'of', 'free', 'or', 'subsidized', 'lipid-lowering', 'medication', ',', 'and', 'treatment', 'adherence', 'support', 'using', 'text', 'message', 'reminders', '.']\n",
      "['pooled', 'relative', 'risks', '-lrb-', 'rrs', '-rrb-', 'with', '95', '%', 'confidence', 'intervals', '-lrb-', 'cis', '-rrb-', 'were', 'calculated', 'using', 'either', 'a', 'fixed-effects', 'or', 'a', 'random-effects', 'model', '.']\n",
      "['the', 'brazilian', 'diabetes', 'society', ',', 'the', 'brazilian', 'society', 'of', 'cardiology', ',', 'and', 'the', 'brazilian', 'endocrinology', 'and', 'metabolism', 'society', 'gathered', 'to', 'form', 'an', 'expert', 'panel', 'including', '28', 'cardiologists', 'and', 'endocrinologists', 'to', 'review', 'the', 'best', 'available', 'evidence', 'and', 'to', 'draft', 'up-to-date', 'an', 'evidence-based', 'guideline', 'with', 'practical', 'recommendations', 'for', 'risk', 'stratification', 'and', 'prevention', 'of', 'cardiovascular', 'disease', 'in', 'diabetes', '.']\n",
      "['neutrophils', ',', 'lymphocytes', ',', 'and', 'monocytes', 'were', 'examined', 'individually', '.']\n",
      "['this', 'study', 'was', 'to', 'determine', 'if', 'acute', 'administration', 'of', 'atorvastatin', 'affect', 'the', 'infarct', 'size-limiting', 'effect', 'of', 'ipc', 'in', 'hyperlipidemic', 'rats', '.']\n",
      "['thus', ',', 'we', 'aimed', 'to', 'determine', 'whether', 'statin', 'use', 'is', 'associated', 'with', 'a', 'reduced', 'risk', 'of', 'developing', 'clinically-defined', 'hip', 'or', 'knee', 'osteoarthritis', '.']\n",
      "['the', 'clinical', 'condition', 'in', 'which', 'patients', 'experience', 'major', 'unacceptable', 'symptoms', 'and/or', 'develop', 'laboratory', 'abnormalities', 'during', 'statin', 'therapy', 'is', 'defined', 'as', 'statin', 'intolerance', '.']\n",
      "['since', 'ldlc', 'lowering', 'has', 'been', 'revolutionized', 'by', 'ali', 'and', 'evo', ',', 'specialty', 'pharmaceutical', 'pricing', 'models', 'will', 'be', 'applied', 'to', 'a', 'mass', 'market', '.']\n",
      "['unfortunately', ',', 'most', 'statin', 'therapies', 'dose-dependently', 'cause', 'insulin', 'resistance', ',', 'increase', 'new', 'onset', 'diabetes', 'risk', 'and', 'exacerbate', 'existing', 'type', '2', 'diabetes', 'mellitus', '.']\n",
      "['this', 'results', 'from', 'discrepancies', 'between', 'the', 'risk', 'stratified', 'by', 'the', 'brazilian', 'guideline', 'and', 'that', 'calculated', 'by', 'the', 'pce', ',', 'particularly', 'because', 'of', 'the', 'risk', 'reclassification', 'based', 'on', 'aggravating', 'factors', '.']\n",
      "['methods', ':', 'all', 'enrolled', 'patients', 'were', 'from', 'the', 'out-patient', 'clinic', 'of', 'the', 'department', 'of', 'tcm', 'at', 'the', '3', '-lrb-', 'rd', '-rrb-', 'affiliated', 'hospital', 'of', 'sun', 'yat-sen', 'university', '.']\n",
      "['fibrates', 'are', 'a', 'class', 'of', 'drugs', 'prescribed', 'to', 'treat', 'dyslipidemia', ',', 'but', 'variation', 'in', 'response', 'has', 'been', 'observed', '.']\n",
      "['lipid', 'profiles', 'and', 'prostate', 'cancer', 'have', 'a', 'controversial', 'relationship', ',', 'and', 'the', 'predictive', 'ability', 'of', 'lipids', 'in', 'determining', 'cancer', 'risk', 'estimation', 'is', 'still', 'questionable', '.']\n",
      "['high-dose', 'simvastatin', 'treatment', 'significantly', 'reduced', 'the', 'messenger', 'ribonucleic', 'acid', '-lrb-', 'mrna', '-rrb-', 'expression', 'of', 'connective', 'tissue', 'growth', 'factor', ',', 'consistent', 'with', 'our', 'previously', 'published', 'work', 'on', 'intradermally', 'injected', 'statins', '.']\n",
      "['neuroinflammation', 'is', 'a', 'prominent', 'component', 'of', 'several', 'neurodegenerative', 'diseases', ',', 'including', 'multiple', 'sclerosis', ',', 'alzheimer', \"'s\", 'disease', ',', 'parkinson', \"'s\", 'disease', ',', 'tauopathies', ',', 'amyotrophic', 'lateral', 'sclerosis', 'and', 'prion', 'diseases', '.']\n",
      "['\\xce\\xb4', '-lrb-', '2', '-rrb-', 'h', 'is', 'significantly', '-lrb-', 'p', '<', '0.001', '-rrb-', 'lower', 'in', 'monacolin', 'k', 'but', 'the', 'ranges', 'of', 'values', 'partially', 'overlap', 'with', 'those', 'of', 'lovastatin', '.']\n",
      "['the', 'prevalence', 'of', 'patients', 'with', 'definite', 'fh', 'was', '0.24', '%', '-lrb-', 'one', 'in', '407', '-rrb-', '-lrb-', '95', '%', 'confidence', 'interval', '-lsb-', 'ci', '-rsb-', ':', '0.06', '%', '-0.42', '%', '-rrb-', ',', 'with', 'probable', 'fh', 'was', '0.68', '%', '-lrb-', 'one', 'in', '148', '-rrb-', '-lrb-', '95', '%', 'ci', ':', '0.38', '%', '-0.98', '%', '-rrb-', ',', 'and', 'with', 'definite', 'or', 'probable', 'fh', 'combined', 'was', '0.92', '%', '-lrb-', 'one', 'in', '108', '-rrb-', '-lrb-', '95', '%', 'ci', ':', '0.58', '%', '-1.26', '%', '-rrb-', '.']\n",
      "['in', 'the', 'study', 'by', 'ham', 'et', 'al.', ',', 'statin', 'use', 'was', 'shown', 'to', 'be', 'a', 'protective', 'factor', 'for', 'presence', 'of', 'falls', '.']\n",
      "['il-4', 'and', 'il-17', 'levels', 'were', 'decreased', ',', 'whereas', 'ifn-\\xce\\xb3', 'levels', 'were', 'significantly', 'increased', 'in', 'the', 'balf', 'of', 'pitavastatin-treated', 'mice', 'compared', 'with', 'the', 'balf', 'of', 'ova-challenged', 'mice', '.']\n",
      "['foram', 'eleg\\xc3\\xadveis', 'para', 'estatina', '24', '%', ',', '17', '%', ',', '4', '%', 'e', '2', '%', 'das', 'mulheres', 'pelos', 'crit\\xc3\\xa9rios', 'br-1', ',', 'br-2', ',', 'eua-1', 'e', 'eua-2', ',', 'respectivamente', '-lrb-', 'p', '<', '0,01', '-rrb-', '.']\n",
      "['the', 'odds', 'ratios', 'for', 'cad', 'and', 'myocardial', 'infarction', '-lrb-', 'mi', '-rrb-', ',', 'adjusted', 'for', 'age', ',', 'gender', ',', 'region', ',', 'smoking', ',', 'hypertension', ',', 'and', 'diabetes', 'mellitus', ',', 'were', '3.71', '-lrb-', '95', '%', 'ci', ':', '1.58-8', '.72', '-rrb-', '-lrb-', 'p', '', '0.003', '-rrb-', 'and', '4.06', '-lrb-', '95', '%', 'ci', ':', '0.89-18', '.55', '-rrb-', '-lrb-', '\\xd1\\x80', '', '0.070', '-rrb-', 'respectively', 'for', 'individuals', 'with', 'definite', 'or', 'probable', 'fh', 'relative', 'to', 'those', 'who', 'were', 'unlikely', 'to', 'have', 'fh', '.']\n",
      "['multivariable', 'cox', 'regression', 'modeling', 'adjusted', 'for', 'known', 'prognostic', 'factors', '.']\n",
      "['recent', 'trials', 'have', 'provided', 'evidence', 'of', 'benefit', 'in', 'reduction', 'of', 'cardiovascular', 'events', 'with', 'these', 'agents', '.']\n",
      "['participants', 'in', 'both', 'groups', 'were', 'classified', 'as', 'statin', 'users', 'or', 'non-statin', 'users', 'depending', 'on', 'history', 'of', 'atorvastatin', 'treatment', '.']\n",
      "['this', 'special', 'report', 'rapidly', 'summarizes', 'the', 'potential', 'of', 'statins', 'in', 'the', 'treatment', 'of', 'brain', 'diseases', 'and', 'the', 'pharmaceutical', 'nanotechnologies', 'that', 'could', 'provide', 'a', 'viable', 'approach', 'to', 'enable', 'these', 'indications', '.']\n",
      "['the', 'combined', 'end', 'point', 'was', 'statistically', 'lower', 'in', 'patients', 'with', 'high', 'levels', 'of', 'gdf-15', 'treated', 'with', 'high-dose', 'statins', 'compared', 'with', 'patients', 'treated', 'with', 'low-dose', 'statins', 'or', 'without', 'statin', 'treatment', '-lrb-', '3.8', '%', 'vs', '22.2', '%', ',', 'hazard', 'ratio', '-lsb-', 'hr', '-rsb-', '', '0.156', ';', '95', '%', 'confidence', 'interval', '-lsb-', 'ci', '-rsb-', ',', '0.047', 'to', '0.519', ';', 'p', '', '0.002', '-rrb-', '.']\n",
      "['this', 'reduction', 'in', 'cancer-specific', 'mortality', 'was', 'greatest', 'in', 'statin-users', 'with', 'oestrogen', '-lrb-', 'er', '-rrb-', 'receptor-positive', 'tumours', '-lrb-', 'hr', '0.69', '95', '%', 'ci', '0.55', ',', '0.85', '-rrb-', '.']\n",
      "['in', 'addition', ',', 'blood', 'samples', 'were', 'drawn', 'to', 'assess', 'cholesterol', 'efflux', 'capacity', '-lrb-', 'cec', '-rrb-', 'and', 'changes', 'in', 'gene', 'expression', 'in', 'peripheral', 'blood', 'mononuclear', 'cells', '-lrb-', 'pbmc', '-rrb-', '.']\n",
      "['patients', \"'\", 'fear', 'of', 'side', 'effects', 'was', 'ranked', 'as', 'the', 'biggest', 'challenge', 'pcps', 'encounter', 'in', 'getting', 'their', 'patients', 'to', 're-initiate', 'statin', 'therapy', '-lrb-', '70', '%', 'of', 'available', 'votes', '-rrb-', '.']\n",
      "['all-cause', 'mortality', '-lrb-', 'median', 'follow-up', ':', '1.8', 'years', '-rrb-', 'was', 'not', 'different', 'between', 'patient', 'groups', '-lrb-', 'type', '1', 'mi', 'mortality', ':', '29.9', '%', ',', 'type', '2', 'mi', ':', '30.8', '%', ',', 'myocardial', 'injury', ':', '29.7', '%', ';', 'log', 'rank', 'p', '', '0.94', '-rrb-', '.']\n",
      "['the', 'median', 'age', '-lrb-', 'iqr', '-rrb-', 'for', 'the', 'cohort', 'at', 'enrollment', 'was', '46', '-lrb-', '40-53', '-rrb-', 'years', ';', '78', '%', 'were', 'male', 'and', '68', '%', 'were', 'african', 'american', '.']\n",
      "['the', 'reasons', 'for', 'publishing', 'this', 'document', 'are', 'discussed', ',', 'in', 'particular', 'appearance', 'of', 'results', 'of', 'conducted', 'during', 'last', '3', 'years', 'clinical', 'trials', 'of', 'new', 'highly', 'effective', 'non-statin', 'medications', '.']\n",
      "['patients', '-lrb-', 'n', '', '720', '-rrb-', 'on', 'maximally', 'tolerated', 'statin', 'dose', 'were', 'treated', 'with', 'alirocumab', '-lrb-', '75/150', 'mg', 'every', '2', 'weeks', '-rrb-', 'or', 'ezetimibe', '-lrb-', '10', 'mg/day', '-rrb-', '.']\n",
      "['inhibition', 'of', 'rac1', 'signaling', 'is', 'of', 'major', 'relevance', 'for', 'the', 'cardioprotective', 'effects', 'of', 'lovastatin', 'in', 'the', 'context', 'of', 'anthracycline-induced', 'cardiotoxicity', '.']\n",
      "['emerging', 'evidence', 'suggests', 'that', 'statins', 'may', 'play', 'a', 'role', 'in', 'the', 'prevention', 'of', 'vte', ',', 'but', 'the', 'evidence', 'has', 'been', 'uncertain', '.']\n",
      "['results', ':', 'a', 'total', 'of', '82', 'patients', 'were', 'enrolled', 'in', 'the', 'study', 'and', '76', 'patients', '-lrb-', 'nk', '39', ',', 'st', '37', '-rrb-', 'completed', 'the', 'study', '.']\n",
      "['many', 'studies', 'using', 'statins', 'have', 'been', 'performed', 'but', 'failed', 'to', 'show', 'remarkable', 'effects', '.']\n",
      "['the', 'findings', 'of', 'this', 'study', 'suggest', 'that', 'a', 'relationship', 'between', 'statin', 'dose', 'and', 'aki', 'may', 'not', 'exist', 'independent', 'of', 'serious', 'muscle', 'injury', '.']\n",
      "['initiatives', 'to', 'enhance', 'statin', 'therapy', 'prescribing', 'should', 'recognize', 'the', 'comprehensive', 'nature', 'of', 'the', 'prescribing', 'process', '.']\n",
      "['previous', 'statin', 'use', 'did', 'not', 'affect', 'in-hospital', 'or', '30-day', 'mortality', '-lrb-', 'or', '0.978', ';', '95', '%', 'ci', '0.339', 'to', '2.274', ';', 'p', '', '0.789', '-rrb-', '.']\n",
      "['the', 'risks', 'and', 'benefits', 'of', 'continued', 'statin', 'therapy', 'after', 'an', 'adverse', 'reaction', 'are', 'not', 'known', '.']\n",
      "['in', 'addition', ',', 'nk', 'significantly', 'increased', 'the', 'level', 'of', 'high-density', 'lipoprotein', 'cholesterol', '-lrb-', 'hdl-c', '-rrb-', '-lrb-', 'p', '<', '0.05', '-rrb-', ',', 'in', 'contrast', ',', 'hdl-c', 'in', 'the', 'st', 'group', 'did', 'not', 'change', '.']\n",
      "['topical', 'treatment', 'with', 'both', 'medium', '-', 'and', 'high-dose', 'simvastatin', 'also', 'significantly', 'reduced', 'scarring', '.']\n",
      "['compared', 'with', 'patients', 'without', 'hl', ',', 'patients', 'with', 'hl', 'had', 'significantly', 'higher', 'rates', 'of', 'ft', '-lrb-', '18.1', '%', 'vs.', '1.9', '%', ';', 'p', '<', '.001', '-rrb-', 'and', 'pt', '-lrb-', '27.2', '%', 'vs.', '9.4', '%', ';', 'p', '<', '.001', '-rrb-', '.']\n",
      "['appropriate', 'candidates', 'for', 'evolocumab', 'primarily', 'are', 'individuals', 'at', 'high', 'cardiovascular', 'risk', ',', 'including', 'those', 'with', 'familial', 'hypercholesterolemia', 'and/or', 'established', 'cardiovascular', 'disease', ',', 'who', 'are', 'already', 'on', 'statin', 'therapy', '.']\n",
      "['when', 'analysed', 'by', 'age', ',', '95', '%', 'of', 'males', 'and', '66', '%', 'of', 'females', 'without', 'cvd', 'in', 'ages', '60-74', 'years', ',', 'including', 'all', 'males', 'and', 'females', 'in', 'ages', '75-84', 'years', ',', 'would', 'require', 'statin', 'therapy', '.']\n",
      "['severe', 'dfi', ',', 'bone', 'involvement', ',', 'and', 'the', 'need', 'for', 'surgical', 'intervention', 'was', 'lower', 'in', 'the', 'experimental', 'group', ',', 'but', 'this', 'difference', 'was', 'not', 'statistically', 'significant', '.']\n",
      "['isso', 'se', 'relaciona', 'com', 'discrep\\xc3\\xa2ncias', 'entre', 'o', 'risco', 'estratificado', 'pela', 'diretriz', 'brasileira', 'e', 'o', 'calculado', 'pelas', 'pce', ',', 'particularmente', 'devido', '\\xc3\\xa0', 'reclassifica\\xc3\\xa7\\xc3\\xa3o', 'de', 'risco', 'baseada', 'em', 'fatores', 'agravantes', '.']\n",
      "['statin-associated', 'muscle', 'disease', '-lrb-', 'sams', '-rrb-', 'is', 'by', 'far', 'the', 'most', 'studied', 'and', 'the', 'most', 'common', 'reason', 'for', 'discontinuation', 'of', 'therapy', '.']\n",
      "['the', 'cohort', 'of', 'consisted', 'of', '6537', 'prostate', 'cancer', 'cases', 'diagnosed', 'in', 'the', 'finnish', 'randomized', 'study', 'of', 'screening', 'for', 'prostate', 'cancer', 'population', 'during', '1996-2012', '.']\n",
      "['the', 'primary', 'endpoint', 'was', 'adverse', 'clinical', 'events', 'at', '12-month', 'follow-up', '-lrb-', 'a', 'composite', 'of', 'all', 'death', ',', 'myocardial', 'infarction', ',', 'revascularization', ',', 'stent', 'thrombosis', ',', 'stroke', ',', 'renal', 'deterioration', ',', 'intervention', 'for', 'peripheral', 'artery', 'disease', ',', 'and', 'admission', 'for', 'cardiac', 'events', '-rrb-', '.']\n",
      "['the', 'prevalence', 'of', 't2dm', 'in', 'hefh', 'patients', 'was', '40', '%', 'lower', 'than', 'that', 'observed', 'in', 'the', 'general', 'population', '.']\n",
      "['we', 'found', 'no', 'dose-response', 'relation', 'between', 'duration', 'of', 'current', 'statin', 'use', 'and', 'the', 'risk', 'of', 'osteoarthritis', ',', 'with', 'similar', 'hrs', 'among', 'patients', 'with', 'less', 'than', '1', 'year', 'of', 'use', '-lrb-', 'hr', '1.09', ';', '95', '%', 'ci', '0.92', 'to', '1.32', '-rrb-', 'as', 'in', 'patients', 'with', 'use', 'for', '3', 'years', 'or', 'more', '-lrb-', 'hr', '1.05', ';', '0.93', 'to', '1.16', '-rrb-', '.']\n",
      "['the', 'results', 'of', 'the', 'study', 'showed', 'that', 'pitavastatin', 'reduced', 'allergen-induced', 'increases', 'in', 'airway', 'resistance', 'and', 'alleviated', 'bronchial', 'tube', 'thickness', 'and', 'goblet', 'cell', 'hyperplasia', 'in', 'lung', 'tissues', '.']\n",
      "['em', 'indiv\\xc3\\xadduos', 'de', '40', 'a', '75', 'anos', 'submetidos', 'consecutivamente', 'a', 'avalia\\xc3\\xa7\\xc3\\xa3o', 'rotineira', 'de', 'sa\\xc3\\xbade', 'em', 'um', '\\xc3\\xbanico', 'centro', ',', 'quatro', 'crit\\xc3\\xa9rios', 'de', 'elegibilidade', 'para', 'estatina', 'foram', 'definidos', ':', 'br-1', ',', 'br-2', '-lrb-', 'ldl-c', 'acima', 'ou', 'pelo', 'menos', '30', 'mg/dl', 'acima', 'da', 'meta', 'preconizada', 'pela', 'diretriz', 'brasileira', ',', 'respectivamente', '-rrb-', ',', 'eua-1', 'e', 'eua-2', '-lrb-', 'risco', 'estimado', 'pelas', 'pce', 'em', '10', 'anos', '\\xe2\\x89\\xa5', '5,0', '%', 'ou', '\\xe2\\x89\\xa5', '7,5', '%', ',', 'respectivamente', '-rrb-', '.']\n",
      "['we', 'observed', '6,921', 'new', 'diabetes', 'cases', '-lrb-', '14.6', '%', '-rrb-', 'over', 'a', 'median', 'follow-up', 'period', 'of', '5.1', 'years', '-lrb-', 'interquartile', 'interval', 'of', '2.6', 'to', '8.2', 'years', '-rrb-', '.']\n",
      "['overall', ',', '37', '%', '-lrb-', '812', 'of', '2,196', '-rrb-', 'were', 'statin', 'eligible', '.']\n",
      "['we', 'excluded', 'studies', 'that', 'included', 'berberine', 'or', 'lovastatin', '.']\n",
      "['information', 'on', 'adverse', 'reactions', 'to', 'statins', 'was', 'obtained', 'from', 'structured', 'electronic', 'medical', 'record', 'data', 'or', 'natural-language', 'processing', 'of', 'narrative', 'provider', 'notes', '.']\n",
      "['there', 'was', 'no', 'evidence', 'of', 'an', 'association', 'between', 'statin', 'use', 'and', 'endometrial', 'cancer', 'risk', 'either', 'among', 'rcts', '-lrb-', 'rr', ',', '0.72', ';', '95', '%', 'ci', ',', '0.19', 'to', '2.67', '-rrb-', 'or', 'among', 'non-randomized', 'studies', '-lrb-', 'rr', ',', '0.94', ';', '95', '%', 'ci', ',', '0.82', 'to', '1.07', '-rrb-', '.']\n",
      "['interestingly', ',', 'only', 'prasugrel', 'significantly', 'reduced', 'scd40', 'ligand', 'and', 'rantes', 'and', 'increased', 'nitrite', 'levels', '.']\n",
      "['with', 'the', 'high', 'incidence', 'of', 'cardiovascular', 'events', 'in', 'the', 'elderly', 'population', 'the', 'effectiveness', 'of', 'statins', 'in', 'reducing', 'mortality', 'from', 'coronary', 'events', 'has', 'been', 'demonstrated', '.']\n",
      "['ischemic', 'postconditioning', '-lrb-', 'ipc', '-rrb-', 'reduces', 'ischemia/reperfusion', '-lrb-', 'i/r', '-rrb-', 'injury', 'under', 'normal', 'conditions', '.']\n",
      "['therefore', ',', 'we', 'sought', 'to', 'perform', 'a', 'systematic', 'search', 'of', 'the', 'literature', 'to', 'explore', 'the', 'relationship', 'among', 'statins', ',', 'metformin', ',', 'and', 'sams', '.']\n",
      "['we', 'report', 'a', 'machine', 'learning', 'method', 'for', 'prediction', 'of', 'future', 'high-risk', 'coronary', 'plaque', 'locations', 'and', 'types', 'in', 'patients', 'under', 'statin', 'therapy', '.']\n",
      "['the', 'centers', 'for', 'medicare', 'and', 'medicaid', 'services', '-lrb-', 'cms', '-rrb-', 'medicare', 'star', 'program', 'provides', 'incentives', 'to', 'health', 'plans', 'when', 'their', 'patients', 'with', 'diabetes', 'meet', 'adherence', 'targets', 'to', 'acei/angiotensin', 'receptor', 'blockers', '-lrb-', 'acei/arb', '-rrb-', 'and', 'statins', '.']\n",
      "['associations', 'were', 'maintained', 'in', 'fully', 'adjusted', 'models', 'of', 'intrusive', 'body', 'pain', 'and', 'difficulty', 'climbing', 'stairs', ',', 'but', 'for', 'chair', 'rise', 'speed', 'they', 'were', 'fully', 'accounted', 'for', 'by', 'inflammation', ',', 'body-size', 'and', 'lifestyle', '.']\n",
      "['the', 'risk', 'decrease', 'was', 'significant', 'only', 'in', 'men', 'managed', 'with', 'androgen', 'deprivation', 'therapy', ',', 'but', 'statistical', 'power', 'was', 'limited', 'to', 'estimate', 'the', 'association', 'in', 'men', 'managed', 'with', 'surgery', 'or', 'radiotherapy', '.']\n",
      "['transatlantic', 'inter-society', 'consensus', 'for', 'the', 'management', 'of', 'peripheral', 'artery', 'disease', '-lrb-', 'tasc', 'ii', '-rrb-', 'type', 'c/d', 'aortoiliac', '-lrb-', '48.0', '%', '-rrb-', 'or', 'femoropopliteal', 'lesions', '-lrb-', '60.2', '%', '-rrb-', 'were', 'frequent', 'targets', 'of', 'endovascular', 'treatment', '.']\n",
      "['they', 'are', 'also', 'important', 'contributors', 'to', 'metabolic', 'diseases', 'including', 'diabetes', 'that', 'further', 'increase', 'cv', 'risk', '.']\n",
      "['while', 'the', 'reduction', 'in', 'both', 'groups', 'was', 'shown', 'to', 'be', 'statistically', 'significant', '-lrb-', 'p', '<', '0.01', '-rrb-', ',', 'the', 'reduction', 'of', 'tc', ',', 'ldl-c', 'and', 'tg', 'in', 'st', 'group', 'was', 'significantly', 'greater', '-lrb-', 'p', '<', '0.05', '-rrb-', '.']\n",
      "['epidemiological', 'evidence', 'worldwide', 'implicates', 'exposures', 'to', 'bacterial', 'toxins', ',', 'heavy', 'metals', ',', 'pesticides', ',', 'and', 'trauma', 'as', 'probable', 'environmental', 'factors', '.']\n",
      "['again', ',', 'those', 'with', 'myocardial', 'infarction', 'had', 'the', 'smallest', 'decrease', 'in', 'statin', 'discontinuation', '-lrb-', '1.49', 'pp', '-rrb-', ',', 'while', 'those', 'with', 'a', 'potential', 'atherosclerotic', 'condition', '-lrb-', '7.05', 'pp', '-rrb-', 'and', 'hypercholesterolemia', 'or', 'primary', 'hypertension', '-lrb-', '6.10', 'pp', '-rrb-', 'had', 'the', 'largest', 'increase', '.']\n",
      "['the', 'relative', 'benefit', 'of', 'higher', 'statin', 'dosing', 'in', 'patients', 'with', 'peripheral', 'artery', 'disease', 'has', 'not', 'been', 'reported', 'previously', '.']\n",
      "['contrary', 'to', 'our', 'initial', 'hypothesis', ',', 'there', 'was', 'a', 'trend', 'toward', 'longer', '-lrb-', 'rather', 'than', 'shorter', '-rrb-', 'aa', 'duration', 'in', 'statin', 'users', 'in', 'the', 'entire', 'dfci', 'cohort', 'and', 'in', 'the', 'enzalutamide', '-', 'and', 'docetaxel-na\\xc3\\xafve', 'jhu', 'patients', '.']\n",
      "['proprotein', 'convertase', 'subtilisin/kexin', 'type', '9', '-lrb-', 'pcsk9', '-rrb-', 'and', 'the', 'identification', 'of', 'its', 'critical', 'role', 'in', 'lipoprotein', 'metabolism', 'has', 'rapidly', 'led', 'to', 'the', 'development', 'of', 'pcsk9', 'inhibition', 'with', 'monoclonal', 'antibodies', '-lrb-', 'mabs', '-rrb-', '.']\n",
      "['twenty', 'new', 'zealand', 'white', 'rabbits', 'were', 'divided', 'into', '2', 'study', 'groups', ',', 'with', '6', 'rabbits', 'receiving', '10', '\\xce\\xbcm', 'pravastatin', 'intradermally', 'at', 'postoperative', 'days', '15', ',', '18', ',', 'and', '21', ',', 'and', '14', 'rabbits', 'receiving', '0.4', '%', ',', '2', '%', ',', 'and', '10', '%', 'simvastatin', 'topical', 'application', 'at', 'postoperative', 'days', '14-25', '.']\n",
      "['coronary', 'artery', 'calcium', 'was', 'positively', 'associated', 'with', 'total', 'and', 'small', 'vldl', 'particles', '-lrb-', 'p', '\\xe2\\x89\\xa4', '0.02', '-rrb-', ',', 'statin', 'dose', '-lrb-', 'p', '', '0.02', '-rrb-', ',', 'and', 'urine', 'albumin-to-creatinine', 'ratio', '-lrb-', 'p', '', '0.04', '-rrb-', ';', 'and', 'negatively', 'associated', 'with', 'free', 'fatty', 'acids', '-lrb-', 'p', '', '0.03', '-rrb-', ',', 'total', 'hdl', '-lrb-', 'p', '', '0.03', '-rrb-', ',', 'large', 'hdl', 'particles', '-lrb-', 'p', '', '0.005', '-rrb-', ',', 'and', 'tacrolimus', 'dose', '-lrb-', 'p', '', '0.02', '-rrb-', '.']\n",
      "['in', 'mice', 'after', 'splenectomy', ',', 'pitavastatin-nps', 'still', 'decreased', 'the', 'number', 'of', 'monocytes/macrophages', 'in', 'the', 'infarcted', 'heart', 'and', 'inhibited', 'post-infarct', 'lv', 'remodeling.nanoparticle-mediated', 'delivery', 'of', 'pitavastatin', 'to', 'monocytes/macrophages', 'may', 'be', 'a', 'novel', 'therapeutic', 'strategy', 'to', 'protect', 'the', 'heart', 'from', 'post-infarct', 'lv', 'remodeling', '.']\n",
      "['adjusted', 'cox', 'models', 'examined', 'cardiovascular', 'disease', 'risk', 'associated', 'with', 'lipoprotein', 'measures', 'according', 'to', 'treatment', 'allocation', '.']\n",
      "['current', 'statin', 'use', 'is', 'associated', 'with', 'reduced', 'concurrent', 'diagnosis', 'of', 'chronic', 'osteomyelitis', ',', 'particularly', 'for', 'a', 'cumulative', 'statin', 'use', '\\xe2\\x89\\xa5', '12', 'months', '.']\n",
      "['comparada', '\\xc3\\xa0', 'diretriz', 'norte-americana', ',', 'a', 'v', 'diretriz', 'brasileira', 'considera', 'uma', 'propor\\xc3\\xa7\\xc3\\xa3o', 'substancialmente', 'maior', 'da', 'popula\\xc3\\xa7\\xc3\\xa3o', 'como', 'eleg\\xc3\\xadvel', 'para', 'estatina', 'em', 'preven\\xc3\\xa7\\xc3\\xa3o', 'prim\\xc3\\xa1ria', '.']\n",
      "['the', 'primary', 'efficacy', 'end', 'point', 'was', 'vasospasm-related', 'delayed', 'ischemic', 'neurological', 'deficits', '-lrb-', 'dind', '-rrb-', ',', 'and', 'the', 'secondary', 'end', 'points', 'were', 'cerebral', 'vasospasm', 'evaluated', 'by', 'digital', 'subtraction', 'angiography', '-lrb-', 'dsa', '-rrb-', ',', 'vasospasm-related', 'new', 'cerebral', 'infarctions', ',', 'and', 'outcome', 'at', 'three', 'months', '.']\n",
      "['the', 'combo', 'ii', 'trial', 'compared', 'the', 'efficacy', 'and', 'safety', 'of', 'alirocumab', 'versus', 'ezetimibe', 'over', '2', 'years', '.']\n",
      "['statins', 'provided', 'minimal', 'benefit', ',', 'however', ',', 'and', 'cpg', 'recommendations', 'proved', 'irrelevant', 'in', 'reducing', 'ldl-c', 'and', 'chd', 'risk', 'in', 'this', 'population', 'of', 'air', 'force', 'aviators', '.']\n",
      "['reactive', 'species', 'production', 'in', 'circulating', 'wbcs', 'of', 'aaa', 'patients', 'and', 'the', 'effect', 'of', 'statins', 'on', 'their', 'production', 'was', 'investigated', '.']\n",
      "['adherence', 'to', 'the', '2013', 'acc/aha', 'guidelines', 'for', 'management', 'of', 'cholesterol', 'by', 'statin', 'therapy', 'in', 'high-risk', 'patients', '.']\n",
      "['a', 'total', 'of', '334,710', 'people', 'aged', '\\xe2\\x89\\xa5', '18', 'years', 'without', 'a', 'history', 'of', 'renal', 'disease', '-lrb-', 'cohort', '1', '-rrb-', 'and', '5,437', 'with', 'non-dialysis', 'dependent', 'chronic', 'kidney', 'disease', '-lrb-', 'cohort', '2', '-rrb-', 'who', 'initiated', 'simvastatin', 'therapy', 'between', '1', 'january', '2006', 'and', '31', 'december', '2013', 'were', 'identified', 'using', 'national', 'pharmaceutical', 'dispensing', 'and', 'hospital', 'discharge', 'data', '.']\n",
      "['he', 'underwent', 'coronary', 'artery', 'bypass', 'graft', '-lrb-', 'cabg', '-rrb-', 'surgery', 'which', 'was', 'uneventful', '.']\n",
      "['this', 'retrospective', 'cohort', 'study', 'included', '47,337', 'patients', 'without', 'diabetes', 'or', 'coronary', 'artery', 'disease', 'at', 'baseline', '-lrb-', 'age', '53', '\\xc2\\xb1', '13', 'years', ',', '48', '%', 'women', ',', '66', '%', 'white', '-rrb-', 'who', 'underwent', 'clinical', 'treadmill', 'stress', 'testing', 'within', 'the', 'henry', 'ford', 'health', 'system', 'from', 'january', '1', ',', '1991', ',', 'to', 'may', '31', ',', '2009', '.']\n",
      "['there', 'was', 'not', 'a', 'statistically', 'significant', 'difference', 'in', 'the', 'value', 'of', 'the', 'tg/hdl', 'ratio', 'between', 'both', 'groups', '.']\n",
      "['familial', 'hypercholesterolemia', '-lrb-', 'fh', '-rrb-', 'is', 'associated', 'with', 'premature', 'atherosclerotic', 'cardiovascular', 'disease', '-lrb-', 'ascvd', '-rrb-', '.']\n",
      "['statin', '-lrb-', 'simvastatin', '-rrb-', 'and', 'non-statin', '-lrb-', 'probucol', '-rrb-', 'cholesterol-lowering', 'agents', ',', 'and', 'a', 'mild-to-severe', 'alzheimer', \"'s\", 'disease', 'drug', '-lrb-', 'donepezil', '-rrb-', 'were', 'served', 'as', 'control', 'drugs', '.']\n",
      "['herein', ',', 'we', 'review', 'the', 'fundamental', 'concepts', 'that', 'surround', 'the', 'use', 'of', 'tracer', 'kinetics', ',', 'we', 'define', 'basic', 'terms', 'and', 'outline', 'guiding', 'principles', 'via', 'theoretical', 'and', 'experimental', 'problems', '.']\n",
      "['multiple', 'methodological', 'weaknesses', 'stymie', 'interpretation', 'of', 'this', 'percentage', ',', 'which', 'is', 'however', 'not', 'inconsistent', 'with', 'estimates', 'that', '5-20', '%', 'of', 'patients', 'taking', 'statins', 'will', 'experience', 'typical', 'side', 'effects', 'at', 'some', 'time', '.']\n",
      "['the', 'study', 'relies', 'on', 'a', 'quasi-experimental', 'design', 'and', 'uses', 'registry', 'data', 'on', 'statin', 'purchases', 'to', 'explore', 'discontinuation', 'and', 'treatment', 'duration', '.']\n",
      "['we', 'studied', '1014', 'statin-treated', 'adults', '-lrb-', '53.3', '%', 'female', ',', 'mean', '66.0', 'years', '-rrb-', 'free', 'of', 'clinical', 'ascvd', 'in', 'the', 'multi-ethnic', 'study', 'of', 'atherosclerosis', '.']\n",
      "['in', 'this', 'regard', ',', 'combined', 'statin-based', 'and', 'renin-angiotensin', 'system', '-lrb-', 'ras', '-rrb-', 'inhibitor', 'therapies', 'demonstrate', 'additive/synergistic', 'beneficial', 'effects', 'on', 'endothelial', 'dysfunction', ',', 'insulin', 'resistance', ',', 'and', 'other', 'metabolic', 'parameters', 'in', 'addition', 'to', 'lowering', 'both', 'cholesterol', 'levels', 'and', 'blood', 'pressure', '.']\n",
      "['pitavastatin', ',', 'the', 'only', 'statin', 'with', 'this', 'profile', ',', 'has', 'not', 'undergone', 'clinical', 'evaluation', 'in', 'oncology', '.']\n",
      "['the', 'cohort', 'was', 'linked', 'to', 'the', 'national', 'prescription', 'database', 'for', 'information', 'on', 'the', 'use', 'of', 'statins', 'and', 'other', 'drugs', '.']\n",
      "['using', 'randomised', 'picking', 'method', ',', 'all', 'patients', 'were', 'randomly', 'assigned', 'to', 'one', 'of', 'two', 'groups', ',', 'nk', 'and', 'statin', '-lrb-', 'st', '-rrb-', 'group', '.']\n",
      "['to', 'evaluate', 'the', 'risk', 'of', 'prostate', 'cancer', 'death', 'among', 'statin', 'users', '.']\n",
      "['fairly', 'limited', 'data', 'reported', 'the', 'incidence', 'and', 'risk', 'of', 'cerebrovascular', 'accident', '-lrb-', 'cva', '-rrb-', 'in', 'autosomal', 'dominant', 'polycystic', 'kidney', 'disease', '-lrb-', 'adpkd', '-rrb-', '.']\n",
      "['statin', 'usage', 'among', 'rural', 'diabetics', 'aged', '\\xe2\\x89\\xa5', '40', 'years', 'increased', 'from', '7.7', '%', 'in', '2010-2012', 'to', '16.6', '%', 'in', '2016', '.']\n",
      "['pitavastatin-nps', 'inhibited', 'mobilization', 'of', 'monocytes', 'from', 'the', 'spleen', 'after', 'mi', '.']\n",
      "['another', '51', '-lrb-', '5', '%', '-rrb-', 'patients', 'were', 'statin', 'intolerant', ',', 'without', 'hefh', 'or', 'cvd', '.']\n",
      "['eighty-five', 'percent', 'of', 'women', 'and', '60', '%', 'of', 'men', 'who', 'were', 'eligible', 'for', 'statin', 'based', 'on', 'the', 'br-1', 'criterion', 'would', 'not', 'be', 'candidates', 'for', 'statin', 'based', 'on', 'the', 'usa-1', 'criterion', '.']\n",
      "['the', 'preferred', 'order', 'of', 'their', 'administration', 'in', 'combination', 'with', 'statins', 'in', 'different', 'categories', 'of', 'patients', 'is', 'also', 'presented', '.']\n",
      "['the', 'stratification', 'by', 'baseline', 'hdl-c', 'levels', 'revealed', 'that', 'only', 'pitavastatin', 'significantly', 'increased', 'hdl-c', 'levels', 'in', 'patients', 'with', 'baseline', 'hdl-c', '\\xe2\\x89\\xa4', '45', 'mg/dl', ',', 'while', 'no', 'changes', 'were', 'observed', 'in', 'patients', 'with', 'higher', 'baseline', 'hdl-c', 'levels', '.']\n",
      "['the', 'databases', 'that', 'were', 'included', 'pubmed', 'and', 'scopus', ',', 'with', 'articles', 'published', 'from', 'january', '2000', 'to', 'may', '2016', '.']\n",
      "['in', 'further', 'analysis', ',', 'the', 'adjusted', 'ors', 'of', 'chronic', 'osteomyelitis', 'were', '0.70', 'for', 'subjects', 'with', 'cumulative', 'statin', 'use', '<', '12', 'months', '-lrb-', '95', '%', 'ci', '0.47', ',', '1.07', '-rrb-', ',', 'and', '0.56', 'for', 'subjects', 'with', 'cumulative', 'statins', 'use', '\\xe2\\x89\\xa5', '12', 'months', '-lrb-', '95', '%', 'ci', '0.41', ',', '0.77', '-rrb-', ',', 'compared', 'with', 'those', 'with', 'no', 'prior', 'statin', 'use', '.']\n",
      "['associations', 'of', 'variants', 'in', 'smad3', ',', 'ipo11', ',', 'and', 'hsd17b13', ',', 'with', 'gene', 'expression', 'changes', 'in', 'mice', 'indicate', 'that', 'tgf-\\xc3\\x9f', 'and', 'nrf2', 'signaling', 'pathways', 'may', 'influence', 'fenofibrate', 'effects', 'on', 'dyslipidemia', 'in', 't2d', 'patients', '.']\n",
      "['statins', 'have', 'also', 'noncholesterol-related', 'effects', ',', 'called', 'pleiotropic', 'effects', ',', 'which', 'arise', 'from', 'statins', \"'\", 'anti-inflammatory', ',', 'immunomodulatory', 'and', 'antioxidant', 'properties', '.']\n",
      "['during', '7.5', 'years', 'of', 'follow-up', ',', 'we', 'identified', '7468', 'out', '-', 'or', 'inpatient', 'treated', 'cases', 'of', 'hip', 'or', 'knee', 'osteoarthritis', '.']\n",
      "['statins', 'have', 'clinical', 'benefits', 'on', 'morbidity', 'and', 'mortality', 'in', 'diabetic', 'patients', 'which', 'are', 'attributed', 'to', 'their', '``', 'pleiotropic', \"''\", 'effects', '.']\n",
      "['in', 'conclusion', ',', 'increased', 'gdf-15', 'plasma', 'concentrations', 'at', 'the', 'time', 'of', 'pci', 'and', 'stent', 'implantation', 'might', 'classify', 'high-risk', 'patients', 'with', 'acs', 'who', 'benefit', 'from', 'high-dose', ',', 'highly', 'efficient', 'statins', '.']\n",
      "['of', 'these', '753', 'patients', ',', '53.5', '%', 'had', 'atherosclerotic', 'cardiovascular', 'diseases', ';', '29.2', '%', 'had', 'diabetes', ';', '0.9', '%', 'had', 'an', 'ldl-c', 'level', '>', '190', 'mg/dl', ';', '10.8', '%', 'had', 'an', 'estimated', '10-year', 'risk', '>', '7.5', '%', ';', 'and', '4.9', '%', 'had', 'no', 'risk', '.']\n",
      "['despite', 'high-intensity', 'statin', '-lrb-', 'prescribed', 'in', '83', '%', 'and', 'combined', 'with', 'ezetimibe', 'in', '42', '%', '-rrb-', ',', 'attainment', 'of', 'ldl-c', 'treatment', 'goals', 'was', 'low', ',', 'and', 'associated', 'with', 'treatment', 'intensity', 'and', 'drug', 'adherence', '.']\n",
      "['seven', 'independent', 'support', 'vector', 'machine', '-lrb-', 'svm', '-rrb-', 'classifiers', 'with', 'seven', 'different', 'feature', 'subsets', 'were', 'trained', 'to', 'predict', 'high-risk', 'plaque', 'types', 'one', 'year', 'later', '.']\n",
      "['increasing', 'recent', 'evidence', 'suggests', 'the', 'possible', 'role', 'of', 'pretreatment', 'with', 'statins', 'in', 'preventing', 'or', 'decreasing', 'morbidity', 'and', 'mortality', 'from', 'infection', '.']\n",
      "['statins', 'work', 'best', 'for', 'secondary', 'cv', 'prevention', '.']\n",
      "['a', 'comprehensive', 'search', 'of', 'electronic', 'databases', ',', 'conference', 'abstracts', 'and', 'clinical', 'trial', 'registers', 'was', 'conducted', 'for', 'published', 'and', 'unpublished', 'results', '.']\n",
      "['similarly', ',', 'there', 'was', 'limited', 'adherence', 'to', 'guidelines', 'regarding', 'the', 'prescriptions', 'of', 'medications', 'for', 'those', 'with', 'established', 'hypertension', '-lrb-', '66', '%', ';', 'n', '', '51', ';', '95', '%', 'ci', '55-77', '%', '-rrb-', ',', 'body', 'mass', 'index', 'targets', 'met', '-lrb-', '40', '%', ';', 'n', '', '31', ';', '95', '%', 'ci', '29-52', '%', '-rrb-', ',', 'and', 'depression', 'screening', '-lrb-', '32', '%', ';', 'n', '', '25', ';', '95', '%', 'ci', '22-44', '%', '-rrb-', '.']\n",
      "['metabolic', 'dysregulation', 'drives', 'tumor', 'initiation', 'in', 'a', 'subset', 'of', 'glioblastomas', 'harboring', 'isocitrate', 'dehydrogenase', '-lrb-', 'idh', '-rrb-', 'mutations', ',', 'but', 'metabolic', 'alterations', 'in', 'glioblastomas', 'with', 'wildtype', 'idh', 'are', 'poorly', 'understood', '.']\n",
      "['at', 'baseline', ',', 'rdw', 'weakly', 'correlated', 'with', 'c-reactive', 'protein', '-lrb-', 'r', '', '0.196', '-rrb-', ',', 'd-dimer', '-lrb-', 'r', '', '0.214', '-rrb-', ',', 'fibrinogen', '-lrb-', 'r', '', '0.192', '-rrb-', ',', 'il-6', '-lrb-', 'r', '', '0.257', '-rrb-', ',', 'cd4', '+', 'dr', '+38', '+', 't', 'cells', '-lrb-', 'r', '', '0.195', '-rrb-', ',', 'and', 'cd4', '+', 'pd1', '+', 't', 'cells', '-lrb-', 'r', '', '0.227', '-rrb-', ',', 'all', 'p', '<', '0.05', '.']\n",
      "['hypercholesterolemia', 'and', 'hypertension', 'are', 'among', 'the', 'most', 'important', 'risk', 'factors', 'for', 'cardiovascular', '-lrb-', 'cv', '-rrb-', 'disease', '.']\n",
      "['at', 'entry', ',', '23', '-lrb-', '33', '%', '-rrb-', 'took', 'statins', 'and', '46', '-lrb-', '67', '%', '-rrb-', 'were', 'statin-intolerant', '.']\n",
      "['renin-angiotensin', 'system', 'inhibitors', 'improve', 'both', 'endothelial', 'dysfunction', 'and', 'insulin', 'resistance', 'in', 'addition', 'to', 'controlling', 'blood', 'pressure', '.']\n",
      "['studies', 'have', 'shown', 'that', 'high', 'breast', 'tumour', 'expression', 'of', 'the', 'statin', 'target', '-lrb-', '3-hydroxy-3-methylglutaryl', 'coenzyme-a', 'reductase', '-rrb-', 'is', 'associated', 'with', 'lymph-node', 'negative', 'cancer', '.']\n",
      "['chd', 'risk', 'was', 'minimally', 'reduced', 'for', 'all', 'participants', 'per', 'the', '2002', 'cpg', 'with', 'the', 'exception', 'of', 'cpg-recommended', 'statin', 'users', ',', 'for', 'whom', 'risk', 'increased', ';', 'chd', 'risk', 'decreased', 'for', 'cpg-recommended', 'statin', 'users', ',', 'but', 'increased', 'for', 'non-cpg-recommended', 'statin', 'users', 'per', 'the', '2013', 'cpg', '.']\n",
      "['a', 'decreasing', 'risk', 'trend', 'was', 'observed', 'by', 'increasing', 'intensity', 'of', 'usage', '-lrb-', 'doses/year', '-rrb-', '.']\n",
      "['all', 'participants', 'who', 'had', 'ldl-cholesterol', 'higher', 'than', '4.9', 'mmol/l', 'and', 'who', 'had', 'ldl-cholesterol', 'less', 'than', 'or', 'equal', 'to', '4.9', 'mmol/l', 'but', 'had', 'statin', 'therapy', 'were', 'examined', 'and', 'interviewed', 'by', 'experts', 'in', 'fh', '.']\n",
      "['four', 'or', '6', 'full-thickness', 'circular', 'dermal', 'punches', '7', 'mm', 'in', 'diameter', 'were', 'made', 'on', 'the', 'ventral', 'surface', 'of', 'the', 'ear', 'down', 'to', 'but', 'not', 'including', 'the', 'perichondrium', '.']\n",
      "['however', ',', 'the', 'exact', 'processes', 'leading', 'to', 'mitochondrial', 'dysfunction', 'are', 'not', 'yet', 'fully', 'understood', '.']\n",
      "['it', 'was', 'also', 'not', 'possible', 'to', 'determine', 'whether', 'patients', 'actually', 'took', 'the', 'statins', '.']\n",
      "['pcps', 'face', 'challenges', 'getting', 'their', 'patients', 'to', 're-initiate', 'statins', ',', 'particularly', 'after', 'a', 'patient', 'reports', 'side', 'effects', '.']\n",
      "['in', 'conclusion', ',', 'adpkd', 'was', 'associated', 'with', 'an', 'increased', 'risk', 'of', 'cva', 'occurrence', '.']\n",
      "['foram', 'estudados', '13.947', 'indiv\\xc3\\xadduos', '-lrb-', '48', '\\xc2\\xb1', '6', 'anos', ',', '71', '%', 'homens', '-rrb-', '.']\n",
      "['c57bl/6', 'mice', 'were', 'treated', 'over', '3', 'weeks', 'with', 'multiple', 'low', 'doses', 'of', 'doxorubicin', '-lrb-', '6', '\\xc3\\x97', '3', 'mg/kg', 'bw', ',', 'i.p.', '-rrb-', 'and', 'the', 'level', 'of', 'dna', 'damage', ',', 'apoptosis', 'and', 'regenerative', 'proliferation', 'as', 'well', 'as', 'pro-inflammatory', ',', 'pro-fibrotic', 'and', 'oxidative', 'stress', 'responses', 'were', 'investigated', '.']\n",
      "['treatment', 'duration', 'was', 'a', 'surrogate', 'for', 'ttp', '.']\n",
      "['data', 'were', 'collected', 'from', 'the', 'dyslipidemia', 'registry', 'of', 'the', 'spanish', 'arteriosclerosis', 'society', '.']\n",
      "['a', 'nationwide', 'case-control', 'study', 'is', 'conducted', 'based', 'on', 'data', 'taken', 'from', 'the', 'taiwan', 'national', 'health', 'insurance', 'program', '.']\n",
      "['pre-diagnostic', 'statin', 'use', 'was', 'not', 'associated', 'with', 'lymph', 'node', 'negative', 'status', 'at', 'diagnosis', '.']\n",
      "['these', 'review', 'article', 'presents', 'the', 'results', 'of', 'major', 'recent', 'studies', 'in', 'cardiovascular', 'prevention', '.']\n",
      "['the', 'median', 'gdf-15', 'plasma', 'concentration', 'was', '3.31', 'ng/ml', '.']\n",
      "['patients', 'with', 'a', 'presumed', 'adverse', 'reaction', 'to', 'a', 'statin', 'between', '2000', 'and', '2011', '.']\n",
      "['associations', 'between', 'statin', 'use', 'and', 'aa', 'duration', 'were', 'estimated', 'using', 'the', 'kaplan-meier', 'method', '.']\n",
      "['the', 'underlying', 'mechanisms', 'are', 'unclear', '.']\n",
      "['methods', 'we', 'included', '2,196', 'participants', '-lrb-', '50.5', '\\xc2\\xb1', '8.1', 'years', 'of', 'age', ';', '55', '%', 'female', '-rrb-', 'who', 'were', 'statin', 'na\\xc3\\xafve', 'and', 'free', 'of', 'cancer', 'at', 'baseline', 'from', 'the', 'offspring', 'and', 'third-generation', 'cohorts', 'of', 'the', 'community-based', 'longitudinal', 'framingham', 'heart', 'study', '.']\n",
      "['multivariable', 'mixed-effects', 'linear', 'regression', 'of', 'repeated', 'measures', 'was', 'used', 'to', 'quantify', 'calcium', 'change', ',', 'and', 'determine', 'if', 'this', 'change', 'was', 'longitudinally', 'associated', 'with', 'risk/protective', 'factors', '.']\n",
      "['studies', 'evaluating', 'genetic', 'predisposition', 'brought', 'new', 'evidence', 'that', 'both', 'ldl', 'cholesterol', 'and', 'systolic', 'blood', 'pressure', 'are', 'independent', 'and', 'multiplicative', 'causal', 'risk', 'factors', 'for', 'cardiovascular', 'events', '.']\n",
      "['identification', 'of', 'arterial', 'locations', 'likely', 'to', 'later', 'develop', 'such', 'high-risk', 'plaques', 'may', 'help', 'prevent', 'mace', '.']\n",
      "['in', 'aaa', 'patients', 'using', 'statins', ',', 'the', 'median', 'nitrotyrosine', 'level', 'in', 'neutrophils', 'was', '646', '-lrb-', 'range', '422-2059', '-rrb-', ',', 'in', 'lymphocytes', '125', '-lrb-', 'range', '74-343', '-rrb-', ',', 'and', 'in', 'monocytes', '586', '-lrb-', 'range', '291-663', '-rrb-', '.']\n",
      "['all', 'rights', 'reserved', '.']\n",
      "['statin', 'adherence', 'and', 'ldl-c', '<', '100', 'mg/dl', 'were', 'associated', 'in', 'all', 'elderly', 'age', 'groups', '-lrb-', 'e.g.', ',', '\\xe2\\x89\\xa5', '85', ':', 'rr', '1.13', '-lsb-', '1.09', ',', '1.16', '-rsb-', '-rrb-', 'and', 'comorbidity', 'levels', '-lrb-', 'e.g.', ',', '\\xe2\\x89\\xa5', '4', ':', 'rr', '1.13', '-lsb-', '1.12', ',', '1.15', '-rsb-', '-rrb-', '.']\n",
      "['reports', 'have', 'highlighted', 'the', 'underutilization', 'of', 'statins', 'in', 'clinical', 'practice', 'and', 'the', 'suboptimal', 'adherence', 'to', 'guideline', 'recommendations', '.']\n",
      "['the', 'mechanism', 'of', 'efficacy', 'for', 'statin', 'treatment', 'through', 'interference', 'with', 'connective', 'tissue', 'growth', 'factor', 'mrna', 'expression', 'was', 'confirmed', '.']\n",
      "['the', 'majority', 'were', 'male', '-lrb-', '82.1', '%', '-rrb-', 'with', 'comorbidities', 'such', 'as', 'diabetes', 'mellitus', '-lrb-', '58.0', '%', '-rrb-', ',', 'hypertension', '-lrb-', '73.4', '%', '-rrb-', ',', 'and', 'coronary', 'artery', 'disease', '-lrb-', 'cad', ';', '55.3', '%', '-rrb-', '.']\n",
      "['adverse', 'events', 'did', 'not', 'differ', '-lrb-', 'p', '>', '0.05', '-rrb-', 'between', 'ali', '75', 'mg', 'and', 'ali-evo', '.']\n",
      "['conclusions', ':', 'our', 'findings', 'from', 'this', 'pioneer', 'clinical', 'study', 'suggests', 'that', 'daily', 'nk', 'supplementation', 'is', 'an', 'effective', 'way', 'to', 'manage', 'the', 'progression', 'of', 'atherosclerosis', 'and', 'potentially', 'may', 'be', 'a', 'better', 'alternative', 'to', 'statins', 'which', 'are', 'commonly', 'used', 'to', 'reduce', 'atherosclerosis', 'and', 'further', 'to', 'prevent', 'cardiovascular', 'attack', 'and', 'stroke', 'in', 'patients', '.']\n",
      "['on', 'ultrasound', 'evaluation', ',', '65', 'shoulders', '-lrb-', '75.5', '%', '-rrb-', 'had', 'no', 'retear', ',', '14', '-lrb-', '16.3', '%', '-rrb-', 'had', 'pt', ',', 'and', '7', '-lrb-', '8.1', '%', '-rrb-', 'had', 'ft.', 'there', 'was', 'no', 'significant', 'difference', 'in', 'retear', 'rate', 'by', 'age', ',', 'technique', ',', 'or', 'tissue', 'quality', '.']\n",
      "['the', 'recent', 'fourier', 'trial', 'demonstrated', 'that', 'evolocumab', 'further', 'reduces', 'cardiovascular', 'events', ',', 'but', 'not', 'mortality', ',', 'in', 'high-risk', 'patients', 'already', 'receiving', 'statin', 'therapy', '.']\n",
      "['approximately', 'one-third', 'of', 'patients', 'received', 'statin', 'therapy', 'at', 'an', 'inappropriate', 'intensity', 'according', 'to', 'the', 'guideline', 'recommendation', '.']\n",
      "['atorvastatin', 'was', 'used', 'in', '49.1', '%', 'of', 'the', 'experimental', 'group', 'cases', 'and', 'in', '66.7', '%', 'of', 'the', 'control', ',', 'and', 'it', 'showed', 'a', 'statistically', 'significant', 'difference', '-lrb-', 'p', '', '.007', '-rrb-', '.']\n",
      "['the', 'risk', 'of', 'adverse', 'events', 'is', 'small', 'compared', 'to', 'the', 'benefits', '.']\n",
      "['pcsk9', 'mabs', 'are', 'already', 'in', 'limited', 'clinical', 'use', 'and', 'are', 'the', 'subject', 'of', 'major', 'cardiovascular', 'outcomes', 'trials', ',', 'which', 'if', 'universally', 'positive', 'could', 'see', 'much', 'wider', 'clinical', 'application', 'of', 'these', 'agents', '.']\n",
      "['in', 'this', 'article', ',', 'we', 'review', 'important', 'studies', 'that', 'focused', 'on', 'the', 'impact', 'of', 'vitamin', 'd', 'on', 'blood', 'pressure', ',', 'myocardial', 'infarction', ',', 'peripheral', 'arterial', 'disease', ',', 'heart', 'failure', ',', 'and', 'statin', 'intolerance', '.']\n",
      "['women', 'with', 'stages', 'i-iii', 'breast', 'cancer', 'were', 'identified', 'from', 'the', 'national', 'cancer', 'registry', 'of', 'ireland', '-lrb-', 'n', '', '6314', '-rrb-', '.']\n",
      "['shared', 'risk', 'profiles', 'and', 'potential', 'benefits', 'of', 'statins', 'between', 'cancer', 'and', 'cardiovascular', 'outcomes', 'may', 'provide', 'a', 'unique', 'opportunity', 'to', 'improve', 'population', 'health', '.']\n",
      "['combined', 'raas', 'blockade', 'and', 'statin', 'therapy', 'effectively', 'reduces', 'the', 'risk', 'of', 'cva', 'in', 'adpkd', '.']\n",
      "['statins', 'are', 'safe', 'and', 'inexpensive', ',', 'and', 'may', 'synergize', 'with', 'novel', 'antiandrogen', 'agents', 'abiraterone', 'via', 'pharmacokinetic', 'interactions', 'and', 'decrease', 'substrate', 'availability', 'for', 'de', 'novo', 'androgen', 'biosynthesis', '.']\n",
      "['those', 'on', 'moderate', '-', 'or', 'high-intensity', 'statins', 'at', 'baseline', '-lrb-', 'compared', 'with', 'low', 'intensity', '-rrb-', 'had', '39', '%', 'lower', 'risks', 'and', 'those', 'who', 'increased', 'statin', 'intensity', '62', '%', 'lower', 'ascvd', 'event', 'risks', '-lrb-', 'p', '<', '.01', '-rrb-', '.']\n",
      "['several', 'studies', 'have', 'evaluated', 'the', 'association', 'between', 'statin', 'use', 'and', 'endometrial', 'cancer', 'risk', '.']\n",
      "['the', 'prevalence', 'of', 't2dm', 'was', 'lower', 'in', 'patients', 'with', 'hefh', 'compared', 'with', 'the', 'general', 'population', '-lrb-', '5.94', '%', 'vs', '9.44', '%', ';', 'or', ':', '0.606', ',', '95', '%', 'ci', '0.486-0', '.755', ',', 'p', '<', '0.001', '-rrb-', '.']\n",
      "['day-1', '-rrb-', '.']\n",
      "['extensive', 'reactive', 'oxygen', 'and', 'nitrogen', 'species', '-lrb-', 'also', 'reactive', 'species', '-rrb-', 'production', 'is', 'a', 'mechanism', 'involved', 'in', 'abdominal', 'aortic', 'aneurysm', '-lrb-', 'aaa', '-rrb-', 'development', '.']\n",
      "['in', 'this', 'study', ',', 'serum', 'hdl/chl', 'was', 'significantly', 'increased', 'in', 'group', '1', 'compared', 'to', 'group', '2', '-lrb-', 'p', '', '.02', '-rrb-', ',', 'and', 'time-statin', 'factor', 'in', 'relation', 'was', 'statistically', 'significant', '-lrb-', 'p', '', '.02', '-rrb-', '.']\n",
      "['patients', 'who', 'developed', 'aki', 'without', 'concurrent', 'serious', 'muscle', 'injury', 'during', 'follow-up', '-lrb-', 'cases', '-rrb-', 'were', 'ascertained', 'using', 'hospital', 'discharge', 'and', 'mortality', 'data', '-lrb-', 'n', '', '931', 'from', 'cohort', '1', ',', 'n', '', '160', 'from', 'cohort', '2', '-rrb-', '.']\n",
      "['after', 'adjustment', 'for', 'covariates', ',', 'a', 'higher', 'ec', 'was', 'associated', 'with', 'a', 'lower', 'risk', 'of', 'incident', 'diabetes', ',', 'irrespective', 'of', 'statin', 'use', '-lrb-', 'p-interaction', '', '0.15', '-rrb-', '.']\n",
      "['cancer', 'mortality', 'occurred', 'in', '34', '-lrb-', '4.2', '%', '-rrb-', 'of', 'the', '812', 'statin-eligible', 'participants', 'versus', 'five', '-lrb-', '0.4', '%', '-rrb-', 'of', 'the', '1,384', 'noneligible', 'participants', '-lrb-', 'sdhr', ',', '12.1', '-lsb-', '4.7', 'to', '31', '-rsb-', ';', 'p', '<', '.001', '-rrb-', '.']\n",
      "['the', 'genetic', 'risk', 'for', 'cad', 'is', 'related', 'to', 'the', 'number', 'of', 'genetic', 'risk', 'variants', 'present', 'and', 'can', 'be', 'expressed', 'as', 'a', 'genetic', 'risk', 'score', '-lrb-', 'grs', '-rrb-', ',', 'by', 'summing', 'the', 'product', 'of', 'the', 'number', 'of', 'high-risk', 'variants', 'inherited', 'by', 'each', 'individual', 'times', 'the', 'log', 'of', 'the', 'odds', 'ratio', '.']\n",
      "['adjusted', 'for', 'baseline', 'fmd', ',', 'hyperlipidemia', 'and', 'statin', 'use', ',', 'the', 'treatment', 'effect', 'on', 'change', 'in', 'fmd', 'favoured', 'prasugrel', 'by', 'an', 'absolute', '1.97', '%', '-lrb-', '95', '%', 'ci', '0.29', '%', 'to', '3.66', '%', ',', 'p', '', '0.023', '-rrb-', '.']\n",
      "['in', 'the', 'control', 'group', ',', 'participants', 'were', 'recommended', 'to', 'undertake', 'exercise', 'of', 'the', 'same', 'intensity', 'as', 'the', 'exercise', 'group', 'but', 'not', 'mandatorily', '.']\n",
      "['by', 'defining', 'a', '\\xce\\xb4', '-lrb-', '13', '-rrb-', 'c', 'threshold', 'value', 'of', '-28.3', '\\xe2\\x80\\xb0', 'for', 'monacolin', 'k', ',', 'addition', 'of', 'lovastatin', 'from', 'a', 'minimum', 'of', '10', '%', 'can', 'be', 'identified', '.']\n",
      "['given', '25', '-lrb-', 'oh', '-rrb-', 'd', 'is', 'modifiable', 'in', 'clinical', 'practice', ',', 'future', 'studies', 'should', 'consider', 'the', 'links', 'between', '25', '-lrb-', 'oh', '-rrb-', 'd', 'status', 'and', 'muscle', 'related', 'outcomes', '.']\n",
      "['the', 'proprotein', 'convertase', 'subtilisin/kexin', 'type', '9', 'inhibitor', 'alirocumab', 'has', 'been', 'shown', 'to', 'substantially', 'reduce', 'low-density', 'lipoprotein', 'cholesterol', '-lrb-', 'ldl-c', '-rrb-', '.']\n",
      "['he', 'was', 'discharged', 'on', 'antiplatelet', ',', 'beta', 'blocker', ',', 'nitrate', ',', 'and', 'statin', '.']\n",
      "['solvent', 'extracts', 'of', 'human', 'and', 'mouse', 'food', 'were', 'also', 'able', 'to', 'block', 'pitavastatin-induced', 'apoptosis', ',', 'suggesting', 'diet', 'might', 'influence', 'the', 'outcome', 'of', 'clinical', 'trials', '.']\n",
      "['expression', 'of', '84', 'inflammatory', 'genes', 'involved', 'in', 'neuroinflammation', 'was', 'also', 'quantitated', '.']\n",
      "['overall', 'agreement', 'was', 'primarily', 'driven', 'by', 'the', 'negative', 'proportion', 'of', 'specific', 'agreement', ';', 'positive', 'agreement', 'was', 'moderate', 'for', 'the', '2002', 'cpg', 'and', 'poor', 'for', 'the', '2013', 'cpg', '.']\n",
      "['statin', 'therapy', 'instead', 'of', 'anticoagulants', 'may', 'be', 'considered', 'in', 'patients', 'who', 'are', 'not', 'candidates', 'for', 'anticoagulant', 'therapy', 'and', 'in', 'some', 'low', 'vte', 'risk', 'patients', '.']\n",
      "['the', 'results', 'showed', 'that', 'adpkd', 'group', 'had', 'significantly', 'higher', 'frequency', 'rate', 'and', 'cumulative', 'incidence', 'of', 'cva', 'as', 'compared', 'with', 'the', 'non-adpkd', 'group', '-lrb-', '8.73', '%', 'v.s.', '3.93', '%', ',', 'p', '<', '0.0001', '-rrb-', '.']\n",
      "['a', 'significantly', 'greater', 'annualized', 'increase', 'in', 'cai', 'was', 'observed', 'in', 'warfarin-treated', 'compared', 'with', 'non-warfarin-treated', 'patients', '-lrb-', 'median', '0.03', ';', 'iqr', ':', '0.0', 'to', '0.08', 'vs.', 'median', '0.02', ';', 'iqr', ':', '0.0', 'to', '0.06', ';', 'p', '<', '0.001', '-rrb-', '.']\n",
      "['incident', 'statin', 'users', 'had', 'a', 'higher', 'level', 'of', 'discontinuation', 'and', 'a', 'larger', 'difference', 'in', 'discontinuation', 'between', '2007', 'and', '2008', '.']\n",
      "['statins', 'have', 'been', 'used', 'to', 'treat', 'hyperlipidemia', 'as', 'well', 'as', 'reduce', 'neuroinflammation', 'and', 'oxidative', 'stress', 'in', 'various', 'tissues', '.']\n",
      "['the', 'occurrence', 'of', 'these', 'adverse', 'events', 'during', 'statin', 'therapy', 'may', 'cause', 'discontinuation', 'of', 'treatment', ',', 'and', 'hence', 'the', 'impossibility', 'of', 'achieving', 'recommended', 'lipid', 'goals', '.']\n",
      "['minimal', 'change', '-lrb-', '0.39', 'mm', '-lrb-', '3', '-rrb-', '/', 'year', ',', 'p', '', '0.02', '-rrb-', 'occurred', 'in', 'coronary', 'artery', 'calcium', 'levels', 'pre', '-', 'to', 'post-transplant', '.']\n",
      "['2017', ';', '88', '-lrb-', '8', '-rrb-', ':752', '-759', '.']\n",
      "['rosuvastatin', 'reduced', 'ldl', 'measures', 'but', 'had', 'variable', 'effects', 'on', 'triglyceride', 'and', 'vldl', 'measures', '.']\n",
      "['pooled', 'analysis', 'based', 'on', 'time-to-event', 'analysis', 'of', 'four', 'population-based', 'large', 'cohorts', ',', 'encompassing', 'in', 'total', '132', '607', 'persons', 'aged', '57', 'to', '91', 'years', 'resident', 'in', 'southern', 'and', 'central', 'sweden', '.']\n",
      "['phosphorylation', 'of', 'pi3k/akt', 'was', 'attenuated', 'in', 'atorvastatin', '+', 'ipc', '+', 'wortmannin', 'group', ',', 'phosphorylation', 'of', 'p42', 'mapk/erk', 'was', 'increased', 'in', 'atorvastatin', '+', 'ipc', 'and', 'atorvastatin', '+', 'ipc', '+', 'wortmannin', 'groups', '.']\n",
      "['potential', 'association', 'between', 'prior', 'statin', 'use', 'and', 'chronic', 'osteomyelitis', 'is', 'examined', '.']\n",
      "['as', 'a', 'proxy', 'for', 'reason', 'for', 'prescription', ',', 'data', 'on', 'filled', 'prescriptions', 'and', 'hospital', 'diagnoses', 'from', 'a', 'danish', 'registry', 'were', 'used', '.']\n",
      "['t2dm', 'prevalence', 'in', 'hefh', 'patients', 'was', 'compared', 'with', 'data', 'of', 'the', 'general', 'population', '.']\n",
      "['the', 'present', 'study', 'is', 'the', 'first', 'to', 'prove', 'the', 'definite', ',', 'statin-induced', 'amelioration', 'of', 'cerebral', 'vasospasm', 'on', 'dsa', '.']\n",
      "['pcps', 'answered', 'questions', 'about', 'statin', 'side', 'effects', ',', 'reasons', 'their', 'patients', 'reported', 'for', 'discontinuing', 'statins', ',', 'how', 'they', 'respond', 'when', 'discontinuation', 'is', 'reported', ',', 'and', 'barriers', 'they', 'encounter', 'in', 'getting', 'their', 'patients', 'to', 're-initiate', 'statin', 'therapy', '.']\n",
      "['white', 'blood', 'cells', '-lrb-', 'wbcs', '-rrb-', 'are', 'a', 'known', 'source', 'of', 'reactive', 'species', '.']\n",
      "['however', ',', 'there', 'have', 'been', 'adverse', 'effects', ',', 'such', 'as', 'myalgia', ',', 'myopathy', ',', 'myonecrosis', ',', 'not', 'to', 'mention', 'the', 'falls', 'as', 'a', 'result', 'of', 'muscle', 'damage', 'with', 'statin', 'use', '.']\n",
      "['there', 'was', 'good', 'adherence', 'to', 'guidelines', 'with', 'regards', 'to', 'anti-platelet', '-lrb-', '84', '%', ';', 'n', '', '65', ';', '95', '%', 'confidence', 'interval', '-lrb-', 'ci', '-rrb-', '74-92', '%', '-rrb-', 'and', 'statin', 'therapy', '-lrb-', '97', '%', ';', 'n', '', '75', ';', '95', '%', 'ci', '91-100', '%', '-rrb-', ',', 'despite', 'a', 'failure', 'to', 'meet', 'cholesterol', 'targets', ',', 'with', 'only', '31', '%', '-lrb-', 'n', '', '24', ';', '95', '%', 'ci', '21-42', '%', '-rrb-', 'of', 'the', 'cohort', 'meeting', 'low-density', 'lipoprotein', 'target', 'values', '.']\n",
      "['this', 'ratio', 'showed', 'a', 'statically', 'significant', 'elevation', '-lrb-', 'p', '', '.04', '-rrb-', '.']\n",
      "['atorvastatin', 'was', 'administered', 'orally', '12', 'hours', 'before', 'myocardial', 'reperfusion', '.']\n",
      "['in', 'patients', 'with', 'peripheral', 'artery', 'disease', 'who', 'were', 'referred', 'for', 'peripheral', 'angiography', 'or', 'endovascular', 'intervention', ',', 'hi', 'statin', 'therapy', 'was', 'associated', 'with', 'improved', 'survival', 'and', 'fewer', 'major', 'adverse', 'cardiovascular', 'events', 'compared', 'with', 'lmi', 'statin', 'therapy', '.']\n",
      "['if', 'we', 'want', 'to', 'favorably', 'influence', 'the', 'cardiovascular', 'atherosclerotic', 'disease', ',', 'it', 'is', 'necessary', 'to', 'significantly', 'lower', 'ldl-c', 'blood', 'levels', '.']\n",
      "['as', 'a', 'result', ',', 'hfcd-fed', 'rats', 'exhibited', 'hypercholesterolaemia', ',', 'accompanied', 'by', 'memory', 'deficit', ',', 'increment', 'of', 'lipid', 'peroxidation', 'and', 'soluble', 'a\\xce\\xb2', 'levels', ',', 'decrement', 'of', 'total', 'antioxidant', 'status', 'and', 'down-regulation', 'of', 'antioxidants', 'genes', 'expression', 'levels', '.']\n",
      "['to', 'expand', 'on', 'this', ',', 'one', 'could', 'argue', 'that', 'virtually', 'all', 'pharmacological', 'interventions', 'attempt', 'to', 'influence', 'the', 'flow', 'of', 'traffic', 'in', 'a', 'biochemical', 'network', ',', 'irrespective', 'of', 'disease', 'or', 'modality', '.']\n",
      "['topical', 'simvastatin', 'significantly', 'reduces', 'scar', 'formation', '.']\n",
      "['atorvastatin', 'changed', 'the', 'rna', 'expression', 'of', '9', 'genes', 'in', 'the', '\\xce\\xb2-adrenergic', 'pathway', 'and', 'corrected', 'the', 'protein', 'expression', 'of', '\\xce\\xb21-adrenoceptor', 'and', '\\xce\\xb21', '/', '\\xce\\xb23-adrenoceptor', 'ratio', ',', 'and', 'multidrug', 'resistance', 'protein', '4', '-lrb-', 'mrp4', '-rrb-', '.']\n",
      "['this', 'is', 'mediated', 'by', 'both', 'separate', 'and', 'interrelated', 'mechanisms', '.']\n",
      "['pitavastatin-induced', 'apoptosis', 'was', 'blocked', 'by', 'geranylgeraniol', 'and', 'mevalonate', ',', 'products', 'of', 'the', 'hmgcr', 'pathway', ',', 'confirming', 'that', 'pitavastatin', 'causes', 'cell', 'death', 'through', 'inhibition', 'of', 'hmgcr', '.']\n",
      "['the', 'mean', 'patient', 'age', 'was', '68.3', '\\xc2\\xb1', '9.4', 'years', '.']\n",
      "['low', 'high', 'density', 'lipoprotein', 'cholesterol', '-lrb-', 'hdl-c', '-rrb-', 'levels', 'represent', 'an', 'independent', 'risk', 'factor', 'for', 'cardiovascular', 'disease', ';', 'in', 'addition', 'to', 'the', 'reduced', 'hdl-c', 'levels', 'commonly', 'observed', 'in', 'patients', 'at', 'cardiovascular', 'risk', ',', 'the', 'presence', 'of', 'dysfunctional', 'hdl', ',', 'i.e.', 'hdl', 'with', 'reduced', 'atheroprotective', 'properties', ',', 'has', 'been', 'reported', '.']\n",
      "['there', 'is', 'a', 'dose', 'response', 'in', 'scar', 'reduction', 'with', 'low', '-', ',', 'medium', '-', 'and', 'high-dose', 'simvastatin', 'topical', 'treatment', '.']\n",
      "['milder', 'disease', 'is', 'common', 'and', 'the', 'more', 'serious', 'form', ',', 'rhabdomyolysis', 'is', 'far', 'rarer', 'with', 'an', 'incidence', 'of', 'approximately', '1', 'in', '10,000', '.']\n",
      "['a', 'maioria', 'dos', 'indiv\\xc3\\xadduos', 'de', 'risco', 'intermedi\\xc3\\xa1rio', 'ou', 'alto', 'pela', 'v', 'diretriz', 'apresentou', 'risco', 'calculado', 'pelas', 'pce', 'baixo', 'e', 'mais', 'de', '70', '%', 'daqueles', 'considerados', 'de', 'alto', 'risco', 'o', 'foram', 'devido', '\\xc3\\xa0', 'presen\\xc3\\xa7a', 'de', 'fator', 'agravante', '.']\n",
      "['markers', 'of', 'myalgia', '-lrb-', 'intrusive', 'body', 'pain', '-rrb-', 'and', 'myopathy', '-lrb-', 'self-reported', 'and', 'performance-based', 'measures', '-rrb-', 'were', 'examined', 'in', '734', 'men', 'and', '822', 'women', '-lrb-', 'mrc', 'national', 'survey', 'of', 'health', 'and', 'development', '-rrb-', '.']\n",
      "['left', 'ventricular', '-lrb-', 'lv', '-rrb-', 'remodeling', 'after', 'myocardial', 'infarction', '-lrb-', 'mi', '-rrb-', 'causes', 'heart', 'failure', '.']\n",
      "['associations', 'with', 'rdw', 'were', 'estimated', 'using', 'linear', 'regression', 'and', 'linear', 'mixed', 'models', '.']\n",
      "['as', 'compared', 'to', 'the', 'north', 'american', 'guideline', ',', 'the', 'v', 'brazilian', 'guideline', 'considers', 'a', 'substantially', 'higher', 'proportion', 'of', 'the', 'population', 'as', 'eligible', 'for', 'statin', 'use', 'in', 'primary', 'prevention', '.']\n",
      "['mitochondrial', 'dysfunction', 'and', 'atrogin-1', 'activation', 'are', 'among', 'the', 'leading', 'possible', 'explanations', 'for', 'sams', '.']\n",
      "['despite', 'the', 'established', 'inverse', 'correlation', 'between', 'hdl-c', 'levels', 'and', 'cardiovascular', 'risk', ',', 'several', 'clinical', 'trials', 'with', 'hdl-c-increasing', 'drugs', '-lrb-', 'such', 'as', 'niacin', ',', 'cetp', 'inhibitors', 'or', 'fibrate', '-rrb-', 'failed', 'to', 'demonstrate', 'that', 'a', 'significant', 'rise', 'in', 'hdl-c', 'levels', 'translate', 'into', 'a', 'cardiovascular', 'benefit', '.']\n",
      "['os', 'respectivos', 'valores', 'para', 'os', 'homens', 'foram', '75', '%', ',', '58', '%', ',', '31', '%', 'e', '17', '%', '-lrb-', 'p', '<', '0,01', '-rrb-', '.']\n",
      "['this', 'effect', 'is', 'mediated', 'by', 'multiple', 'modifications', 'in', 'expression', 'of', 'proteins', 'in', 'the', '\\xce\\xb2-adrenergic', 'signaling', 'pathway', ',', 'particularly', 'through', 'the', 'nos', 'pathway', '.']\n",
      "['the', 'case', 'group', 'includes', '2,338', 'subjects', 'aged', '20-84', 'years', 'newly', 'diagnosed', 'for', 'chronic', 'osteomyelitis', 'from', '2000', 'to', '2013', ';', 'the', 'control', 'group', 'included', '2,338', 'randomly', 'selected', 'subjects', 'without', 'chronic', 'osteomyelitis', 'matched', 'for', 'sex', ',', 'age', ',', 'and', 'index', 'year', '.']\n",
      "['female', 'sex', ',', 'estimated', 'glomerular', 'filtration', 'rate', ',', 'procedural', 'time', ',', 'left', 'ventricular', 'end-diastolic', 'pressure', '-lrb-', 'lvedp', '-rrb-', 'and', 'fractional', 'flow', 'reserve', 'measurement', 'independently', 'predicted', 'any', 'pmn', ';', 'whereas', ',', 'only', 'lvedp', 'and', 'log-transformed', 'n-terminal', 'pro-brain', 'natriuretic', 'peptide', 'independently', 'predicted', 'major', 'pmn', '.']\n",
      "['two', 'hundred', 'eighty-four', 'consecutive', 'patients', ',', 'who', 'underwent', 'percutaneous', 'coronary', 'intervention', '-lrb-', 'pci', '-rrb-', 'for', 'acs', ',', 'were', 'included', 'in', 'a', 'prospective', 'registry', '.']\n",
      "['this', 'simulation', 'model', 'study', 'used', 'a', 'large', 'administrative', 'database', 'of', 'us', 'medical', 'and', 'pharmacy', 'claims', 'to', 'identify', 'a', 'cohort', 'of', '105', '269', 'patients', 'with', 'ascvd', 'enrolled', 'from', 'january', '1', ',', '2012', ',', 'through', 'december', '31', ',', '2013', ',', 'who', 'met', 'the', 'inclusion', 'criteria', '-lrb-', 'database', 'cohort', '-rrb-', '.']\n",
      "['after', 'propensity', 'score', 'adjustment', ',', 'the', 'results', 'remained', 'significant', '-lrb-', 'adjusted', 'hr', 'for', 'high-dose', 'statins', '', '0.148', ';', '95', '%', 'ci', ',', '0.045', 'to', '0.494', ';', 'p', '', '0.002', '-rrb-', '.']\n",
      "['demographics', 'including', 'age', '-lrb-', '68', '\\xc2\\xb1', '12', 'versus', '67', '\\xc2\\xb1', '10', 'years', ',', 'p', '', '0.25', '-rrb-', ',', 'smoking', 'history', '-lrb-', '76', '%', 'versus', '80', '%', ',', 'p', '', '0.42', '-rrb-', ',', 'diabetes', 'mellitus', '-lrb-', '54', '%', 'versus', '48', '%', ',', 'p', '', '0.17', '-rrb-', ',', 'and', 'hypertension', '-lrb-', '88', '%', 'versus', '89', '%', ',', 'p', '', '0.78', '-rrb-', 'were', 'similar', 'between', 'groups', '-lrb-', 'lmi', 'versus', 'hi', '-rrb-', '.']\n",
      "['the', 'experimental', 'results', 'showed', 'that', 'our', 'machine', 'learning', 'method', 'predicted', 'future', 'tcfa', 'with', 'correctness', 'of', '85.9', '%', ',', '81.7', '%', ',', 'and', '77.0', '%', '-lrb-', 'g-mean', '-rrb-', 'for', 'baseline', 'plaque', 'phenotypes', 'of', 'tcfa', ',', 'thick-cap', 'fibroatheroma', ',', 'and', 'non-fibroatheroma', ',', 'respectively', '.']\n",
      "['in', 'this', 'review', ',', 'we', 'aim', 'to', 'present', 'the', 'basic', 'mechanisms', 'for', 'each', 'class', 'of', 'commonly', 'used', 'non-insulin-based', 'glucose-lowering', 'drugs', 'and', 'to', 'discuss', 'the', 'effect', 'of', 'these', 'medications', 'on', 'cv', 'events', '.']\n",
      "['statin', 'use', 'is', 'not', 'associated', 'with', 'reduced', 'risk', 'of', 'consultation', 'or', 'surgery', 'for', 'osteoarthritis', 'of', 'the', 'hip', 'or', 'knee', '.']\n",
      "['the', 'median', 'rdw', 'for', 'the', 'cohort', 'was', '13.4', '%', '-lrb-', '12.9-14', '.0', '-rrb-', '.']\n",
      "['updated', 'guidelines', 'emphasize', 'targeted', 'reduction', 'of', 'overall', 'cv', 'risks', 'but', 'do', 'not', 'explicitly', 'incorporate', 'potential', 'adverse', 'metabolic', 'outcomes', 'that', 'also', 'influence', 'cv', 'health', '.']\n",
      "['in', 'the', 'ali-evo', 'group', '-lrb-', 'n', '', '40', '-rrb-', ',', 'median', 'ldlc', 'fell', 'from', '165', 'mg/dl', 'at', 'entry', 'to', '70', 'mg/dl', '-lrb-', 'median', '-', '59', '%', ',', 'p', '<', '.0001', '-rrb-', '.']\n",
      "['doxorubicin', 'induced', 'subacute', 'cardiotoxicity', 'which', 'was', 'reflected', 'on', 'the', 'level', 'of', 'residual', 'dna', 'damage', ',', 'frequency', 'of', 'apoptotic', 'and', 'mitotic', 'cells', 'as', 'well', 'as', 'elevated', 'mrna', 'expression', 'of', 'markers', 'of', 'heart', 'failure', ',', 'remodeling', 'and', 'mitochondrial', 'biogenesis', '.']\n",
      "['we', 'enrolled', 'statin-na\\xc3\\xafve', 'subjects', 'with', 'cad', '-lrb-', 'n', '', '31', '-rrb-', 'who', 'underwent', 'coronary', 'artery', 'bypass', 'surgery', 'and', 'control', 'subjects', '-lrb-', 'n', '', '116', '-rrb-', 'who', 'were', 'free', 'from', 'cad', 'as', 'evaluated', 'by', 'coronary', 'ct', 'angiography', '.']\n",
      "['after', 'adjusting', 'for', 'age', ',', 'gender', 'and', 'atherosclerotic', 'risk', 'factors', 'with', 'multivariate', 'analysis', ',', 'adpkd', 'independently', 'carried', '2.34', '-', 'and', '5.12-fold', 'risk', 'for', 'occurrence', 'of', 'cva', 'and', 'hemorrhagic', 'stroke', '-lrb-', '95', '%', 'ci', ':', '2.02-2', '.72', 'and', '4.01-6', '.54', '-rrb-', ',', 'respectively', '.']\n",
      "['prediagnostic', 'statin', 'use', 'was', 'not', 'associated', 'with', 'risk', 'of', 'prostate', 'cancer', 'death', '-lrb-', 'hr', '0.92', ';', '95', '%', 'confidence', 'interval', '0.75-1', '.12', '-rrb-', '.']\n",
      "['attempts', 'to', 'assure', 'proper', 'statin', 'prescribing', 'and', 'utilization', 'can', 'help', 'in', 'achieving', 'better', 'clinical', 'outcomes', 'of', 'statin', 'therapy', '.']\n",
      "['these', 'observations', 'suggest', 'that', ',', 'besides', 'its', 'high', 'ldl-c-lowering', 'effect', ',', 'pitavastatin', 'also', 'exhibits', 'a', 'significantly', 'higher', 'ability', 'to', 'increase', 'hdl-c', 'levels', 'and', 'may', 'also', 'positively', 'affect', 'the', 'quality', 'and', 'functionality', 'of', 'hdl', 'particles', '.']\n",
      "['the', 'study', 'determined', 'the', 'effect', 'of', 'thymoquinone', 'rich', 'fraction', '-lrb-', 'tqrf', '-rrb-', 'and', 'thymoquinone', '-lrb-', 'tq', '-rrb-', 'in', 'the', 'forms', 'of', 'nano', '-', 'and', 'conventional', 'emulsions', 'on', 'learning', 'and', 'memory', ',', 'lipid', 'peroxidation', ',', 'total', 'antioxidant', 'status', ',', 'antioxidants', 'genes', 'expression', 'and', 'soluble', '\\xce\\xb2-amyloid', '-lrb-', 'a\\xce\\xb2', '-rrb-', 'levels', 'in', 'rats', 'fed', 'with', 'a', 'high', 'fat-cholesterol', 'diet', '-lrb-', 'hfcd', '-rrb-', '.']\n",
      "['common', 'variants', 'in', 'smad3', 'and', 'ipo11', 'were', 'marginally', 'associated', 'with', 'lipid', 'changes', 'in', 'black', 'subjects', '-lrb-', 'p', '<', '5x10', '-lrb-', '-6', '-rrb-', '-rrb-', '.']\n",
      "['moreover', ',', 'eat', 'is', 'a', 'useful', 'marker', 'of', 'subacute', 'cardiotoxicity', 'caused', 'by', 'persisting', 'harmful', 'effects', 'of', 'doxorubicin', '.']\n",
      "['the', 'present', 'study', 'was', 'conducted', 'as', 'an', 'observational', 'retrospective', 'research', 'from', 'april', '2010', 'to', 'december', '2014', 'with', 'patients', 'over', '18', 'years', 'of', 'age', 'which', 'were', 'assigned', 'to', 'statins', 'or', 'control', 'groups', '.']\n",
      "['1732', 'patients', 'were', 'included', '.']\n",
      "['aaa', 'patients', 'treated', 'with', 'statins', 'had', 'a', 'lower', 'peroxynitrite', 'footprint', 'in', 'neutrophils', 'than', 'non-statin', 'users', '.']\n",
      "['under', 'the', '2014', 'nice', 'guidelines', ',', '11.8', 'million', '-lrb-', '37', '%', '-rrb-', 'adults', 'in', 'england', 'aged', '30-84', 'years', ',', 'including', 'almost', 'all', 'males', '>', '60', 'years', 'in', 'all', 'females', '>', '75', 'years', ',', 'require', 'statin', 'therapy', '.']\n",
      "['in', 'the', 'past', '2', 'decades', ',', 'numerous', 'experimental', 'and', 'observational', 'studies', 'have', 'highlighted', 'the', 'role', 'of', 'vitamin', 'd', 'in', 'immunity', ',', 'metabolic', 'syndrome', '-lrb-', 'obesity', 'and', 'diabetes', '-rrb-', ',', 'cancers', ',', 'renal', 'disease', ',', 'memory', ',', 'and', 'neurological', 'dysfunction', '.']\n",
      "['since', 'no', 'negative', 'drug-drug', 'interaction', 'is', 'known', 'and', 'statins', 'are', 'widely', 'used', 'and', 'inexpensive', ',', 'further', 'studies', 'assessing', 'the', 'use', 'of', 'abiraterone', 'plus', 'statins', 'are', 'warranted', '.']\n",
      "['myc', 'promotes', 'metabolic', 'reprogramming', 'in', 'cancer', ',', 'but', 'targeting', 'myc', 'has', 'proven', 'notoriously', 'challenging', '.']\n",
      "['we', 'reviewed', 'patients', 'with', 'symptomatic', 'peripheral', 'artery', 'disease', 'who', 'underwent', 'peripheral', 'angiography', 'and/or', 'endovascular', 'intervention', 'from', '2006', 'to', '2013', 'who', 'were', 'not', 'taking', 'other', 'lipid-lowering', 'medications', '.']\n",
      "['this', 'study', 'assessed', 'statin', 'use', 'among', 'diabetics', 'and', 'those', 'with', 'coronary', 'heart', 'disease', '-lrb-', 'chd', '-rrb-', 'in', 'vellore', ',', 'tamil', 'nadu', '.']\n",
      "['patients', 'with', 'heterozygous', 'familial', 'hypercholesterolemia', '-lrb-', 'hefh', '-rrb-', 'have', 'been', 'reported', 'to', 'be', 'less', 'vulnerable', 'to', 'type', '2', 'diabetes', 'mellitus', '-lrb-', 't2dm', '-rrb-', ',', 'although', 'the', 'mechanism', 'is', 'unknown', '.']\n",
      "['current', 'guidelines', 'on', 'the', 'treatment', 'of', 'blood', 'cholesterol', 'recommend', 'continuous', 'maintenance', 'of', 'high-intensity', 'statin', 'treatment', 'in', 'drug-eluting', 'stent', '-lrb-', 'des', '-rrb-', '-', 'treated', 'patients', '.']\n",
      "['in', 'a', 'multivariate', 'model', ',', 'warfarin', 'was', 'independently', 'associated', 'with', 'an', 'increasing', 'cai', '-lrb-', 'odds', 'ratio', ':', '1.16', ';', '95', '%', 'confidence', 'interval', ':', '1.05', 'to', '1.28', ';', 'p', '', '0.003', '-rrb-', '.']\n",
      "['the', 'combined', 'end', 'point', 'at', '3', 'months', 'after', 'pci', 'consisted', 'of', 'cardiovascular', 'death', ',', 'nonfatal', 'myocardial', 'infarction', ',', 'and', 'unstable', 'angina', '.']\n",
      "['btics', 'preferentially', 'express', 'mevalonate', 'pathway', 'enzymes', ',', 'which', 'we', 'find', 'regulated', 'by', 'novel', 'myc', 'binding', 'sites', ',', 'validating', 'an', 'additional', 'transcriptional', 'activation', 'role', 'of', 'myc', 'in', 'cancer', 'metabolism', '.']\n",
      "['the', 'primary', 'composite', 'outcome', 'was', 'time', 'to', 'a', 'cardiovascular', 'event', '-lrb-', 'myocardial', 'infarction', 'or', 'stroke', '-rrb-', 'or', 'death', '.']\n",
      "['pre-clinical', 'and', 'retrospective', 'studies', 'of', 'patients', 'using', 'statins', 'to', 'reduce', 'plasma', 'cholesterol', 'have', 'suggested', 'that', 'statins', 'may', 'be', 'useful', 'to', 'treat', 'cancer', '.']\n",
      "['statin', 'eligibility', 'was', 'determined', 'per', 'american', 'college', 'of', 'cardiology/american', 'heart', 'association', 'guidelines', ',', 'and', 'subclinical', 'coronary', 'atherosclerosis', 'was', 'assessed', 'by', 'computed', 'tomography', '.']\n",
      "['statins', 'are', 'used', 'for', 'the', 'primary', 'and', 'secondary', 'prevention', 'of', 'cardiovascular', 'disease', 'by', 'inhibiting', 'cholesterol', 'synthesis', 'in', 'the', 'liver', '.']\n",
      "['features', 'of', 'high-risk', 'coronary', 'artery', 'plaques', 'prone', 'to', 'major', 'adverse', 'cardiac', 'events', '-lrb-', 'mace', '-rrb-', 'were', 'identified', 'by', 'intravascular', 'ultrasound', '-lrb-', 'ivus', '-rrb-', 'virtual', 'histology', '-lrb-', 'vh', '-rrb-', '.']\n",
      "['the', 'statin', 'dose', 'tended', 'to', 'correlate', 'negatively', 'with', 'nitrotyrosine', 'in', 'neutrophils', '-lrb-', 'rs', '-0.32', ',', 'p', '', '.06', '-rrb-', '.']\n",
      "['the', 'incidence', 'of', 'mace', 'was', 'significantly', 'associated', 'with', 'major', 'pmn', '.']\n",
      "['cardiovascular', 'disease', '-lrb-', 'cvd', '-rrb-', 'accounts', 'for', '>', '17', 'million', 'deaths', 'globally', 'every', 'year', ',', 'and', 'this', 'figure', 'is', 'predicted', 'to', 'rise', 'to', '>', '23', 'million', 'by', '2030', '.']\n",
      "['cardiovascular', 'disease', '-lrb-', 'cvd', '-rrb-', 'is', 'a', 'leading', 'cause', 'of', 'morbidity', 'and', 'mortality', 'among', 't2dm', 'patients', '.']\n",
      "['968', 'patients', 'at', 'an', 'average', 'age', 'of', '60', 'have', 'reached', 'a', 'significant', 'decline', 'in', 'the', 'levels', 'of', 'serum', 'ldl-cholesterol', '-lrb-', 'from', '2.39', 'to', '0.95', 'mmol/l', '-rrb-', 'in', 'the', 'branch', 'of', 'the', 'combined', 'therapy', ',', 'which', 'led', 'to', 'a', 'considerable', 'reduction', 'of', 'percent', 'atheroma', 'volume', 'in', 'the', 'coronary', 'artery', 'by', '0.95', '%', '-lrb-', 'in', 'the', 'branch', 'of', 'the', 'statin-only', 'therapy', ',', 'the', 'percent', 'atheroma', 'volume', 'increased', 'by', '0.05', '%', '-rrb-', '.']\n",
      "['after', 'treatment', 'intensification', ',', '99.3', '%', 'could', 'achieve', 'an', 'ldl-c', 'level', 'of', 'less', 'than', '70', 'mg/dl', ',', 'including', '67.3', '%', 'with', 'statin', 'monotherapy', ',', '18.7', '%', 'with', 'statins', 'plus', 'ezetimibe', ',', 'and', '14', '%', 'with', 'add-on', 'pcsk9', 'inhibitor', '.']\n",
      "['all', 'three', 'statin', 'treatments', 'reduced', 'total', 'serum', 'cholesterol', '\\xe2\\x89\\xa5', '40', '%', 'in', 'mice', '.']\n",
      "['18', 'samples', 'of', 'red', 'yeast', 'rice', 'powder', 'and', '18', 'samples', 'of', 'lovastatin', 'were', 'collected', '.']\n",
      "['the', 'carotid', 'plaque', 'size', 'and', 'cca-imt', 'reduced', 'from', '-lrb-', '0.25', '\\xc2\\xb1', '0.12', '-rrb-', 'cm', '-lrb-', '2', '-rrb-', 'to', '-lrb-', '0.16', '\\xc2\\xb1', '0.10', '-rrb-', 'cm', '-lrb-', '2', '-rrb-', 'and', 'from', '-lrb-', '1.13', '\\xc2\\xb1', '0.12', '-rrb-', 'mm', 'to', '-lrb-', '1.01', '\\xc2\\xb1', '0.11', '-rrb-', 'mm', ',', 'repectively', '.']\n",
      "['data', 'were', 'collected', 'from', 'australian', 'general', 'practitioners', 'for', '77', 'hiv-infected', 'patients', 'with', 'a', 'median', 'age', 'of', '59', '-lrb-', 'range', '54-64', '-rrb-', '.']\n",
      "['this', 'study', 'demonstrates', 'a', 'significance', 'assessment', 'of', 'the', 'plasma', 'lipid', 'profiles', 'of', 'subjects', 'with', 'prostate', 'cancer', '.']\n",
      "['following', 'propensity-weighted', 'adjustment', 'for', 'clinical', 'trial', 'and', 'a', 'range', 'of', 'clinical', ',', 'ultrasonic', ',', 'and', 'laboratory', 'parameters', ',', 'there', 'was', 'no', 'significant', 'difference', 'in', 'the', 'annualized', 'change', 'in', 'pav', 'in', 'the', 'presence', 'and', 'absence', 'of', 'warfarin', 'treatment', '-lrb-', '0.33', '\\xc2\\xb1', '0.05', '%', 'vs.', '0.25', '\\xc2\\xb1', '0.05', '%', ';', 'p', '', '0.17', '-rrb-', '.']\n",
      "['evolocumab', 'is', 'a', 'fully', 'humanized', 'monoclonal', 'antibody', 'that', 'inhibits', 'pcsk9', ',', 'an', 'enzyme', 'that', 'binds', 'to', 'ldl', 'receptors', 'and', 'prevents', 'them', 'from', 'recycling', 'to', 'the', 'hepatocyte', 'surface', '.']\n",
      "['to', 'determine', 'risk', 'factor', 'levels', 'required', 'to', 'exceed', 'the', 'risk', 'threshold', 'for', 'statin', 'therapy', ',', 'and', 'to', 'estimate', 'the', 'number', 'of', 'adults', 'in', 'england', 'who', 'would', 'require', 'statin', 'therapy', 'under', 'the', 'guidelines', '.']\n",
      "['nearly', 'half', '-lrb-', '41', '%', 'and', '45', '%', '-rrb-', 'were', 'statin', 'users', '.']\n",
      "['statins', 'have', 'become', 'the', 'cornerstone', 'of', 'the', 'management', 'of', 'dyslipidaemia', '.']\n",
      "['islet', 'transplant', 'may', 'stabilize', 'coronary', 'artery', 'calcium', ',', 'with', 'optimal', 'management', 'of', 'lipids', 'and', 'kidney', 'function', 'remaining', 'key', 'therapeutic', 'targets', '.']\n",
      "['the', 'mesh', 'terms', 'used', 'for', 'the', 'search', 'were', '``', 'falls', \"''\", 'and', '``', 'statin', \"''\", '.']\n",
      "['individuals', 'with', 'type', '2', 'diabetes', '-lrb-', 't2d', '-rrb-', 'and', 'dyslipidemia', 'are', 'at', 'an', 'increased', 'risk', 'of', 'cardiovascular', 'disease', '.']\n",
      "['to', 'determine', 'whether', 'statin', 'use', 'affects', 'survival', 'in', 'patients', 'with', 'metastatic', 'castration-resistant', 'prostate', 'cancer', '-lrb-', 'mcrpc', '-rrb-', 'treated', 'with', 'abiraterone', '.']\n",
      "['the', 'change', 'in', 'discontinuation', 'varied', 'with', 'the', 'indication', 'for', 'statin', 'use', '.']\n",
      "['overall', 'safety', 'was', 'similar', 'in', 'both', 'treatment', 'groups', 'at', '2', 'years', 'and', 'during', 'the', 'first', 'versus', 'the', 'second', 'year', '.']\n",
      "['meanwhile', ',', 'tq', 'was', 'acquired', 'commercially', 'and', 'prepared', 'into', 'thymoquinone', 'nanoemulsion', '-lrb-', 'tqne', '-rrb-', '.']\n",
      "['in', 'healthy', 'individuals', 'in', 'primary', 'prevention', ':', 'to', 'assess', 'the', 'relationship', 'between', 'cardiovascular', 'risk', 'categorized', 'according', 'to', 'the', 'v', 'brazilian', 'guideline', 'on', 'dyslipidemia', 'and', 'the', 'risk', 'calculated', 'by', 'the', 'pooled', 'cohort', 'equations', '-lrb-', 'pce', '-rrb-', ';', 'to', 'compare', 'the', 'proportion', 'of', 'individuals', 'eligible', 'for', 'statins', ',', 'according', 'to', 'different', 'criteria', '.']\n",
      "['the', 'hdl/chl', ',', 'ldl/chl', ',', 'and', 'tg/hdl', 'ratios', 'were', 'used', 'for', 'better', 'fit', 'and', 'comparison', '.']\n",
      "['relative', 'to', 'current', 'use', 'of', '20mg', 'simvastatin', 'daily', ',', 'the', 'adjusted', 'odds', 'ratios', 'and', '95', '%', 'confidence', 'intervals', '-lrb-', '95', '%', 'ci', '-rrb-', 'in', 'cohort', '1', 'for', 'current', 'use', 'of', '40mg', 'and', '80mg', 'were', '0.9', '-lrb-', '95', '%', 'ci', '0.7-1', '.2', '-rrb-', 'and', '1.3', '-lrb-', '95', '%', 'ci', '0.7-2', '.3', '-rrb-', ',', 'respectively', '.']\n",
      "['patients', 'treated', 'with', 'a', 'statin', 'plus', 'abiraterone', 'appeared', 'to', 'live', 'longer', 'than', 'those', 'treated', 'with', 'abiraterone', 'only', '.']\n",
      "['in', 'stratified', 'analyses', ',', 'these', 'findings', 'were', 'independent', 'of', 'any', 'individual', 'causative', 'risk', 'factor', 'such', 'as', 'body', 'mass', 'index', ',', 'age', ',', 'or', 'smoking', 'status', '.']\n",
      "['relative', 'risks', 'were', 'estimated', 'for', 'associations', 'between', 'pre-diagnostic', 'statin', 'use', 'and', 'lymph', 'node', 'status', '.']\n",
      "['the', 'glagov', 'study', 'is', 'a', 'multicentric', ',', 'double-blinded', 'and', 'placebo-controlled', 'study', 'which', 'during', 'a', '76-week', 'period', 'followed', 'an', 'impact', 'of', 'the', 'treatment', 'with', 'evolocumab', '-lrb-', 'pcsk9i', '-rrb-', 'together', 'with', 'statin', 'on', 'the', 'status', 'of', 'coronary', 'atherosclerosis', 'in', 'patients', 'with', 'ischemic', 'heart', 'disease', ',', 'and', 'in', 'comparison', 'with', 'the', 'statin', 'treatment', '.']\n",
      "['objective', ':', 'to', 'investigate', 'the', 'relationship', 'between', 'apob/a1', 'ratio', 'and', 'the', 'characteristics', 'of', 'tissue', 'components', 'of', 'their', 'left', 'main', 'coronary', 'artery', '-lrb-', 'lmca', '-rrb-', 'plaque', '.']\n",
      "['dysregulation', 'of', 'the', 'renin-angiotensin', 'system', 'is', 'an', 'important', 'pathophysiological', 'mechanism', 'linking', 'insulin', 'resistance', 'and', 'endothelial', 'dysfunction', 'to', 'atherogenesis', '.']\n",
      "['statins', 'have', 'proved', 'to', 'have', 'a', 'very', 'good', 'safety', 'profile', '.']\n",
      "['a', 'total', 'of', '4.3', '%', 'of', 'all', '25,700', 'mentions', 'of', 'statins', 'also', 'mentioned', 'typical', 'stain-related', 'side', 'effects', '.']\n",
      "['topical', 'application', 'has', 'many', 'advantages', 'over', 'intradermal', 'injection', '.']\n",
      "['absolute', 'and', 'percent', 'change', 'in', 'ldlc', 'was', 'independent', 'of', 'statin', 'use', '.']\n",
      "['residual', 'atherothrombotic', 'risk', 'remains', 'higher', 'in', 'patients', 'with', 'versus', 'without', 'diabetes', 'mellitus', '-lrb-', 'dm', '-rrb-', 'despite', 'statin', 'therapy', '.']\n",
      "['however', ',', 'when', 'the', 'animal', 'diet', 'was', 'supplemented', 'with', 'geranylgeraniol', ',', 'pitavastatin', 'failed', 'to', 'prevent', 'tumour', 'growth', '.']\n",
      "['however', ',', 'gliosis', 'and', 'prpres', 'deposition', 'were', 'similar', 'in', 'statin-treated', 'and', 'untreated', 'infected', 'mice', '.']\n",
      "['ldl-c', 'levels', 'marginally', 'decreased', 'for', 'all', 'participants', 'except', 'non-cpg-recommended', 'statin', 'users', 'per', 'the', '2002', 'cpg', '.']\n",
      "['the', 'risk', 'decrease', 'was', 'dose-dependent', 'and', 'observed', 'especially', 'among', 'patients', 'treated', 'with', 'hormone', 'therapy', '.']\n",
      "['the', 'mean', 'age', 'was', '64.2', '\\xc2\\xb1', '14.3', 'years', '.']\n",
      "['a', 'total', 'of', '2,647', 'patients', 'with', 'adpkd', 'were', 'selected', 'from', '1,000,000', 'general', 'population', 'after', 'excluding', 'patients', 'with', 'age', '<', '18', ',', 'renal', 'replacement', 'therapy', 'and', 'concomitant', 'diagnosis', 'of', 'cva', '.']\n",
      "['in', 'the', 'dfci', 'cohort', ',', 'there', 'was', 'a', 'trend', 'toward', 'longer', 'aa', 'duration', 'in', 'statin', 'users', ':', '14.2', 'versus', '9.2', 'months', '-lrb-', 'hr', '0.79', ',', '95', '%', 'ci', ':', '0.57-1', '.09', ',', 'p', '', '0.14', '-rrb-', '.']\n",
      "['still', ',', 'low', 'brain', 'concentrations', 'after', 'oral', 'drug', 'administration', 'hinder', 'the', 'clinical', 'application', 'of', 'statins', 'in', 'these', 'pathologies', '.']\n",
      "['moreover', ',', 'doxorubicin', 'caused', 'diastolic', 'dysfunction', 'as', 'reflected', 'by', 'increased', 'e-wave', 'acceleration', 'time', '-lrb-', 'eat', '-rrb-', ',', 'which', 'again', 'was', 'prevented', 'by', 'pharmacological', 'inhibition', 'of', 'rac1', '.']\n",
      "['therefore', ',', 'we', 'hypothesized', 'that', 'anti-inflammatory', 'therapy', 'by', 'nanoparticle-mediated', 'monocyte/macrophage-targeting', 'delivery', 'of', 'pitavastatin', 'may', 'protect', 'the', 'heart', 'from', 'post-infarct', 'lv', 'remodeling.male', 'c57bl/6', 'mice', 'were', 'subjected', 'to', 'permanent', 'coronary', 'ligation', 'and', 'pitavastatin-incorporating', 'nanoparticles', '-lrb-', 'pitavastatin-nps', '-rrb-', 'were', 'intravenously', 'injected', 'for', '3', 'to', '5', 'consecutive', 'days', '.']\n",
      "['there', 'was', 'evidence', 'that', 'residual', 'risk', 'prediction', 'during', 'statin', 'therapy', 'could', 'be', 'significantly', 'improved', 'through', 'the', 'inclusion', 'of', 'key', 'vldl', 'measures', '-lrb-', 'harrell', 'c-index', '0.780', 'versus', '0.712', ';', 'p', '<', '0.0001', '-rrb-', '.']\n",
      "['numerous', 'studies', 'have', 'explored', 'the', 'relationship', 'between', 'cholesterol', 'and', 'cvd', 'and', 'there', 'is', 'now', 'consensus', 'that', 'dyslipidaemia', 'is', 'a', 'causal', 'factor', 'in', 'the', 'pathogenesis', 'of', 'atherosclerosis', '.']\n",
      "['of', 'the', '1090', 'patients', ',', '140', '-lrb-', '13', '%', '-rrb-', 'had', 'hefh', 'by', 'clinical', 'diagnostic', 'criteria', 'and/or', 'cvd', 'with', 'ldlc', '>', '100', 'mg/dl', 'despite', '\\xe2\\x89\\xa5', '2', 'months', 'on', 'mtdllt', ',', 'meeting', 'fda', 'insurance', 'criteria', 'for', 'ali', 'or', 'evo', 'therapy', '.']\n",
      "['compared', 'to', '2007', ',', 'statin', 'discontinuation', 'among', 'prevalent', 'users', 'in', '2008', 'increased', 'by', '2.97', 'percentage', 'points', '-lrb-', 'pp', '-rrb-', '.']\n",
      "['the', 'article', 'provides', 'comments', 'on', '2016', 'american', 'college', 'of', 'cardiology', 'expert', 'consensus', 'decision', 'pathway', 'on', 'the', 'role', 'of', 'non-statin', 'therapies', 'for', 'ldl-cholesterol', 'lowering', 'in', 'the', 'management', 'of', 'atherosclerotic', 'cardiovascular', 'disease', 'risk', '.']\n",
      "['then', ',', 'each', 'pcp', 'independently', 'ranked', 'their', 'top', 'three', 'responses', 'to', 'each', 'question', '.']\n",
      "['the', 'purpose', 'of', 'this', 'study', 'is', 'to', 'conduct', 'a', 'systematic', 'review', 'to', 'assess', 'the', 'literature', 'on', 'the', 'association', 'between', 'statin', 'use', 'and', 'the', 'risk', 'of', 'falls', '.']\n",
      "['consecutive', 'adult', 'patients', 'discharged', 'with', 'a', 'prescription', 'for', 'any', 'of', 'the', 'statin', 'medications', 'group', 'between', '1', 'june', '2015', 'and', '31', 'december', '2015', '.']\n",
      "['aha', '10-year', 'calculated', 'cvd', 'risk', 'fell', 'from', '10.2', 'to', '5.5', '%', '-lrb-', 'median', '-', '28', '%', ',', 'p', '<', '.0001', '-rrb-', ',', 'and', 'by', 'the', 'nih', 'calculator', 'from', '14.2', 'to', '3.6', '%', '-lrb-', 'median', '-', '78', '%', ',', 'p', '<', '.0001', '-rrb-', '.']\n",
      "['this', 'observational', 'study', 'investigated', 'reactive', 'species', 'production', 'in', 'vivo', 'and', 'ex', 'vivo', 'in', 'circulating', 'wbcs', 'of', 'aaa', 'patients', ',', 'using', 'venous', 'blood', 'from', 'patients', 'prior', 'to', 'elective', 'aaa', 'repair', '-lrb-', 'n', '', '34', ';', '18', 'statin', 'users', '-rrb-', 'and', 'from', 'healthy', 'volunteers', '-lrb-', 'n', '', '10', '-rrb-', '.']\n",
      "['we', 'report', 'a', 'very', 'young', 'man', 'with', 'heterozygous', 'familial', 'hypercholesterolemia', '-lrb-', 'fh', '-rrb-', 'with', 'apoe', 'haplotype', 'and', 'a', 'significant', 'cardiac', 'family', 'history', 'who', 'underwent', 'cardiac', 'catheterization', 'for', 'intermittent', 'episodes', 'of', 'exertional', 'dyspnea', 'and', 'was', 'noted', 'to', 'have', 'a', 'severe', 'triple', 'vessel', 'coronary', 'artery', 'disease', '-lrb-', 'cad', '-rrb-', '.']\n",
      "['we', 'assessed', 'the', 'effects', 'of', 'statin', 'use', 'in', 'patients', 'with', 'advanced', 'prostate', 'cancer', 'receiving', 'abiraterone', '.']\n",
      "['mice', 'were', 'sensitized', 'and', 'challenged', 'with', 'ovalbumin', '-lrb-', 'ova', '-rrb-', 'to', 'establish', 'the', 'asthma', 'model', '.']\n",
      "['here', ',', 'we', 'review', 'current', 'advances', 'in', 'gene-environment', 'interactions', 'in', 'als', 'animal', 'models', '.']\n",
      "['on', 'routine', 'health', 'maintenance', 'evaluation', ',', 'he', 'had', 'no', 'cardiac', 'complaints', 'and', 'had', 'been', 'tolerating', 'well', 'his', 'activities', 'of', 'daily', 'living', '.']\n",
      "['we', 'examined', 'ascvd', 'event', 'rates', 'by', 'national', 'lipid', 'association', 'risk', 'groups', 'over', '11-year', 'follow-up', 'and', 'the', 'relation', 'of', 'standard', 'risk', 'factors', ',', 'biomarkers', ',', 'and', 'subclinical', 'atherosclerosis', 'measures', 'with', 'residual', 'ascvd', 'event', 'risk', '.']\n",
      "['for', 'predicting', 'pb', '\\xe2\\x89\\xa5', '70', '%', ',', 'correctness', 'was', '80.8', '%', 'for', 'baseline', 'pb', '\\xe2\\x89\\xa5', '70', '%', 'and', '85.6', '%', 'for', '50', '%', '\\xe2\\x89\\xa4', 'pb', '<', '70', '%', '.']\n",
      "['somehow', ',', 'tqrfne', 'was', 'more', 'prominent', 'than', 'those', 'intervention', 'groups', 'and', 'control', 'drugs', 'in', 'brain', 'biomarkers', 'concomitant', 'to', 'gene', 'and', 'protein', 'expression', 'levels', '.']\n",
      "['the', 'patients', 'with', 'a', 'high', 'apob/a1', 'ratio', 'had', 'alarger', 'fibrolipid', 'volume', 'and', 'a', 'smaller', 'fibrous', 'volume', 'compared', 'to', 'patients', 'with', 'a', 'low', 'apob/a1', 'ratio', '-lrb-', '17.5', '%', '\\xc2\\xb1', '1.2', '%', 'vs', '9.0', '%', '\\xc2\\xb1', '1.0', '%', ',', 'p', '', '0.03', 'and', '55.1', '%', '\\xc2\\xb1', '2.1', '%', 'vs', '63.9', '%', '\\xc2\\xb1', '1.8', '%', ',', 'p', '<', '0.01', '-rrb-', '.']\n",
      "['the', 'guideline', 'includes', '59', 'recommendations', 'covering', ':', '-lrb-', '1', '-rrb-', 'the', 'impact', 'of', 'new', 'anti-hyperglycemic', 'drugs', 'and', 'new', 'lipid', 'lowering', 'drugs', 'on', 'cardiovascular', 'risk', ';', '-lrb-', '2', '-rrb-', 'a', 'guide', 'to', 'statin', 'use', ',', 'including', 'new', 'definitions', 'of', 'ldl-cholesterol', 'and', 'in', 'non-hdl-cholesterol', 'targets', ';', '-lrb-', '3', '-rrb-', 'evaluation', 'of', 'silent', 'myocardial', 'ischemia', 'and', 'subclinical', 'atherosclerosis', 'in', 'patients', 'with', 'diabetes', ';', '-lrb-', '4', '-rrb-', 'hypertension', 'treatment', ';', 'and', '-lrb-', '5', '-rrb-', 'the', 'use', 'of', 'antiplatelet', 'therapy', '.']\n",
      "['large-scale', 'studies', 'with', 'a', 'clinically', 'important', 'outcome', 'are', 'needed', '.']\n",
      "['this', 'document', 'outlines', 'the', 'diagnostic', 'and', 'therapeutic', 'pathways', 'for', 'the', 'clinical', 'management', 'of', 'patients', 'with', 'hypercholesterolaemia', 'and', 'statin', 'intolerance', '.']\n",
      "['although', 'statins', 'are', 'reported', 'to', 'alleviate', 'anthracycline-induced', 'cardiotoxicity', 'in', 'vivo', ',', 'the', 'molecular', 'mechanisms', 'involved', 'remain', 'elusive', '.']\n",
      "['recent', 'meta-analyses', 'suggest', 'that', 'pre-diagnostic', 'statin', 'use', 'is', 'associated', 'with', 'reduced', 'breast', 'cancer-specific', 'mortality', '.']\n",
      "['using', 'multivariate', 'linear', 'regression', 'analysis', 'after', 'adjustment', 'for', 'the', 'above-mentioned', 'confounding', 'factors', ',', 'the', 'apob/a1', 'ratio', 'had', 'a', 'significantly', 'positive', 'correlation', 'with', 'fibrolipid', 'volume', '-lrb-', 'r', '', '0.445', ',', '\\xce\\xb2', '', '0.29', ',', 'p', '', '0.010', '-rrb-', 'and', 'had', 'a', 'negative', 'correlation', 'with', 'fibrous', 'volume', '-lrb-', 'r', '', '-0.567', ',', '\\xce\\xb2', '', '-0.32', ',', 'p', '', '0.011', '-rrb-', ',', 'suggesting', 'that', 'the', 'apob/a1', 'ratio', 'was', 'associated', 'with', 'the', 'vulnerability', 'of', 'the', 'lmca', 'plaque', '.']\n",
      "[':', 'purpose', ':', 'red', 'yeast', 'rice', '-lrb-', 'ryr', '-rrb-', 'supplementation', 'has', 'become', 'a', 'popular', 'alternative', 'to', 'statin', 'therapy', 'in', 'treating', 'hypercholesterolemia', '.']\n",
      "['more', 'directly', ',', 'high-dose', 'simvastatin', 'treatment', 'also', 'significantly', 'reduced', 'the', 'mrna', 'expression', 'of', 'collagen', '1a1', '.']\n",
      "['in', 'such', 'conditions', ',', 'the', 'ability', 'to', 'decrease', 'neuroinflammation', 'by', 'drug', 'therapy', 'may', 'influence', 'disease', 'progression', '.']\n",
      "['among', '909', 'patients', ',', '629', '-lrb-', '69', '%', '-rrb-', 'were', 'prescribed', 'statins', ',', 'and', '124', '-lrb-', '13.6', '%', '-rrb-', 'were', 'treated', 'with', 'hi', 'statin', 'therapy', '.']\n",
      "['accumulating', 'evidence', 'suggests', 'that', 'an', 'inflammatory', 'response', 'is', 'implicated', 'in', 'the', 'process', 'of', 'post-infarct', 'lv', 'remodeling', '.']\n",
      "['in', 'the', 'second', 'study', 'by', 'scott', 'et', 'al.', ',', 'there', 'was', 'an', 'increased', 'risk', 'of', 'falls', '-lrb-', 'p', '', '.029', '-rrb-', 'and', 'an', 'impairment', 'in', 'muscle', 'strength', 'and', 'quality', 'muscle', '-lrb-', 'p', '', '.033', 'and', 'p', '', '.046', ',', 'respectively', '-rrb-', '.']\n",
      "['statins', 'have', 'been', 'recently', 'proposed', 'as', 'adjuvants', 'in', 'the', 'treatment', 'of', 'sepsis', ',', 'but', 'its', 'effects', 'on', 'mortality', 'show', 'conflicting', 'results', 'worldwide', '.']\n",
      "['after', 'adjustment', 'for', 'clinical', 'parameters', ',', 'rdw', 'remained', 'positively', 'associated', 'with', 'cd4', '+38', '+', 'dr', '+', 'and', 'cd4', '+', 'pd1', '+', 't', 'cells', 'across', 'all', 'time', 'points', '-lrb-', 'p', '', '0.05', '-rrb-', '.']\n",
      "['statin', 'use', 'for', 'chd', 'was', 'below', '50', '%', 'although', 'higher', 'than', 'the', 'use', 'among', 'diabetics', ',', 'indicating', 'the', 'need', 'to', 'address', 'this', 'low', 'rate', 'of', 'usage', 'among', 'these', 'high-risk', 'groups', '.']\n",
      "['statin', 'use', 'among', '422', 'diabetics', 'aged', '\\xe2\\x89\\xa5', '40', 'years', 'with', 'low-density', 'lipoprotein', '\\xe2\\x89\\xa5', '70', 'mg/dl', 'was', '13.4', '%', 'in', 'urban', 'and', '7.6', '%', 'among', 'rural', '.']\n",
      "['areas', 'covered', ':', 'this', 'review', 'summarizes', 'the', 'available', 'epidemiological', 'and', 'interventional', 'evidence', 'on', 'the', 'role', 'of', 'statins', 'in', 'vte', 'prevention', ';', 'the', 'postulated', 'biologic', 'mechanisms', 'involved', ';', 'outlines', 'areas', 'of', 'outstanding', 'uncertainty', ';', 'and', 'the', 'implications', 'for', 'clinical', 'practice', '.']\n",
      "['we', 'conducted', 'a', 'search', 'of', 'four', 'electronic', 'databases-psycinfo', ',', 'cinahl', ',', 'pubmed', ',', 'and', 'scopus-using', 'the', 'terms', 'red', 'yeast', 'rice', 'and', 'cholesterol', '.']\n",
      "['relative', 'risk', 'of', 'chronic', 'osteomyelitis', 'associated', 'with', 'statin', 'use', 'was', 'measured', 'by', 'the', 'odds', 'ratio', '-lrb-', 'or', '-rrb-', 'with', '95', '%', 'confidence', 'interval', '-lrb-', 'ci', '-rrb-', 'using', 'the', 'conditional', 'logistic', 'regression', 'model', '.']\n",
      "['for', 'all', 'individuals', ',', 'the', 'demographic', ',', 'clinical', ',', 'and', 'laboratory', 'findings', 'were', 'registered', '.']\n",
      "['it', 'has', 'been', 'proved', 'that', 'statins', 'are', 'effective', 'for', 'primary', 'or', 'secondary', 'cvd', 'prophylaxis', '.']\n",
      "['micro-array', 'analysis', 'and', 'immunoblotting', 'were', 'performed', 'in', 'left', 'ventricular', 'homogenates', '.']\n",
      "['one', 'hundred', 'six', 'patients', '-lrb-', '74.6', '%', '-rrb-', 'of', 'the', 'high', 'gdf-15', 'group', 'and', '122', 'patients', '-lrb-', '85.9', '%', '-rrb-', 'of', 'the', 'low', 'gdf-15', 'group', 'received', 'high-dose', 'statins', '.']\n",
      "['basic', 'recommendations', 'include', 'blood', 'pressure', 'management', 'with', 'a', 'goal', 'of', '<', '140', 'mm', 'hg', 'systolic', 'pressure', ',', 'statin', 'therapy', 'in', 'all', 'patients', '\\xe2\\x89\\xa5', '40', 'years', 'of', 'age', 'with', 'diabetes', '-lrb-', 'moderate', 'intensity', 'for', 'all', ',', 'and', 'high', 'intensity', 'if', 'at', 'high', 'risk', 'of', 'cvd', 'events', '-rrb-', ',', 'and', 'aspirin', 'therapy', 'in', 'all', 'adults', 'at', 'increased', 'cv', 'risk', '-lrb-', '10-year', 'risk', 'of', 'cvd', 'events', '>', '10', '%', '-rrb-', '.']\n",
      "['there', 'was', 'a', 'significant', 'reduction', 'in', 'low', 'density', 'lipoprotein-cholesterol', '-lrb-', 'ldl-c', '-rrb-', ',', 'an', 'increase', 'in', 'cec', 'and', 'beneficial', 'changes', 'in', 'plaque', 'morphology', 'including', 'increase', 'in', 'fibrous', 'cap', 'thickness', 'and', 'decrease', 'in', 'the', 'prevalence', 'of', 'thin', 'cap', 'fibro-atheroma', 'by', 'optical', 'coherence', 'tomography', 'in', 'dm', 'and', 'non-dm', 'patients', '.']\n",
      "['inclisiran', 'is', 'a', 'promising', 'rna-based', 'therapy', 'that', 'promotes', 'the', 'degradation', 'of', 'pcsk9', 'mrna', 'transcripts', 'and', 'has', 'similar', 'efficacy', 'to', 'mabs', 'but', 'with', 'a', 'much', 'longer', 'duration', 'of', 'action', '.']\n",
      "['pcps', 'reported', 'statin', 're-challenge', 'as', 'their', 'most', 'common', 'response', 'when', 'a', 'patient', 'discontinues', 'statin', 'use', '-lrb-', '31', '%', 'of', 'available', 'votes', '-rrb-', '.']\n",
      "['persistent', 'anti-drug', 'antibody', 'responses', 'were', 'observed', 'in', '1.3', '%', '-lrb-', '6', 'of', '454', '-rrb-', 'of', 'alirocumab-treated', 'versus', '0.4', '%', '-lrb-', '1', 'of', '231', '-rrb-', 'of', 'ezetimibe-treated', 'patients', '.']\n",
      "['after', 'propensity', 'weighting', ',', 'hi', 'statin', 'therapy', 'was', 'associated', 'with', 'improved', 'survival', '-lrb-', 'hazard', 'ratio', 'for', 'mortality', ':', '0.52', ';', '95', '%', 'confidence', 'interval', ',', '0.33-0', '.81', ';', 'p', '', '0.004', '-rrb-', 'and', 'decreased', 'major', 'adverse', 'cardiovascular', 'events', '-lrb-', 'hazard', 'ratio', ':', '0.58', ';', '95', '%', 'confidence', 'interval', '0.37-0', '.92', ',', 'p', '', '0.02', '-rrb-', '.']\n",
      "['data', 'were', 'analyzed', 'from', 'december', '2015', 'to', 'may', '2017', '.']\n",
      "['in', 'the', 'ali', '75', 'mg', 'group', '-lrb-', 'n', '', '29', '-rrb-', ',', 'entry', 'ldlc', 'fell', 'from', '115', 'to', '68', 'mg/dl', '-lrb-', 'median', '-', '39', '%', ',', 'p', '<', '.0001', '-rrb-', '.']\n",
      "['conclusion', 'in', 'this', 'community-based', 'primary', 'prevention', 'cohort', ',', 'guideline-based', 'statin', 'eligibility', 'accurately', 'identified', 'patients', 'at', 'a', 'higher', 'risk', 'of', 'developing', 'cancer', 'and', 'cancer-related', 'mortality', '.']\n",
      "['venous', 'thromboembolism', '-lrb-', 'vte', '-rrb-', 'is', 'an', 'important', 'cause', 'of', 'preventable', 'morbidity', 'and', 'mortality', '.']\n",
      "['following', 'the', 'treatments', 'for', '26', 'weeks', ',', 'there', 'was', 'a', 'significant', 'reduction', 'in', 'cca-imt', 'and', 'carotid', 'plaque', 'size', 'in', 'both', 'groups', 'compared', 'with', 'the', 'baseline', 'before', 'treatment', '.']\n",
      "['we', 'hypothesized', 'that', 'a', 'long-acting', 'statin', 'would', 'be', 'more', 'effective', ',', 'due', 'to', 'a', 'longer', 'half-life', 'and', 'stronger', 'pleiotropic', 'effects', '.']\n",
      "['whether', 'cac', 'score', 'can', 'assist', 'in', 'guiding', 'the', 'decision', 'to', 'initiate', 'statin', 'treatment', 'for', 'primary', 'prevention', 'in', 'older', 'adults', 'requires', 'further', 'investigation', '.']\n",
      "['this', 'review', 'article', 'points', 'to', 'summarize', 'the', 'current', 'evidence', 'confirming', 'the', 'role', 'of', 'statins', 'in', 't2dm', 'patients', 'and', 'to', 'provide', 'an', 'overview', 'of', 'factors', 'that', 'may', 'affect', 'statins', \"'\", 'prescribing', 'patterns', 'and', 'compliance', 'in', 'clinical', 'practice', '.']\n",
      "['creatinine', 'levels', 'on', 'days', '3', 'and', '14', 'were', 'substantially', 'higher', 'in', 'statins', 'group', '-lrb-', '1.80', '\\xc2\\xb1', '1.39', 'vs.', '1.45', '\\xc2\\xb1', '1.47', 'mg/dl', '-rrb-', '-lrb-', 'p', '', '0.010', '-rrb-', 'and', '-lrb-', '1.42', '\\xc2\\xb1', '1.14', 'vs.', '1.09', '\\xc2\\xb1', '1.05', 'mg/dl', '-rrb-', '-lrb-', 'p', '', '0.009', '-rrb-', ',', 'respectively', '.']\n",
      "['in', 'contrast', ',', 'simvastatin', 'therapy', 'did', 'not', 'reduce', 'any', 'of', 'the', 'tested', 'genes', ',', 'but', 'did', 'slightly', 'increase', 'the', 'expression', 'of', 'ccl2', 'and', 'cxcl13', '.']\n",
      "['red', 'yeast', 'rice', '-lrb-', 'ryr', '-rrb-', 'is', 'a', 'dietary', 'supplement', 'obtained', 'from', 'rice', 'fermented', 'with', 'the', 'mould', 'monascus', 'purpureus', '.']\n",
      "['despite', 'statin', 'therapy', ',', 'age', '-', 'and', 'race-standardized', 'ascvd', 'rates', 'per', '1000', 'person-years', 'for', 'men', 'and', 'women', 'were', 'both', '4.9', 'for', 'low/moderate', 'risk', ',', '19.1', 'and', '14.2', 'for', 'high', 'risk', ',', 'and', '35.6', 'and', '26.7', 'for', 'very', 'high', 'risk', ',', 'respectively', '.']\n",
      "['to', 'examine', 'the', 'relationship', 'between', 'continuation', 'of', 'statin', 'therapy', '-lrb-', 'any', 'prescription', 'within', '12', 'months', 'after', 'an', 'adverse', 'reaction', '-rrb-', 'and', 'clinical', 'outcomes', '.']\n",
      "['this', 'result', 'is', 'attributable', ',', 'in', 'part', ',', 'to', 'the', 'young', 'age', 'of', 'the', 'study', 'cohort', 'and', 'the', 'short', 'follow-up', 'period.tvaryanas', 'ap', ',', 'mahaney', 'hj', ',', 'schroeder', 'vm', ',', 'maupin', 'gm', '.']\n",
      "['there', 'were', '33', 'patients', '-lrb-', '38.8', '%', '-rrb-', 'who', 'had', 'the', 'diagnosis', 'of', 'hl', ',', 'and', 'all', 'were', 'taking', 'a', 'statin', 'medication', '.']\n",
      "['a', 'prospective', 'trial', 'showed', 'individuals', 'with', 'high', 'grs', 'had', '91', '%', 'greater', 'risk', 'of', 'cardiac', 'events', ',', 'and', 'individuals', 'with', 'a', 'healthy', 'lifestyle', 'had', '46', '%', 'fewer', 'cardiac', 'events', 'than', 'an', 'unfavorable', 'lifestyle', '.']\n",
      "['under', 'the', 'nice', 'guidelines', ',', '11.8', 'million', 'males', 'and', 'females', '-lrb-', '37', '%', 'of', 'the', 'adults', 'aged', '30-84', 'years', '-rrb-', 'would', 'require', 'statin', 'therapy', ',', 'most', 'of', 'them', '-lrb-', '9.8', 'million', '-rrb-', 'for', 'primary', 'prevention', '.']\n"
     ]
    }
   ],
   "source": [
    "for k,v in co_occurrence_dict.iteritems():\n",
    "    print v"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 85,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('-lsb-', 'statin')  Very negative 2\n",
      "('-lsb-', 'statin')  Very negative 2\n",
      "('-lsb-', 'statin')  Negative 2\n",
      "('-lsb-', 'statin')  Negative 2\n"
     ]
    }
   ],
   "source": [
    "h = {('-lsb-', 'statin'): [' Very negative',\n",
    "              ' Very negative',\n",
    "              ' Negative',\n",
    "              ' Negative']}\n",
    "\n",
    "for k,v in h.iteritems():\n",
    "    for vv in v:\n",
    "        print k, vv, v.count(vv)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 118,
   "metadata": {
    "collapsed": false
   },
   "outputs": [],
   "source": [
    "sent_dict = defaultdict(list)\n",
    "words_dict = defaultdict(list)\n",
    "\n",
    "\n",
    "#Assuming these are the key words we are curious about.\n",
    "search_phrase = ['australian','statin']\n",
    "\n",
    "#Searching through the dictionary\n",
    "for k,v in co_occurrence_dict.iteritems():\n",
    "    for vv in v:\n",
    "        if \"statin\" in v:\n",
    "            words_dict[(vv, \"statin\")].append(k[0])\n",
    "\n",
    "for k, v in words_dict.iteritems():\n",
    "    for vv in set(v):\n",
    "        if \"-\" not in vv:\n",
    "            sent_dict[k].append({vv: v.count(vv)})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 120,
   "metadata": {
    "collapsed": false
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "('connective', 'statin') {' Negative': 1}\n",
      "('-rrb-', 'statin') {' Negative': 67}\n",
      "('-rrb-', 'statin') {' Very negative': 20}\n",
      "('0.029', 'statin') {' Negative': 1}\n",
      "('particles', 'statin') {' Negative': 2}\n",
      "('factor-15', 'statin') {' Negative': 1}\n",
      "('consensus', 'statin') {' Negative': 1}\n",
      "('hypertension', 'statin') {' Negative': 3}\n",
      "('change', 'statin') {' Negative': 3}\n",
      "('selected', 'statin') {' Negative': 1}\n",
      "('might', 'statin') {' Negative': 1}\n",
      "('v', 'statin') {' Negative': 1}\n",
      "('considered', 'statin') {' Negative': 3}\n",
      "('prediagnostic', 'statin') {' Negative': 1}\n",
      "('low-dose', 'statin') {' Negative': 1}\n",
      "('0.4', 'statin') {' Negative': 1}\n",
      "('guideline-based', 'statin') {' Negative': 1}\n",
      "('rural', 'statin') {' Negative': 1}\n",
      "('decreased', 'statin') {' Negative': 2}\n",
      "('maximal-tolerated', 'statin') {' Very negative': 1}\n",
      "('bodies', 'statin') {' Negative': 1}\n",
      "('men', 'statin') {' Negative': 1}\n",
      "('pitavastatin', 'statin') {' Negative': 1}\n",
      "('homologous', 'statin') {' Negative': 1}\n",
      "('patients', 'statin') {' Negative': 27}\n",
      "('patients', 'statin') {' Neutral': 2}\n",
      "('patients', 'statin') {' Very negative': 1}\n",
      "('outcomes', 'statin') {' Negative': 1}\n",
      "('necessary', 'statin') {' Negative': 1}\n",
      "('receiving', 'statin') {' Negative': 3}\n",
      "('dyslipidemia', 'statin') {' Negative': 1}\n",
      "('could', 'statin') {' Negative': 1}\n",
      "('pectoris', 'statin') {' Very negative': 1}\n",
      "('dying', 'statin') {' Neutral': 1}\n",
      "('unit', 'statin') {' Negative': 1}\n",
      "('diabetic', 'statin') {' Negative': 1}\n",
      "('rhabdomyolysis', 'statin') {' Very negative': 1}\n",
      "('endpoint', 'statin') {' Negative': 1}\n",
      "('as', 'statin') {' Negative': 6}\n",
      "('as', 'statin') {' Neutral': 1}\n",
      "('as', 'statin') {' Very negative': 1}\n",
      "('intensity', 'statin') {' Negative': 4}\n",
      "('.', 'statin') {' Positive': 2}\n",
      "('.', 'statin') {' Negative': 88}\n",
      "('.', 'statin') {' Neutral': 3}\n",
      "('.', 'statin') {' Very negative': 4}\n",
      "('50.5', 'statin') {' Negative': 1}\n",
      "('occurring', 'statin') {' Negative': 1}\n",
      "('7.5', 'statin') {' Negative': 1}\n",
      "('hdl-c', 'statin') {' Very negative': 1}\n",
      "('levels', 'statin') {' Negative': 5}\n",
      "('0.1', 'statin') {' Negative': 1}\n",
      "('received', 'statin') {' Negative': 2}\n",
      "('received', 'statin') {' Very negative': 1}\n",
      "('mg/dl', 'statin') {' Negative': 1}\n",
      "('henan', 'statin') {' Very negative': 1}\n",
      "('profile', 'statin') {' Negative': 1}\n",
      "('42', 'statin') {' Negative': 1}\n",
      "('least', 'statin') {' Negative': 1}\n",
      "('using', 'statin') {' Negative': 2}\n",
      "('ali', 'statin') {' Very negative': 2}\n",
      "('specific', 'statin') {' Negative': 1}\n",
      "('individuals', 'statin') {' Negative': 3}\n",
      "('individuals', 'statin') {' Neutral': 1}\n",
      "('mean', 'statin') {' Negative': 1}\n",
      "('positively', 'statin') {' Negative': 1}\n",
      "('0.01', 'statin') {' Negative': 1}\n",
      "('underwent', 'statin') {' Negative': 2}\n",
      "('goals', 'statin') {' Negative': 1}\n",
      "('and/or', 'statin') {' Negative': 1}\n",
      "('cardiology/american', 'statin') {' Negative': 1}\n",
      "('cardiology/american', 'statin') {' Neutral': 1}\n",
      "('a', 'statin') {' Positive': 2}\n",
      "('a', 'statin') {' Negative': 23}\n",
      "('a', 'statin') {' Neutral': 2}\n",
      "('a', 'statin') {' Very negative': 2}\n",
      "('vte', 'statin') {' Negative': 2}\n",
      "('evolocumab', 'statin') {' Negative': 3}\n",
      "('evolocumab', 'statin') {' Very negative': 1}\n",
      "('enhance', 'statin') {' Negative': 1}\n",
      "('eligible', 'statin') {' Negative': 4}\n",
      "('adults', 'statin') {' Negative': 6}\n",
      "('cancer', 'statin') {' Negative': 9}\n",
      "('cancer', 'statin') {' Neutral': 2}\n",
      "('growth', 'statin') {' Negative': 2}\n",
      "('assigned', 'statin') {' Negative': 3}\n",
      "('20', 'statin') {' Negative': 1}\n",
      "('6.10', 'statin') {' Negative': 1}\n",
      "('affects', 'statin') {' Negative': 1}\n",
      "('can', 'statin') {' Negative': 4}\n",
      "('25', 'statin') {' Negative': 1}\n",
      "('evidence', 'statin') {' Negative': 2}\n",
      "('arterial', 'statin') {' Negative': 1}\n",
      "(',', 'statin') {' Positive': 3}\n",
      "(',', 'statin') {' Negative': 95}\n",
      "(',', 'statin') {' Neutral': 1}\n",
      "(',', 'statin') {' Very negative': 17}\n",
      "('evaluated', 'statin') {' Negative': 1}\n",
      "('evaluated', 'statin') {' Very negative': 1}\n",
      "('women', 'statin') {' Negative': 2}\n",
      "('standard-of-care', 'statin') {' Very negative': 1}\n",
      "('98', 'statin') {' Very negative': 1}\n",
      "('des', 'statin') {' Negative': 2}\n",
      "('des', 'statin') {' Neutral': 1}\n",
      "('requires', 'statin') {' Negative': 1}\n",
      "('respectively', 'statin') {' Negative': 4}\n",
      "('heart', 'statin') {' Negative': 3}\n",
      "('heart', 'statin') {' Neutral': 1}\n",
      "('performed', 'statin') {' Very negative': 1}\n",
      "('female', 'statin') {' Negative': 1}\n",
      "('then', 'statin') {' Very negative': 1}\n",
      "('appropriate', 'statin') {' Negative': 1}\n",
      "('varied', 'statin') {' Negative': 1}\n",
      "('possible', 'statin') {' Negative': 1}\n",
      "('ear', 'statin') {' Negative': 1}\n",
      "('hazards', 'statin') {' Negative': 1}\n",
      "('new', 'statin') {' Negative': 5}\n",
      "('c-index', 'statin') {' Negative': 1}\n",
      "('fu', 'statin') {' Negative': 1}\n",
      "('11.8', 'statin') {' Negative': 2}\n",
      "('many', 'statin') {' Positive': 1}\n",
      "('many', 'statin') {' Negative': 1}\n",
      "('negatively', 'statin') {' Negative': 1}\n",
      "('despite', 'statin') {' Negative': 2}\n",
      "('despite', 'statin') {' Very negative': 1}\n",
      "('0.36-0', 'statin') {' Negative': 1}\n",
      "('implantation', 'statin') {' Negative': 1}\n",
      "('implantation', 'statin') {' Neutral': 1}\n",
      "('scar', 'statin') {' Negative': 2}\n",
      "('40-75', 'statin') {' Negative': 1}\n",
      "('10', 'statin') {' Negative': 1}\n",
      "('0.80', 'statin') {' Negative': 1}\n",
      "('4', 'statin') {' Negative': 2}\n",
      "('40', 'statin') {' Negative': 2}\n",
      "('overall', 'statin') {' Negative': 2}\n",
      "('serious', 'statin') {' Negative': 1}\n",
      "('heterozygous', 'statin') {' Very negative': 1}\n",
      "(\"'s\", 'statin') {' Negative': 1}\n",
      "(\"'s\", 'statin') {' Very negative': 1}\n",
      "('confidence', 'statin') {' Negative': 3}\n",
      "('confidence', 'statin') {' Very negative': 1}\n",
      "('74-92', 'statin') {' Very negative': 1}\n",
      "('sixty-one', 'statin') {' Negative': 1}\n",
      "('type', 'statin') {' Positive': 2}\n",
      "('type', 'statin') {' Negative': 2}\n",
      "('type', 'statin') {' Very negative': 1}\n",
      "('kidney', 'statin') {' Very negative': 1}\n",
      "('-rsb-', 'statin') {' Negative': 2}\n",
      "('-rsb-', 'statin') {' Very negative': 2}\n",
      "('cholesterol', 'statin') {' Negative': 4}\n",
      "('cholesterol', 'statin') {' Very negative': 5}\n",
      "('analyzed', 'statin') {' Very negative': 1}\n",
      "('recommended', 'statin') {' Negative': 2}\n",
      "('51', 'statin') {' Negative': 1}\n",
      "('insufficient', 'statin') {' Very negative': 1}\n",
      "('inappropriate', 'statin') {' Negative': 1}\n",
      "('variable', 'statin') {' Negative': 1}\n",
      "('high-risk', 'statin') {' Negative': 4}\n",
      "('also', 'statin') {' Negative': 1}\n",
      "('previous', 'statin') {' Negative': 1}\n",
      "('side', 'statin') {' Negative': 1}\n",
      "('measures', 'statin') {' Negative': 1}\n",
      "('unknown', 'statin') {' Neutral': 1}\n",
      "('reductions', 'statin') {' Negative': 1}\n",
      "('2007', 'statin') {' Negative': 4}\n",
      "('8-yr', 'statin') {' Negative': 1}\n",
      "('benefit', 'statin') {' Negative': 1}\n",
      "('llt', 'statin') {' Very negative': 1}\n",
      "('control', 'statin') {' Negative': 2}\n",
      "('learning', 'statin') {' Negative': 1}\n",
      "('compared', 'statin') {' Negative': 7}\n",
      "('sample', 'statin') {' Negative': 1}\n",
      "('2', 'statin') {' Positive': 1}\n",
      "('2', 'statin') {' Negative': 4}\n",
      "('increase', 'statin') {' Positive': 1}\n",
      "('increase', 'statin') {' Negative': 1}\n",
      "('increase', 'statin') {' Very negative': 1}\n",
      "('regression', 'statin') {' Negative': 1}\n",
      "('inclusion', 'statin') {' Negative': 1}\n",
      "('persistently', 'statin') {' Negative': 1}\n",
      "('lmca', 'statin') {' Very negative': 1}\n",
      "('ldl-cholesterol', 'statin') {' Negative': 3}\n",
      "('have', 'statin') {' Negative': 3}\n",
      "('have', 'statin') {' Very negative': 1}\n",
      "('be', 'statin') {' Negative': 4}\n",
      "('\\xce\\xb4', 'statin') {' Negative': 2}\n",
      "('interval', 'statin') {' Negative': 3}\n",
      "('interval', 'statin') {' Very negative': 1}\n",
      "('-', 'statin') {' Negative': 1}\n",
      "('-', 'statin') {' Very negative': 1}\n",
      "('older', 'statin') {' Negative': 1}\n",
      "('differentiation', 'statin') {' Negative': 1}\n",
      "('observational', 'statin') {' Very negative': 1}\n",
      "('must', 'statin') {' Negative': 1}\n",
      "('2008', 'statin') {' Negative': 5}\n",
      "('chronic', 'statin') {' Negative': 2}\n",
      "('chronic', 'statin') {' Very negative': 1}\n",
      "('drugs', 'statin') {' Negative': 3}\n",
      "('which', 'statin') {' Negative': 2}\n",
      "('probucol', 'statin') {' Negative': 1}\n",
      "('drug-eluting', 'statin') {' Negative': 1}\n",
      "('ezetimibe', 'statin') {' Negative': 2}\n",
      "('days', 'statin') {' Negative': 2}\n",
      "('presence', 'statin') {' Negative': 1}\n",
      "('60-74', 'statin') {' Negative': 1}\n",
      "('5.52', 'statin') {' Negative': 1}\n",
      "('ultrasound', 'statin') {' Very negative': 1}\n",
      "('percutaneous', 'statin') {' Negative': 1}\n",
      "('history', 'statin') {' Negative': 1}\n",
      "('cholesterol-lowering', 'statin') {' Negative': 1}\n",
      "('association', 'statin') {' Negative': 4}\n",
      "('association', 'statin') {' Neutral': 1}\n",
      "('association', 'statin') {' Very negative': 1}\n",
      "('developing', 'statin') {' Negative': 2}\n",
      "('developing', 'statin') {' Neutral': 1}\n",
      "('characteristics', 'statin') {' Very negative': 2}\n",
      "('consecutively', 'statin') {' Negative': 1}\n",
      "('whether', 'statin') {' Negative': 5}\n",
      "('whether', 'statin') {' Neutral': 1}\n",
      "('groups', 'statin') {' Negative': 4}\n",
      "('infected', 'statin') {' Positive': 1}\n",
      "('primary', 'statin') {' Negative': 7}\n",
      "('reducing', 'statin') {' Negative': 1}\n",
      "('37', 'statin') {' Negative': 3}\n",
      "('utilization', 'statin') {' Negative': 2}\n",
      "('10-year', 'statin') {' Negative': 2}\n",
      "('significantly', 'statin') {' Negative': 2}\n",
      "('tissue', 'statin') {' Negative': 1}\n",
      "('tissue', 'statin') {' Very negative': 2}\n",
      "('half-life', 'statin') {' Negative': 1}\n",
      "('60', 'statin') {' Negative': 2}\n",
      "('%', 'statin') {' Negative': 39}\n",
      "('%', 'statin') {' Very negative': 9}\n",
      "('mtd', 'statin') {' Very negative': 1}\n",
      "('high-dose', 'statin') {' Negative': 3}\n",
      "('data', 'statin') {' Positive': 1}\n",
      "('0.005', 'statin') {' Negative': 1}\n",
      "('8185', 'statin') {' Negative': 1}\n",
      "('length', 'statin') {' Negative': 1}\n",
      "('three', 'statin') {' Negative': 1}\n",
      "('underwentpercutaneous', 'statin') {' Very negative': 1}\n",
      "('urine', 'statin') {' Negative': 1}\n",
      "('statin', 'statin') {' Positive': 3}\n",
      "('statin', 'statin') {' Negative': 96}\n",
      "('statin', 'statin') {' Neutral': 3}\n",
      "('statin', 'statin') {' Very negative': 4}\n",
      "('following', 'statin') {' Negative': 1}\n",
      "('0.29', 'statin') {' Negative': 1}\n",
      "('would', 'statin') {' Negative': 5}\n",
      "('other', 'statin') {' Neutral': 1}\n",
      "('associated', 'statin') {' Negative': 9}\n",
      "('accuracy', 'statin') {' Neutral': 1}\n",
      "('stabilization', 'statin') {' Negative': 1}\n",
      "('9.8', 'statin') {' Negative': 1}\n",
      "('are', 'statin') {' Negative': 4}\n",
      "('enrolled', 'statin') {' Negative': 1}\n",
      "('indication', 'statin') {' Negative': 1}\n",
      "('inhibitors', 'statin') {' Negative': 1}\n",
      "('inhibitors', 'statin') {' Very negative': 1}\n",
      "('0.7', 'statin') {' Negative': 1}\n",
      "('had', 'statin') {' Negative': 6}\n",
      "('relationship', 'statin') {' Negative': 1}\n",
      "('apob', 'statin') {' Very negative': 1}\n",
      "('non-statin', 'statin') {' Negative': 2}\n",
      "('cox', 'statin') {' Negative': 1}\n",
      "('lymph', 'statin') {' Negative': 1}\n",
      "('may', 'statin') {' Negative': 4}\n",
      "('may', 'statin') {' Very negative': 1}\n",
      "('acute', 'statin') {' Negative': 1}\n",
      "('acute', 'statin') {' Very negative': 1}\n",
      "('usa-1', 'statin') {' Negative': 3}\n",
      "('non-culprit', 'statin') {' Negative': 1}\n",
      "('frequently', 'statin') {' Negative': 1}\n",
      "('center', 'statin') {' Negative': 1}\n",
      "('17', 'statin') {' Negative': 2}\n",
      "('without', 'statin') {' Negative': 5}\n",
      "('patient', 'statin') {' Negative': 1}\n",
      "('prospectively', 'statin') {' Very negative': 1}\n",
      "('incidence', 'statin') {' Neutral': 1}\n",
      "('75-84', 'statin') {' Negative': 1}\n",
      "('concentration', 'statin') {' Negative': 1}\n",
      "('quasi-experimental', 'statin') {' Positive': 1}\n",
      "('often', 'statin') {' Negative': 1}\n",
      "('one-third', 'statin') {' Negative': 1}\n",
      "('0.320', 'statin') {' Negative': 1}\n",
      "('aged', 'statin') {' Negative': 3}\n",
      "('quantitative', 'statin') {' Negative': 1}\n",
      "('no', 'statin') {' Negative': 1}\n",
      "('cancer-related', 'statin') {' Negative': 1}\n",
      "('versus', 'statin') {' Negative': 2}\n",
      "('examined', 'statin') {' Negative': 3}\n",
      "('7.05', 'statin') {' Negative': 1}\n",
      "('randomly', 'statin') {' Negative': 3}\n",
      "('high-intensity', 'statin') {' Negative': 7}\n",
      "('high-intensity', 'statin') {' Neutral': 2}\n",
      "('simvastatin', 'statin') {' Negative': 2}\n",
      "('0', 'statin') {' Negative': 1}\n",
      "('good', 'statin') {' Very negative': 1}\n",
      "('focused', 'statin') {' Negative': 1}\n",
      "('again', 'statin') {' Negative': 1}\n",
      "('65', 'statin') {' Very negative': 1}\n",
      "('primarily', 'statin') {' Negative': 1}\n",
      "('increasing', 'statin') {' Very negative': 1}\n",
      "('proportional', 'statin') {' Negative': 1}\n",
      "('k', 'statin') {' Negative': 2}\n",
      "('silent', 'statin') {' Negative': 1}\n",
      "('pci', 'statin') {' Negative': 1}\n",
      "('attainment', 'statin') {' Negative': 1}\n",
      "('term', 'statin') {' Negative': 1}\n",
      "('pce', 'statin') {' Negative': 1}\n",
      "('proprotein', 'statin') {' Negative': 1}\n",
      "('proprotein', 'statin') {' Very negative': 1}\n",
      "('apoa1', 'statin') {' Very negative': 1}\n",
      "('30', 'statin') {' Negative': 1}\n",
      "('9', 'statin') {' Negative': 1}\n",
      "('9', 'statin') {' Very negative': 1}\n",
      "('image', 'statin') {' Negative': 1}\n",
      "('prostate', 'statin') {' Negative': 6}\n",
      "('guideline', 'statin') {' Negative': 6}\n",
      "('interference', 'statin') {' Negative': 1}\n",
      "('suggest', 'statin') {' Negative': 3}\n",
      "('suggest', 'statin') {' Very negative': 1}\n",
      "('vessel', 'statin') {' Negative': 2}\n",
      "('from', 'statin') {' Negative': 5}\n",
      "('from', 'statin') {' Very negative': 2}\n",
      "('assure', 'statin') {' Negative': 1}\n",
      "('1', 'statin') {' Positive': 1}\n",
      "('1', 'statin') {' Negative': 1}\n",
      "('2,196', 'statin') {' Negative': 2}\n",
      "('driven', 'statin') {' Negative': 1}\n",
      "('denmark', 'statin') {' Negative': 1}\n",
      "('combined', 'statin') {' Negative': 3}\n",
      "('including', 'statin') {' Negative': 5}\n",
      "('including', 'statin') {' Very negative': 1}\n",
      "('given', 'statin') {' Negative': 1}\n",
      "('participants', 'statin') {' Negative': 4}\n",
      "('level', 'statin') {' Negative': 1}\n",
      "('level', 'statin') {' Very negative': 1}\n",
      "('node', 'statin') {' Negative': 1}\n",
      "('june', 'statin') {' Very negative': 2}\n",
      "('during', 'statin') {' Negative': 1}\n",
      "('less', 'statin') {' Negative': 1}\n",
      "('taken', 'statin') {' Negative': 1}\n",
      "('prevalent', 'statin') {' Negative': 4}\n",
      "('prescribing', 'statin') {' Negative': 4}\n",
      "('females', 'statin') {' Negative': 4}\n",
      "('mass', 'statin') {' Negative': 1}\n",
      "('approved', 'statin') {' Very negative': 1}\n",
      "('97', 'statin') {' Very negative': 1}\n",
      "('contains', 'statin') {' Negative': 1}\n",
      "('detect', 'statin') {' Negative': 1}\n",
      "('american', 'statin') {' Negative': 2}\n",
      "('american', 'statin') {' Neutral': 1}\n",
      "('apob/a1', 'statin') {' Very negative': 1}\n",
      "('served', 'statin') {' Negative': 1}\n",
      "('suggests', 'statin') {' Negative': 1}\n",
      "('individual', 'statin') {' Negative': 1}\n",
      "('their', 'statin') {' Very negative': 1}\n",
      "('we', 'statin') {' Positive': 1}\n",
      "('we', 'statin') {' Negative': 9}\n",
      "('we', 'statin') {' Neutral': 2}\n",
      "('negative', 'statin') {' Negative': 2}\n",
      "('having', 'statin') {' Negative': 1}\n",
      "('continuous', 'statin') {' Negative': 1}\n",
      "('continuous', 'statin') {' Neutral': 1}\n",
      "('812', 'statin') {' Negative': 1}\n",
      "('process', 'statin') {' Negative': 1}\n",
      "('\\xc2\\xb1', 'statin') {' Negative': 3}\n",
      "('pcsk9', 'statin') {' Negative': 1}\n",
      "('severe', 'statin') {' Very negative': 1}\n",
      "('blood', 'statin') {' Negative': 2}\n",
      "('blood', 'statin') {' Very negative': 1}\n",
      "('mainly', 'statin') {' Negative': 1}\n",
      "('submitted', 'statin') {' Negative': 1}\n",
      "('hundred', 'statin') {' Negative': 1}\n",
      "('our', 'statin') {' Negative': 2}\n",
      "('adherence', 'statin') {' Negative': 2}\n",
      "('adherence', 'statin') {' Very negative': 1}\n",
      "('baseline', 'statin') {' Negative': 4}\n",
      "('failure', 'statin') {' Negative': 1}\n",
      "('failure', 'statin') {' Very negative': 1}\n",
      "('343,438', 'statin') {' Negative': 1}\n",
      "('health', 'statin') {' Negative': 2}\n",
      "('stable', 'statin') {' Negative': 3}\n",
      "('stable', 'statin') {' Neutral': 1}\n",
      "('stable', 'statin') {' Very negative': 1}\n",
      "('at', 'statin') {' Negative': 10}\n",
      "('at', 'statin') {' Neutral': 1}\n",
      "('66', 'statin') {' Negative': 1}\n",
      "('virtualhistology', 'statin') {' Very negative': 1}\n",
      "('infarction', 'statin') {' Negative': 3}\n",
      "('17.81', 'statin') {' Negative': 1}\n",
      "('includes', 'statin') {' Negative': 1}\n",
      "('users', 'statin') {' Negative': 8}\n",
      "('potential', 'statin') {' Negative': 3}\n",
      "('oncology', 'statin') {' Negative': 1}\n",
      "('care', 'statin') {' Negative': 2}\n",
      "('<', 'statin') {' Negative': 2}\n",
      "('low-intensity', 'statin') {' Negative': 3}\n",
      "('design', 'statin') {' Positive': 1}\n",
      "('design', 'statin') {' Negative': 1}\n",
      "('stay', 'statin') {' Negative': 1}\n",
      "('delay', 'statin') {' Negative': 1}\n",
      "('50', 'statin') {' Negative': 1}\n",
      "('elevated', 'statin') {' Negative': 1}\n",
      "('male', 'statin') {' Negative': 1}\n",
      "('modification', 'statin') {' Negative': 1}\n",
      "('qrisk2', 'statin') {' Negative': 1}\n",
      "('cumulative', 'statin') {' Negative': 1}\n",
      "('was', 'statin') {' Negative': 16}\n",
      "('was', 'statin') {' Very negative': 1}\n",
      "('both', 'statin') {' Negative': 1}\n",
      "('both', 'statin') {' Very negative': 1}\n",
      "('receive', 'statin') {' Negative': 1}\n",
      "('reassess', 'statin') {' Negative': 1}\n",
      "('wide', 'statin') {' Negative': 1}\n",
      "('3', 'statin') {' Negative': 1}\n",
      "('consider', 'statin') {' Negative': 1}\n",
      "('monacolin', 'statin') {' Negative': 3}\n",
      "('factors', 'statin') {' Negative': 1}\n",
      "('randomised', 'statin') {' Negative': 1}\n",
      "('optimizing', 'statin') {' Negative': 1}\n",
      "('diabetes', 'statin') {' Negative': 3}\n",
      "('nonuse', 'statin') {' Negative': 1}\n",
      "('after', 'statin') {' Negative': 7}\n",
      "('after', 'statin') {' Neutral': 1}\n",
      "('95', 'statin') {' Negative': 8}\n",
      "('95', 'statin') {' Very negative': 3}\n",
      "('0.04', 'statin') {' Negative': 1}\n",
      "('result', 'statin') {' Neutral': 1}\n",
      "('daily', 'statin') {' Negative': 2}\n",
      "('0.0001', 'statin') {' Negative': 1}\n",
      "('most', 'statin') {' Negative': 3}\n",
      "('>', 'statin') {' Negative': 2}\n",
      "('current', 'statin') {' Positive': 1}\n",
      "('current', 'statin') {' Negative': 2}\n",
      "('nontarget', 'statin') {' Negative': 1}\n",
      "('picking', 'statin') {' Negative': 1}\n",
      "('between', 'statin') {' Negative': 6}\n",
      "('0.519', 'statin') {' Negative': 1}\n",
      "('repatha', 'statin') {' Very negative': 1}\n",
      "('residual', 'statin') {' Negative': 1}\n",
      "('convertase', 'statin') {' Negative': 1}\n",
      "('convertase', 'statin') {' Very negative': 1}\n",
      "('meta-analyses', 'statin') {' Negative': 1}\n",
      "('threshold', 'statin') {' Negative': 1}\n",
      "('diseases', 'statin') {' Negative': 1}\n",
      "('part', 'statin') {' Negative': 1}\n",
      "('ratio', 'statin') {' Negative': 2}\n",
      "('ratio', 'statin') {' Very negative': 2}\n",
      "('exceed', 'statin') {' Negative': 1}\n",
      "('method', 'statin') {' Negative': 2}\n",
      "('mortality', 'statin') {' Negative': 5}\n",
      "('distinguishable', 'statin') {' Negative': 1}\n",
      "('included.we', 'statin') {' Very negative': 1}\n",
      "('model', 'statin') {' Negative': 1}\n",
      "('improved', 'statin') {' Positive': 1}\n",
      "('improved', 'statin') {' Negative': 1}\n",
      "('alzheimer', 'statin') {' Negative': 1}\n",
      "('high-density', 'statin') {' Very negative': 1}\n",
      "('agents', 'statin') {' Negative': 1}\n",
      "('prescribed', 'statin') {' Negative': 3}\n",
      "('0.65-0', 'statin') {' Negative': 1}\n",
      "('controls', 'statin') {' Negative': 1}\n",
      "('muscle', 'statin') {' Negative': 1}\n",
      "('muscle', 'statin') {' Very negative': 1}\n",
      "('-lrb-', 'statin') {' Negative': 67}\n",
      "('-lrb-', 'statin') {' Very negative': 20}\n",
      "('investigated', 'statin') {' Negative': 1}\n",
      "('investigated', 'statin') {' Neutral': 1}\n",
      "('point', 'statin') {' Negative': 2}\n",
      "('.025', 'statin') {' Negative': 1}\n",
      "('mild-to-severe', 'statin') {' Negative': 1}\n",
      "('condition', 'statin') {' Negative': 1}\n",
      "('these', 'statin') {' Neutral': 1}\n",
      "('breast', 'statin') {' Negative': 3}\n",
      "('ratios', 'statin') {' Negative': 1}\n",
      "('among', 'statin') {' Negative': 7}\n",
      "('0.712', 'statin') {' Negative': 1}\n",
      "('dose', 'statin') {' Negative': 4}\n",
      "('dose', 'statin') {' Very negative': 2}\n",
      "('meet', 'statin') {' Very negative': 1}\n",
      "('included', 'statin') {' Negative': 2}\n",
      "('and', 'statin') {' Positive': 2}\n",
      "('and', 'statin') {' Negative': 71}\n",
      "('and', 'statin') {' Very negative': 5}\n",
      "('mellitus', 'statin') {' Negative': 1}\n",
      "('higher', 'statin') {' Negative': 4}\n",
      "('higher', 'statin') {' Neutral': 1}\n",
      "('discontinued', 'statin') {' Negative': 1}\n",
      "('discontinuation', 'statin') {' Positive': 1}\n",
      "('discontinuation', 'statin') {' Negative': 9}\n",
      "('atherosclerosis', 'statin') {' Negative': 2}\n",
      "('trials', 'statin') {' Negative': 1}\n",
      "('9.6', 'statin') {' Negative': 1}\n",
      "('either', 'statin') {' Negative': 1}\n",
      "('interactions', 'statin') {' Negative': 1}\n",
      "('effectiveness', 'statin') {' Positive': 1}\n",
      "('therapy', 'statin') {' Positive': 1}\n",
      "('therapy', 'statin') {' Negative': 27}\n",
      "('therapy', 'statin') {' Very negative': 3}\n",
      "('aki', 'statin') {' Negative': 1}\n",
      "('aki', 'statin') {' Very negative': 1}\n",
      "('', 'statin') {' Negative': 21}\n",
      "('', 'statin') {' Very negative': 3}\n",
      "('2016', 'statin') {' Negative': 1}\n",
      "('2016', 'statin') {' Very negative': 1}\n",
      "('further', 'statin') {' Negative': 2}\n",
      "('that', 'statin') {' Positive': 1}\n",
      "('that', 'statin') {' Negative': 9}\n",
      "('that', 'statin') {' Very negative': 1}\n",
      "('.8', 'statin') {' Negative': 1}\n",
      "('adjuncts', 'statin') {' Very negative': 1}\n",
      "('classified', 'statin') {' Negative': 1}\n",
      "('studies', 'statin') {' Negative': 2}\n",
      "('studies', 'statin') {' Very negative': 2}\n",
      "('contrast', 'statin') {' Negative': 1}\n",
      "('guidelines', 'statin') {' Negative': 9}\n",
      "('guidelines', 'statin') {' Very negative': 1}\n",
      "('danish', 'statin') {' Negative': 1}\n",
      "('attempts', 'statin') {' Negative': 1}\n",
      "('8.1', 'statin') {' Negative': 1}\n",
      "('took', 'statin') {' Very negative': 1}\n",
      "('proportion', 'statin') {' Negative': 1}\n",
      "('instead', 'statin') {' Negative': 1}\n",
      "('settings', 'statin') {' Negative': 1}\n",
      "('duration', 'statin') {' Positive': 1}\n",
      "('duration', 'statin') {' Negative': 1}\n",
      "('reductase', 'statin') {' Negative': 1}\n",
      "('examinations', 'statin') {' Negative': 1}\n",
      "('acc/aha', 'statin') {' Negative': 1}\n",
      "('exist', 'statin') {' Negative': 1}\n",
      "('none', 'statin') {' Very negative': 1}\n",
      "('group', 'statin') {' Negative': 2}\n",
      "('aspirin', 'statin') {' Negative': 2}\n",
      "('aspirin', 'statin') {' Neutral': 1}\n",
      "('assessed', 'statin') {' Negative': 1}\n",
      "('especially', 'statin') {' Negative': 1}\n",
      "('points', 'statin') {' Negative': 1}\n",
      "('na\\xc3\\xafve', 'statin') {' Negative': 1}\n",
      "('22.2', 'statin') {' Negative': 1}\n",
      "('currently', 'statin') {' Neutral': 1}\n",
      "('plasma', 'statin') {' Negative': 1}\n",
      "('2.274', 'statin') {' Negative': 1}\n",
      "('institute', 'statin') {' Negative': 1}\n",
      "('national', 'statin') {' Negative': 1}\n",
      "('death', 'statin') {' Negative': 5}\n",
      "('criterion', 'statin') {' Negative': 2}\n",
      "('purchases', 'statin') {' Positive': 1}\n",
      "('tacrolimus', 'statin') {' Negative': 1}\n",
      "('it', 'statin') {' Negative': 3}\n",
      "('validated', 'statin') {' Negative': 1}\n",
      "('distinguish', 'statin') {' Negative': 1}\n",
      "('community-based', 'statin') {' Negative': 2}\n",
      "('prescription', 'statin') {' Negative': 3}\n",
      "('intervention', 'statin') {' Negative': 1}\n",
      "('intervention', 'statin') {' Very negative': 1}\n",
      "('high', 'statin') {' Negative': 3}\n",
      "('attention', 'statin') {' Negative': 1}\n",
      "('continued', 'statin') {' Negative': 1}\n",
      "('in', 'statin') {' Positive': 1}\n",
      "('in', 'statin') {' Negative': 64}\n",
      "('in', 'statin') {' Neutral': 2}\n",
      "('in', 'statin') {' Very negative': 2}\n",
      "('21-42', 'statin') {' Very negative': 1}\n",
      "('cohort', 'statin') {' Negative': 1}\n",
      "('cohort', 'statin') {' Very negative': 1}\n",
      "('2010', 'statin') {' Very negative': 1}\n",
      "('some', 'statin') {' Negative': 1}\n",
      "('0.978', 'statin') {' Negative': 1}\n",
      "('newspaper', 'statin') {' Negative': 1}\n",
      "('pressure', 'statin') {' Negative': 1}\n",
      "('.98', 'statin') {' Negative': 1}\n",
      "('confirmed', 'statin') {' Negative': 1}\n",
      "('adjunct', 'statin') {' Negative': 1}\n",
      "('event', 'statin') {' Negative': 3}\n",
      "('months', 'statin') {' Negative': 2}\n",
      "('months', 'statin') {' Neutral': 1}\n",
      "('1458', 'statin') {' Negative': 1}\n",
      "('cardiac', 'statin') {' Negative': 1}\n",
      "('framingham', 'statin') {' Negative': 1}\n",
      "('-70', 'statin') {' Negative': 1}\n",
      "('rate', 'statin') {' Negative': 1}\n",
      "('anti-platelet', 'statin') {' Very negative': 1}\n",
      "('2014', 'statin') {' Negative': 2}\n",
      "('over', 'statin') {' Positive': 1}\n",
      "('40mg', 'statin') {' Negative': 1}\n",
      "('initiate', 'statin') {' Negative': 1}\n",
      "('however', 'statin') {' Negative': 2}\n",
      "('atherosclerotic', 'statin') {' Negative': 2}\n",
      "('atherosclerotic', 'statin') {' Very negative': 1}\n",
      "('future', 'statin') {' Negative': 1}\n",
      "('above', 'statin') {' Negative': 2}\n",
      "('status', 'statin') {' Negative': 1}\n",
      "('disease', 'statin') {' Negative': 5}\n",
      "('disease', 'statin') {' Very negative': 1}\n",
      "('long', 'statin') {' Negative': 2}\n",
      "('fourier', 'statin') {' Negative': 1}\n",
      "('subclinical', 'statin') {' Negative': 2}\n",
      "('d', 'statin') {' Negative': 1}\n",
      "('north', 'statin') {' Negative': 1}\n",
      "('sought', 'statin') {' Neutral': 1}\n",
      "('shown', 'statin') {' Negative': 2}\n",
      "('there', 'statin') {' Negative': 2}\n",
      "('there', 'statin') {' Very negative': 1}\n",
      "('evaluation', 'statin') {' Negative': 2}\n",
      "('.92', 'statin') {' Negative': 1}\n",
      "('candidates', 'statin') {' Negative': 3}\n",
      "('reason', 'statin') {' Negative': 2}\n",
      "('noncardiovascular', 'statin') {' Neutral': 1}\n",
      "('relies', 'statin') {' Positive': 1}\n",
      "('an', 'statin') {' Negative': 6}\n",
      "('known', 'statin') {' Negative': 2}\n",
      "('praluent', 'statin') {' Very negative': 1}\n",
      "('regards', 'statin') {' Very negative': 1}\n",
      "('based', 'statin') {' Negative': 2}\n",
      "('3-hydroxy-3-methylglutaryl', 'statin') {' Negative': 1}\n",
      "('0.023', 'statin') {' Negative': 1}\n",
      "('defined', 'statin') {' Negative': 1}\n",
      "('diagnosis', 'statin') {' Negative': 4}\n",
      "('lipoprotein', 'statin') {' Negative': 1}\n",
      "('lipoprotein', 'statin') {' Very negative': 4}\n",
      "('.018', 'statin') {' Negative': 1}\n",
      "('injury', 'statin') {' Negative': 1}\n",
      "('injury', 'statin') {' Very negative': 2}\n",
      "('pharmacokinetics', 'statin') {' Positive': 1}\n",
      "('demonstrated', 'statin') {' Negative': 3}\n",
      "('smallest', 'statin') {' Negative': 1}\n",
      "('0.339', 'statin') {' Negative': 1}\n",
      "('c', 'statin') {' Negative': 1}\n",
      "('late', 'statin') {' Negative': 1}\n",
      "('late', 'statin') {' Neutral': 2}\n",
      "('third-generation', 'statin') {' Negative': 1}\n",
      "('another', 'statin') {' Negative': 1}\n",
      "('potency', 'statin') {' Very negative': 1}\n",
      "('coronary', 'statin') {' Negative': 5}\n",
      "('coronary', 'statin') {' Very negative': 1}\n",
      "('impact', 'statin') {' Negative': 2}\n",
      "('impact', 'statin') {' Neutral': 1}\n",
      "('antiplatelet', 'statin') {' Negative': 1}\n",
      "('atorvastatin', 'statin') {' Positive': 1}\n",
      "('atorvastatin', 'statin') {' Negative': 2}\n",
      "('myocardial', 'statin') {' Negative': 4}\n",
      "('score', 'statin') {' Negative': 1}\n",
      "('monitoring', 'statin') {' Negative': 1}\n",
      "('the', 'statin') {' Positive': 3}\n",
      "('the', 'statin') {' Negative': 63}\n",
      "('the', 'statin') {' Neutral': 4}\n",
      "('the', 'statin') {' Very negative': 10}\n",
      "('all', 'statin') {' Negative': 7}\n",
      "('ivus-vh', 'statin') {' Very negative': 1}\n",
      "('tc', 'statin') {' Very negative': 1}\n",
      "('initiatives', 'statin') {' Negative': 1}\n",
      "('lovastatin', 'statin') {' Negative': 3}\n",
      "('maintenance', 'statin') {' Negative': 1}\n",
      "('reduction', 'statin') {' Negative': 1}\n",
      "('mechanism', 'statin') {' Negative': 1}\n",
      "('males', 'statin') {' Negative': 4}\n",
      "('all-cause', 'statin') {' Negative': 1}\n",
      "('people', 'statin') {' Negative': 1}\n",
      "('people', 'statin') {' Very negative': 1}\n",
      "('better', 'statin') {' Negative': 1}\n",
      "('progression', 'statin') {' Negative': 1}\n",
      "('time-dependent', 'statin') {' Negative': 1}\n",
      "('tumour', 'statin') {' Negative': 1}\n",
      "('1000', 'statin') {' Negative': 2}\n",
      "('aim', 'statin') {' Negative': 2}\n",
      "('83', 'statin') {' Negative': 1}\n",
      "('meeting', 'statin') {' Very negative': 1}\n",
      "('recommendations', 'statin') {' Negative': 1}\n",
      "('pathways', 'statin') {' Negative': 1}\n",
      "('undergone', 'statin') {' Negative': 1}\n",
      "('work', 'statin') {' Negative': 1}\n",
      "('prevent', 'statin') {' Negative': 2}\n",
      "('usa-2', 'statin') {' Negative': 2}\n",
      "('low', 'statin') {' Negative': 2}\n",
      "('prediction', 'statin') {' Negative': 2}\n",
      "('estimated', 'statin') {' Negative': 2}\n",
      "('osteomyelitis', 'statin') {' Negative': 2}\n",
      "('br-2', 'statin') {' Negative': 2}\n",
      "('diabetics', 'statin') {' Negative': 1}\n",
      "('clinically', 'statin') {' Negative': 2}\n",
      "('clinically', 'statin') {' Neutral': 1}\n",
      "('application', 'statin') {' Negative': 1}\n",
      "('before', 'statin') {' Negative': 2}\n",
      "('reduced', 'statin') {' Negative': 4}\n",
      "('20mg', 'statin') {' Negative': 1}\n",
      "('with', 'statin') {' Positive': 1}\n",
      "('with', 'statin') {' Negative': 40}\n",
      "('with', 'statin') {' Very negative': 5}\n",
      "('hrs', 'statin') {' Negative': 1}\n",
      "(';', 'statin') {' Negative': 18}\n",
      "(';', 'statin') {' Very negative': 5}\n",
      "('mrna', 'statin') {' Negative': 1}\n",
      "('uses', 'statin') {' Positive': 1}\n",
      "('index', 'statin') {' Negative': 1}\n",
      "('analysis', 'statin') {' Negative': 1}\n",
      "('determine', 'statin') {' Negative': 1}\n",
      "('determine', 'statin') {' Neutral': 1}\n",
      "('nature', 'statin') {' Negative': 1}\n",
      "('for', 'statin') {' Negative': 23}\n",
      "('clinical', 'statin') {' Negative': 5}\n",
      "('clinical', 'statin') {' Very negative': 1}\n",
      "('followed', 'statin') {' Negative': 1}\n",
      "('13', 'statin') {' Negative': 1}\n",
      "('offspring', 'statin') {' Negative': 1}\n",
      "('causes', 'statin') {' Neutral': 1}\n",
      "('where', 'statin') {' Very negative': 1}\n",
      "('estimate', 'statin') {' Negative': 1}\n",
      "('inconsistent', 'statin') {' Very negative': 1}\n",
      "('follow-up', 'statin') {' Negative': 2}\n",
      "('single', 'statin') {' Negative': 1}\n",
      "('should', 'statin') {' Negative': 2}\n",
      "('analysed', 'statin') {' Negative': 1}\n",
      "('percent', 'statin') {' Negative': 2}\n",
      "('risk', 'statin') {' Negative': 16}\n",
      "('risk', 'statin') {' Neutral': 1}\n",
      "('risk', 'statin') {' Very negative': 1}\n",
      "('determined', 'statin') {' Negative': 1}\n",
      "('longitudinal', 'statin') {' Negative': 1}\n",
      "('coenzyme-a', 'statin') {' Negative': 1}\n",
      "('2013', 'statin') {' Negative': 1}\n",
      "('2013', 'statin') {' Neutral': 1}\n",
      "('treatment', 'statin') {' Positive': 1}\n",
      "('treatment', 'statin') {' Negative': 24}\n",
      "('treatment', 'statin') {' Neutral': 2}\n",
      "('treatment', 'statin') {' Very negative': 1}\n",
      "('medication', 'statin') {' Negative': 1}\n",
      "('ideal', 'statin') {' Negative': 1}\n",
      "('body', 'statin') {' Negative': 1}\n",
      "('underused', 'statin') {' Negative': 1}\n",
      "('monotherapy', 'statin') {' Negative': 3}\n",
      "('monotherapy', 'statin') {' Neutral': 1}\n",
      "('mg', 'statin') {' Negative': 1}\n",
      "('homozygous', 'statin') {' Very negative': 1}\n",
      "('criteria', 'statin') {' Negative': 2}\n",
      "('criteria', 'statin') {' Neutral': 1}\n",
      "('by', 'statin') {' Negative': 12}\n",
      "('59', 'statin') {' Negative': 1}\n",
      "('ryr', 'statin') {' Negative': 1}\n",
      "('alirocumab', 'statin') {' Very negative': 1}\n",
      "('general', 'statin') {' Negative': 1}\n",
      "('0.780', 'statin') {' Negative': 1}\n",
      "('effects', 'statin') {' Negative': 1}\n",
      "('key', 'statin') {' Negative': 1}\n",
      "('rates', 'statin') {' Negative': 1}\n",
      "('fatty', 'statin') {' Negative': 1}\n",
      "('hypocholesterolemic', 'statin') {' Negative': 1}\n",
      "('demonstrate', 'statin') {' Negative': 1}\n",
      "('21.2', 'statin') {' Negative': 1}\n",
      "('report', 'statin') {' Negative': 1}\n",
      "('methods', 'statin') {' Negative': 1}\n",
      "('methods', 'statin') {' Very negative': 1}\n",
      "('to', 'statin') {' Positive': 2}\n",
      "('to', 'statin') {' Negative': 28}\n",
      "('to', 'statin') {' Neutral': 2}\n",
      "('to', 'statin') {' Very negative': 6}\n",
      "('isolated', 'statin') {' Negative': 1}\n",
      "('end', 'statin') {' Negative': 2}\n",
      "('media', 'statin') {' Negative': 3}\n",
      "('featuring', 'statin') {' Negative': 1}\n",
      "('used', 'statin') {' Negative': 2}\n",
      "('vldl', 'statin') {' Negative': 2}\n",
      "('two', 'statin') {' Negative': 1}\n",
      "('pre-diagnostic', 'statin') {' Negative': 2}\n",
      "('populations', 'statin') {' Negative': 1}\n",
      "('3.534', 'statin') {' Negative': 1}\n",
      "('fmd', 'statin') {' Negative': 2}\n",
      "('subjects', 'statin') {' Negative': 1}\n",
      "('study', 'statin') {' Positive': 2}\n",
      "('study', 'statin') {' Negative': 6}\n",
      "('6', 'statin') {' Negative': 1}\n",
      "('nice', 'statin') {' Negative': 3}\n",
      "('2.5', 'statin') {' Negative': 1}\n",
      "('ward', 'statin') {' Negative': 1}\n",
      "('recommend', 'statin') {' Negative': 3}\n",
      "('-lsb-', 'statin') {' Negative': 2}\n",
      "('-lsb-', 'statin') {' Very negative': 2}\n",
      "('lowering', 'statin') {' Negative': 1}\n",
      "('lowering', 'statin') {' Very negative': 2}\n",
      "('occurred', 'statin') {' Negative': 1}\n",
      "('n', 'statin') {' Negative': 4}\n",
      "('n', 'statin') {' Very negative': 3}\n",
      "('subtilisin/kexin', 'statin') {' Negative': 1}\n",
      "('subtilisin/kexin', 'statin') {' Very negative': 1}\n",
      "('is', 'statin') {' Negative': 11}\n",
      "('is', 'statin') {' Neutral': 1}\n",
      "('is', 'statin') {' Very negative': 1}\n",
      "('postdiagnostic', 'statin') {' Negative': 1}\n",
      "('angina', 'statin') {' Negative': 1}\n",
      "('angina', 'statin') {' Very negative': 1}\n",
      "('statistically', 'statin') {' Negative': 1}\n",
      "('important', 'statin') {' Negative': 1}\n",
      "('ldl-c', 'statin') {' Negative': 4}\n",
      "('ldl-c', 'statin') {' Very negative': 1}\n",
      "('exercise', 'statin') {' Negative': 1}\n",
      "('familial', 'statin') {' Negative': 1}\n",
      "('familial', 'statin') {' Very negative': 1}\n",
      "('31', 'statin') {' Very negative': 1}\n",
      "('was10', 'statin') {' Negative': 1}\n",
      "('conclusion', 'statin') {' Negative': 1}\n",
      "('experts', 'statin') {' Negative': 1}\n",
      "('only', 'statin') {' Negative': 1}\n",
      "('only', 'statin') {' Very negative': 1}\n",
      "('0.156', 'statin') {' Negative': 1}\n",
      "('per', 'statin') {' Negative': 1}\n",
      "('intolerant', 'statin') {' Negative': 1}\n",
      "('0.873', 'statin') {' Negative': 1}\n",
      "('plaque', 'statin') {' Negative': 1}\n",
      "('number', 'statin') {' Negative': 1}\n",
      "('large', 'statin') {' Negative': 1}\n",
      "('than', 'statin') {' Negative': 2}\n",
      "('404,052', 'statin') {' Negative': 1}\n",
      "('0.789', 'statin') {' Negative': 1}\n",
      "('nevertheless', 'statin') {' Negative': 1}\n",
      "('rabbit', 'statin') {' Negative': 1}\n",
      "('larger', 'statin') {' Negative': 1}\n",
      "('5', 'statin') {' Negative': 2}\n",
      "('st', 'statin') {' Negative': 2}\n",
      "('treated', 'statin') {' Positive': 1}\n",
      "('treated', 'statin') {' Negative': 4}\n",
      "('free', 'statin') {' Negative': 2}\n",
      "('definitions', 'statin') {' Negative': 1}\n",
      "('depending', 'statin') {' Negative': 2}\n",
      "('findings', 'statin') {' Negative': 1}\n",
      "('findings', 'statin') {' Very negative': 1}\n",
      "('benefits', 'statin') {' Negative': 1}\n",
      "('30-84', 'statin') {' Negative': 2}\n",
      "('guide', 'statin') {' Negative': 1}\n",
      "('guiding', 'statin') {' Negative': 1}\n",
      "('million', 'statin') {' Negative': 3}\n",
      "('stent', 'statin') {' Negative': 1}\n",
      "('under', 'statin') {' Negative': 4}\n",
      "('previously', 'statin') {' Negative': 2}\n",
      "('while', 'statin') {' Negative': 1}\n",
      "('one', 'statin') {' Negative': 3}\n",
      "('favoured', 'statin') {' Negative': 1}\n",
      "('k.', 'statin') {' Negative': 1}\n",
      "('drug', 'statin') {' Negative': 2}\n",
      "('aboved', 'statin') {' Very negative': 1}\n",
      "('lymph-node', 'statin') {' Negative': 1}\n",
      "('12', 'statin') {' Negative': 2}\n",
      "('12', 'statin') {' Neutral': 1}\n",
      "('particularly', 'statin') {' Negative': 1}\n",
      "('decision', 'statin') {' Negative': 1}\n",
      "('machine', 'statin') {' Negative': 1}\n",
      "('targets', 'statin') {' Negative': 1}\n",
      "('targets', 'statin') {' Very negative': 1}\n",
      "('ldl-c/hdl-c', 'statin') {' Very negative': 1}\n",
      "('resurveyed', 'statin') {' Negative': 1}\n",
      "('evaluate', 'statin') {' Negative': 1}\n",
      "('harrell', 'statin') {' Negative': 1}\n",
      "('largest', 'statin') {' Negative': 1}\n",
      "('0.02', 'statin') {' Negative': 3}\n",
      "('use', 'statin') {' Negative': 24}\n",
      "('practice', 'statin') {' Negative': 2}\n",
      "('independent', 'statin') {' Negative': 2}\n",
      "('5.0', 'statin') {' Negative': 2}\n",
      "('effect', 'statin') {' Negative': 1}\n",
      "('recorded', 'statin') {' Negative': 1}\n",
      "('tg', 'statin') {' Very negative': 1}\n",
      "('hypercholesterolemia', 'statin') {' Negative': 3}\n",
      "('hypercholesterolemia', 'statin') {' Very negative': 1}\n",
      "('.033', 'statin') {' Negative': 1}\n",
      "('prior', 'statin') {' Negative': 1}\n",
      "('1.6', 'statin') {' Negative': 1}\n",
      "('treatments', 'statin') {' Negative': 1}\n",
      "('events', 'statin') {' Negative': 2}\n",
      "('events', 'statin') {' Neutral': 2}\n",
      "('vs', 'statin') {' Negative': 4}\n",
      "('therefore', 'statin') {' Negative': 1}\n",
      "('because', 'statin') {' Negative': 1}\n",
      "('identify', 'statin') {' Negative': 1}\n",
      "('identify', 'statin') {' Neutral': 1}\n",
      "('pp', 'statin') {' Negative': 5}\n",
      "('2.97', 'statin') {' Negative': 1}\n",
      "('pravastatin', 'statin') {' Negative': 1}\n",
      "('been', 'statin') {' Negative': 2}\n",
      "('been', 'statin') {' Very negative': 1}\n",
      "('ascvd', 'statin') {' Negative': 1}\n",
      "('artery', 'statin') {' Negative': 1}\n",
      "('anticoagulant', 'statin') {' Negative': 2}\n",
      "('albumin-to-creatinine', 'statin') {' Negative': 1}\n",
      "('acs', 'statin') {' Negative': 1}\n",
      "('those', 'statin') {' Negative': 5}\n",
      "('donepezil', 'statin') {' Negative': 1}\n",
      "('91-100', 'statin') {' Very negative': 1}\n",
      "('time', 'statin') {' Negative': 1}\n",
      "('vh-ivus', 'statin') {' Negative': 1}\n",
      "('cancer-specific', 'statin') {' Negative': 2}\n",
      "('amount', 'statin') {' Negative': 1}\n",
      "('explore', 'statin') {' Positive': 1}\n",
      "('explore', 'statin') {' Negative': 1}\n",
      "('assessment', 'statin') {' Negative': 2}\n",
      "('but', 'statin') {' Negative': 4}\n",
      "('but', 'statin') {' Very negative': 1}\n",
      "('values', 'statin') {' Very negative': 2}\n",
      "('absolute', 'statin') {' Negative': 2}\n",
      "('four', 'statin') {' Negative': 1}\n",
      "('four', 'statin') {' Very negative': 1}\n",
      "('chd', 'statin') {' Negative': 1}\n",
      "('prasugrel', 'statin') {' Negative': 1}\n",
      "('differences', 'statin') {' Negative': 1}\n",
      "('trial', 'statin') {' Negative': 1}\n",
      "('almost', 'statin') {' Negative': 1}\n",
      "('risks', 'statin') {' Negative': 1}\n",
      "('registry', 'statin') {' Positive': 1}\n",
      "(':', 'statin') {' Negative': 2}\n",
      "(':', 'statin') {' Very negative': 1}\n",
      "('\\xe2\\x89\\xa4', 'statin') {' Negative': 1}\n",
      "('small', 'statin') {' Negative': 1}\n",
      "('syndrome', 'statin') {' Negative': 1}\n",
      "('investigation', 'statin') {' Negative': 1}\n",
      "('england', 'statin') {' Negative': 2}\n",
      "('chemically', 'statin') {' Negative': 1}\n",
      "('intensive', 'statin') {' Negative': 1}\n",
      "('considers', 'statin') {' Negative': 1}\n",
      "('group-patients', 'statin') {' Negative': 2}\n",
      "('\\xe2\\x89\\xa5', 'statin') {' Negative': 5}\n",
      "('factor', 'statin') {' Negative': 2}\n",
      "('reaction', 'statin') {' Negative': 2}\n",
      "('t2dm', 'statin') {' Negative': 2}\n",
      "('1.49', 'statin') {' Negative': 1}\n",
      "('24', 'statin') {' Negative': 1}\n",
      "('24', 'statin') {' Very negative': 1}\n",
      "('required', 'statin') {' Negative': 1}\n",
      "('peripheral', 'statin') {' Negative': 1}\n",
      "('h', 'statin') {' Negative': 1}\n",
      "('tomography', 'statin') {' Negative': 1}\n",
      "('combination', 'statin') {' Negative': 1}\n",
      "('4.1', 'statin') {' Negative': 1}\n",
      "('calcium', 'statin') {' Negative': 1}\n",
      "('one-year', 'statin') {' Negative': 1}\n",
      "('goal', 'statin') {' Negative': 1}\n",
      "('of', 'statin') {' Positive': 1}\n",
      "('of', 'statin') {' Negative': 66}\n",
      "('of', 'statin') {' Neutral': 7}\n",
      "('of', 'statin') {' Very negative': 8}\n",
      "('cvd', 'statin') {' Negative': 4}\n",
      "('cvd', 'statin') {' Very negative': 1}\n",
      "('eligibility', 'statin') {' Negative': 3}\n",
      "('eligibility', 'statin') {' Neutral': 1}\n",
      "('already', 'statin') {' Negative': 2}\n",
      "('college', 'statin') {' Negative': 1}\n",
      "('college', 'statin') {' Neutral': 1}\n",
      "('locations', 'statin') {' Negative': 1}\n",
      "('.12', 'statin') {' Negative': 1}\n",
      "('identified', 'statin') {' Negative': 1}\n",
      "('hdl', 'statin') {' Negative': 2}\n",
      "('discontinue', 'statin') {' Negative': 1}\n",
      "('article', 'statin') {' Negative': 2}\n",
      "('non-hdl-cholesterol', 'statin') {' Negative': 1}\n",
      "('in-hospital', 'statin') {' Negative': 1}\n",
      "('0.75-1', 'statin') {' Negative': 1}\n",
      "('differ', 'statin') {' Negative': 1}\n",
      "('hyperlipidemia', 'statin') {' Negative': 1}\n",
      "('through', 'statin') {' Negative': 2}\n",
      "('types', 'statin') {' Negative': 1}\n",
      "('3.8', 'statin') {' Negative': 1}\n",
      "('low-density', 'statin') {' Negative': 1}\n",
      "('low-density', 'statin') {' Very negative': 3}\n",
      "('on', 'statin') {' Positive': 2}\n",
      "('on', 'statin') {' Negative': 15}\n",
      "('on', 'statin') {' Neutral': 2}\n",
      "('user', 'statin') {' Negative': 1}\n",
      "('help', 'statin') {' Negative': 2}\n",
      "('12-month', 'statin') {' Negative': 1}\n",
      "('hazard', 'statin') {' Negative': 2}\n",
      "('them', 'statin') {' Negative': 1}\n",
      "('intravascular', 'statin') {' Very negative': 1}\n",
      "('fh', 'statin') {' Negative': 1}\n",
      "('province', 'statin') {' Very negative': 1}\n",
      "('adverse', 'statin') {' Negative': 4}\n",
      "('adverse', 'statin') {' Neutral': 2}\n",
      "('triglyceride', 'statin') {' Negative': 1}\n",
      "('triglyceride', 'statin') {' Very negative': 1}\n",
      "('assist', 'statin') {' Negative': 1}\n",
      "('anticoagulants', 'statin') {' Negative': 1}\n",
      "('recommendation', 'statin') {' Negative': 1}\n",
      "('routine', 'statin') {' Negative': 1}\n",
      "('ldlc', 'statin') {' Negative': 1}\n",
      "('ldlc', 'statin') {' Very negative': 2}\n",
      "('years', 'statin') {' Negative': 9}\n",
      "('0.766', 'statin') {' Negative': 1}\n",
      "('0.047', 'statin') {' Negative': 1}\n",
      "('cardiovascular', 'statin') {' Negative': 8}\n",
      "('cardiovascular', 'statin') {' Very negative': 1}\n",
      "('ages', 'statin') {' Negative': 2}\n",
      "('1.97', 'statin') {' Negative': 1}\n",
      "('age', 'statin') {' Negative': 3}\n",
      "('affect', 'statin') {' Negative': 1}\n",
      "('mixed', 'statin') {' Negative': 1}\n",
      "('gdf-15', 'statin') {' Negative': 3}\n",
      "('anti-hyperglycemic', 'statin') {' Negative': 1}\n",
      "('concurrent', 'statin') {' Negative': 1}\n",
      "('account', 'statin') {' Negative': 1}\n",
      "('account', 'statin') {' Very negative': 1}\n",
      "('more', 'statin') {' Negative': 1}\n",
      "('efficacy', 'statin') {' Negative': 2}\n",
      "('acids', 'statin') {' Negative': 1}\n",
      "('0.353', 'statin') {' Negative': 1}\n",
      "('hydrophobic', 'statin') {' Negative': 1}\n",
      "('intolerance', 'statin') {' Negative': 2}\n",
      "('require', 'statin') {' Negative': 4}\n",
      "('who', 'statin') {' Negative': 9}\n",
      "('who', 'statin') {' Very negative': 1}\n",
      "('were', 'statin') {' Negative': 17}\n",
      "('were', 'statin') {' Very negative': 3}\n",
      "('cohorts', 'statin') {' Negative': 1}\n",
      "('accurately', 'statin') {' Negative': 1}\n",
      "('drug-drug', 'statin') {' Negative': 1}\n",
      "('vitamin', 'statin') {' Negative': 1}\n",
      "('algorithm', 'statin') {' Negative': 1}\n",
      "('into', 'statin') {' Negative': 1}\n",
      "('into', 'statin') {' Very negative': 1}\n",
      "('0.03', 'statin') {' Negative': 2}\n",
      "('increased', 'statin') {' Negative': 2}\n",
      "('ischemia', 'statin') {' Negative': 1}\n",
      "('approximately', 'statin') {' Negative': 1}\n",
      "('interviewed', 'statin') {' Negative': 1}\n",
      "('des-treated', 'statin') {' Negative': 2}\n",
      "('hr', 'statin') {' Negative': 5}\n",
      "('lipids', 'statin') {' Very negative': 1}\n",
      "('decrease', 'statin') {' Negative': 1}\n",
      "('biosynthetic', 'statin') {' Negative': 1}\n",
      "('according', 'statin') {' Negative': 2}\n",
      "('serum', 'statin') {' Negative': 1}\n",
      "('hospital', 'statin') {' Negative': 1}\n",
      "('hospital', 'statin') {' Very negative': 1}\n",
      "('target', 'statin') {' Negative': 1}\n",
      "('target', 'statin') {' Very negative': 1}\n",
      "('prevention', 'statin') {' Negative': 6}\n",
      "('0.92', 'statin') {' Negative': 1}\n",
      "('eighty-five', 'statin') {' Negative': 1}\n",
      "('optimize', 'statin') {' Negative': 1}\n",
      "('covering', 'statin') {' Negative': 1}\n",
      "('mmol/l', 'statin') {' Negative': 2}\n",
      "('recognize', 'statin') {' Negative': 1}\n",
      "('established', 'statin') {' Negative': 1}\n",
      "('this', 'statin') {' Negative': 11}\n",
      "('proper', 'statin') {' Negative': 1}\n",
      "('nk', 'statin') {' Negative': 3}\n",
      "('75', 'statin') {' Negative': 1}\n",
      "('75', 'statin') {' Very negative': 1}\n",
      "('lipid', 'statin') {' Negative': 2}\n",
      "('4.9', 'statin') {' Negative': 2}\n",
      "('total', 'statin') {' Negative': 3}\n",
      "('total', 'statin') {' Very negative': 2}\n",
      "('retrospective', 'statin') {' Negative': 1}\n",
      "('not', 'statin') {' Negative': 10}\n",
      "('computed', 'statin') {' Negative': 1}\n",
      "('br-1', 'statin') {' Negative': 3}\n",
      "('population', 'statin') {' Negative': 1}\n",
      "('cac', 'statin') {' Negative': 1}\n",
      "('topical', 'statin') {' Negative': 1}\n",
      "('or', 'statin') {' Negative': 12}\n",
      "('or', 'statin') {' Neutral': 2}\n",
      "('or', 'statin') {' Very negative': 4}\n",
      "('3.66', 'statin') {' Negative': 1}\n",
      "('measured', 'statin') {' Very negative': 1}\n",
      "('percentage', 'statin') {' Negative': 1}\n",
      "('55', 'statin') {' Negative': 1}\n",
      "('ci', 'statin') {' Negative': 5}\n",
      "('ci', 'statin') {' Very negative': 3}\n",
      "('sex', 'statin') {' Negative': 1}\n",
      "('has', 'statin') {' Positive': 1}\n",
      "('has', 'statin') {' Negative': 3}\n",
      "('significant', 'statin') {' Negative': 1}\n",
      "('reduces', 'statin') {' Negative': 1}\n",
      "('reduces', 'statin') {' Neutral': 1}\n",
      "('did', 'statin') {' Negative': 1}\n",
      "('equal', 'statin') {' Negative': 1}\n",
      "('hefh', 'statin') {' Negative': 1}\n",
      "('hefh', 'statin') {' Very negative': 1}\n",
      "('0.58', 'statin') {' Negative': 1}\n",
      "('lower', 'statin') {' Negative': 3}\n",
      "('0.002', 'statin') {' Negative': 1}\n",
      "('when', 'statin') {' Negative': 4}\n",
      "('84', 'statin') {' Very negative': 1}\n",
      "('expression', 'statin') {' Negative': 2}\n",
      "('comprehensive', 'statin') {' Negative': 1}\n",
      "('mice', 'statin') {' Positive': 1}\n",
      "('mice', 'statin') {' Negative': 1}\n",
      "('brazilian', 'statin') {' Negative': 2}\n",
      "('review', 'statin') {' Negative': 2}\n",
      "('excellence', 'statin') {' Negative': 1}\n",
      "('incident', 'statin') {' Negative': 3}\n",
      "('difference', 'statin') {' Negative': 2}\n",
      "('evo', 'statin') {' Very negative': 3}\n",
      "('substantially', 'statin') {' Negative': 1}\n",
      "('30-day', 'statin') {' Negative': 1}\n",
      "('000', 'statin') {' Negative': 1}\n",
      "('p', 'statin') {' Negative': 18}\n",
      "('adjusted', 'statin') {' Negative': 1}\n",
      "('recent', 'statin') {' Negative': 2}\n",
      "('achieving', 'statin') {' Negative': 1}\n",
      "('icu', 'statin') {' Negative': 1}\n",
      "('statins', 'statin') {' Positive': 1}\n",
      "('statins', 'statin') {' Negative': 6}\n",
      "('statin-related', 'statin') {' Very negative': 1}\n"
     ]
    }
   ],
   "source": [
    "for k, v in sent_dict.iteritems():\n",
    "    for vv in v:\n",
    "        print k, vv"
   ]
  }
 ],
 "metadata": {
  "anaconda-cloud": {},
  "kernelspec": {
   "display_name": "Python 2",
   "language": "python",
   "name": "python2"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.12"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
